<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>JP2022546763A - 
  Immunogenic composition against intestinal disease and method for its preparation
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/JP2022546763A/en">
    <meta name="description" content="
   
    The present disclosure provides Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. Novel immunogenic monovalent and polyvalent polysaccharide-protein conjugate vaccine compositions comprising polysaccharides selected from enteritidis and alternatives to polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation with respect to an improved method of The present disclosure uses the compositions disclosed herein to elicit an immune response against Salmonella typhi and non-typhoid related diseases in a subject and/or to reduce or reduce Salmonella typhi and non-typhoid related diseases in a subject. It further relates to a method for preventing. Vaccines induce bactericidal antibodies and are useful in preventing gastroenteritis, enteric fever and typhoid fever.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Immunogenic composition against intestinal disease and method for its preparation
 
     ">
    <meta name="DC.date" content="2020-09-02" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    The present disclosure provides Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. Novel immunogenic monovalent and polyvalent polysaccharide-protein conjugate vaccine compositions comprising polysaccharides selected from enteritidis and alternatives to polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation with respect to an improved method of The present disclosure uses the compositions disclosed herein to elicit an immune response against Salmonella typhi and non-typhoid related diseases in a subject and/or to reduce or reduce Salmonella typhi and non-typhoid related diseases in a subject. It further relates to a method for preventing. Vaccines induce bactericidal antibodies and are useful in preventing gastroenteritis, enteric fever and typhoid fever.
   
 
   ">
    <meta name="citation_patent_application_number" content="JP:2022514468A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/c8/27/74/d218fd5b7f744c/JP2022546763A.pdf">
    <meta name="citation_patent_publication_number" content="JP:2022546763:A">
    <meta name="DC.date" content="2022-11-08">
    <meta name="DC.contributor" content="デーレー，ラジーブ・ムホーラサカント" scheme="inventor">
    <meta name="DC.contributor" content="ピサール，サンバージー・シャンカル" scheme="inventor">
    <meta name="DC.contributor" content="アナムラジュ，ダタトレーヤ・サルマ" scheme="inventor">
    <meta name="DC.contributor" content="アバラスカール，ニクヒル・ダタトレー" scheme="inventor">
    <meta name="DC.contributor" content="ハンデカリ，ヨーゲシ・ツカラム" scheme="inventor">
    <meta name="DC.contributor" content="タクリカール，アニル・ピラジラオ" scheme="inventor">
    <meta name="DC.contributor" content="ゴエル，スニール・クマール" scheme="inventor">
    <meta name="DC.contributor" content="カマット，チャンドラシェーカル・ドワルカナト" scheme="inventor">
    <meta name="DC.contributor" content="チャバン，ビシャール・バーラト" scheme="inventor">
    <meta name="DC.contributor" content="セラム インスティチュート オブ インディア プライベイト リミテッド" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Immunogenic composition against intestinal disease and method for its preparation
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Japanese</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA533136443" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">本開示は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓから選択される多糖体を含む新規免疫原性一価および多価多糖体－タンパク質コンジュゲートワクチン組成物、ならびに多糖体発酵、多糖体精製、多糖体－タンパク質コンジュゲーションおよび安定な製剤化の代替の改善された方法に関する。本開示は、本明細書に開示される組成物を使用して、対象においてＳａｌｍｏｎｅｌｌａ ｔｙｐｈｉおよび非チフス関連疾患に対する免疫応答を誘発するため、ならびに／または対象においてＳａｌｍｏｎｅｌｌａ ｔｙｐｈｉおよび非チフス関連疾患を低減もしくは防止するための方法さらに関する。ワクチンは、殺菌性抗体を誘発し、胃腸炎、腸熱および腸チフスの防止に有用である。</span>The present disclosure provides Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. Novel immunogenic monovalent and polyvalent polysaccharide-protein conjugate vaccine compositions comprising polysaccharides selected from enteritidis and alternatives to polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation with respect to an improved method of The present disclosure uses the compositions disclosed herein to elicit an immune response against Salmonella typhi and non-typhoid related diseases in a subject and/or to reduce or reduce Salmonella typhi and non-typhoid related diseases in a subject. It further relates to a method for preventing. Vaccines induce bactericidal antibodies and are useful in preventing gastroenteritis, enteric fever and typhoid fever.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">17</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/19/f4/bd/0d2c88065fe779/2022546763000098.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/ff/0a/a8/a5691ddc37ff71/2022546763000099.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/63/8e/9a/bf2a8fcc4b2078/2022546763000100.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/4c/13/5b/1cb5c8024eb542/2022546763000101.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/e1/cc/9b/859901f5bee563/2022546763000102.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/ac/ce/e7/34a28220bd40fa/2022546763000103.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/73/84/bc/600f9105089a3f/2022546763000104.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/d8/fc/43/3cf6228fff90e8/2022546763000105.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/5a/ea/f7/ceb969896413a9/2022546763000106.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/6a/36/2a/7862b31011a650/2022546763000107.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/68/60/ec/2439b02f41a782/2022546763000108.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/70/25/ab/aa8a6c06681e9e/2022546763000109.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/73/fb/1a/0c022a04370742/2022546763000110.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0b/4d/18/51e05766b7679e/2022546763000111.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/dd/13/e2/bd59343d62bb3e/2022546763000112.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/22/be/21/0f0af2461af752/2022546763000113.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/01/45/bf/cd1edd3f05ef29/2022546763000114.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/02"><a id="link" href="#" class="style-scope state-modifier">A61K39/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacterial antigens</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/025"><a id="link" href="#" class="style-scope state-modifier">A61K39/025</a></state-modifier>
                  <span class="description style-scope classification-tree">Enterobacteriales, e.g. Enterobacter</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K39/0275"><a id="link" href="#" class="style-scope state-modifier">A61K39/0275</a></state-modifier>
                  <span class="description style-scope classification-tree">Salmonella</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/02"><a id="link" href="#" class="style-scope state-modifier">A61K47/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Inorganic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/06"><a id="link" href="#" class="style-scope state-modifier">A61K47/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/08"><a id="link" href="#" class="style-scope state-modifier">A61K47/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/10"><a id="link" href="#" class="style-scope state-modifier">A61K47/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/06"><a id="link" href="#" class="style-scope state-modifier">A61K47/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/08"><a id="link" href="#" class="style-scope state-modifier">A61K47/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/12"><a id="link" href="#" class="style-scope state-modifier">A61K47/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Carboxylic acids; Salts or anhydrides thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/06"><a id="link" href="#" class="style-scope state-modifier">A61K47/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/16"><a id="link" href="#" class="style-scope state-modifier">A61K47/16</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/18"><a id="link" href="#" class="style-scope state-modifier">A61K47/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/06"><a id="link" href="#" class="style-scope state-modifier">A61K47/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/22"><a id="link" href="#" class="style-scope state-modifier">A61K47/22</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/06"><a id="link" href="#" class="style-scope state-modifier">A61K47/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/26"><a id="link" href="#" class="style-scope state-modifier">A61K47/26</a></state-modifier>
                  <span class="description style-scope classification-tree">Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/62"><a id="link" href="#" class="style-scope state-modifier">A61K47/62</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/64"><a id="link" href="#" class="style-scope state-modifier">A61K47/64</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6415"><a id="link" href="#" class="style-scope state-modifier">A61K47/6415</a></state-modifier>
                  <span class="description style-scope classification-tree">Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/62"><a id="link" href="#" class="style-scope state-modifier">A61K47/62</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/64"><a id="link" href="#" class="style-scope state-modifier">A61K47/64</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/646"><a id="link" href="#" class="style-scope state-modifier">A61K47/646</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P31/00"><a id="link" href="#" class="style-scope state-modifier">A61P31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P31/04"><a id="link" href="#" class="style-scope state-modifier">A61P31/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibacterial agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K2039/60"><a id="link" href="#" class="style-scope state-modifier">A61K2039/60</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K2039/6031"><a id="link" href="#" class="style-scope state-modifier">A61K2039/6031</a></state-modifier>
                  <span class="description style-scope classification-tree">Proteins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/6037"><a id="link" href="#" class="style-scope state-modifier">A61K2039/6037</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/70"><a id="link" href="#" class="style-scope state-modifier">A61K2039/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Multivalent vaccine</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02"><a id="link" href="#" class="style-scope state-modifier">Y02</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A"><a id="link" href="#" class="style-scope state-modifier">Y02A</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A50/00"><a id="link" href="#" class="style-scope state-modifier">Y02A50/00</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y02A50/30"><a id="link" href="#" class="style-scope state-modifier">Y02A50/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 12 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">JP2022546763A</h2>
                  <p class="tagline style-scope patent-result">Japan</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Published unexamined patent application (based on international application)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/c8/27/74/d218fd5b7f744c/JP2022546763A.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;polysorbate&quot;,&quot;antigen&quot;,&quot;salmonella enterica&quot;,&quot;enterica serovar&quot;,&quot;sugar&quot;]" data-before="20190903"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/JP2022546763A"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2022546763A/ja"><a id="link" href="#" class="style-scope state-modifier">Japanese</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="デーレー，ラジーブ・ムホーラサカント"><a id="link" href="#" class="style-scope state-modifier">デーレー，ラジーブ・ムホーラサカント</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="ピサール，サンバージー・シャンカル"><a id="link" href="#" class="style-scope state-modifier">ピサール，サンバージー・シャンカル</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="アナムラジュ，ダタトレーヤ・サルマ"><a id="link" href="#" class="style-scope state-modifier">アナムラジュ，ダタトレーヤ・サルマ</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="アバラスカール，ニクヒル・ダタトレー"><a id="link" href="#" class="style-scope state-modifier">アバラスカール，ニクヒル・ダタトレー</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="ハンデカリ，ヨーゲシ・ツカラム"><a id="link" href="#" class="style-scope state-modifier">ハンデカリ，ヨーゲシ・ツカラム</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="タクリカール，アニル・ピラジラオ"><a id="link" href="#" class="style-scope state-modifier">タクリカール，アニル・ピラジラオ</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="ゴエル，スニール・クマール"><a id="link" href="#" class="style-scope state-modifier">ゴエル，スニール・クマール</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="カマット，チャンドラシェーカル・ドワルカナト"><a id="link" href="#" class="style-scope state-modifier">カマット，チャンドラシェーカル・ドワルカナト</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="チャバン，ビシャール・バーラト"><a id="link" href="#" class="style-scope state-modifier">チャバン，ビシャール・バーラト</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JOP20200214A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">JO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JOP/2020/0214A</div>
                <div class="style-scope application-timeline">Filing date: 2019-09-03</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2020</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CR20220132A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CR20220132A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4025246A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP20781107.6A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20230149524A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/753,248</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PE20221442A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PE</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PE2022000363A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BR112022003892A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BR112022003892A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MA56283A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MA56283A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2021044436A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/IN2020/050763</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN114728053A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN202080074655.7A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20220087437A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020227011108A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX2022002693A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2022002693A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2020343943A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2020343943A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3149972A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3149972A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022546763A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2022514468A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/GB2603362A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">GB</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: GB2204276.6A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4249061A3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP23184552.0A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-02</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR119884A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP200102458A</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-03</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2022</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL291006A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL291006A</div>
                <div class="style-scope application-timeline">Filing date: 2022-03-01</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ZA202203368B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">ZA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ZA2022/03368A</div>
                <div class="style-scope application-timeline">Filing date: 2022-03-22</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CO2022003789A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CONC2022/0003789A</div>
                <div class="style-scope application-timeline">Filing date: 2022-03-29</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ECSP22031077A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">EC</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ECSENADI202231077A</div>
                <div class="style-scope application-timeline">Filing date: 2022-04-01</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application JP2022514468A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2020-09-02</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="セラム インスティチュート オブ インディア プライベイト リミテッド"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by セラム インスティチュート オブ インディア プライベイト リミテッド</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2022-11-08</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022546763A/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of JP2022546763A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2023-08-01</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JPWO2021044436A5/ja"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of JPWO2021044436A5</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Pending</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (21)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=JP&amp;NR=2022546763A&amp;KC=A&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/JP/2022546763/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/JP2022546763A">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Japanese</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES349143636" lang="EN" load-source="google" class="style-scope patent-text">
  <technical-field class="style-scope patent-text">
    <p num="0001" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示は、ワクチン製造の分野に関し、より詳細には、本開示は、サルモネラ菌によって引き起こされる感染および非チフス性サルモネラ菌感染に対する予防のための免疫原性組成物、ならびにその調製のための方法に関する。
</span>
  FIELD OF THE DISCLOSURE The present disclosure relates to the field of vaccine production, and more particularly, the present disclosure relates to immunogenic compositions for prophylaxis against infections caused by Salmonella and non-typhoidal Salmonella infections, and methods for their preparation.
</span>
    </p>
  </technical-field>
  <background-art class="style-scope patent-text">
    <p num="0002" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書の以下の背景技術情報は、本開示に関するが、必ずしも先行技術であるとは限らない。<br class="style-scope patent-text">
  サルモネラ菌感染は、依然として、世界全体、特に発展途上国において、毎年数百万人が罹患する重大な健康問題である。サルモネラ菌感染は、腸炎を引き起こすことがあり、これは、正常および免疫不全のいずれの個体においても菌血症（腸熱）および胃腸炎を合併し得る。
</span>The following background information in this specification is related to the present disclosure and is not necessarily prior art.<br class="style-scope patent-text"> Salmonella infections remain a major health problem affecting millions of people each year throughout the world, especially in developing countries. Salmonella infection can cause enteritis, which can be complicated by bacteremia (intestinal fever) and gastroenteritis in both normal and immunocompromised individuals.</span>
    </p>
    <p num="0003" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  サルモネラ属は腸内細菌科に属し、グラム陰性非芽胞形成通性嫌気性桿菌を含む。Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ（Ｓ．ｔｙｐｈｉ）、ならびにＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ（Ｓ．ｐａｒａｔｙｐｈｉ）ＡおよびＢは、他の多数のサルモネラ菌血清型によって引き起こされる、より一般的な自己治癒性の急性胃腸炎とは区別される、ヒトにおいてのみ生じる全身の熱病である腸熱を引き起こす。チフスおよびパラチフスを含むサルモネラ属のメンバーによって引き起こされる腸熱は、発展途上国の人口における重大な疾病および死亡率負荷を構成し続けており（Ｌａｎｃｅｔ  ２００５；３６６：７４９  ７６２）、旅行者の注意すべきリスクを表している（Ｌａｎｃｅｔ  Ｉｎｆｅｃｔ  Ｄｉｓ．２００５：５（１０）：６２３～６２８）。腸チフスは、依然として、低および中所得国（ＬＭＩＣ）における風土病である。毎年１２．５～２０．６百万例の腸熱が、ＬＭＩＣ、特に南アジアおよびサハラ以南アフリカにおいて生じる（Ｌａｎｃｅｔ  Ｇｌｏｂ  Ｈｅａｌ．２０１４；２：ｅ５７０～ｅ５８０およびＪ  Ｇｌｏｂ  Ｈｅａｌｔｈ．２０１２；２：１０４０１）。Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉは、ネパール、カンボジアおよび中国を含むアジアの一部における腸の割合増加の原因である。Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉは、インド亜大陸および東南アジアで最高の負荷を有する。腸チフスが非常に風土性があるネパールにおける研究の１つでは、都市用水がＳ．ｔｙｐｈｉおよびＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａの両方で汚染されていることが見出された（ＰＬｏＳ  Ｎｅｇｌ  Ｔｒｏｐ  Ｄｉｓ．２０１６年１月；１０（１）：ｅ０００４３４６およびＰＬｏＳ  Ｎｅｇｌ  Ｔｒｏｐ  Ｄｉｓ．２０１３；７（８）：ｅ２３９１）。
</span>
  The genus Salmonella belongs to the family Enterobacteriaceae and includes Gram-negative non-sporeforming facultative anaerobic bacilli. Salmonella enterica serovar typhi (S. typhi) and Salmonella enterica serovar paratyphi (S. paratyphi) A and B are distinct from the more common self-healing acute gastroenteritis caused by many other Salmonella serotypes. It causes enteric fever, a systemic fever that occurs only in humans. Enteric fever caused by members of the genus Salmonella, including typhoid and paratyphoid fever, continues to constitute a significant morbidity and mortality burden in the population of developing countries (Lancet 2005;366:749 762) and is a cautionary tale for travelers. (Lancet Infect Dis. 2005:5(10):623-628). Typhoid fever remains endemic in low and middle income countries (LMIC). 12.5-20.6 million cases of enteric fever occur each year in LMIC, especially in South Asia and sub-Saharan Africa (Lancet Glob Heal. 2014;2:e570-e580 and J Glob Health.2012;2:10401). . Salmonella paratyphi is responsible for increased intestinal proportions in parts of Asia, including Nepal, Cambodia and China. Salmonella paratyphi has the highest load in the Indian subcontinent and Southeast Asia. In one study in Nepal, where typhoid fever is highly endemic, municipal water was contaminated with S. cerevisiae. typhi and Salmonella enterica serovar paratyphi A (PLoS Negl Trop Dis. 2016 Jan;10(1):e0004346 and PLoS Negl Trop Dis. 2013;7(8): e2391).
</span>
    </p>
    <p num="0004" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  非チフス性Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ（ＮＴＳ）血清型は、世界的に侵襲性サルモネラ菌疾患の重要な原因である。２，５００種を超えるＮＴＳ血清型のうち、ＮＴＳ血清型ｔｙｐｈｉｍｕｒｉｕｍおよびｅｎｔｅｒｉｔｉｄｉｓは、世界中で報告されたＮＴＳのすべてのヒト単離物の８０パーセント近くを占める。さらに、血清型ｅｎｔｅｒｉｔｉｄｉｓ（ＳＥ）およびｔｙｐｈｉｍｕｒｉｕｍ（ＳＴｍ）によって引き起こされる侵襲性の非チフス性サルモネラ菌（ｉＮＴＳ）感染は、サハラ以南アフリカにおける主要な小児健康問題である。ＮＴＳは、近年、世界的に若年の小児および免疫不全個体、ならびに年配者における侵襲性の細菌感染の主原因として益々認識されるようになっている。これらの２種の血清型はまた、工業先進国の健康な小児および成人における胃腸炎の主原因でもある。ＮＴＳはまた、重度の腸外の侵襲性の菌血症を引き起こすことがあり、これは、ｉＮＴＳと呼ばれる。ｉＮＴＳは、通常、熱病として現れる。実際、ｉＮＴＳは多くの場合、成人および小児の両方において、胃腸管徴候なしに生じる。
</span>
  Nontyphoid Salmonella enterica (NTS) serovars are an important cause of invasive Salmonella disease worldwide. Of the over 2,500 NTS serotypes, NTS serotypes typhimurium and enteritidis account for nearly 80 percent of all reported human isolates of NTS worldwide. In addition, invasive non-typhoid salmonella (iNTS) infections caused by serovars enteritidis (SE) and typhimurium (STm) are a major childhood health problem in sub-Saharan Africa. NTS is increasingly recognized worldwide in recent years as the leading cause of invasive bacterial infections in young children and immunocompromised individuals, as well as in the elderly. These two serotypes are also the leading cause of gastroenteritis in healthy children and adults in industrialized countries. NTS can also cause severe extra-intestinal invasive bacteremia, termed iNTS. iNTS usually presents as a febrile illness. In fact, iNTS often occurs without gastrointestinal symptoms in both adults and children.
</span>
    </p>
    <p num="0005" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２，５００種を超える非チフス血清型のうち、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ亜種ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ（Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ）およびＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ（Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ）は、世界中で報告されたＮＴＳのすべてのヒト単離物の８０パーセント近くを占める。ＮＴＳは、近年、サハラ以南アフリカの若年の小児およびＨＩＶ感染個体、ならびに世界的に年配者および免疫不全個体における侵襲性の細菌感染の主原因として益々認識されるようになっている。
</span>
  Of the more than 2,500 non-typhoid serotypes, Salmonella enterica subsp. enterica serovar typhimurium (S. typhimurium) and Salmonella enterica serovar enteritidis (S. enteritidis) account for all human isolates of NTS reported worldwide. occupy nearly 80% of the In recent years, NTS has become increasingly recognized as a major cause of invasive bacterial infections in young children and HIV-infected individuals in sub-Saharan Africa, and in the elderly and immunocompromised individuals worldwide.
</span>
    </p>
    <p num="0006" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２０１０年のＮＴＳ胃腸炎の世界の発生数は９３百万例と推定され、そのうち約８０．３百万例は、食物媒介性の伝染であり、１５５，０００例の死亡を伴った。ＮＴＳの経済的負担は、先進諸国において莫大である。米国単独では、ＮＴＳは、年間ＵＳ＄３３億の費用がかかり、１７，０００質調整生存年の損失があり、大部分は何らかの食物媒介性の病原体である。既に言及した通り、ＮＴＳはまた、重度の腸外の侵襲性の菌血症を引き起こすことがあり、これは、ｉＮＴＳと呼ばれる。サルモネラ菌の侵襲性の感染は、発展途上諸国全体でより一般的であり、熱帯アフリカにおいて、とりわけ若年の小児およびＨＩＶを有する個体における菌血症の最も一般的な原因になっている。これは、通常、熱病として現れる。実際、ｉＮＴＳは多くの場合、成人および小児の両方において、胃腸管徴候なしに生じる。ｉＮＴＳの徴候は、マラリアと同様であり、発熱および発汗（９０パーセント超）、ならびに脾腫（４０パーセント）を含む。ｉＮＴＳがアフリカにおいてそのように問題である理由は明確ではないが、これは、アフリカで見出され、他所では見出されない、侵襲性の増加したｉＮＴＳ菌の別個の単系統群（例えば、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  ＳＴ３１３）、ＨＩＶ感染、マラリアおよび栄養失調に関連する宿主免疫の低下、ならびに例えば、汚染水の供給によるヒトからヒトへの伝染の機会の増加に関連し得、ＨＩＶに感染したアフリカ人の成人におけるＮＴＳ菌血症は、高死亡率（最大４７パーセント）および再発率（４３パーセント）を伴う。
</span>
  The global incidence of NTS gastroenteritis in 2010 was estimated at 93 million cases, of which approximately 80.3 million were food-borne infections and were associated with 155,000 deaths. The economic burden of NTS is enormous in developed countries. In the United States alone, NTS costs US$3.3 billion annually and causes a loss of 17,000 quality-adjusted life years, mostly some food-borne pathogen. As already mentioned, NTS can also cause severe extra-intestinal invasive bacteremia, termed iNTS. Invasive infections with Salmonella are more common throughout the developing world and are the most common cause of bacteremia in tropical Africa, especially in young children and individuals with HIV. It usually presents as fever. In fact, iNTS often occurs without gastrointestinal symptoms in both adults and children. Symptoms of iNTS are similar to malaria and include fever and sweating (&gt;90 percent) and splenomegaly (40 percent). It is not clear why iNTS is such a problem in Africa, but this may be due to a separate monophyletic group of iNTS bacteria found in Africa and not elsewhere with increased invasiveness (e.g., S. cerevisiae). typhimurium ST313), HIV infection, reduced host immunity associated with malaria and malnutrition, and HIV-infected African adults, which may be associated with an increased chance of human-to-human transmission due to, for example, contaminated water supplies. NTS bacteremia in is associated with high mortality (up to 47 percent) and recurrence rates (43 percent).
</span>
    </p>
    <p num="0007" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  チフス性および非チフス性サルモネラ菌関連感染を処置するために、抗生物質が使用され、抗菌薬の選択および処置の長さは、費用および抗生物質の有効性、抵抗の局所パターンおよび患者の処置応答によって決定される。先進諸国および発展途上諸国の両方において、侵襲性の菌血症および胃腸炎の合併症の重要な原因として複数の抗生物質抵抗性株が出現しており、入院および死亡につながることが益々認識されるようになっている。
</span>
  Antibiotics are used to treat typhoid- and non-typhoid-associated Salmonella-associated infections, the choice of antibiotic and the length of treatment depending on the cost and effectiveness of the antibiotic, the local pattern of resistance and the patient's response to treatment. It is determined. In both developed and developing countries, it is increasingly recognized that multiple antibiotic-resistant strains are emerging as important causes of invasive bacteremia and complications of gastroenteritis, leading to hospitalization and death. It has become so.
</span>
    </p>
    <p num="0008" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  処置に利用可能なツールの有効性が低くなっているため、チフス性および非チフス性サルモネラ菌関連感染の問題は増加し続けているようであり、疾患制御の努力のため、ワクチン開発が重要な優先事項になっている。ワクチンはまた、チフス性および非チフス性サルモネラ菌関連感染が風土病である地区に旅行する人のための重要な防御ツールでもある。
</span>
  The problem of typhoid and non-typhoidal Salmonella-associated infections appears to continue to increase as the tools available for treatment become less effective, making vaccine development an important priority for disease control efforts. has become a matter. Vaccines are also important protective tools for persons traveling to areas where typhoid and non-typhoidal Salmonella-associated infections are endemic.
</span>
    </p>
    <p num="0009" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  現在、ｉ）チフスコンジュゲートワクチン（ＴＣＶ）、ｉｉ）非コンジュゲートＶｉ多糖体（ＶｉＰＳ）ワクチン、およびｉｉｉ）弱毒生Ｔｙ２１ａワクチンの３種類のチフスワクチンが、使用を認可されている。世界保健機関（ＷＨＯ）は、チフスワクチンのさらなる使用を推奨しており、チフスコンジュゲートワクチン（ＴＣＶ）が好ましいとしている（ＷＨＯ  ｐｏｓｉｔｉｏｎ  ｐａｐｅｒ．Ｗｋｌｙ  Ｅｐｉｄｅｍｉｏｌ  Ｒｅｃ  ２０１８；９３：１５３～７２）。
</span>
  Currently, three typhoid vaccines are licensed for use: i) the typhoid conjugate vaccine (TCV), ii) the unconjugated Vi polysaccharide (ViPS) vaccine, and iii) the live attenuated Ty21a vaccine. The World Health Organization (WHO) recommends further use of typhoid vaccines, with typhoid conjugate vaccines (TCV) being preferred (WHO position paper. Wkly Epidemiol Rec 2018;93:153-72).
</span>
    </p>
    <p num="0010" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｓ．ｐａｒａｔｙｐｈｉ用のワクチンは、現在、入手できない。同様に、チフス性および非チフス性サルモネラ菌に対する免疫を同時に付与することができる免疫原性組成物／ワクチンへのニーズが存在している。
</span>
  S. No vaccine for paratyphi is currently available. Similarly, there is a need for an immunogenic composition/vaccine that can simultaneously confer immunity against typhoid and non-typhoidal Salmonella.
</span>
    </p>
    <p num="0011" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  現在利用可能なワクチンの欠点は、それらがいずれも、Ｓ．ｔｙｐｈｉのみを対象としていることである。Ｓ．ｐａｒａｔｙｐｈｉ  Ａは、Ｓ．ｔｙｐｈｉと同じ地理的分布で腸熱を引き起こし、これらの疾患は、臨床的に区別できない。したがって、南および東南アジアにおいて、両方の血清型に対して防御できるワクチンは、１種に制限されるワクチンよりも価値があると考えられる。また、サハラ以南アフリカにおいて、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓについて同じことがあてはまり、これは、この地域に関して、ＮＴＳ血清型に対してさらに防御できるワクチンの重要性を示している。
</span>
  A drawback of the currently available vaccines is that they all cause S. cerevisiae. It is intended only for typhi. S. paratyphi A is S. paratyphi A. typhi, causing enteric fever with the same geographical distribution, these diseases are clinically indistinguishable. Therefore, in South and Southeast Asia, a vaccine that can protect against both serotypes would be more valuable than a vaccine that is restricted to one. Also in sub-Saharan Africa, S. typhimurium and S. The same is true for S. enteritidis, which indicates the importance of a vaccine that can further protect against NTS serotypes for this region.
</span>
    </p>
    <p num="0012" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  パイプライン中のワクチン候補薬が、胃腸炎およびｉＮＴＳの侵襲性の症状の両方に対して防御性であるかは不明である。ＬＭＩＣにおけるチフスの疾病負荷への理解が深まる一方、チフス性および非チフス性サルモネラ菌感染に対して防御するコンジュゲートワクチンへの世界的医療需要は重要性を増している。チフスコンジュゲートワクチンへの需要のピークはおそらく２０２３～２０２６年に生じ、１３３カ国で年間３００百万用量にせまると推定されている（Ｃｌｉｎ  Ｉｎｆｅｃｔ  Ｄｉｓ．２０１９年３月１５日；６８（補遺２）：Ｓ１５４～Ｓ１６０）。
</span>
  It is unclear whether vaccine candidates in the pipeline are protective against both gastroenteritis and aggressive manifestations of iNTS. While the typhoid disease burden in LMIC is better understood, the global medical need for conjugate vaccines that protect against typhoid and non-typhoid Salmonella infections is of increasing importance. It is estimated that peak demand for typhoid conjugate vaccines will likely occur in 2023-2026, approaching 300 million doses per year in 133 countries (Clin Infect Dis. 15 March 2019; 68 (supplement 2)). : S154 to S160).
</span>
    </p>
    <p num="0013" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、上流、下流、コンジュゲーションおよび製剤開発は、多くの場合、市場への生物製剤の早期導入および人口の需要との合致において律速段階になり得る。上流には、初期細胞単離および培養から、細胞バンキング、細菌発酵プロセスの培養増殖および最終収穫までの全プロセスが含まれる。細胞培養は、１００～５００ミリリットルから、３～２０，０００リットルのバイオリアクターに規模拡大される。さらなるステップには、サルモネラ菌多糖体の一次回収、ならびに細胞および破片の除去が含まれる。さらに、費用効果的なサルモネラ菌多糖体に基づくコンジュゲートワクチン開発を促進するためには、構造的にインタクトな多糖体を高収率および高純度で得る必要がある。４０％未満の収率が、サルモネラ属菌種多糖体に関して以前に報告されている。新規の供給方策および改善された発酵媒体を用いることによって莢膜多糖体（ＣＰＳ）「発酵収穫段階収率」を増加させることは、前記目的を実現するための好ましい手法の１つである。Ｍｅｒｒｉｔｔら（２０００）は、５００リットル製造規模バイオリアクターでの流加培養により、バッチ培養と比較した場合およそ４倍、細胞密度および莢膜多糖体の収率が増加したことを示した。
</span>
  Additionally, upstream, downstream, conjugation and formulation development can often be rate limiting steps in the early introduction of biologics to the market and meeting population demand. Upstream includes the entire process from initial cell isolation and culture to cell banking, culture growth and final harvesting of the bacterial fermentation process. Cell cultures are scaled from 100-500 milliliters to 3-20,000 liter bioreactors. Further steps include primary recovery of Salmonella polysaccharide and removal of cells and debris. Furthermore, to facilitate the development of cost-effective Salmonella polysaccharide-based conjugate vaccines, there is a need to obtain structurally intact polysaccharides in high yield and purity. Yields of less than 40% have been previously reported for Salmonella spp. polysaccharides. Increasing the capsular polysaccharide (CPS) "fermentation harvest stage yield" by using novel feeding strategies and improved fermentation media is one of the preferred approaches to achieve the above objectives. Merritt et al. (2000) showed that fed-batch culture in a 500 liter production scale bioreactor increased cell density and yield of capsular polysaccharide by approximately 4-fold when compared to batch culture.
</span>
    </p>
    <p num="0014" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  他の病原菌、例えば、Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  Ｂ型およびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓによる莢膜多糖体産生の研究は、産生が発酵条件（温度、ｐＨ、ＤＯ、浸透圧）および培地成分に依存し、これらの最適条件は、それぞれの細菌で異なったことを示した。Ｚｈａｎら（２００２）は同様に、ｐＨ制御および流加発酵への変更により、細胞の収率および莢膜多糖体の産生が増加したことを示した。
</span>
  Studies of capsular polysaccharide production by other pathogens, such as Haemophilus influenzae type B and Neisseria meningitidis, show that production depends on fermentation conditions (temperature, pH, DO, osmolarity) and media components, the optimum conditions of which are: It showed that each bacterium was different. Zhan et al. (2002) similarly showed that pH control and changes to fed-batch fermentation increased cell yield and capsular polysaccharide production.
</span>
    </p>
    <p num="0015" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  莢膜多糖体の発現は、浸透圧などの特定の発酵条件に関連して高度に調節され、浸透圧が高い場合、多糖体の合成の減少が報告されている。<br class="style-scope patent-text">
  多糖体は、グルコース、カザミノ酸およびリン酸イオンの様々な濃度下で産生された。
</span>Expression of capsular polysaccharides is highly regulated in relation to certain fermentation conditions such as osmotic pressure, and a decrease in polysaccharide synthesis has been reported when osmotic pressure is high.<br class="style-scope patent-text"> Polysaccharides were produced under various concentrations of glucose, casamino acids and phosphate ions.</span>
    </p>
    <p num="0016" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｂａｒｕｑｕｅ－Ｒａｍｏｓら、２００５は、Ｎ．Ｍｅｎｉｎｇｉｔｉｄｉｓ（血清群Ｃ）を培地中で培養し、グルコース濃度を１．０ｇ／ｌ未満に維持した場合、より高い収率の莢膜多糖体が得られたこと、および低酸素分圧がより高い多糖体産生に好ましいことを示した。さらに、供給溶液中の濃カザミノ酸により最終細胞密度が制限されることが観察された。さらに、特定培地中での増殖および多糖体収率はまた、炭水化物対窒素源の比に依存する。Ｓ．ｔｙｐｈｉの流加発酵法の１つでは、アンモニアが、流加培地と共に窒素源として供給された。しかしながら、Ａｕｒｅｏｂａｓｉｄｉｕｍ  ｐｕｌｌｕｌａｎｓによる多糖体形成は、培地中のアンモニア窒素源により影響を受け、過剰なアンモニウムイオンが存在した場合、それ以外がその合成を支持する条件下であってさえ、その収率が低下したことが観察された（Ａｐｐｌ  Ｍｉｃｒｏｂｉｏｌ  Ｂｉｏｔｅｃｈｎｏｌ（１９９０）３２：６３７～６４４）。
</span>
  Baruque-Ramos et al., 2005, N.W. Meningitidis (serogroup C) was cultured in medium and the glucose concentration was maintained below 1.0 g/l resulting in higher yields of capsular polysaccharide and higher hypoxia It was shown to be favorable for polysaccharide production. Furthermore, it was observed that the concentration of casamino acids in the feed solution limited the final cell density. In addition, growth and polysaccharide yield in specific media also depend on the ratio of carbohydrate to nitrogen source. S. In one fed-batch fermentation method of typhi, ammonia was supplied as a nitrogen source along with the feed medium. However, polysaccharide formation by Aureobasidium pullulans is affected by ammonia nitrogen sources in the medium, and the presence of excess ammonium ions reduces its yield, even under conditions otherwise favoring its synthesis. (Appl Microbiol Biotechnol (1990) 32:637-644).
</span>
    </p>
    <p num="0017" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  特定培地中での増殖および多糖体合成は、窒素源としてアンモニアに代えてアミノ酸が用いられた場合に最大であった。<br class="style-scope patent-text">
  特定培地中の窒素源として、カザミノ酸の使用が報告されている。しかしながら、ウシカゼイン由来である可能性が最も高い動物由来のカザミノ酸は、アレルゲンとして報告されており、使用が制限される。さらに、特定培地中の窒素源としてカゼイン消化物／トリプトン培地の使用が報告されているが、これは、選好性生物の増殖を支持しない場合がある。
</span>Growth and polysaccharide synthesis in defined media were greatest when amino acids were used instead of ammonia as the nitrogen source.<br class="style-scope patent-text"> The use of casamino acids as nitrogen sources in specific media has been reported. However, casamino acids of animal origin, most likely derived from bovine casein, have been reported as allergens, limiting their use. Additionally, the use of casein digest/tryptone media as a nitrogen source in defined media has been reported, but this may not support the growth of fastidious organisms.</span>
    </p>
    <p num="0018" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  化学的特定培地への動物成分不含加水分解物（Ｂａｃｔｏ  ＴＣ  Ｙｅａｓｔｏｌａｔｅ、Ｐｈｙｔｏｎｅ  Ｐｅｐｔｏｎｅ）の添加は、細胞密度、培養生存率および生産性を適時に増加させる手法の１つである。加水分解物は、培地に栄養補助をもたらすアミノ酸、小ペプチド、炭水化物、ビタミンおよびミネラルで構成されるタンパク質消化物である。大豆、小麦および酵母からの非動物由来の加水分解物は、細胞培養培地において一般に使用され、多糖体収率を改善するために供給される（ＵＳ９２８４３７１参照）。しかしながら、その組成が複雑であるために、ロット毎のばらつき、培地を粘性にする望ましくないはたらきによって、酵母抽出物および加水分解物が、培地変動の大きな原因になり得る。大規模発酵の間の泡の形成は、ｉ）泡相への細胞および培養培地の損失に起因して莢膜多糖体収率を低下させ得、ｉｉ）泡がはじけるとせん断力が生じるため細胞に悪影響であり得、ｉｉｉ）結果として、泡がなくなると無菌状態が損なわれ、ｉｖ）発泡により出口フィルターが詰まった場合、加圧につながり得る。
</span>
  Addition of animal component-free hydrolysates (Bacto TC Yeastolate, Phytone Peptone) to chemically defined media is one approach to timely increase cell density, culture viability and productivity. Hydrolysates are protein digests composed of amino acids, small peptides, carbohydrates, vitamins and minerals that provide nutritional support to the medium. Non-animal derived hydrolysates from soybeans, wheat and yeast are commonly used in cell culture media to provide improved polysaccharide yields (see US9284371). However, due to the complexity of their composition, lot-to-lot variability, yeast extracts and hydrolysates can be a significant source of medium variability due to their undesirable tendency to make the medium viscous. The formation of foam during large scale fermentation can i) reduce capsular polysaccharide yield due to loss of cells and culture medium to the foam phase, and ii) cells due to shear forces generated when the foam pops. iii) as a result, loss of foam can compromise sterility, and iv) if foam plugs the outlet filter, it can lead to pressurization.
</span>
    </p>
    <p num="0019" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  発酵細胞上清は、精製の様々なステップにかけられて、精製多糖体が単離され、タンパク質、核酸およびリポ多糖などの宿主細胞不純物が除去される。ろ過技術は、下流の処理または宿主細胞不純物からの細菌多糖体の精製において重要な役割を果たす。下流は、細菌培養物の不活化、培地からの細胞の分離、生成物の単離、濃縮、精製を含む。下流の処理は、複雑であるために、プロセスの最も課題となる部分である。
</span>
  Fermentation cell supernatants are subjected to various steps of purification to isolate purified polysaccharides and to remove host cell impurities such as proteins, nucleic acids and lipopolysaccharides. Filtration technology plays an important role in downstream processing or purification of bacterial polysaccharides from host cell impurities. Downstream includes inactivation of bacterial cultures, separation of cells from culture medium, product isolation, concentration and purification. Downstream processing is the most challenging part of the process due to its complexity.
</span>
    </p>
    <p num="0020" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  それぞれの細菌は、同じ細菌の異なる莢膜多糖体および異なる血清型を有し、細菌莢膜多糖体の化学構造がさらに異なる。適切な場合は、Ｓ．ｔｙｐｈｉが、Ｃ－２でＮアセチル化され、Ｃ－３でＯアセチル化されたα（１－４）－Ｄ－ＧａｌｐＡの直鎖状ホモポリマーであるＶｉ多糖体カプセルを発現する場合である。ＮおよびＯアセチルは表面を占め、Ｖｉの抗原性および免疫原性の両方に必須である一方、反対に、Ｓ．ｐａｒａｔｙｐｈｉ  ＡおよびＢ、ならびにＮＴＳ（まれに例外がある）は、莢膜多糖体を発現しない。むしろ、それらの表面多糖体は、リポ多糖のＯ多糖体（ＯＰＳ）である。それらは、一般的な三糖主鎖→２）－α－Ｄ－Ｍａｎｐ－（１→４）－α－Ｌ－Ｒｈａｐ－（１→３）－α－Ｄ－Ｇａｌｐ－（１→）（これは血清学的にエピトープ１２を構成する）を共有する。しかしながら、反復三糖のマンノースでα－（３→６）に結合したジデオキシヘキソース糖の結果、サルモネル群に特性を付与する免疫優性エピトープが生じる。Ｓ．ｔｙｐｈｉｍｕｒｉｕｍの場合、三糖主鎖エピトープ１２のガラクトースは、α－（１→６）グルコシル化されることになる。（参照：Ｌｉｎｄｂｅｒｇ  ＡＡ、Ｌｅ  Ｍｉｎｏｒ  Ｌ．Ｓｅｒｏｌｏｇｙ  ｏｆ  Ｓａｌｍｏｎｅｌｌａ：Ｂｅｒｇａｎ  Ｔ編、Ｍｅｔｈｏｄｓ  ｉｎ  Ｍｉｃｒｏｂｉｏｌｏｇｙ：Ａｃａｄｅｍｉｃ  Ｐｒｅｓｓ、１９８４：１～１４１）。
</span>
  Each bacterium has a different capsular polysaccharide and a different serotype of the same bacterium, further differing in the chemical structure of the bacterial capsular polysaccharide. If appropriate, S.M. typhi express the Vi polysaccharide capsule, a linear homopolymer of α(1-4)-D-GalpA N-acetylated at C-2 and O-acetylated at C-3. N and O acetyl occupy the surface and are essential for both Vi antigenicity and immunogenicity, whereas S. paratyphi A and B, and NTS (with rare exceptions) do not express capsular polysaccharide. Rather, their surface polysaccharides are lipopolysaccharide O-polysaccharides (OPS). They have a general trisaccharide backbone→2)-α-D-Manp-(1→4)-α-L-Rhap-(1→3)-α-D-Galp-(1→) (which constitute epitope 12 serologically). However, the dideoxyhexose sugar linked to α-(3→6) at the mannose of the repeating trisaccharide results in an immunodominant epitope that confers the properties of the Salmonel group. S. typhimurium, the galactose of the trisaccharide backbone epitope 12 will be α-(1→6) glucosylated. (See: Lindberg AA, Le Minor L. Serology of Salmonella: Bergan T, ed., Methods in Microbiology: Academic Press, 1984:1-141).
</span>
    </p>
    <p num="0021" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  細菌多糖体構造のこの多様性により、これらの多糖体の精製はより課題となり、困難になる。多糖体を含むワクチンは、特定の品質基準を満たす必要がある。<br class="style-scope patent-text">
  大規模容積で実施可能なこれまでの精製方法には、溶媒を使用し、ｐＨを操作し、デオキシコール酸ナトリウム、Ｔｒｉｔｏｎ－Ｘなどの洗剤を使用した、核酸および脂質などの不純物の溶解および沈殿が含まれる。
</span>This diversity of bacterial polysaccharide structures makes the purification of these polysaccharides more challenging and difficult. Vaccines containing polysaccharides must meet certain quality standards.<br class="style-scope patent-text"> Previous purification methods that can be performed in large volumes include the use of solvents, manipulation of pH, and the use of detergents such as sodium deoxycholate, Triton-X to dissolve and precipitate impurities such as nucleic acids and lipids. is included.</span>
    </p>
    <p num="0022" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  デオキシコール酸ナトリウム（ＤＯＣ）は、低刺激性の洗剤であり、多糖体精製に最も一般的に使用される洗剤の１つである。コアステロイド構造を有するデオキシコール酸ナトリウムは、変性しにくく、その可溶化強度は限られており、それは、化学構造に影響することなくエンドトキシンを破壊し、したがって、デオキシコール酸ナトリウムの除去の際、エンドトキシンはその生物活性を取り戻す。また、ＤＯＣに基づく手順は、多糖体、とりわけシアル酸含有多糖体からの夾雑物の除去に効果的に作用しない。これは、下流の処理の間に形成されるリポ多糖－タンパク質結合に対するＤＯＣの弱い洗剤活性に起因し得、最終単離多糖体における高レベルのエンドトキシンおよびタンパク質含有量につながる。さらに、デオキシコール酸ナトリウムは動物由来生成物であり、最終生成物中のその残留量の存在でさえ、規制当局および特定の宗教共同体により許容されない生成物になることがある。
</span>
  Sodium deoxycholate (DOC) is a mild detergent and one of the most commonly used detergents for polysaccharide purification. Sodium deoxycholate, which has a core steroid structure, is difficult to denature and its solubilizing strength is limited, it destroys endotoxins without affecting the chemical structure, thus upon removal of sodium deoxycholate, Endotoxin regains its biological activity. Also, DOC-based procedures do not work effectively to remove contaminants from polysaccharides, especially sialic acid-containing polysaccharides. This may be due to the weak detergent activity of DOC on lipopolysaccharide-protein bonds formed during downstream processing, leading to high levels of endotoxin and protein content in the final isolated polysaccharide. Additionally, sodium deoxycholate is an animal-derived product and even the presence of residual amounts thereof in the final product may result in an unacceptable product by regulatory authorities and certain religious communities.
</span>
    </p>
    <p num="0023" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｔｒｉｔｏｎ－Ｘの使用の不利点は、抽出相に残留洗剤が残存し、除去には、すべての残留物を除去するための膨大な洗浄が必要なことである。<br class="style-scope patent-text">
  一部のＣＰＳ型では、タンパク質夾雑物の除去のための酢酸亜鉛／硫酸アンモニウム／クエン酸ナトリウムによる沈殿も含まれる。しかしながら、高レベルの純度に到達させるためには、繰り返し硫酸アンモニウム沈殿を実施する必要があり、プロセスがより煩雑で労働集約的になる。さらに、時折、これにより莢膜多糖体も沈殿し、総多糖体の損失につながる。
</span>A disadvantage of using Triton-X is that residual detergent remains in the extraction phase and removal requires extensive washing to remove all residue.<br class="style-scope patent-text"> Some CPS types also include precipitation with zinc acetate/ammonium sulfate/sodium citrate to remove protein contaminants. However, in order to reach high levels of purity, repeated ammonium sulfate precipitations have to be performed, making the process more cumbersome and labor intensive. In addition, sometimes this also precipitates the capsular polysaccharide, leading to a loss of total polysaccharide.</span>
    </p>
    <p num="0024" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  いくつかの他の方法は酵素を使用しており、酵素は、タンパク質および核酸夾雑物の分解を助けるが、しかしながら、酵素および加水分解材料の除去は、圧倒されるような作業であり、目的の生成物の損失につながることがある。さらに、規制当局は、プリオンの夾雑のリスクのために、ヒト向けの製品における動物酵素の使用を制限している。酵素の利用は、高コストであることの他、ｃＧＭＰフレームワークにより多くの規制問題、例えば、酵素の由来（動物または組換え）、異なるベンダーおよびロット間での酵素活性のばらつきなどを導入する。
</span>
  Some other methods use enzymes, which aid in the breakdown of protein and nucleic acid contaminants, however, removal of enzymes and hydrolysed materials can be a daunting task and is not desirable. May lead to loss of product. In addition, regulatory agencies limit the use of animal enzymes in human products due to the risk of prion contamination. In addition to being expensive, the use of enzymes introduces more regulatory issues into the cGMP framework, such as enzyme origin (animal or recombinant), variability in enzyme activity between different vendors and lots.
</span>
    </p>
    <p num="0025" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  いくつかの他の方法は、残留タンパク質および／または核酸材料の分解のためのＢｅｎｚｏｎａｓｅ、Ｐｒｏｔｅｉｎａｓｅ  ＫまたはＮａｒｇａｓｅに続いて、クロマトグラフィー精製を使用し、その結果、コストが高くなり、プロセスは容易には大規模化できなくなる。
</span>
  Some other methods use Benzonase, Proteinase K or Nargase for degradation of residual protein and/or nucleic acid material, followed by chromatographic purification, resulting in higher costs and easier processes. cannot be scaled up.
</span>
    </p>
    <p num="0026" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  いくつかの他の方法は、細菌多糖体のエンドトキシンの分離のために、フェノール、ブタノール、トルエンおよびクロロホルムのような毒性有機溶媒を使用する。この方法は、費用および時間がかかる。さらに、毒性廃棄物を生成する毒性有機溶媒を用いた作業は望ましくない。
</span>
  Some other methods use toxic organic solvents such as phenol, butanol, toluene and chloroform for endotoxin separation of bacterial polysaccharides. This method is expensive and time consuming. Furthermore, working with toxic organic solvents that produce toxic waste is undesirable.
</span>
    </p>
    <p num="0027" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ワクチンに特異的な多糖体には高純度が必要とされるため、分別沈殿、イオン交換クロマトグラフィー、ゲルろ過および親和性クロマトグラフィーに基づく新しい精製方法の開発につながった。サイズ排除クロマトグラフィー、イオン交換クロマトグラフィーおよび疎水性相互作用クロマトグラフィーのようなクロマトグラフィー技術は、タンパク質および核酸夾雑物の効果的な除去による細菌多糖体の単離のために成功裡に使用された。ＷＨＯ基準書による細菌多糖体の単離の成功にも関わらず、クロマトグラフィー技術の使用は、複数工程の労力および時間のかかる試料調製を含み、大規模化の問題を含み、莢膜多糖体の回収率が劇的に損なわれ、したがって、工業規模での下流の処理のための低コストの選択肢には適さない。さらに、これらの夾雑物を除去するための新しい精製ステップの追加により、プロセスの複雑さが増加し、最終収率が低下し、経済コストが増加する。
</span>
  The need for high purity of vaccine-specific polysaccharides has led to the development of new purification methods based on fractional precipitation, ion exchange chromatography, gel filtration and affinity chromatography. Chromatographic techniques such as size exclusion chromatography, ion exchange chromatography and hydrophobic interaction chromatography have been successfully used for the isolation of bacterial polysaccharides with effective removal of protein and nucleic acid contaminants. . Despite the success of isolating bacterial polysaccharides according to the WHO standards, the use of chromatographic techniques involves multiple steps of laborious and time-consuming sample preparation, involves scale-up problems, and is associated with large-scale isolation of capsular polysaccharides. Recovery is dramatically compromised and thus not suitable as a low cost option for downstream processing on an industrial scale. Furthermore, the addition of new purification steps to remove these contaminants increases process complexity, lowers final yields, and increases economic costs.
</span>
    </p>
    <p num="0028" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以前に報告された精製プロセスによって得られたＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ精製多糖体は、２５～５０ＥＵ／μｇのエンドトキシン含有量を有する。<br class="style-scope patent-text">
  したがって、サルモネラ菌多糖体の回収率を最大にする一方、不純物を許容されるレベルまで除去することを目的とした代替の精製方法論のニーズが存在する。
</span>Salmonella typhi purified polysaccharides obtained by previously reported purification processes have an endotoxin content of 25-50 EU/μg.<br class="style-scope patent-text"> Therefore, there is a need for alternative purification methodologies aimed at maximizing the recovery of Salmonella polysaccharide while removing impurities to acceptable levels.</span>
    </p>
    <p num="0029" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  酸加水分解、アルカリ分解、過ヨウ素酸による酸化、オゾン分解（Ｗａｎｇら、Ｃａｒｂ．  Ｒｅｓ．１９９９、３１９、１～４、１４１～１４７）、酵素加水分解、超音波処理（Ｐａｗｌｏｗｓｋｉら、Ｖａｃｃｉｎｅ、２０００、１８．１８、１８７３～１８８５）、電子ビーム断片化（Ｐａｗｌｏｗｓｋｉら、Ｍｉｃｒｏ  Ｌｅｔｔ、１９９９、１７４．２、２５５～２６３）などの様々な方法が、細菌および非細菌多糖体の解重合（サイジング）のために記載されている。しかしながら、酸加水分解およびアルカリ分解は、時間がかかり、得られるサイズが低減された試料は、高多分散性を有する。また、過ヨウ素酸による酸化は、一部の多糖体の不安定な抗原エピトープに対して有害効果を有する。さらに、オゾン分解は、β－Ｄ－アルドシド結合を含有する多糖体でのみ使用でき、今日までに単離されたエンドグリカナーゼはごくわずかである。ＵＳ２００９００４１８０２は、Ｅｍｕｌｓｉｆｌｅｘ  Ｃ－５０（従来のホモジナイザー）（Ａｖｅｓｔｉｎ）による髄膜炎菌多糖体の断片化を開示している。しかしながら、従来のホモジナイザーは、各サイクルのわずかな瞬間（およそ７％）についてピーク圧力で動作し、ばらつきがより幅広くなり、生成物の安定性が低くなり、必要とされるはずのものよりも多くの回数実行するか、またはより高い圧力を使用する必要がある。
</span>
  acid hydrolysis, alkaline hydrolysis, periodate oxidation, ozonolysis (Wang et al., Carb. Res. 1999, 319, 1-4, 141-147), enzymatic hydrolysis, sonication (Pawlowski et al., Vaccine, 2000 , 18.18, 1873-1885), electron beam fragmentation (Pawlowski et al., Micro Lett, 1999, 174.2, 255-263) are used for the depolymerization (sizing) of bacterial and non-bacterial polysaccharides. listed for However, acid hydrolysis and alkaline degradation are time consuming and the resulting size-reduced samples have high polydispersities. Oxidation by periodic acid also has detrimental effects on labile antigenic epitopes on some polysaccharides. Furthermore, ozonolysis can only be used with polysaccharides containing β-D-aldosidic linkages, and very few endoglycanases have been isolated to date. US20090041802 discloses fragmentation of meningococcal polysaccharides with an Emulsiflex C-50 (conventional homogenizer) (Avestin). However, conventional homogenizers operate at peak pressure for a fraction of the time (approximately 7%) of each cycle, leading to wider variability, less product stability, and more number of times or use a higher pressure.
</span>
    </p>
    <p num="0030" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  超音波による処理は、多糖体を解重合するために使用されている（例えば、ＷＯ２０１０／０５５２５０を参照されたい）。しかしながら、超音波解重合法は、低効率であるため、大量の多糖体の工業解重合には適さない。
</span>
  Treatment with ultrasound has been used to depolymerize polysaccharides (see, eg, WO2010/055250). However, the ultrasonic depolymerization method is not suitable for industrial depolymerization of large amounts of polysaccharides due to its low efficiency.
</span>
    </p>
    <p num="0031" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＵＳ２００９０２３４１０８は、炭酸ナトリウム緩衝液（ｐＨ９．０）を用いた化学処理による肺炎球菌血清型１多糖体の部分的脱アセチル化の方法を記載している。この方法は、時間がかかり、免疫原性部分を破壊しやすく、これはコンジュゲートの免疫原性に影響し得る。
</span>
  US20090234108 describes a method for partial deacetylation of pneumococcal serotype 1 polysaccharide by chemical treatment with sodium carbonate buffer (pH 9.0). This method is time consuming and prone to destroying immunogenic moieties, which can affect the immunogenicity of the conjugate.
</span>
    </p>
    <p num="0032" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  上で述べたすべての理由で、多糖体または多糖誘導体の解重合のための単純で低コストの方法が、当技術分野においてなお望まれている。<br class="style-scope patent-text">
  多糖－タンパク質コンジュゲートワクチンを製造することは、コンジュゲーションプロセスに関与する特定の担体タンパク質および天然多糖に特異的である。
</span>For all the reasons mentioned above, a simple and low-cost method for the depolymerization of polysaccharides or polysaccharide derivatives is still desired in the art.<br class="style-scope patent-text"> The production of polysaccharide-protein conjugate vaccines is specific to the particular carrier protein and native polysaccharide involved in the conjugation process.</span>
    </p>
    <p num="0033" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  様々なコンジュゲーション技術が、当技術分野で公知である。コンジュゲートは、ＴＳＴＵ、１－シアノ－４－ジメチルアミノピリジニウムテトラフルオロボレート（ＣＤＡＰ）コンジュゲーション化学を使用して、直接還元的アミノ化法、カルボジイミドコンジュゲーション化学、ヒドラジド、活性エステル、ノルボラン（ｎｏｒｂｏｒａｎｅ）、ｐ－ニトロ安息香酸、Ｎ－ヒドロキシスクシンイミド、Ｓ－ＮＨＳ、ＥＤＣによって調製できる。
</span>
  Various conjugation techniques are known in the art. Conjugation was performed using TSTU, 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) conjugation chemistry, direct reductive amination methods, carbodiimide conjugation chemistry, hydrazides, active esters, norborane , p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC.
</span>
    </p>
    <p num="0034" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  活性化多糖体は、直接またはスペーサー（リンカー）基を介して担体タンパク質のアミノ基にカップリングされる。先行技術において開示されるコンジュゲーションに使用されるリンカーは、Ｎ－スクシンイミジル－３－（２－ピリジルジチオ）プロピオネート（ＳＰＤＰ）（ＳＺＵら；１９８７）である。他のリンカー、Ｂ－プロピオンアミド（ＷＯ００／１０５９９）、ニトロフェニル－エチルアミン（Ｇｅｖｅｒら（１９７９）Ｍｅｄ  Ｍｉｃｒｏｂｉｏｌ  Ｉｍｍｕｎｏｌ  １６５；１７１～２８８）、ハロゲン化ハロアルキル（米国特許第４，０５７，６８５号）、グリコシド結合（米国特許第４，６７３，５７４号）、ヘキサンジアミンおよび６－アミノカプロン酸（米国特許第４，４５９，２８６号）。Ｍａｒｂｕｒｇら、Ｊ．Ａｍ．Ｃｈｅｍ．Ｓｏｃ．、１０８、５２８２（１９８６）は、二遺伝子スペーサーによる多糖体および免疫原性タンパク質のコンジュゲートの１つの方法を開示した。タンパク質（ＰＲＯ）は、ペンダント求核性または求電子性基を示すように誘導体化され（ＰＲＯ<sup class="style-scope patent-text">＊</sup>）、一方、パートナー多糖体（Ｐｓ）は、反対の反応性のペンダント基を示すように官能化された（Ｐｓ<sup class="style-scope patent-text">＊</sup>）。Ｐｓ<sup class="style-scope patent-text">＊</sup>をＰＲＯ<sup class="style-scope patent-text">＊</sup>と組み合わせる際、ＰｓをＰＲＯに（Ｐｓ－ＰＲＯ）共有結合させる二遺伝子スペーサーが形成された。酸加水分解の際、二遺伝子スペーサー（リンカー）は、通常ではないアミノ酸として放出され、アミノ酸分析により定量化され、これによって、共有結合能を証明する手段が提供される。
</span>The activated polysaccharide is coupled to amino groups of the carrier protein either directly or via a spacer (linker) group. A linker used for conjugation disclosed in the prior art is N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (SZU et al.; 1987). Other linkers, B-propionamide (WO00/10599), nitrophenyl-ethylamine (Gever et al. (1979) Med Microbiol Immunol 165; 171-288), haloalkyl halides (US Pat. No. 4,057,685), glycosides conjugates (US Pat. No. 4,673,574), hexanediamine and 6-aminocaproic acid (US Pat. No. 4,459,286). Marburg et al., J. Am. Am. Chem. Soc. , 108, 5282 (1986) disclosed one method of conjugation of a polysaccharide and an immunogenic protein via a bigenic spacer. The protein (PRO) is derivatized (PRO <sup class="style-scope patent-text">*</sup> ) to exhibit pendant nucleophilic or electrophilic groups, while the partner polysaccharide (Ps) is functionalized to exhibit pendant groups of opposite reactivity. (Ps <sup class="style-scope patent-text">*</sup> ). When Ps <sup class="style-scope patent-text">*</sup> was combined with PRO <sup class="style-scope patent-text">*</sup> , a bigenic spacer was formed covalently linking Ps to PRO (Ps-PRO). Upon acid hydrolysis, the bigenic spacer (linker) is released as an unusual amino acid and quantified by amino acid analysis, providing a means of demonstrating covalent binding capacity.</span>
    </p>
    <p num="0035" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  多糖体－タンパク質コンジュゲートワクチンの多糖体成分は、コンジュゲートの種類、製剤成分および保存条件に依存した速度でのゆるやかな解重合を受ける。これは、生成物の安定性に悪影響を及ぼし得る遊離多糖体の増加につながる。多糖体－担体タンパク質コンジュゲートは、コンジュゲーション後、さらなる処理、凍結乾燥または液体および固体製剤中での保存の間、遊離多糖体を放出することが公知である。担体タンパク質に共有結合したサルモネラ菌多糖体（すなわち、コンジュゲート多糖体）のみが、臨床防御のために免疫学的に重要であり、過剰なレベルの非結合多糖体は、潜在的に多糖体への免疫反応低下をもたらし得る（ＷＨＯ／ＴＲＳ／９２４  頁番号１４、Ａ．３．３．５参照）。特に、文献で報告されたＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉコンジュゲートは、最大３４％の高い遊離多糖体含有量および５％を超える高い遊離タンパク質含有量を有し、これは、より低いコンジュゲーション効率およびコンジュゲートのより低い安定性を示し、これは望ましくない。したがって、１０％未満の遊離多糖体含有量を示すワクチンへのニーズが存在する。
</span>
  The polysaccharide component of polysaccharide-protein conjugate vaccines undergoes slow depolymerization at a rate that depends on the type of conjugate, formulation components and storage conditions. This leads to an increase in free polysaccharide that can adversely affect product stability. Polysaccharide-carrier protein conjugates are known to release free polysaccharide after conjugation during further processing, lyophilization or storage in liquid and solid formulations. Only Salmonella polysaccharides covalently attached to a carrier protein (i.e., conjugated polysaccharides) are immunologically important for clinical protection, and excessive levels of unconjugated polysaccharides potentially compromise the polysaccharide. It can lead to decreased immune response (see WHO/TRS/924 p.14, A.3.3.5). In particular, the Salmonella typhi conjugates reported in the literature have high free polysaccharide contents of up to 34% and high free protein contents of over 5%, which is due to lower conjugation efficiencies and more It exhibits low stability, which is undesirable. Therefore, there is a need for vaccines that exhibit less than 10% free polysaccharide content.
</span>
    </p>
    <p num="0036" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実際、すべてのワクチン候補薬を製造および製剤化するために用いることができる総括的プロセスを有することが可能であったなら、プロセス開発に必要な時間および資源は大幅に削減されるであろう。これは、臨床試験に導入され得る臨床候補薬の数に大きな影響を与え得る。また、プラットフォームを使用して開発されたものを含む初期段階臨床試験のために開発されたプロセスは、プロセスの経済性、収率、プール容積およびスループットに関して最適ではない場合があり、後期段階または商業キャンペーンのために必要とされる量を製造するのには適さない場合がある。別の重要な考慮事項は、プロセス開発が治療候補薬の臨床試験への導入前に生じる必要があることを考慮したプロセス開発の速度である。Ａｂｈｉｎａｖ  Ａ．Ｓｈｕｋｌａら、Ｊｏｕｒｎａｌ  ｏｆ  Ｃｈｒｏｍａｔｏｇｒａｐｈｙ  Ｂ、８４８（２００７）２８～３９参照。
</span>
  Indeed, if it were possible to have a comprehensive process that could be used to manufacture and formulate all vaccine candidates, the time and resources required for process development would be greatly reduced. This can have a significant impact on the number of clinical candidates that can enter clinical trials. Also, processes developed for early-stage clinical trials, including those developed using platforms, may not be optimal in terms of process economics, yield, pool volume and throughput, and may not be suitable for late-stage or commercial trials. It may not be suitable for manufacturing the quantities needed for the campaign. Another important consideration is the speed of process development given that process development must occur prior to introduction of a therapeutic candidate into clinical trials. Abhinav A. See Shukla et al., Journal of Chromatography B, 848 (2007) 28-39.
</span>
    </p>
    <p num="0037" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、サルモネラ菌疾病負荷は、電力および冷蔵の利用性が不十分であることが多く、したがって、温度変動域にわたるワクチン安定性がこれらの地域ではより関連性が高いと推測される発展途上国において高い。
</span>
  In addition, Salmonella disease burden is higher in developing countries where the availability of electricity and refrigeration is often inadequate and therefore vaccine stability over temperature ranges is assumed to be more relevant in these regions. .
</span>
    </p>
    <p num="0038" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  したがって、良好な免疫原性、安全性および費用の可負担を含む複数の基準を満たす、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓに対して効果的なワクチンを製造するための効率的なプラットフォームプロセス、特に、ｉ）発酵および精製プロセスにわたる改善された多糖体収率、ｉｉ）最適なパーセンテージ回収率および最小の不純物レベルを示す改善された精製プロセス、ならびにｉｉｉ）ワクチン中の多糖体－タンパク質コンジュゲートの改善された比、ｉｖ）低粘度、凝集の回避を示し、幅広い温度範囲にわたる長期間安定性を示す改善された製剤を提供するプラットフォームプロセスへのニーズが存在する。
</span>
  Therefore, a Salmonella serotype strain S. cerevisiae that satisfies multiple criteria, including good immunogenicity, safety and affordability. typhi, S. paratyphi A, S.; typhimurium and S. Efficient platform processes for manufacturing vaccines effective against enteritidis, in particular exhibiting i) improved polysaccharide yields over fermentation and purification processes, ii) optimal percentage recovery and minimal impurity levels An improved purification process and iii) an improved ratio of polysaccharide-protein conjugates in the vaccine, iv) an improved formulation exhibiting low viscosity, avoidance of aggregation and long-term stability over a wide temperature range. There is a need for platform processes to provide.
</span>
    </p>
    <p num="0039" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  先行技術の前述の制限を克服し、長期間にわたって満たされていないと感じられていた世界的な医療ニーズを解決するために、出願人は、改善された、代替の発酵、精製、コンジュゲーションプロセス、一価サルモネラチフスコンジュゲートの調製のための製剤、ならびにＳａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉ（Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｂ、Ｃ）ならびに非チフス性Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒｓ  ｔｙｐｈｉｍｕｒｉｕｍ（Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ）およびｅｎｔｅｒｉｔｉｄｉｓ（Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ）由来の少なくとも１種の追加のコンジュゲートを含む多価ワクチンを提案する。
</span>
  To overcome the aforementioned limitations of the prior art and to solve a long felt unmet global medical need, Applicants have developed an improved and alternative fermentation, purification and conjugation process. , formulations for the preparation of monovalent Salmonella typhi conjugates and at least from Salmonella paratyphi (S. paratyphi A, B, C) and non-typhoid Salmonella enterica serovars typhimurium (S. typhimurium) and enteritidis (S. enteritidis) A multivalent vaccine containing one additional conjugate is proposed.
</span>
    </p>
  </background-art>
  <summary-of-invention class="style-scope patent-text">
    <tech-problem class="style-scope patent-text">
      <p num="0040" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の目的は、先行技術の１つもしくは複数の問題を改善すること、または少なくとも有用な代替物を提供することである。<br class="style-scope patent-text">
  本開示の目的は、ヒトにおいてサルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓによって引き起こされる感染を予防および処置するための効果的なワクチン製剤を開発することである。
</span>SUMMARY OF THE DISCLOSURE It is an object of the present disclosure to ameliorate one or more problems of the prior art, or at least to provide a useful alternative.<br class="style-scope patent-text"> The purpose of the present disclosure is to provide information on Salmonella serovar strain S. pneumoniae in humans. typhi, S. paratyphi A, S.; typhimurium and S. To develop effective vaccine formulations to prevent and treat infections caused by M. enteritidis.</span>
      </p>
      <p num="0041" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の別の目的は、工業規模で用いられ得る、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を含む多糖体－タンパク質コンジュゲートワクチンの製造のための改善された方法を提供することである。
</span>
  Another object of the present disclosure is Salmonella serotype strain S. cerevisiae that can be used on an industrial scale. typhi, S. paratyphi A, S.; typhimurium and S. It is an object of the present invention to provide improved methods for the production of polysaccharide-protein conjugate vaccines comprising polysaccharides from S. enteritidis.
</span>
      </p>
      <p num="0042" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓのいずれか由来の多糖体を含む一価多糖体－タンパク質コンジュゲートワクチンを提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. to provide a monovalent polysaccharide-protein conjugate vaccine comprising a polysaccharide from any of S. enteritidis.
</span>
      </p>
      <p num="0043" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓのいずれか由来の多糖体をその任意の組合せで含む二価多糖体－タンパク質コンジュゲートワクチンを提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. to provide a bivalent polysaccharide-protein conjugate vaccine comprising polysaccharides from any of S. enteritidis in any combination thereof.
</span>
      </p>
      <p num="0044" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体をその任意の組合せで含む多価多糖体－タンパク質コンジュゲートワクチンを提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. It is an object of the present invention to provide a polyvalent polysaccharide-protein conjugate vaccine containing polysaccharides from S. enteritidis in any combination thereof.
</span>
      </p>
      <p num="0045" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓの多糖体を製造するための改善された流加方法を提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. An object of the present invention is to provide an improved fed-batch process for producing polysaccharides of S. enteritidis.
</span>
      </p>
      <p num="0046" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体の改善された精製方法を提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. An object of the present invention is to provide an improved method for purifying polysaccharides from S. enteritidis.
</span>
      </p>
      <p num="0047" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、担体タンパク質へのサルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体（サイズ低減ありまたはなし）の改善されたコンジュゲーション方法を提供することである。
</span>
  Yet another object of the present disclosure is the use of Salmonella serotype strain S. cerevisiae to carrier proteins. typhi, S. paratyphi A, S.; typhimurium and S. The objective is to provide an improved method of conjugation of polysaccharides (with or without size reduction) from S. enteritidis.
</span>
      </p>
      <p num="0048" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、リンカー（スペーサー）分子ありまたはなしでの、担体タンパク質へのサルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体（サイズ低減ありまたはなし）のコンジュゲーション方法を提供することである。
</span>
  Yet another object of the present disclosure is to link Salmonella serovar S. cerevisiae to a carrier protein with or without a linker (spacer) molecule. typhi, S. paratyphi A, S.; typhimurium and S. To provide a method for conjugation of polysaccharides (with or without size reduction) from S. enteritidis.
</span>
      </p>
      <p num="0049" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示のなお別の目的は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓに対する感染の防御もしくは処置を付与する、またはその臨床症状の発症もしくは進行を防止、改善もしくは遅延するのに効果的な適切な濃度で乳幼児および成人に投与される適切な単回用量および多回用量バイアルの多糖体－タンパク質コンジュゲートを含む免疫原性ワクチン製剤を提供することである。
</span>
  Yet another object of the present disclosure is the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. suitable single and multiple doses administered to infants and adults at suitable concentrations effective to confer protection or treatment of infection against, or to prevent, ameliorate or delay the onset or progression of clinical symptoms of To provide an immunogenic vaccine formulation comprising a dose vial of a polysaccharide-protein conjugate.
</span>
      </p>
      <p num="0050" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の他の目的および利点は、本開示の範囲を限定することは意図されない以下の記載からより明らかになるであろう。
</span>
  Other objects and advantages of this disclosure will become more apparent from the following description, which is not intended to limit the scope of this disclosure.
</span>
      </p>
    </tech-problem>
    <tech-solution class="style-scope patent-text">
      <p num="0051" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示は、<br class="style-scope patent-text">
  ａ）多糖体－タンパク質コンジュゲートの１種または複数を含む免疫原性組成物であって、多糖体が、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来である、免疫原性組成物；<br class="style-scope patent-text">
  ｂ）サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を培養および処理するための流加方法；<br class="style-scope patent-text">
  ｃ）サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を得るための下流処理ステップ；<br class="style-scope patent-text">
  ｄ）リンカー分子の存在または非存在下での、担体タンパク質へのサルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体（サイズ低減ありまたはなし）のコンジュゲーション方法；ならびに<br class="style-scope patent-text">
  ｅ）対象に治療有効量の免疫原性組成物を投与することにより対象において免疫応答を誘発して、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓに対する感染の防御もしくは処置を付与する、またはその臨床症状の発症もしくは進行を防止、改善もしくは遅延するための方法<br class="style-scope patent-text">
を提供する。
</span>This disclosure is<br class="style-scope patent-text"> a) An immunogenic composition comprising one or more polysaccharide-protein conjugates, wherein the polysaccharide is Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. an immunogenic composition, which is derived from C. enteritidis;<br class="style-scope patent-text"> b) Salmonella serotype strain S. typhi, S. paratyphi A, S.; typhimurium and S. a fed-batch method for culturing and processing polysaccharides from enteritidis;<br class="style-scope patent-text"> c) Salmonella serotype strain S. typhi, S. paratyphi A, S.; typhimurium and S. downstream processing steps to obtain polysaccharides from enteritidis;<br class="style-scope patent-text"> d) attachment of Salmonella serovar S. cerevisiae to a carrier protein in the presence or absence of a linker molecule; typhi, S. paratyphi A, S.; typhimurium and S. and e) inducing an immune response in a subject by administering a therapeutically effective amount of an immunogenic composition to Salmonella serovar strain S. . typhi, S. paratyphi A, S.; typhimurium and S. methods for conferring protection or treatment of infection against, or preventing, ameliorating or delaying the onset or progression of clinical symptoms of, C. enteritidis.</span>
      </p>
    </tech-solution>
  </summary-of-invention>
  <description-of-drawings class="style-scope patent-text">
    <p num="0052" class="style-scope patent-text">
      <figref num="1" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１：多糖体、タンパク質およびコンジュゲートの比較（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．３）を参照。</span>See Figure 1: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.3).</span>
      </figref>
      <figref num="2" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図２：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．３）のクロマトグラムを参照。</span>See Figure 2: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:0.8:1.3).</span>
      </figref>
      <figref num="3" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図３：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．１）の比較を参照。</span>See Figure 3: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.1).</span>
      </figref>
      <figref num="4" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図４：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．１）のクロマトグラムを参照。</span>See Figure 4: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP 1:0.8:1.1).</span>
      </figref>
      <figref num="5" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図５：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）の比較を参照。</span>See Figure 5: Comparison of polysaccharide, protein and conjugate (PS:PR:CPIP is 1:1:1.3).</span>
      </figref>
      <figref num="6" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図６：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）の比較を参照。</span>See Figure 6: Comparison of polysaccharide, protein and conjugate (PS:PR:CPIP is 1:1:1.3).</span>
      </figref>
      <figref num="7" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図７：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）のクロマトグラムを参照。</span>See Figure 7: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:1:1.3).</span>
      </figref>
      <figref num="8" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図８：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．２５）の比較を参照。</span>See Figure 8: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.25).</span>
      </figref>
      <figref num="9" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図９：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．２５）のクロマトグラムを参照。</span>See Figure 9: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:0.8:1.25).</span>
      </figref>
      <figref num="10" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１０：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ１：０．９：１．３）の比較を参照。</span>See Figure 10: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP1:0.9:1.3).</span>
      </figref>
      <figref num="11" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１１：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．９：１．３）のクロマトグラムを参照。</span>See Figure 11: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP 1:0.9:1.3).</span>
      </figref>
      <figref num="12" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１２：コンジュゲーション反応の進行を示すクロマトグラム（２３時間の時点で反応をクエンチ）を参照。</span>See Figure 12: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 23 hours).</span>
      </figref>
      <figref num="13" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１３：コンジュゲーション反応の進行を示すクロマトグラムを参照。</span>See Figure 13: Chromatogram showing the progress of the conjugation reaction.</span>
      </figref>
      <figref num="14" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１４：コンジュゲーション反応の進行を示すクロマトグラム（２０時間の時点で反応をクエンチ）を参照。</span>See Figure 14: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 20 hours).</span>
      </figref>
      <figref num="15" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１５：精製コンジュゲート（プールした画分）を示すクロマトグラムを参照。</span>See Figure 15: Chromatogram showing purified conjugate (pooled fractions).</span>
      </figref>
      <figref num="16" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１６：コンジュゲーション反応の進行を示すクロマトグラム（４時間の時点で反応をクエンチ）を参照。</span>See Figure 16: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 4 hours).</span>
      </figref>
      <figref num="17" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">図１７：精製コンジュゲートを示すクロマトグラムを参照。</span>Figure 17: See chromatogram showing purified conjugate.</span>
      </figref>
    </p>
  </description-of-drawings>
  <description-of-embodiments class="style-scope patent-text">
    <p num="0053" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示は様々な実施形態が可能であり得るが、ある特定の実施形態が、以下の詳細な議論に示され、本開示は、本開示の原理の例証と考えることができ、本開示の範囲を本明細書において例示および開示されるものに限定することは意図されないことが理解される。
</span>
  While the present disclosure is capable of various embodiments, certain specific embodiments are set forth in the following detailed discussion, which can be considered an exemplification of the principles of the disclosure and the scope of the disclosure. is not intended to be limited to that illustrated and disclosed herein.
</span>
    </p>
    <p num="0054" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態は、当業者に本開示の範囲を十分かつ完全に伝えるために提供される。本開示の実施形態の完全な理解を提供するために、特定の構成成分およびプロセスに関する多数の詳細が示される。実施形態で提供される詳細は、本開示の範囲を限定すると解釈されるべきではないことが、当業者には明らかであろう。一部の実施形態では、周知の組成物、周知のプロセスおよび周知の技術は、詳細には記載されない。
</span>
  Rather embodiments are provided so that this disclosure will fully and completely convey the scope of this disclosure to those skilled in the art. Numerous details are set forth regarding specific components and processes in order to provide a thorough understanding of the embodiments of the present disclosure. It will be apparent to those skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the disclosure. In some embodiments, well-known compositions, well-known processes, and well-known techniques are not described in detail.
</span>
    </p>
    <p num="0055" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示において使用される用語は、特定の実施形態を説明することのみを目的とし、そのような用語は、本開示の範囲を限定すると考えるべきではない。本開示において使用される場合、「１つの（ａ）」、「１つの（ａｎ）」および「その（ｔｈｅ）」という形態は、文脈が明らかにそうでないことを示唆していない限り、同様に複数形を含むことが意図され得る。
</span>
  The terminology used in this disclosure is for the purpose of describing particular embodiments only, and such terminology is not to be construed as limiting the scope of the disclosure. As used in this disclosure, the forms "a," "an," and "the" refer to the same, unless the context clearly dictates otherwise. may be intended to include the plural.
</span>
    </p>
    <p num="0056" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「含む（ｃｏｍｐｒｉｓｅｓ）」、「含むこと（ｃｏｍｐｒｉｓｉｎｇ）」、「含むこと（ｉｎｃｌｕｄｉｎｇ）」および「有する（ｈａｖｉｎｇ）」という用語は、オープンエンドの移行句であり、したがって、述べられた特徴、整数、ステップ、操作、要素、モジュール、ユニットおよび／または構成成分の存在を特定するが、１つまたは複数の他の特徴、整数、ステップ、操作、要素、構成成分および／またはその群の存在または追加を禁じない。本開示の方法において開示されるステップの特定の順序は、記載または例示される通りにそれらを実施するために必ずしも必要であるとは限らないと解釈される。追加または代替のステップが用いられてもよいこともまた理解される。
</span>
  The terms "comprises," "comprising," "including," and "having" are open-ended transitional phrases, thus the stated features, integers, specifying the presence of steps, operations, elements, modules, units and/or components, but not specifying the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof don't forbid It is to be understood that the specific order of the steps disclosed in the methods of the present disclosure are not necessarily required to perform them as described or illustrated. It is also understood that additional or alternative steps may be used.
</span>
    </p>
    <p num="0057" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第１の、第２の、第３のなどの用語は、本開示の範囲を限定すると解釈されるべきではなく、前述の用語は、１つの要素、構成成分、領域、層または区画を、別の構成成分、領域、層または区画から区別するためにのみ使用され得る。第１の、第２の、第３のなどの用語は、本明細書で使用される場合、本開示によって明らかに示唆されない限り、特定の配列または順序を含意しない。本開示は、免疫原性組成物およびこれを調製するための方法を提供する。
</span>
  Terms such as first, second, third, etc. should not be construed as limiting the scope of this disclosure, as the foregoing terms refer to one element, component, region, layer or section to another. can only be used to distinguish from components, regions, layers or compartments of The terms first, second, third, etc., as used herein, do not imply any particular arrangement or order unless clearly suggested by this disclosure. The present disclosure provides immunogenic compositions and methods for preparing same.
</span>
    </p>
    <p num="0058" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「ワクチン」という用語は、「免疫原性組成物」という用語で任意選択で置換可能であり、逆も同様である。<br class="style-scope patent-text">
  「Ｄ抗原単位」（「国際単位」またはＩＵとも呼ばれる）：ポリオウイルスのＤ抗原形態は、防御中和抗体を誘導する。本明細書において（例えば、本発明のワクチンにおいて）言及されるＤ抗原単位は、最終ワクチンの製剤化前のそれぞれの吸着していないバルクＩＰＶ抗原型の総Ｄ抗原単位測定値であり、これは、製剤化ワクチンの各ヒト用量に添加される（典型的には０．５ｍＬ最終容積）。Ｄ抗原単位を測定する信頼性の高い方法は、当技術分野で周知であり、例えば、欧州薬局方によって公開されている。例えば、Ｄ抗原単位は、以下の実施例１（「ＥＬＩＳＡによるＤ抗原定量化」）に記載の通りのＥＬＩＳＡ試験を使用して測定され得る。欧州薬局方は、そのような方法を製造業者間で標準化するための試験試料（Ｅｕｒｏｐｅａｎ  Ｐｈａｒｍａｃｏｐｏｅｉａ  Ｂｉｏｌｏｇｉｃａｌ  Ｒｅｆｅｒｅｎｃｅ  Ｐｒｅｐａｒａｔｉｏｎ－Ｐｈ．Ｅｕｒ．Ｓｅｃｒｅｔａｒｉａｔから入手可能、例えば、コードＰ  ２１６  ００００）を提供している（Ｐｈａｒｍｅｕｒｏｐａ  Ｓｐｅｃｉａｌ  Ｉｓｓｕｅ、Ｂｉｏ  ９６－２）。したがって、Ｄ抗原単位値は、当技術分野で十分理解されている。
</span>The term "vaccine" is optionally interchangeable with the term "immunogenic composition" and vice versa.<br class="style-scope patent-text"> "D-antigen unit" (also called "international unit" or IU): The D-antigen form of poliovirus induces protective neutralizing antibodies. The D antigen units referred to herein (e.g., in vaccines of the invention) are the total D antigen unit measurements of each non-adsorbed bulk IPV serotype prior to formulation of the final vaccine, which is , is added to each human dose of formulated vaccine (typically 0.5 mL final volume). Reliable methods for measuring D antigen units are well known in the art and published, for example, by the European Pharmacopoeia. For example, D antigen units can be measured using an ELISA test as described in Example 1 below ("D antigen quantification by ELISA"). The European Pharmacopoeia provides test samples (available from the European Pharmacopoeia Biological Reference Preparation—Ph. Special Issue, Bio 96-2). Therefore, D antigen unit values are well understood in the art.</span>
    </p>
    <p num="0059" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「用量」という用語は、本明細書において、典型的には、本発明のワクチンの１回の投与であり、これは、典型的には１回の注射である。ヒト典型用量は０．５ｍＬである。当然のことながら、ワクチン投与スケジュールにおいて様々な用量が投与されてもよい。
</span>
  The term "dose" as used herein is typically one administration of the vaccine of the invention, which is typically one injection. A typical human dose is 0.5 mL. Of course, various doses may be administered in the vaccination schedule.
</span>
    </p>
    <p num="0060" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「ＩＰＶ」という用語またはこれらの構成成分を含む免疫原性組成物は、本明細書において、不活化ポリオウイルス１型（例えば、好ましく使用されるＭａｈｏｎｅｙ）、２型（例えば、ＭＥＦ－１）もしくは３型（例えば、Ｓａｕｋｅｔｔ）、またはこれらの型のいずれか２つもしくは３つすべてのＳａｂｉｎ血清型１、２、３組合せを意味することが意図される。本発明の目的のための全（または標準）用量（それぞれＳａｌｋに基づくＩＰＶ型１、２および３の４０－８－３２  Ｄ抗原単位）ＩＰＶ免疫原性組成物の一例は、Ｐｏｌｉｏｖａｃ（登録商標）（Ｓｅｒｕｍ  Ｉｎｓｔｉｔｕｔｅ  ｏｆ  Ｉｎｄｉａ  Ｐｖｔ．Ｌｔｄ．）であり得る。
</span>
  The term "IPV" or immunogenic compositions comprising these components, as used herein, refers to inactivated poliovirus type 1 (e.g. the preferably used Mahoney), type 2 (e.g. MEF-1) or It is intended to mean type 3 (eg, Saukett), or Sabin serotypes 1, 2, 3 combinations of any two or all three of these types. An example of a full (or standard) dose (40-8-32 D antigen units of Salk-based IPV types 1, 2 and 3, respectively) IPV immunogenic composition for the purposes of the present invention is Poliovac® (Serum Institute of India Pvt. Ltd.).
</span>
    </p>
    <p num="0061" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「糖」という用語は、本明細書全体を通して、多糖体またはオリゴ糖を示してもよく、かつその両方を含む。莢膜糖抗原は、全長多糖体であってもよく、または、莢膜糖抗原は、細菌「サイズの糖」および「オリゴ糖」に拡大解釈されてもよい（これは少数の反復単位を自然に有するか、または取り扱い性のためにサイズを低減した多糖体であるが、宿主においてなお防御免疫応答を誘導することが可能である）。
</span>
  The term "sugar" may refer to polysaccharides or oligosaccharides throughout the specification and includes both. The capsular saccharide antigen may be a full-length polysaccharide, or the capsular saccharide antigen may be extended to bacterial "size saccharides" and "oligosaccharides" (which naturally consist of a small number of repeating units). or polysaccharides that have been reduced in size for ease of handling, but are still capable of inducing a protective immune response in the host).
</span>
    </p>
    <p num="0062" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１の実施形態によると、免疫原性組成物は、多糖体－タンパク質コンジュゲートの１種または複数を含んでもよく、多糖体は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来である。
</span>
  According to a first embodiment of the present disclosure, the immunogenic composition may comprise one or more polysaccharide-protein conjugates, wherein the polysaccharide is Salmonella serovar strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis.
</span>
    </p>
    <p num="0063" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第２の実施形態によると、流加プロセスによってサルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を得る方法は、以下のステップの任意の部分集合またはすべてを含んでもよい：<br class="style-scope patent-text">
  １．  発酵培地組成物中での細菌の接種、培養および収穫、<br class="style-scope patent-text">
  ２．  不活化、<br class="style-scope patent-text">
  ３．  分離、<br class="style-scope patent-text">
  ４．  清澄化、および<br class="style-scope patent-text">
  ５．  滅菌ろ過。
</span>According to a second embodiment of the present disclosure, Salmonella serotype strain S. cerevisiae is produced by a fed-batch process. typhi, S. paratyphi A, S.; typhimurium and S. A method of obtaining polysaccharides from S. enteritidis may comprise any subset or all of the following steps:<br class="style-scope patent-text"> 1. inoculation, cultivation and harvesting of bacteria in the fermentation medium composition;<br class="style-scope patent-text"> 2. inactivation,<br class="style-scope patent-text"> 3. separation,<br class="style-scope patent-text"> 4. 5. clarification; Sterile filtration.</span>
    </p>
    <p num="0064" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第１の態様によると、発酵培地組成物は、炭素源、マグネシウム塩、リン酸源、酵母抽出物および大豆加水分解物を含んでもよい。炭素源は、グルコース、マンニトール、スクロース、ラクトース、フルクトースおよびトレハロース、好ましくはグルコースからなる群から選択できる。マグネシウム塩は、塩化マグネシウム、硫酸マグネシウム、好ましくは硫酸マグネシウム七水和物から選択されてもよい。カリウム源は、リン酸水素二ナトリウム七水和物、リン酸二水素ナトリウム一水和物、リン酸カリウムおよびリン酸二カリウムから選択されてもよい。好ましくは、カリウム源は、リン酸水素二ナトリウム七水和物、リン酸二水素ナトリウムの組合せである。好ましくは、大豆加水分解物はｈｙｓｏｙである。
</span>
  According to a first aspect of the second embodiment, the fermentation medium composition may comprise a carbon source, a magnesium salt, a phosphate source, yeast extract and soy hydrolysate. The carbon source can be selected from the group consisting of glucose, mannitol, sucrose, lactose, fructose and trehalose, preferably glucose. The magnesium salt may be selected from magnesium chloride, magnesium sulfate, preferably magnesium sulfate heptahydrate. The potassium source may be selected from disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate monohydrate, potassium phosphate and dipotassium phosphate. Preferably, the potassium source is a combination of disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate. Preferably, the soy hydrolyzate is hysoy.
</span>
    </p>
    <p num="0065" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらにこれに従って、発酵培地は、Ａｎｔｉｆｏａｍ  ２０４、Ａｎｔｉｆｏａｍ  Ｃ、ＳＥ－１５、Ｙ－３０、Ａｎｔｉｆｏａｍ  ＥＸ－Ｃｅｌｌ、Ｓ１８４（純シリコン油）、ＳＬＭ５４４７４（ポリプロピレングリコール：ＰＰＧ）、ＶＰ１１３３（シリコン油／ＰＰＧ混合物）、ＢＲＥＯＸ（ポリアルキレングリコール）、Ｊ６７３  ＳＴＲＵＫＴＯＬ（植物ベースのアルコキシ化脂肪酸エステル）およびＷａｃｋｅｒ－Ｃｈｅｍｉｅ  Ｃｏ．のＳＥ９（１０％シリコン油成分を含む水性エマルジョン）の群から選択される消泡剤をさらに含んでもよい。消泡剤と大豆加水分解物および酵母抽出物との組合せは、多糖体の収率の改善を補助し得る。なお好ましくは、消泡剤は、Ａｎｔｉｆｏａｍ  ＣまたはＪ６７３  ＳＴＲＵＫＴＯＬであってもよい。
</span>
  Further in accordance with this, the fermentation medium is Antifoam 204, Antifoam C, SE-15, Y-30, Antifoam EX-Cell, S184 (pure silicone oil), SLM54474 (polypropylene glycol: PPG), VP1133 (silicone oil/PPG mixture). , BREOX (polyalkylene glycol), J673 STRUKTOL (plant-based alkoxylated fatty acid ester) and Wacker-Chemie Co.; of SE9 (aqueous emulsion containing 10% silicone oil component). The combination of antifoam agents with soy hydrolysate and yeast extract can help improve polysaccharide yield. Still preferably, the defoamer may be Antifoam C or J673 STRUKTOL.
</span>
    </p>
    <p num="0066" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の実施形態によると、酵母抽出物は、酵母自己溶解物、限外ろ過酵母抽出物または合成酵母抽出物であってもよい。酵母抽出物は、ＢＤ  ＢＢＬ（商標）、ＢＤ  ＢＡＣＴＯ（商標）、Ｄｉｆｃｏ（商標）などから選択されてもよい。好ましい実施形態では、酵母抽出物は、Ｄｉｆｃｏ（商標）Ｙｅａｓｔ  Ｅｘｔｒａｃｔ、ＵＦなどの限外ろ過酵母抽出物であってもよい。大豆加水分解物は、これらに限定されないが、大豆ミール、大豆ペプトンおよび大豆粉から選択されてもよい。一実施形態では、大豆加水分解物は、Ｄｉｆｃｏ（商標）Ｓｅｌｅｃｔ  Ｐｈｙｔｏｎｅ（商標）ＵＦであってもよい。別の実施形態では、大豆加水分解物はｈｙｓｏｙであってもよい。
</span>
  According to embodiments of the present disclosure, the yeast extract may be yeast autolysate, ultrafiltered yeast extract or synthetic yeast extract. Yeast extracts may be selected from BD BBL™, BD BACTO™, Difco™, and the like. In a preferred embodiment, the yeast extract may be an ultrafiltered yeast extract such as Difco™ Yeast Extract, UF. Soy hydrolysates may be selected from, but not limited to, soy meal, soy peptone and soy flour. In one embodiment, the soy hydrolyzate may be Difco™ Select Phytone™ UF. In another embodiment, the soy hydrolyzate may be hysoy.
</span>
    </p>
    <p num="0067" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  消泡剤、大豆ペプトンおよび酵母抽出物の組合せにより、他の培地と比較して、収穫収率が改善する。<br class="style-scope patent-text">
  第２の実施形態の第２の態様によると、方法は、発酵が既に進んでいる場合、供給物を固定割合で特定の固定時間間隔で組み込み、および／または段階毎にバッチサイズが比例して増加する複数の段階を含む、発酵の流加モードによる連続供給を可能にすることによる二段方策に従ってもよい。
</span>The combination of antifoam, soy peptone and yeast extract improves harvest yield compared to other media.<br class="style-scope patent-text"> According to a second aspect of the second embodiment, the method incorporates the feed in fixed proportions at specific fixed time intervals when the fermentation is already advanced, and/or batch sizes are proportionately A two-stage strategy may be followed by allowing continuous feeding with a fed-batch mode of fermentation involving multiple stages of incrementation.</span>
    </p>
    <p num="0068" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第３の態様によると、発酵パラメーターは、<br class="style-scope patent-text">
  温度：３６．０±２℃<br class="style-scope patent-text">
  撹拌：１５０～６００ｒｐｍ<br class="style-scope patent-text">
  ｐＨ：７．０±０．５<br class="style-scope patent-text">
  溶存酸素：３０％～９０％<br class="style-scope patent-text">
  空気（ｎｌ／分）：２～１０<br class="style-scope patent-text">
  ガス流：６０～６００ｎｌ／分<br class="style-scope patent-text">
  浸透圧：４００～６００ｍＯｓｍ／ｋｇ<br class="style-scope patent-text">
で構成されてもよい。
</span>According to a third aspect of the second embodiment, the fermentation parameters are<br class="style-scope patent-text"> Temperature: 36.0±2°C<br class="style-scope patent-text"> Stirring: 150-600rpm<br class="style-scope patent-text"> pH: 7.0±0.5<br class="style-scope patent-text"> Dissolved oxygen: 30% to 90%<br class="style-scope patent-text"> Air (nl/min): 2-10<br class="style-scope patent-text"> Gas flow: 60-600 nl/min Osmotic pressure: 400-600 mOsm/kg<br class="style-scope patent-text"> may consist of</span>
    </p>
    <p num="0069" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第４の態様によると、細菌培養物の不活化は、ホルマリンを使用して実施されてもよい。<br class="style-scope patent-text">
  なお好ましくは、細菌培養物の不活化は、０．１～２％ｖ／ｖの範囲、好ましくは０．５％ｖ／のホルムアルデヒドを使用し、３４～３８℃、好ましくは３６℃で、５～１２時間、好ましくは８～１２時間インキュベートして実施されてもよい。
</span>According to a fourth aspect of the second embodiment, inactivation of the bacterial culture may be performed using formalin.<br class="style-scope patent-text"> Still preferably, the inactivation of the bacterial culture is carried out at 34-38°C, preferably 36°C, using formaldehyde in the range 0.1-2% v/v, preferably 0.5% v/v, at 5°C. Incubation may be performed for ˜12 hours, preferably 8-12 hours.</span>
    </p>
    <p num="0070" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第５の態様によると、分離は、遠心によって実施されてもよい。なお好ましくは、分離は、温度２～８℃、ＲＰＭ７０００～８０００、遠心時間４０～６０分のパラメーター設定の遠心によって実施されてもよい。
</span>
  According to a fifth aspect of the second embodiment, separation may be performed by centrifugation. Still preferably, the separation may be performed by centrifugation with the parameter settings temperature 2-8° C., RPM 7000-8000, centrifugation time 40-60 minutes.
</span>
    </p>
    <p num="0071" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第６の態様によると、清澄化は、深層ろ過によって実施されてもよい。<br class="style-scope patent-text">
  第２の実施形態の第７の態様によると、清澄化収穫物は、０．２μＭ滅菌フィルターを使用したろ過により滅菌されてもよい。
</span>According to a sixth aspect of the second embodiment, clarification may be performed by depth filtration.<br class="style-scope patent-text"> According to a seventh aspect of the second embodiment, the clarified harvest may be sterilized by filtration using a 0.2 μM sterilizing filter.</span>
    </p>
    <p num="0072" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第２の実施形態の第８の態様によると、発酵段階における粗製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  Ｖｉ多糖体（ＶｉＰｓ）収率は、少なくとも４０％であってもよく、平均Ｖｉ多糖体収率は、１００ｍｇ／Ｌ～５０００ｍｇ／Ｌ、より好ましくは１００～７００ｍｇ／Ｌの範囲であり得る。
</span>
  According to an eighth aspect of the second embodiment, the crude Salmonella enterica serovar typhi Vi polysaccharide (ViPs) yield in the fermentation step may be at least 40%, and the average Vi polysaccharide yield is 100 mg/ It may range from L to 5000 mg/L, more preferably from 100 to 700 mg/L.
</span>
    </p>
    <p num="0073" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第３の実施形態によると、発酵収穫物は、所望の品質のＶｉ多糖体（ＶｉＰｓ）を得るために、以下の下流精製ステップの任意の部分集合に、または任意の順序で、またはそのすべてに供されてもよい：<br class="style-scope patent-text">
  ａ）約０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）による細菌莢膜多糖体収穫物の清澄化、<br class="style-scope patent-text">
  ｂ）接線流限外ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａまたはｋＤ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｃ）タンパク質、核酸およびリポ多糖の変性のためのアニオン性またはカチオン性洗剤、エチレンジアミン四酢酸（ＥＤＴＡ）（４～１０ｍＭ）および酢酸ナトリウム（５％～１０％）による処理、<br class="style-scope patent-text">
  ｄ）アルコール沈殿（４０％～７０％）、<br class="style-scope patent-text">
  ｅ）遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｆ）過剰な洗剤の除去のためのアルカリ塩による処理に続いて、遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｇ）接線流ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａまたはｋＤ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｈ）アニオン性またはカチオン性洗剤による処理、<br class="style-scope patent-text">
  ｉ）遠心および約０．４５マイクロメートル～約０．２マイクロメートルの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｊ）塩化ナトリウム（０．１Ｍ～２Ｍ）の存在下、アルコール（５０％～７０％）でペレットを洗浄することによるタンパク質および核酸不純物の除去、<br class="style-scope patent-text">
  ｋ）アルコール（＜７５％ＯＲ＞９５％）を利用することによる多糖体の選択的沈殿、<br class="style-scope patent-text">
  ｌ）多糖体をＷＦＩに溶解し、接線流ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａまたはｋＤ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換に供するステップ、ならびに<br class="style-scope patent-text">
  ｍ）滅菌条件下、約０．２マイクロメートルの孔径を有する少なくとも１つの滅菌フィルターを通した滅菌ろ過。
</span>According to a third embodiment of the present disclosure, the fermentation harvest is subjected to any subset of the following downstream purification steps, or in any order, to obtain the desired quality of Vi polysaccharides (ViPs), or It may serve all:<br class="style-scope patent-text"> a) clarification of the bacterial capsular polysaccharide harvest by direct flow filtration (DFF) through at least one membrane having a pore size of about 0.2 micrometers;<br class="style-scope patent-text"> b) concentration by tangential flow ultrafiltration (TFF) and buffer exchange by diafiltration (DF) using membranes with 10-300 kDa or kD molecular weight cutoff (MWCO);<br class="style-scope patent-text"> c) treatment with anionic or cationic detergents, ethylenediaminetetraacetic acid (EDTA) (4-10 mM) and sodium acetate (5%-10%) for denaturation of proteins, nucleic acids and lipopolysaccharides;<br class="style-scope patent-text"> d) alcohol precipitation (40%-70%);<br class="style-scope patent-text"> e) centrifugation and filtration by direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.2 μM;<br class="style-scope patent-text"> f) treatment with alkaline salts for removal of excess detergent, followed by centrifugation and filtration by direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.2 μM;<br class="style-scope patent-text"> g) concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using membranes with a molecular weight cutoff (MWCO) of 10-300 kDa or kD;<br class="style-scope patent-text"> h) treatment with anionic or cationic detergents,<br class="style-scope patent-text"> i) filtration by centrifugation and direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.45 micrometers to about 0.2 micrometers;<br class="style-scope patent-text"> j) removal of protein and nucleic acid impurities by washing the pellet with alcohol (50%-70%) in the presence of sodium chloride (0.1M-2M);<br class="style-scope patent-text"> k) selective precipitation of polysaccharides by utilizing alcohols (&lt;75% OR&gt;95%);<br class="style-scope patent-text"> l) dissolving the polysaccharide in WFI and subjecting it to concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using membranes with a molecular weight cutoff (MWCO) of 10-300 kDa or kD, and m) sterile filtration through at least one sterile filter having a pore size of about 0.2 micrometers under sterile conditions.</span>
    </p>
    <p num="0074" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第３の実施形態の第１の態様によると、精製方法は、クロマトグラフィーステップを含まなくてもよい。<br class="style-scope patent-text">
  第３の実施形態の第２の態様によると、精製方法の結果、所望のＯ－アセチルレベル（２．０ｍｍｏｌ超／多糖体１ｇ）を有する約４０％～６５％の大きな回収率がもたらされ得、精製Ｖｉ多糖体収率は１０００～４０００ｍｇ／Ｌの範囲であり得、平均分子量は４０～４００ｋＤａの範囲であり得、１％未満のタンパク質／ペプチド、２％未満の核酸、多糖体（ＰＳ）１μｇ当たり１００ＥＵ未満のエンドトキシン、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に５０％超のＰＳが溶出する）を含有する。
</span>According to a first aspect of the third embodiment, the method of purification may not comprise a chromatography step.<br class="style-scope patent-text"> According to a second aspect of the third embodiment, the purification method results in a high recovery of about 40%-65% with the desired O-acetyl level (greater than 2.0 mmol/g of polysaccharide). Obtained, purified Vi polysaccharide yield can range from 1000-4000 mg/L, average molecular weight can range from 40-400 kDa, less than 1% protein/peptide, less than 2% nucleic acid, polysaccharide (PS ) contains less than 100 EU endotoxin per μg, molecular size distribution (greater than 50% PS elutes before reaching a distribution coefficient (KD) of 0.25).</span>
    </p>
    <p num="0075" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製Ｖｉ多糖体の平均分子量は、４０～４００ｋＤａの範囲であり得る。<br class="style-scope patent-text">
  第３の実施形態の第３の態様によると、アニオン性洗剤は、硫酸アルキル、ドデシル硫酸ナトリウム（ＳＤＳ）、デオキシコール酸ナトリウム、ドデシルスルホン酸ナトリウム、ｓ－アルキル硫酸ナトリウム、脂肪アルコールポリオキシエチレンエーテル硫酸ナトリウム、オレイル硫酸ナトリウム、Ｎ－オレオイルポリ（アミノ酸）ナトリウム、アルキルベンゼンスルホン酸ナトリウム、アルファオレフィンスルホン酸ナトリウム、アルキルスルホン酸ナトリウム、アルファ－スルホモノカルボン酸エステル、脂肪酸スルホアルキルエステル、スクシネートスルホネート、アルキルナフタレンスルホネート、アルカンスルホン酸ナトリウム、リグニンスルホン酸ナトリウムおよびアルキルグリセリルエーテルスルホン酸ナトリウムを含む群から選択されてもよい。
</span>Still preferably, the average molecular weight of the purified Vi polysaccharide may range from 40 to 400 kDa.<br class="style-scope patent-text"> According to a third aspect of the third embodiment, the anionic detergent is alkyl sulfate, sodium dodecyl sulfate (SDS), sodium deoxycholate, sodium dodecylsulfonate, sodium s-alkyl sulfate, fatty alcohol polyoxyethylene ether Sodium sulfate, sodium oleyl sulfate, N-oleoyl poly(amino acid) sodium, sodium alkylbenzene sulfonate, sodium alpha olefin sulfonate, sodium alkyl sulfonate, alpha-sulfomonocarboxylic acid ester, fatty acid sulfoalkyl ester, succinate sulfonate , alkyl naphthalene sulfonates, sodium alkane sulfonates, sodium lignin sulfonates and sodium alkyl glyceryl ether sulfonates.</span>
    </p>
    <p num="0076" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記アニオン性洗剤は、硫酸アルキルであり得、より好ましくは、０．１％～２０％の範囲、より好ましくは１～２０％の範囲の最終濃度でドデシル硫酸ナトリウムが保持液に添加され、２５℃～３０℃で２時間撹拌されてもよい。
</span>
  Still preferably, said anionic detergent may be an alkyl sulfate, more preferably sodium dodecyl sulfate in the retentate at a final concentration in the range of 0.1% to 20%, more preferably in the range of 1 to 20%. may be added and stirred at 25° C.-30° C. for 2 hours.
</span>
    </p>
    <p num="0077" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第３の実施形態の第４の態様によると、アルコール沈殿は、メタノール、エタノール、ｎ－プロピルアルコール、イソプロピルアルコール、アセトンもしくはｔ－ブチルアルコール、またはその組合せを使用して実施されてもよい。
</span>
  According to a fourth aspect of the third embodiment, alcohol precipitation may be performed using methanol, ethanol, n-propyl alcohol, isopropyl alcohol, acetone or t-butyl alcohol, or combinations thereof.
</span>
    </p>
    <p num="0078" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記アルコールはエタノールであり得る。<br class="style-scope patent-text">
  第３の実施形態の第５の態様によると、アルカリ塩は、ナトリウム、カリウム、カルシウムおよびマグネシウム塩の群から選択されてもよい。より好ましくは、アルカリ塩は、塩化カリウム、酢酸カリウム、硫酸カリウム、炭酸カリウム、重炭酸カリウム、リン酸カリウム、リン酸水素カリウム、リン酸二水素カリウム、硝酸カリウムおよび他のカリウム塩からなる群から選択されるカリウム塩、またはその２種以上の組合せであってもよい。
</span>Still preferably, the alcohol may be ethanol.<br class="style-scope patent-text"> According to a fifth aspect of the third embodiment, the alkali salt may be selected from the group of sodium, potassium, calcium and magnesium salts. More preferably, the alkali salt is selected from the group consisting of potassium chloride, potassium acetate, potassium sulfate, potassium carbonate, potassium bicarbonate, potassium phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, potassium nitrate and other potassium salts. or a combination of two or more thereof.</span>
    </p>
    <p num="0079" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記カリウム塩は、上清と混合された０．１Ｍ～２Ｍの範囲の最終濃度の塩化カリウムであり得、その溶解の際、混合物を、２～８℃で＞３時間インキュベートした。
</span>
  Still preferably, said potassium salt may be potassium chloride at a final concentration ranging from 0.1 M to 2 M mixed with the supernatant, upon dissolution the mixture was incubated at 2-8° C. for &gt;3 hours. .
</span>
    </p>
    <p num="0080" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第３の実施形態の第６の態様によると、カチオン性洗剤は、セチルトリメチルアンモニウム塩、テトラブチルアンモニウム塩、ミリスチルトリメチルアンモニウム塩およびヘキサジメトリン臭化物を含む群、またはその組合せから選択されてもよい。
</span>
  According to a sixth aspect of the third embodiment, the cationic detergent may be selected from the group comprising cetyltrimethylammonium salts, tetrabutylammonium salts, myristyltrimethylammonium salts and hexadimethrine bromide, or combinations thereof.
</span>
    </p>
    <p num="0081" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記カチオン性洗剤は、０．１％～１２％の範囲の最終濃度のセチルトリメチルアンモニウム臭化物（ＣＴＡＢ）であり得、好ましくは２％～３％で、保持液に添加され、２５℃～３０℃で１～２時間撹拌されてもよい。
</span>
  Still preferably, said cationic detergent may be cetyltrimethylammonium bromide (CTAB) at a final concentration ranging from 0.1% to 12%, preferably at 2% to 3%, added to the retentate, 25 C. to 30.degree. C. and may be stirred for 1 to 2 hours.
</span>
    </p>
    <p num="0082" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第３の実施形態の第７の態様によると、最終精製多糖体バルクは、－２０℃以下で保存されてもよい。<br class="style-scope patent-text">
  本開示の第４の実施形態によると、発酵収穫物は、Ｓａｌｍｏｎｅｌｌａ  Ｐａｒａｔｙｐｈｉ  Ａリポ多糖（ＬＰＳ）から所望の品質のＯ特異的多糖体を得るために以下の下流精製ステップの任意の部分集合に、または任意の順序で、またはそのすべてに供されてもよい：<br class="style-scope patent-text">
  ａ）遠心および分離、<br class="style-scope patent-text">
  ｂ）接線流限外ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｃ）ＬＰＳの酸加水分解、<br class="style-scope patent-text">
  ｄ）遠心および分離、<br class="style-scope patent-text">
  ｅ）中和、<br class="style-scope patent-text">
  ｆ）約０．４５および０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）によるＬＰＳの清澄化、<br class="style-scope patent-text">
  ｇ）アニオン性またはカチオン性洗剤による処理、<br class="style-scope patent-text">
  ｈ）遠心および分離、<br class="style-scope patent-text">
  ｉ）約０．４５～０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）、<br class="style-scope patent-text">
ｊ）接線流限外ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
ｋ）アルコール沈殿（４０％～７０％）、<br class="style-scope patent-text">
ｌ）遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
ｍ）過剰な洗剤の除去のためのアルカリ塩による処理に続いて、遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
ｎ）接線流ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
ｏ）塩化ナトリウム（０．１Ｍ～２Ｍ）の存在下、アルコール（５０％～７０％）でペレットを洗浄することによるタンパク質および核酸不純物の除去、<br class="style-scope patent-text">
ｐ）多糖体をＷＦＩに溶解し、接線流ろ過（ＴＦＦ）による濃縮および１０～３００ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換に供するステップ、ならびに<br class="style-scope patent-text">
ｑ）滅菌条件下、約０．２マイクロメートルの孔径を有する少なくとも１つの滅菌フィルターを通した滅菌ろ過。
</span>According to a seventh aspect of the third embodiment, the final purified polysaccharide bulk may be stored at -20°C or below.<br class="style-scope patent-text"> According to a fourth embodiment of the present disclosure, the fermentation harvest is subjected to any subset of the following downstream purification steps to obtain the desired quality of O-specific polysaccharide from Salmonella Paratyphi A lipopolysaccharide (LPS): Or may be served in any order or all of:<br class="style-scope patent-text"> a) centrifugation and separation,<br class="style-scope patent-text"> b) concentration by tangential flow ultrafiltration (TFF) and buffer exchange by diafiltration (DF) using membranes with a molecular weight cutoff (MWCO) of 10-300 kDa;<br class="style-scope patent-text"> c) acid hydrolysis of LPS,<br class="style-scope patent-text"> d) centrifugation and separation;<br class="style-scope patent-text"> e) neutralization;<br class="style-scope patent-text"> f) clarification of LPS by direct flow filtration (DFF) through at least one membrane having pore sizes of about 0.45 and 0.2 micrometers;<br class="style-scope patent-text"> g) treatment with anionic or cationic detergents,<br class="style-scope patent-text"> h) centrifugation and separation,<br class="style-scope patent-text"> i) direct flow filtration (DFF) through at least one membrane having a pore size of about 0.45-0.2 micrometers;<br class="style-scope patent-text"> j) concentration by tangential flow ultrafiltration (TFF) and buffer exchange by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 10-300 kDa;<br class="style-scope patent-text"> k) alcohol precipitation (40%-70%);<br class="style-scope patent-text"> l) filtration by centrifugation and direct flow filtration (DFF) through at least one clarification filter with a pore size of about 0.2 μM;<br class="style-scope patent-text"> m) treatment with alkaline salts for removal of excess detergent, followed by centrifugation and filtration by direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.2 μM;<br class="style-scope patent-text"> n) concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using membranes with a molecular weight cutoff (MWCO) of 10-300 kDa;<br class="style-scope patent-text"> o) removal of protein and nucleic acid impurities by washing the pellet with alcohol (50%-70%) in the presence of sodium chloride (0.1M-2M);<br class="style-scope patent-text"> p) dissolving the polysaccharide in WFI and subjecting it to concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 10-300 kDa, and q) Sterile filtration through at least one sterile filter with a pore size of about 0.2 micrometers under sterile conditions.</span>
    </p>
    <p num="0083" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第１の態様によると、ＬＰＳの酸加水分解は、好ましくは酢酸（最終濃度０．５～５％）ｐＨ約２．０～３．０を使用し、温度３０～９０℃および約１００～２００分の時間、実施されてもよい。
</span>
  According to a first aspect of the fourth embodiment, the acid hydrolysis of LPS preferably uses acetic acid (final concentration 0.5-5%) pH about 2.0-3.0, temperature 30-90 °C and a time of about 100-200 minutes.
</span>
    </p>
    <p num="0084" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第２の態様によると、酸加水分解中和は、好ましくは、７．０の最終ｐＨを達成するためにアンモニア水を使用して、実施されてもよい。<br class="style-scope patent-text">
  第４の実施形態の第３の態様によると、アニオン性洗剤は、硫酸アルキル、ドデシル硫酸ナトリウム、デオキシコール酸ナトリウム、ドデシルスルホン酸ナトリウム、ｓ－アルキル硫酸ナトリウム、脂肪アルコールポリオキシエチレンエーテル硫酸ナトリウム、オレイル硫酸ナトリウム、Ｎ－オレオイルポリ（アミノ酸）ナトリウム、アルキルベンゼンスルホン酸ナトリウム、アルファオレフィンスルホン酸ナトリウム、アルキルスルホン酸ナトリウム、アルファ－スルホモノカルボン酸エステル、脂肪酸スルホアルキルエステル、スクシネートスルホネート、アルキルナフタレンスルホネート、アルカンスルホン酸ナトリウム、リグニンスルホン酸ナトリウムおよびアルキルグリセリルエーテルスルホン酸ナトリウムを含む群から選択されてもよい。
</span>According to a second aspect of the fourth embodiment, acid hydrolytic neutralization may preferably be performed using aqueous ammonia to achieve a final pH of 7.0.<br class="style-scope patent-text"> According to a third aspect of the fourth embodiment, the anionic detergent is alkyl sulfate, sodium dodecyl sulfate, sodium deoxycholate, sodium dodecyl sulfonate, sodium s-alkyl sulfate, sodium fatty alcohol polyoxyethylene ether sulfate, Sodium oleyl sulfate, sodium N-oleoyl poly(amino acid), sodium alkylbenzenesulfonate, sodium alpha olefin sulfonate, sodium alkylsulfonate, alpha-sulfomonocarboxylic acid ester, fatty acid sulfoalkyl ester, succinate sulfonate, alkylnaphthalene It may be selected from the group comprising sulfonates, sodium alkane sulfonates, sodium lignin sulfonates and sodium alkyl glyceryl ether sulfonates.</span>
    </p>
    <p num="0085" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記アニオン性洗剤は、０．１％～２０％の範囲の最終濃度のデオキシコール酸ナトリウムであり得、より好ましくは１～２％の範囲で、保持液に添加され、２５℃～３０℃で１０～１２０分間撹拌されてもよい。
</span>
  Still preferably, said anionic detergent may be sodium deoxycholate at a final concentration in the range 0.1% to 20%, more preferably in the range 1-2%, added to the retentate at 25°C. It may be stirred at ~30°C for 10-120 minutes.
</span>
    </p>
    <p num="0086" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第４の態様によると、アルコール沈殿は、メタノール、エタノール、ｎ－プロピルアルコール、イソプロピルアルコール、アセトンもしくはｔ－ブチルアルコール、またはその組合せを使用して実施されてもよい。
</span>
  According to a fourth aspect of the fourth embodiment, alcohol precipitation may be performed using methanol, ethanol, n-propyl alcohol, isopropyl alcohol, acetone or t-butyl alcohol, or combinations thereof.
</span>
    </p>
    <p num="0087" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記アルコールはエタノールであり得る。<br class="style-scope patent-text">
  第４の実施形態の第５の態様によると、アルカリ塩は、ナトリウム、カリウム、カルシウムおよびマグネシウム塩の群から選択されてもよい。より好ましくは、アルカリ塩は、塩化カリウム、酢酸カリウム、硫酸カリウム、炭酸カリウム、重炭酸カリウム、リン酸カリウム、リン酸水素カリウム、リン酸二水素カリウム、硝酸カリウムおよび他のカリウム塩からなる群から選択されるカリウム塩、またはその２種以上の組合せであってもよい。
</span>Still preferably, the alcohol may be ethanol.<br class="style-scope patent-text"> According to a fifth aspect of the fourth embodiment, the alkali salt may be selected from the group of sodium, potassium, calcium and magnesium salts. More preferably, the alkali salt is selected from the group consisting of potassium chloride, potassium acetate, potassium sulfate, potassium carbonate, potassium bicarbonate, potassium phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, potassium nitrate and other potassium salts. or a combination of two or more thereof.</span>
    </p>
    <p num="0088" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、前記カリウム塩は、上清と混合された０．１Ｍ～２Ｍの範囲の最終濃度の塩化カリウムであり得、その溶解の際、混合物を、２～８℃で＞３時間インキュベートした。
</span>
  Still preferably, said potassium salt may be potassium chloride at a final concentration ranging from 0.1 M to 2 M mixed with the supernatant, upon dissolution the mixture was incubated at 2-8° C. for &gt;3 hours. .
</span>
    </p>
    <p num="0089" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第６の態様によると、カチオン性洗剤は、セチルトリメチルアンモニウム塩、テトラブチルアンモニウム塩、ミリスチルトリメチルアンモニウム塩およびヘキサジメトリン臭化物を含む群、またはその組合せから選択されてもよい。
</span>
  According to a sixth aspect of the fourth embodiment, the cationic detergent may be selected from the group comprising cetyltrimethylammonium salts, tetrabutylammonium salts, myristyltrimethylammonium salts and hexadimethrine bromide, or combinations thereof.
</span>
    </p>
    <p num="0090" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第７の態様によると、精製方法は、クロマトグラフィーステップを含まなくてもよい。<br class="style-scope patent-text">
  第４の実施形態の第８の態様によると、精製方法は、結果になり得る。
</span>According to a seventh aspect of the fourth embodiment, the method of purification may not comprise a chromatography step.<br class="style-scope patent-text"> According to an eighth aspect of the fourth embodiment, the purification method can result.</span>
    </p>
    <p num="0091" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第９の態様によると、方法は、エンドトキシン（ＰＳ１μｇ当たり＜１００ＥＵのエンドトキシン）、タンパク質（＜１％）および核酸（＜２％）不純物の大幅な低減、好適には４０％～６５％の範囲のより高い莢膜多糖体回収率と共に、所望のＯ－アセチルレベル（＞２．０ｍｍｏｌ／多糖体１ｇ）をもたらし、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に＞５０％のＰＳが溶出する）および精製Ｏ特異的多糖体の平均分子量は、４０～２００ｋＤａの範囲であり得る。
</span>
  According to a ninth aspect of the fourth embodiment, the method provides a significant reduction, preferably 40%, of endotoxin (&lt;100 EU endotoxin per μg PS), protein (&lt;1%) and nucleic acid (&lt;2%) impurities. Resulting in desired O-acetyl levels (&gt;2.0 mmol/g polysaccharide) along with higher capsular polysaccharide recovery ranging from ~65% to reach a molecular size distribution (distribution coefficient (KD) of 0.25). &gt;50% PS elutes before) and the average molecular weight of the purified O-specific polysaccharide can range from 40-200 kDa.
</span>
    </p>
    <p num="0092" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第４の実施形態の第１０の態様によると、最終精製多糖体バルクは、－２０℃以下で保存されてもよい。<br class="style-scope patent-text">
  本開示の第５の実施形態によると、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、カルボジイミド、還元的アミノ化またはシアニル化コンジュゲーション反応を使用して、担体タンパク質（ＣＰ）に共有結合されてもよい。
</span>According to a tenth aspect of the fourth embodiment, the final purified polysaccharide bulk may be stored at -20°C or below.<br class="style-scope patent-text"> According to a fifth embodiment of the present disclosure, purified Salmonella enterica serovar strain S. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis polysaccharide may be covalently attached to a carrier protein (CP) using carbodiimide, reductive amination or cyanylation conjugation reactions.</span>
    </p>
    <p num="0093" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の第１の態様によると、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、破傷風毒素、破傷風トキソイド（ＴＴ）、ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａトキソイド、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓトキソイド、Ｃｌｏｓｔｒｉｄｉｕｍ  ｐｅｒｆｒｉｎｇｅｎｓトキソイド、Ｅ．ｃｏｌｉ  ＬＴ、Ｅ．ｃｏｌｉ  ＳＴ、Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ易熱性毒素－Ｂサブユニット、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ外膜複合体、ｒＥＰＡ、Ｈ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ、Ｆｌａｇｅｌｌｉｎ  ＦｌｉＣ、カブトガニヘモシアニン、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａ由来のエキソトキシンＡ、外膜複合体ｃ（ＯＭＰＣ）、ポリン、トランスフェリン結合タンパク質、ニューモリシン、肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）、肺炎球菌表面アドヘシンＡ（ＰｓａＡ）、肺炎球菌ＰｈｔＤ、肺炎球菌表面タンパク質ＢＶＨ－３およびＢＶＨ－１１、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの防御抗原（ＰＡ）、ならびにＢａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの無毒化浮腫因子（ＥＦ）および致死因子（ＬＦ）、オボアルブミン、キーホールリンペットヘモシアニン（ＫＬＨ）、ヒト血清アルブミン、ウシ血清アルブミン（ＢＳＡ）、ツベルクリンの精製タンパク質誘導体（ＰＰＤ）、合成ペプチド、ヒートショックプロテイン、百日咳タンパク質、サイトカイン、リンホカイン、ホルモン、成長因子、Ｎ  １９などの様々な病原体由来抗原からの複数のヒトＣＤ４＋  Ｔ細胞エピトープを含む人工タンパク質、鉄取り込みタンパク質、リンカーありまたはなしのＣ．ｄｉｆｆｉｃｉｌｅおよびＳ．ａｇａｌａｃｔｉａｅタンパク質由来の毒素ＡまたはＢ、ならびにその断片、誘導体、変形を含む群から選択される担体タンパク質（ＣＰ）に共有結合していてもよい。
</span>
  According to a first aspect of the fifth embodiment, the purified Salmonella enterica serovar strain S. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis polysaccharides include tetanus toxin, tetanus toxoid (TT), diphtheria toxoid (DT), CRM197, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, E. coli LT, E. coli ST, Escherichia coli heat-labile toxin-B subunit, Neisseria meningitidis outer membrane complex, rEPA, H. influenzae protein D, Flagellin FliC, horseshoe crab hemocyanin, exotoxin A from Pseudomonas aeruginosa, outer membrane complex c (OMPC), porin, transferrin binding protein, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11, protective antigen (PA) of Bacillus anthracis, and detoxified edema factor (EF) and lethal factor (LF) of Bacillus anthracis, ovalbumin , keyhole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA), purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, N Engineered proteins containing multiple human CD4+ T cell epitopes from various pathogen-derived antigens such as 19, iron uptake proteins, C. elegans with or without linkers. difficile and S. It may be covalently attached to a carrier protein (CP) selected from the group comprising toxin A or B from the agalactiae protein, and fragments, derivatives and variants thereof.
</span>
    </p>
    <p num="0094" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ  Ｖｉ多糖体とのコンジュゲーションに使用される担体タンパク質は、破傷風トキソイドであってもよい。Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体は、好ましくは、破傷風トキソイド、ジフテリアトキソイドまたはＣＲＭ１９７から選択される担体タンパク質に個々にコンジュゲートしていてもよい。以下の多糖体－担体タンパク質コンジュゲートを含む免疫原性組成物が、本開示に従って想定される：破傷風トキソイドにコンジュゲートしたＳ．ｔｙｐｈｉ、ＴＴまたはＤＴまたはＣＲＭ１９７にコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ、ＴＴまたはＤＴまたはＣＲＭ１９７にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＴＴまたはＤＴまたはＣＲＭ１９７にコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓ；破傷風トキソイドにコンジュゲートしたＳ．ｔｙｐｈｉ、破傷風トキソイドにコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ；ＣＲＭ１９７にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＣＲＭ１９７にコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓ；ならびに破傷風トキソイドにコンジュゲートしたＳ．ｔｙｐｈｉ、ＤＴにコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ；ＣＲＭ１９７にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍおよび破傷風トキソイドにコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓおよび破傷風トキソイドにコンジュゲートしたＳ．ｔｙｐｈｉ、ＣＲＭ１９７にコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ；ＣＲＭ１９７にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍおよび破傷風トキソイドにコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓ。
</span>
  Still preferably, the carrier protein used for conjugation with the Salmonella typhi Vi polysaccharide may be tetanus toxoid. S. paratyphi A, S.; typhimurium and S. The polysaccharides from S. enteritidis may be individually conjugated, preferably to a carrier protein selected from tetanus toxoid, diphtheria toxoid or CRM197. Immunogenic compositions comprising the following polysaccharide-carrier protein conjugates are envisioned according to the present disclosure: S. cerevisiae conjugated to tetanus toxoid. S. typhi, TT or DT or CRM197 conjugated S. paratyphi A, TT or DT or S. paratyphi conjugated to CRM197. typhimurium and S. typhimurium conjugated to TT or DT or CRM197. S. enteritidis; S. enteritidis conjugated to tetanus toxoid. typhi, S. cerevisiae conjugated to tetanus toxoid. S. paratyphi A; S. typhimurium and CRM197 conjugated as well as S. enteritidis conjugated to tetanus toxoid. typhi, S. cerevisiae conjugated to DT. S. paratyphi A; typhimurium and S. cerevisiae conjugated to tetanus toxoid. S. enteritidis and conjugated to tetanus toxoid. typhi, S. typhi conjugated to CRM197. S. paratyphi A; typhimurium and S. cerevisiae conjugated to tetanus toxoid. enteritidis.
</span>
    </p>
    <p num="0095" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＣＲＭ１９７は、Ｐｆｅｎｅｘ  ＵＳＡからのＰｓｅｕｄｏｍｏｎａｓ  ｆｌｕｏｒｅｓｃｅｎｓの組換え株ＣＳ４６３－００３（ＭＢ１０１）から獲得される。
</span>
  According to the present disclosure, CRM197 is obtained from Pseudomonas fluorescens recombinant strain CS463-003 (MB101) from Pfenex USA.
</span>
    </p>
    <p num="0096" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＴＴは、Ｃｅｎｔｒａｌ  ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）、Ｎａｔｉｏｎａｌ  Ｃｏｎｔｒｏｌ  Ａｕｔｈｏｒｉｔｙ、Ｋａｓａｕｌｉ、Ｈｉｍａｃｈａｌ  Ｐｒａｄｅｓｈ、Ｉｎｄｉａから得たＣｌｏｓｔｒｉｄｉｕｍ  Ｔｅｔａｎｉ（Ｈａｒｖａｒｄ  Ｎｏ４９２０５）から獲得される。Ｃｅｎｔｒａｌ  ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）は、この株をＮＶＩ、Ｎｅｔｈｅｒｌａｎｄから獲得した。
</span>
  According to the present disclosure, TT is obtained from Clostridium Tetani obtained from the Central Research Institute (CRI), National Control Authority, Kasauli, Himachal Pradesh, India (Harvard No 49205). The Central Research Institute (CRI) obtained this strain from NVI, Netherlands.
</span>
    </p>
    <p num="0097" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＤＴは、Ｃｅｎｔｒａｌ  Ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）、Ｋａｓａｕｌｉ、Ｈｉｍａｃｈａｌ  Ｐｒａｄｅｓｈ、Ｉｎｄｉａから得られた株である、Ｃｏｒｎｙｎｅｂａｃｔｅｒｉｕｍ  ｄｉｐｈｔｈｅｒｉａｅ  Ｐａｒｋ－Ｗｉｌｌｉａｍｓ  Ｎｕｍｂｅｒ  ８株の培養物から製造される。
</span>
  According to the present disclosure, DT is produced from a culture of Cornynebacterium diphtheriae Park-<figure-callout id="8" label="Williams Number" filenames="2022546763000111.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Williams Number</a></figure-callout> 8 strain, a strain obtained from the Central Research Institute (CRI), Kasauli, Himachal Pradesh, India.
</span>
    </p>
    <p num="0098" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の第２の態様によると、コンジュゲーション前に、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、ＦｅＣｌ３、Ｈ２Ｏ２、メタ過ヨウ素酸ナトリウムおよび酢酸ナトリウムの群から選択される化学的手段、または高圧細胞破壊およびホモジナイザーの群から選択される機械的手段によって解重合／サイジングに供されてもよい。
</span>
  According to a second aspect of the fifth embodiment, prior to conjugation, the purified Salmonella enterica serovar S. cerevisiae is purified. typhi, S. paratyphi A, S.; typhimurium and S. The enteritidis polysaccharide is subjected to depolymerization/sizing by chemical means selected from the group of FeCl3, H2O2, sodium metaperiodate and sodium acetate, or mechanical means selected from the group of high pressure cell disruptors and homogenizers. may
</span>
    </p>
    <p num="0099" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、高圧細胞破壊によって解重合／サイジングに供されてもよい。
</span>
  Even more preferably, purified Salmonella enterica serotype strain S. typhi, S. paratyphi A, S.; typhimurium and S. The enteritidis polysaccharide may be subjected to depolymerization/sizing by high pressure cell disruption.
</span>
    </p>
    <p num="0100" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ多糖体（ＶｉＰｓ）は、酢酸ナトリウム（５％～１０％）による解重合／サイジングに供されてもよく、ここで、ＶｉＰｓの平均分子量は、４０～４００ｋＤａの範囲であり得る。
</span>
  Still preferably, the purified Salmonella enterica serovar typhi polysaccharides (ViPs) may be subjected to depolymerization/sizing with sodium acetate (5%-10%), wherein the average molecular weight of the ViPs is between 40-400 kDa. can be a range.
</span>
    </p>
    <p num="0101" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ多糖体（ＶｉＰｓ）は、酢酸ナトリウム（５％～１０％）による解重合／サイジングに供されてもよく、ここで、ＶｉＰｓの平均分子量は、１００～２５０ｋＤａの範囲であり得る。
</span>
  Still preferably, the purified Salmonella enterica serovar typhi polysaccharides (ViPs) may be subjected to depolymerization/sizing with sodium acetate (5%-10%), wherein the average molecular weight of the ViPs is between 100-250 kDa. can be a range.
</span>
    </p>
    <p num="0102" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  出願人は、部分的にサイズ低減された多糖体を使用して調製されたコンジュゲートのコンジュゲーション効率／コンジュゲート収率、免疫原性が、全長多糖体から調製されたコンジュゲートと比較してより高いことを見出した。また、多糖体のサイズ低減により、溶液の粘度が低下し、反応性末端基の数が増加し、その両方の因子が、共有結合形成の頻度増加に寄与する。
</span>
  Applicants have found that the conjugation efficiency/conjugate yield, immunogenicity of conjugates prepared using partially size-reduced polysaccharides are compared to conjugates prepared from full-length polysaccharides. found higher. Polysaccharide size reduction also reduces solution viscosity and increases the number of reactive end groups, both factors contributing to an increased frequency of covalent bond formation.
</span>
    </p>
    <p num="0103" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なおあるいは、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、解重合／サイジングに供されなくてもよい。
</span>
  Alternatively, purified Salmonella enterica serovar strain S. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis polysaccharide may not be subjected to depolymerization/sizing.
</span>
    </p>
    <p num="0104" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の第３の態様によると、コンジュゲーション前に、担体タンパク質（ＣＰ）は、カルボジイミド、還元的アミノ化またはシアニル化反応を使用して、ヒドラジン、カルボヒドラジド、塩化ヒドラジン、ジヒドラジド、ε－アミノヘキサン酸、クロロヘキサノールジメチルアセタール、Ｄ－グルクロノラクトン、シスタミンおよびｐ－ニトロフェニルエチルアミン、ヘキサンジアミン、エチレンジアミン、１，６－ジアミノオキシヘキサンまたはβ－プロピオンアミド（ｐｒｏｐｉｎａｍｉｄｏ）、ニトロフェニルエチルアミン、ハロゲン化ハロアルキル、６－アミノカプロン酸、ならびにその組合せからなる群から選択されるヘテロまたはホモ二官能性リンカーを介してアミノおよび／またはカルボキシル基を含むように誘導体化されてもよい。
</span>
  According to a third aspect of the fifth embodiment, prior to conjugation, the carrier protein (CP) is hydrazine, carbohydrazide, hydrazine chloride, dihydrazide, using carbodiimide, reductive amination or cyanylation reactions. ε-aminohexanoic acid, chlorohexanol dimethylacetal, D-glucuronolactone, cystamine and p-nitrophenylethylamine, hexanediamine, ethylenediamine, 1,6-diaminooxyhexane or β-propinamide, nitrophenylethylamine, It may be derivatized to contain amino and/or carboxyl groups via hetero- or homobifunctional linkers selected from the group consisting of haloalkyl halides, 6-aminocaproic acid, and combinations thereof.
</span>
    </p>
    <p num="0105" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、ヘテロまたはホモ二官能性リンカーは、ジヒドラジド、より好ましくはアジピン酸ジヒドラジドであってもよい。<br class="style-scope patent-text">
  ヒドラジド基は、例えば、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）などのカルボジイミドの存在下、ヒドラジン、カルボヒドラジド、スクシニルジヒドラジド、アジピン酸ジヒドラジド、塩化ヒドラジン（例えば、ヒドラジン二塩酸塩）または任意の他のジヒドラジドとの反応によって、カルボジイミド、還元的アミノ化、シアニル化反応を使用して、タンパク質のアスパラギン酸およびグルタミン酸残基のカルボキシル基によりタンパク質に導入され得る。ＥＤＣは、ヒドラジンまたはジヒドラジドとのタンパク質反応物質を活性化および変性するための触媒として用いられる。
</span>Still preferably, the hetero- or homobifunctional linker may be a dihydrazide, more preferably adipic acid dihydrazide.<br class="style-scope patent-text"> A hydrazide group can be formed by, for example, hydrazine, carbohydrazide, succinyl dihydrazide, adipic acid dihydrazide, hydrazine chloride (e.g., hydrazine dihydrochloride) in the presence of a carbodiimide such as 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC). ) or by reaction with any other dihydrazide, carboxyl groups of aspartic and glutamic acid residues of the protein using carbodiimide, reductive amination, cyanylation reactions. EDC is used as a catalyst to activate and denature protein reactants with hydrazine or dihydrazides.</span>
    </p>
    <p num="0106" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）などのカルボジイミドの存在下でのアジピン酸ジヒドラジド（ＡＤＨ）との担体タンパク質（ＣＰ）の反応は、５～７、より好ましくは６のｐＨで実施されてもよい。
</span>
  Still preferably, the reaction of the carrier protein (CP) with adipic acid dihydrazide (ADH) in the presence of a carbodiimide such as 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) is 5-7, more It may preferably be carried out at a pH of 6.
</span>
    </p>
    <p num="0107" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  したがって、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）などのカルボジイミドの存在下でのアジピン酸ジヒドラジド（ＡＤＨ）との担体タンパク質（ＣＰ）の反応は、ｐＨを約６から約７～８に上昇させることによって停止されてもよい。
</span>
  Thus, the reaction of carrier protein (CP) with adipic acid dihydrazide (ADH) in the presence of a carbodiimide such as 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) reduces the pH from about 6 to about 7 It may be stopped by increasing to ~8.
</span>
    </p>
    <p num="0108" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  あるいは、ＡＤＨによる担体タンパク質の誘導体化後、方法は、１０ｋＤａまたは３０ｋＤａまたは５０ｋＤａ分画分子量（ＭＷＣＯ）のいずれかの膜を使用した透析ろ過（ＤＦ）による緩衝液交換および０．２ｕフィルターを使用した滅菌ろ過のステップであって、これによって、ＡＤＨ誘導体化担体タンパク質を、少なくとも１０容積緩衝液交換するか、または好適なゲルろ過カラムを通過させ、実質的にすべての未反応化合物、残留ＡＤＨおよび残留ＥＤＣを除去し、精製ＡＤＨ誘導体化担体タンパク質を得る、ステップをさらに含んでもよい。
</span>
  Alternatively, after derivatization of the carrier protein with ADH, the method employed buffer exchange by diafiltration (DF) using either 10 kDa or 30 kDa or 50 kDa molecular weight cutoff (MWCO) membranes and a 0.2 u filter. A step of sterile filtration, whereby the ADH-derivatized carrier protein is buffer-exchanged at least 10 times or passed through a suitable gel filtration column to remove substantially all unreacted compound, residual ADH and residues. A further step of removing EDC to obtain a purified ADH-derivatized carrier protein may be included.
</span>
    </p>
    <p num="0109" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なおあるいは、コンジュゲーション前に、担体タンパク質は、ヘテロまたはホモ二官能性リンカーを介してアミノおよび／またはカルボキシル基を含むように誘導体化されなくてもよい。
</span>
  Alternatively, prior to conjugation, the carrier protein may not be derivatized to contain amino and/or carboxyl groups via hetero- or homobifunctional linkers.
</span>
    </p>
    <p num="0110" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の第３の態様によると、コンジュゲーション前に、精製Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、カルボジイミド、還元的アミノ化またはシアニル化反応を使用して、ヒドラジン、カルボヒドラジド、塩化ヒドラジン、ジヒドラジド、その混合物、ε－アミノヘキサン酸、クロロヘキサノールジメチルアセタール、Ｄ－グルクロノラクトン、シスタミンおよびｐ－ニトロフェニルエチルアミン、ヘキサンジアミン、エチレンジアミン、１，６－ジアミノオキシヘキサンまたはβ－プロピオンアミド、ニトロフェニルエチルアミン、ハロゲン化ハロアルキル、６－アミノカプロン酸、ならびにその組合せからなる群から選択されるヘテロまたはホモ二官能性リンカーを介してアミノおよび／またはカルボキシル基を含むように誘導体化されてもよい。
</span>
  According to a third aspect of the fifth embodiment, prior to conjugation, the purified Salmonella enterica serovar S. cerevisiae is purified. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis polysaccharides are prepared using carbodiimides, reductive amination or cyanylation reactions to form hydrazine, carbohydrazide, hydrazine chloride, dihydrazides, mixtures thereof, ε-aminohexanoic acid, chlorohexanol dimethylacetal, D-glucuronolactone, cystamine and a heterocyclic compound selected from the group consisting of p-nitrophenylethylamine, hexanediamine, ethylenediamine, 1,6-diaminooxyhexane or β-propionamide, nitrophenylethylamine, haloalkyl halides, 6-aminocaproic acid, and combinations thereof. or may be derivatized to contain amino and/or carboxyl groups via homobifunctional linkers.
</span>
    </p>
    <p num="0111" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、ヘテロまたはホモ二官能性リンカーは、ジヒドラジド、より好ましくはアジピン酸ジヒドラジドであってもよい。<br class="style-scope patent-text">
  ヒドラジド基は、カルボジイミド、還元的アミノ化、シアニル化反応を使用することによって、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体に導入することができ、例えば、臭化シアン（ＣＮＢｒ）の存在下、ヒドラジン、カルボヒドラジド、スクシニルジヒドラジド、アジピン酸ジヒドラジド、塩化ヒドラジン（例えば、ヒドラジン二塩酸塩）または任意の他のジヒドラジドとの多糖体の反応により、Ｖｉ多糖体のヒドラジド誘導体が形成され得る。
</span>Still preferably, the hetero- or homobifunctional linker may be a dihydrazide, more preferably adipic acid dihydrazide.<br class="style-scope patent-text"> The hydrazide group was isolated from Salmonella enterica serovar S. cerevisiae by using carbodiimide, reductive amination, cyanylation reactions. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis polysaccharide, for example, in the presence of cyanogen bromide (CNBr), hydrazine, carbohydrazide, succinyl dihydrazide, adipic acid dihydrazide, hydrazine chloride (e.g. hydrazine dihydrochloride) or any other dihydrazide Hydrazide derivatives of the Vi polysaccharide can be formed by reaction of the polysaccharide with.</span>
    </p>
    <p num="0112" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰは、シアニル化コンジュゲーション化学を使用して、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化され、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される。
</span>
  Still preferably, the Salmonella enterica serovar Paratyphi A OSP is derivatized with an adipic acid dihydrazide (ADH) linker using cyanylation conjugation chemistry, wherein the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoro Borate (CPPT) (CPIP), 1-Cyano-imidazole (1-CI), 1-Cyanobenzotriazole (1-CBT), 1-Cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”) , p-nitrophenylcyanate and N-cyanotriethylammonium tetrafluoroborate (“CTEA”) or 2-cyanopyridazin-3(2H)one (2-CPO).
</span>
    </p>
    <p num="0113" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰは、シアニル化コンジュゲーション化学を使用して、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化され、シアニル化試薬は、ＯＳＰ：ＡＤＨの重量比１：１～１：１０で混合された１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）であり、ＯＳＰ：ＣＰＰＴの比は、０．５～１．５であってもよく、反応は、７～１０の範囲のｐＨで、１～２時間の反応継続時間、２℃～３０℃の範囲の温度で実施される。
</span>
  Still preferably, the Salmonella enterica serovar Paratyphi A OSP is derivatized with an adipic acid dihydrazide (ADH) linker using cyanylation conjugation chemistry, wherein the cyanylating reagent is in a weight ratio of OSP:ADH of 1:1 to 1 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP) mixed at :10, the ratio of OSP:CPPT may be from 0.5 to 1.5, and the reaction is It is carried out at a pH in the range of 7-10, with a reaction duration of 1-2 hours, at a temperature in the range of 2°C-30°C.
</span>
    </p>
    <p num="0114" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態のなお別の態様によると、コンジュゲーション前に、多糖体は、ヘテロまたはホモ二官能性リンカーを介してアミノおよび／またはカルボキシル基を含むように誘導体化されなくてもよい。
</span>
  According to yet another aspect of the fifth embodiment, the polysaccharide may not be derivatized to contain amino and/or carboxyl groups via hetero- or homobifunctional linkers prior to conjugation.
</span>
    </p>
    <p num="0115" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の好ましい態様では、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ多糖体（ＶｉＰｓ）は、カルボジイミドコンジュゲーション化学を使用して担体タンパク質に共有結合されてもよく、任意の水溶性カルボジイミド、より好ましくは１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）が触媒として使用され得る。
</span>
  In a preferred aspect of the fifth embodiment, Salmonella enterica serovar typhi polysaccharides (ViPs) may be covalently attached to carrier proteins using carbodiimide conjugation chemistry, any water soluble carbodiimide, more preferably 1- Ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) can be used as a catalyst.
</span>
    </p>
    <p num="0116" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、Ｖｉ多糖体は、カルボジイミドコンジュゲーション化学を使用してＡＤＨ誘導体化担体タンパク質に共有結合されてもよく、任意の水溶性カルボジイミド、より好ましくは１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）が触媒として使用され得る。
</span>
  More preferably, the Vi polysaccharide may be covalently attached to the ADH-derivatized carrier protein using carbodiimide conjugation chemistry, any water-soluble carbodiimide, more preferably 1-ethyl-3(3-dimethylaminopropyl ) Carbodiimide (EDC) can be used as a catalyst.
</span>
    </p>
    <p num="0117" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、Ｖｉ多糖体は、カルボジイミドコンジュゲーション化学を使用してＡＤＨ誘導体化破傷風トキソイドに共有結合されてもよく、任意の水溶性カルボジイミド、より好ましくは１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）が触媒として使用され得る。
</span>
  More preferably, the Vi polysaccharide may be covalently attached to the ADH-derivatized tetanus toxoid using carbodiimide conjugation chemistry, any water-soluble carbodiimide, more preferably 1-ethyl-3(3-dimethylaminopropyl ) Carbodiimide (EDC) can be used as a catalyst.
</span>
    </p>
    <p num="0118" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なおあるいは、ＡＤＨ誘導体化Ｖｉ多糖体は、カルボジイミドコンジュゲーション化学を使用してＡＤＨ誘導体化破傷風トキソイドに共有結合されてもよく、任意の水溶性カルボジイミド、より好ましくは１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）が触媒として使用され得る。
</span>
  Still alternatively, the ADH-derivatized Vi polysaccharide may be covalently attached to the ADH-derivatized tetanus toxoid using carbodiimide conjugation chemistry, using any water-soluble carbodiimide, more preferably 1-ethyl-3(3-dimethyl Aminopropyl)carbodiimide (EDC) can be used as a catalyst.
</span>
    </p>
    <p num="0119" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なおあるいは、ＡＤＨ誘導体化Ｖｉ多糖体は、カルボジイミドコンジュゲーション化学を使用して破傷風トキソイドに共有結合されてもよく、任意の水溶性カルボジイミド、より好ましくは１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）が触媒として使用され得る。
</span>
  Still alternatively, the ADH-derivatized Vi polysaccharide may be covalently attached to tetanus toxoid using carbodiimide conjugation chemistry, any water-soluble carbodiimide, more preferably 1-ethyl-3(3-dimethylaminopropyl) Carbodiimide (EDC) can be used as a catalyst.
</span>
    </p>
    <p num="0120" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製ＶｉＰｓは、ＶｉＰｓ：ＥＤＡＣの重量比１：０．５～１：２で混合された１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＡＣ）の存在下でのカルボジイミドコンジュゲーション反応を使用して担体タンパク質（ＣＰ）に共有結合され、Ｖｉ多糖体および担体タンパク質の比は、０．５～１．５であってもよく、反応は、５～７の範囲のｐＨ、２℃～３０℃の範囲の温度で実施される。
</span>
  Even more preferably, purified ViPs are prepared by carbodiimide conjugation in the presence of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDAC) mixed at a ViPs:EDAC weight ratio of 1:0.5 to 1:2. covalently attached to a carrier protein (CP) using a gating reaction, the ratio of Vi polysaccharide to carrier protein may be between 0.5 and 1.5, the reaction is carried out at pH in the range of 5-7, It is carried out at temperatures ranging from 2°C to 30°C.
</span>
    </p>
    <p num="0121" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態のなお別の態様によると、Ｖｉ多糖体（ＶｉＰｓ）は、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）の存在下でＡＤＨ誘導体化破傷風トキソイド（ＴＴ）に共有結合されてもよく、ＶｉＰｓ：ＴＴ：ＥＤＣの重量比は、１：１：２であり得、Ｖｉ多糖体および破傷風トキソイドの濃度は、０．１ｍｇ／ｍＬ～１０．０ｍｇ／ｍＬであってもよく、Ｖｉ多糖体および破傷風トキソイドの比は、０．５～１．５であってもよい。
</span>
  According to still another aspect of the fifth embodiment, Vi polysaccharides (ViPs) are treated with ADH-derivatized tetanus toxoid (TT) in the presence of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC). may be covalently bound, the weight ratio of ViPs:TT:EDC can be 1:1:2, and the concentration of Vi polysaccharide and tetanus toxoid is 0.1 mg/mL to 10.0 mg/mL; Alternatively, the ratio of Vi polysaccharide and tetanus toxoid may be between 0.5 and 1.5.
</span>
    </p>
    <p num="0122" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態のなお別の態様によると、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）の存在下での誘導体化破傷風トキソイド（ＴＴ）とのＶｉ多糖体（ＶｉＰｓ）の反応は、５～７の範囲、より好ましくは６のｐＨ、２℃～３０℃、より好ましくは１０～２５℃の範囲の温度で実施されてもよく、コンジュゲーション変換効率は、≧７０％、より好ましくは≧９０％であり、コンジュゲートの分子サイズは、好ましくは１０００～１６００ｋＤａである。
</span>
  According to still another aspect of the fifth embodiment, the synthesis of Vi polysaccharides (ViPs) with derivatized tetanus toxoid (TT) in the presence of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) The reaction may be carried out at a pH in the range of 5-7, more preferably 6, at a temperature in the range of 2° C.-30° C., more preferably 10-25° C., with a conjugation conversion efficiency of ≧70%, More preferably ≧90% and the molecular size of the conjugate is preferably between 1000 and 1600 kDa.
</span>
    </p>
    <p num="0123" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＣ）などのカルボジイミドの存在下での誘導体化破傷風トキソイド（ＴＴ）およびＶｉ多糖体（ＶｉＰｓ）の反応は、ｐＨを約６から約７～８に上昇させることによって停止されてもよい。
</span>
  Additionally, the reaction of derivatized tetanus toxoid (TT) and Vi polysaccharides (ViPs) in the presence of carbodiimides such as 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) reduces the pH from about 6 to about It may be stopped by increasing to 7-8.
</span>
    </p>
    <p num="0124" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態の一態様によると、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ多糖体（ＯＳＰ）は、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される。
</span>
  According to one aspect of the fifth embodiment, S. The paratyphi A polysaccharide (OSP) may be conjugated to carrier proteins using cyanylation conjugation chemistry, where the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1 -cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”), p-nitrophenylcyanate and N- is selected from the group of cyanotriethylammonium tetrafluoroborate (“CTEA”) or 2-cyanopyridazin-3(2H)one (2-CPO);
</span>
    </p>
    <p num="0125" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰは、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）または（ＣＰＩＰ）である。
</span>
  More preferably, S.I. A paratyphi A OSP may be conjugated to a carrier protein using cyanylation conjugation chemistry, where the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) or (CPIP) .
</span>
    </p>
    <p num="0126" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、精製Ｓ．ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰは、シアニル化コンジュゲーション化学を使用して担体タンパク質（ＣＰ）に共有結合され、シアニル化試薬は、ＯＳＰ：ＣＰＰＴの重量比１：０．５～１：２で混合された１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）であり、ＯＳＰおよび担体タンパク質の比は、０．５～１．５であってもよく、反応は、５～７の範囲のｐＨ、２℃～３０℃の範囲の温度で実施される。
</span>
  Even more preferably, purified S. The paratyphi A OSP was covalently attached to a carrier protein (CP) using cyanylation conjugation chemistry, and the cyanylating reagents were mixed in weight ratios of OSP:CPPT from 1:0.5 to 1:2. Cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), the ratio of OSP and carrier protein may be between 0.5 and 1.5, the reaction is carried out at pH in the range of 5-7, 2°C. It is carried out at temperatures in the range of -30°C.
</span>
    </p>
    <p num="0127" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ多糖体ＯＳＰとのコンジュゲーションに使用される担体タンパク質は、破傷風トキソイドであってもよい。<br class="style-scope patent-text">
  なお好ましくは、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ多糖体ＯＳＰとのコンジュゲーションに使用される担体タンパク質は、ジフテリアトキソイドであってもよい。
</span>Preferably, S.I. The carrier protein used for conjugation with the paratyphi A polysaccharide OSP may be tetanus toxoid.<br class="style-scope patent-text"> Preferably, S.I. The carrier protein used for conjugation with the paratyphi A polysaccharide OSP may be diphtheria toxoid.</span>
    </p>
    <p num="0128" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ多糖体ＯＳＰとのコンジュゲーションに使用される担体タンパク質は、ＣＲＭ１９７であってもよい。<br class="style-scope patent-text">
  第５の実施形態のなお別の態様によると、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体は、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される。
</span>Preferably, S.I. The carrier protein used for conjugation with the paratyphi A polysaccharide OSP may be CRM197.<br class="style-scope patent-text"> According to still another aspect of the fifth embodiment, the S.E. typhimurium polysaccharides may be conjugated to carrier proteins using cyanylation conjugation chemistry, where the cyanylating reagents are 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”), p-nitrophenylcyanate and N-cyanotriethylammonium tetrafluoroborate selected from the group of fluoroborates (“CTEA”) or 2-cyanopyridazin-3(2H)ones (2-CPO);</span>
    </p>
    <p num="0129" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体は、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）である。
</span>
  More preferably, S.I. typhimurium polysaccharides may be conjugated to carrier proteins using cyanylation conjugation chemistry, where the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT).
</span>
    </p>
    <p num="0130" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体とのコンジュゲーションに使用される担体タンパク質は、破傷風トキソイドであってもよい。<br class="style-scope patent-text">
  なお好ましくは、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体とのコンジュゲーションに使用される担体タンパク質は、ジフテリアトキソイドであってもよい。
</span>Preferably, S.I. The carrier protein used for conjugation with the typhimurium polysaccharide may be tetanus toxoid.<br class="style-scope patent-text"> Preferably, S.I. The carrier protein used for conjugation with the typhimurium polysaccharide may be diphtheria toxoid.</span>
    </p>
    <p num="0131" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体とのコンジュゲーションに使用される担体タンパク質は、ＣＲＭ１９７であってもよい。<br class="style-scope patent-text">
  第５の実施形態のなお別の態様によると、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される。
</span>Preferably, S.I. The carrier protein used for conjugation with the typhimurium polysaccharide may be CRM197.<br class="style-scope patent-text"> According to still another aspect of the fifth embodiment, the S.E. The enteritidis polysaccharides may be conjugated to carrier proteins using cyanylation conjugation chemistry, where the cyanylating reagents are 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”), p-nitrophenylcyanate and N-cyanotriethylammonium tetrafluoroborate selected from the group of fluoroborates (“CTEA”) or 2-cyanopyridazin-3(2H)ones (2-CPO);</span>
    </p>
    <p num="0132" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体は、シアニル化コンジュゲーション化学を使用して担体タンパク質にコンジュゲートしてもよく、シアニル化試薬は、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）である。
</span>
  More preferably, S.I. enteritidis polysaccharides may be conjugated to carrier proteins using cyanylation conjugation chemistry, where the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT).
</span>
    </p>
    <p num="0133" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体とのコンジュゲーションに使用される担体タンパク質は、破傷風トキソイドであってもよい。<br class="style-scope patent-text">
  なお好ましくは、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体とのコンジュゲーションに使用される担体タンパク質は、ジフテリアトキソイドであってもよい。
</span>Preferably, S.I. The carrier protein used for conjugation with the S. enteritidis polysaccharide may be tetanus toxoid.<br class="style-scope patent-text"> Preferably, S.I. The carrier protein used for conjugation with the S. enteritidis polysaccharide may be diphtheria toxoid.</span>
    </p>
    <p num="0134" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体とのコンジュゲーションに使用される担体タンパク質は、ＣＲＭ１９７であってもよい。<br class="style-scope patent-text">
  出願人は、適切なリンカー、適切なサイズの多糖体を使用し、コンジュゲーションの代替方法、多糖体対タンパク質の比、多糖体対カップリング剤の比を利用することによって、最終多糖体－タンパク質コンジュゲートを安定化するための方法を見出した。この方法により、ワクチン中の多糖体－タンパク質コンジュゲートの比の改善がもたらされ得、これにより次に、コンジュゲート中の遊離糖および遊離タンパク質の数が減少し得、担体タンパク質抑制の低下、コンジュゲートの滅菌ろ過性の改善、より良好なコンジュゲーションの制御、および部分内架橋の増加により、間接的に良好な免疫応答がもたらされる。
</span>Preferably, S.I. The carrier protein used for conjugation with the S. enteritidis polysaccharide may be CRM197.<br class="style-scope patent-text"> Applicants have found that the final polysaccharide-protein A method has been found to stabilize the conjugate. This method may result in an improved ratio of polysaccharide-protein conjugate in the vaccine, which in turn may reduce the number of free sugars and free proteins in the conjugate, reducing carrier protein suppression, Improved sterile filterability of the conjugate, better control of conjugation, and increased intra-partial cross-linking indirectly lead to better immune responses.</span>
    </p>
    <p num="0135" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  出願人は、様々な因子が、多糖体およびタンパク質のカップリングに影響を及ぼし、これは、ＶｉＰｓの分子量、選択された担体タンパク質の種類、使用される多糖体：担体タンパク質の量の比、官能基の活性化、スペーサーの使用およびコンジュゲーション化学に依存することを見出した。
</span>
  Applicants believe that various factors influence polysaccharide and protein coupling, including the molecular weight of the ViPs, the type of carrier protein selected, the polysaccharide:carrier protein amount ratio used, the functional We have found that it depends on the activation of the group, the use of spacers and the conjugation chemistry.
</span>
    </p>
    <p num="0136" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  第５の実施形態のなお別の態様によると、コンジュゲーション反応後、方法は、接線流限外ろ過（ＴＦＦ）による濃縮および１００ｋＤａまたは３００ｋＤａ分画分子量（ＭＷＣＯ）のいずれかを有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換のステップを含んでもよく、これによって、コンジュゲートバルクが少なくとも３倍濃縮され、実質的にすべての未反応化合物、非コンジュゲート多糖体、非コンジュゲートタンパク質および残留ＥＤＣが除去され、精製Ｖｉ多糖体コンジュゲートワクチンが得られる。
</span>
  According to still another aspect of the fifth embodiment, after the conjugation reaction, the method used concentration by tangential flow ultrafiltration (TFF) and a membrane with either 100 kDa or 300 kDa molecular weight cut off (MWCO). A step of buffer exchange by diafiltration (DF) may be included, which concentrates the conjugate bulk at least 3-fold to remove substantially all unreacted compound, unconjugated polysaccharide, unconjugated protein and residuals. EDC is removed, resulting in a purified Vi polysaccharide conjugate vaccine.
</span>
    </p>
    <p num="0137" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、方法は、ゲルろ過クロマトグラフィーを含んでもよく、これによって、コンジュゲートバルクが少なくとも３倍濃縮され、実質的にすべての未反応化合物、非コンジュゲート多糖体、非コンジュゲートタンパク質および残留ＥＤＣが除去され、精製Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体コンジュゲートワクチンが得られ、コンジュゲート収率は≧５０％である。
</span>
  Additionally, the method may comprise gel filtration chromatography, whereby the conjugate bulk is concentrated at least 3-fold to remove substantially all unreacted compound, unconjugated polysaccharide, unconjugated protein and residual EDC. Removed and purified S. typhi, S. paratyphi A, S.; typhimurium and S. A S. enteritidis polysaccharide conjugate vaccine is obtained with a conjugate yield of ≧50%.
</span>
    </p>
    <p num="0138" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、精製方法は、限外ろ過およびゲルろ過クロマトグラフィーの組合せを含んでもよい。<br class="style-scope patent-text">
  第６の実施形態によると、免疫原性組成物は、担体タンパク質にコンジュゲートしたＳ．ｔｙｐｈｉ  Ｖｉ多糖体または担体タンパク質にコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ  多糖体または担体タンパク質にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍまたは担体タンパク質にコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓのいずれかを含む一価ワクチンであってもよい。
</span>Additionally, purification methods may involve a combination of ultrafiltration and gel filtration chromatography.<br class="style-scope patent-text"> According to a sixth embodiment, the immunogenic composition comprises S. cerevisiae conjugated to a carrier protein. S. typhi Vi polysaccharide or carrier protein conjugated to S. paratyphi A conjugated to a polysaccharide or carrier protein. typhimurium or S. typhimurium conjugated to a carrier protein. It may be a monovalent vaccine containing either S. enteritidis.</span>
    </p>
    <p num="0139" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第７の実施形態によると、免疫原性組成物は、以下の少なくとも１つの二価組合せを含んでもよい：<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質（ＣＰ）コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質（ＣＰ）コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質（ＣＰ）コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質（ＣＰ）コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原。
</span>According to a seventh embodiment of the disclosure, the immunogenic composition may comprise at least one bivalent combination of:<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein (CP) conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein (CP) conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein (CP) conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein (CP) conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen.</span>
    </p>
    <p num="0140" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0141" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0142" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0143" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0144" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第８の実施形態によると、免疫原性組成物は、以下の少なくとも１つの三価組合せを含んでもよい：<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質（ＣＰ）コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原。
</span>According to an eighth embodiment of the disclosure, the immunogenic composition may comprise at least one trivalent combination of:<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein (CP) conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen.</span>
    </p>
    <p num="0145" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0146" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0147" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0148" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0149" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第９の実施形態によると、四価免疫原性組成物は、ｉ）担体タンパク質（ＣＰ）にコンジュゲートしたＳ．ｔｙｐｈｉ  Ｖｉ多糖体、ｉｉ）担体タンパク質にコンジュゲートしたＳ．ｐａｒａｔｙｐｈｉ  Ａ多糖体、ｉｉｉ）担体タンパク質にコンジュゲートしたＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体、およびｉｖ）担体タンパク質にコンジュゲートしたＳ．ｔｙｐｈｉｍｕｒｉｕｍ多糖体を含んでもよい。
</span>
  According to a ninth embodiment of the present disclosure, the tetravalent immunogenic composition comprises i) S. cerevisiae conjugated to a carrier protein (CP). typhi Vi polysaccharide, ii) S. cerevisiae conjugated to a carrier protein; iii) S. paratyphi A polysaccharide conjugated to a carrier protein; enteritidis polysaccharide, and iv) S. enteritidis conjugated to a carrier protein. typhimurium polysaccharide.
</span>
    </p>
    <p num="0150" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0151" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0152" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0153" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0154" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１０の実施形態によると、免疫原性組成物は、これらに限定されないが、Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉ  Ｂ、Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉ  Ｃ、サルモネラ菌抗原、例えば、外膜小胞、外膜タンパク質（例えば、ＯｍｐＣ、ＯｍｐＤ、ＯｍｐＦ）、シデロフォア（エンテロバクチン）、ＩＩＩ型分泌系タンパク質（例えば、ＳｉｐＢ、ＳｉｐＤ、ＳｓｅＢ、ＳｓｅＣおよびＰｒｇＩ）、フラゲリン、非チフス性サルモネラ属菌種、赤痢菌、Ｓｈｉｇｅｌｌａ  ｓｏｎｎｅｉ、Ｓｈｉｇｅｌｌａ  ｄｙｓｅｎｔｅｒｉａｅ、Ｓｈｉｇｅｌｌａ  ｆｌｅｘｎｅｒｉ、Ｓｈｉｇｅｌｌａ  ｂｏｙｄｉｉ、Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ、エンテロバクター種、エルシニア種、シュードモナス種、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａ、Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ（ａ、ｃ、ｄ、ｅ、ｆ血清型および非莢膜型株）、肝炎（Ａ、Ｃ、Ｄ、Ｅ、ＦおよびＧ株）、インフルエンザ、ブドウ球菌属菌種、Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ  ａｕｒｅｕｓ、Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ  ａｕｒｅｕｓ５型、Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ  ａｕｒｅｕｓ８型、連鎖球菌属菌種、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ｐｎｅｕｍｏｎｉａｅ（１、２、３、４、５、６Ａ、６Ｂ、６Ｃ、６Ｄ、６Ｅ、６Ｇ、６Ｈ、７Ａ、７Ｂ、７Ｃ、７Ｆ、８、９Ａ、９Ｌ、９Ｆ、９Ｎ、９Ｖ、１０Ｆ、１０Ｂ、１０Ｃ、１０Ａ、１１Ａ、１１Ｆ、１１Ｂ、１１Ｃ、１１Ｄ、１１Ｅ、１２Ａ、１２Ｂ、１２Ｆ、１３、１４、１５Ａ、１５Ｃ、１５Ｂ、１５Ｆ、１６Ａ、１６Ｆ、１７Ａ、１７Ｆ、１８Ｃ、１８Ｆ、１８Ａ、１８Ｂ、１９Ａ、１９Ｂ、１９Ｃ、１９Ｆ、２０、２０Ａ、２０Ｂ、２１、２２Ａ、２２Ｆ、２３Ａ、２３Ｂ、２３Ｆ、２４Ａ、２４Ｂ、２４Ｆ、２５Ｆ、２５Ａ、２７、２８Ｆ、２８Ａ、２９、３１、３２Ｆ、３２Ａ、３３Ａ、３３Ｃ、３３Ｄ、３３Ｅ、３３Ｆ、３３Ｂ、３４、４５、３８、３５Ａ、３５Ｂ、３５Ｃ、３５Ｆ、３６、３７、３８、３９、４０、４１Ｆ、４１Ａ、４２、４３、４４、４５、４６、４７Ｆ、４７Ａ、４８）、Ａ群連鎖球菌、Ｂ群連鎖球菌（群Ｉａ、Ｉｂ、ＩＩ、ＩＩＩ、ＩＶ、Ｖ、Ｖｌ、ＶＩＩ  ＶＩＩ、ＶＩＩＩおよびＩＸ）、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ、Ｈａｅｍｏｐｈｉｌｕｓ  ｐｎｅｕｍｏｎｉａ、Ｈｅｌｉｃｏｂａｃｔｅｒ  ｐｙｌｏｒｉ、Ｃｈｌａｍｙｄｉａ  ｐｎｅｕｍｏｎｉａｅ、Ｃｈｌａｍｙｄｉａ  ｔｒａｃｈｏｍａｔｉｓ、Ｕｒｅａｐｌａｓｍａ  ｕｒｅａｌｙｔｉｃｕｍ、Ｍｙｃｏｐｌａｓｍａ  ｐｎｅｕｍｏｎｉａｅ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ｐｙｏｇｅｎｅｓ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ａｇａｌａｃｔｉａｅ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ｖｉｒｉｄａｎｓ、Ｅｎｔｅｒｏｃｏｃｃｕｓｆａｅｃａｌｉｓ、Ｅｎｔｅｒｏｃｏｃｃｕｓ  ｆａｅｃｉｕｍ、Ｅｎｔｅｒｏｃｏｃｃｕｓ  ｆａｅｃａｌｉｓ  Ｎｅｉｓｓｅｒｉａ  ｇｏｎｏｒｒｈｏｅａｅ、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓ、Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ、Ｐａｓｔｅｕｒｅｌｌａ  ｐｅｓｔｉｓ、カンピロバクター属菌種、Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ、クロストリジウム属菌種、Ｃｌｏｓｔｒｉｄｉｕｍ  ｔｅｔａｎｉ、Ｃｌｏｓｔｒｉｄｉｕｍ  ｄｉｆｆｉｃｉｌｅ、マイコバクテリウム属菌種、Ｍｙｃｏｂａｃｔｅｒｉｕｍ  ｔｕｂｅｒｃｕｌｏｓｉｓ、Ｍ．ｃａｔａｒｒｈａｌｉｓ、Ｋｌｅｂｓｉｅｌｌａ  ｐｎｅｕｍｏｎｉａｅ、トレポネーマ属菌種、ボレリア属菌種、Ｂｏｒｒｅｌｉａ  ｂｕｒｇｄｏｒｆｅｒｉ、レプトスピラ属菌種、Ｈｅｍｏｐｈｉｌｕｓ  ｄｕｃｒｅｙｉ、Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ  ｄｉｐｈｔｈｅｒｉａ、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓ、Ｂｏｒｄｅｔｅｌｌａ  ｐａｒａｐｅｒｔｕｓｓｉｓ、Ｂｏｒｄｅｔｅｌｌａ  ｂｒｏｎｃｈｉｓｅｐｔｉｃａ、赤痢菌属菌種、エーリキア属（Ｅｒｌｉｃｈｉａ）菌種、リケッチア属菌種およびＮ．ｍｅｎｉｎｇｉｔｉｄｉｓ多糖体（Ａ、Ｂ、Ｃ、Ｄ、Ｗ１３５、Ｘ、Ｙ、Ｚおよび２９Ｅ）無細胞性百日咳抗原、変性アデニレートシクラーゼ、マラリア抗原（ＲＴＳ、Ｓ）、脾脱疽、デング熱、マラリア、麻疹、流行性耳下腺炎、風疹、ＢＣＧ、ヒトパピローマウイルス、日本脳炎、デング熱、ジカ、エボラ、チクングニア熱、ポリオウイルス、ロタウイルス、天然痘、黄熱病、フラビウイルス、帯状疱疹および水痘ウイルス抗原からなる群から選択される１種または複数の抗原をさらに含んでもよい。
</span>
  According to a tenth embodiment of the present disclosure, the immunogenic composition includes, but is not limited to Salmonella paratyphi B, Salmonella paratyphi C, Salmonella antigens such as outer membrane vesicles, outer membrane proteins (e.g. OmpC, OmpD, OmpF), siderophores (enterobactin), type III secretion system proteins (e.g. SipB, SipD, SseB, SseC and PrgI), flagellin, non-typhoidal Salmonella spp., Shigella, Shigella sonnei, Shigella dysenteriae, Shigella flexneri, Shigella boydii, Escherichia coli, Enterobacter sp., Yersinia sp., Pseudomonas sp., Pseudomonas aeruginosa, Haemophilus influenzae (a, c, d, e, f serotypes and noncapsular strains), hepatitis (A, C, D, E, F and G strains), influenza, Staphylococcus spp., Staphylococcus aureus, Staphylococcus aureus type 5, Staphylococcus aureus type 8, Streptococcus spp., Streptococcus pneumoniae (1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 6G, 6H, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9F, 9N, 9V, 10F, 10B, 10C, 10A, 11A, 11F, 11B, 11C, 11D, 11E, 12A, 12B, 12F, 13, 14, 15A, 15C, 15B, 15F, 16A, 16F, 17A, 17F, 18C, 18F, 18A, 18B, 19A, 19B, 19C, 19F, 20, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24A, 24B, 24F, 25F, 25A, 27, 28F, 28A, 29, 31, 32F, 32A, 33A, 33C, 33D, 33E, 33F, 33B, 34, 45, 38, 35A, 35B, 35C, 35F, 36, 37, 38, 39, 40, 41F, 41A, 42, 43, 44, 45, 46, 47F, 47A, 48), group A streptococci, group B Streptococcus (Groups Ia, Ib, II, III, IV, V, Vl, VII VII, VIII and IX), Neisseria meningitidis, Haemophili ｌｕｓ  ｐｎｅｕｍｏｎｉａ、Ｈｅｌｉｃｏｂａｃｔｅｒ  ｐｙｌｏｒｉ、Ｃｈｌａｍｙｄｉａ  ｐｎｅｕｍｏｎｉａｅ、Ｃｈｌａｍｙｄｉａ  ｔｒａｃｈｏｍａｔｉｓ、Ｕｒｅａｐｌａｓｍａ  ｕｒｅａｌｙｔｉｃｕｍ、Ｍｙｃｏｐｌａｓｍａ  ｐｎｅｕｍｏｎｉａｅ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ｐｙｏｇｅｎｅｓ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ａｇａｌａｃｔｉａｅ、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  ｖｉｒｉｄａｎｓ、Ｅｎｔｅｒｏｃｏｃｃｕｓｆａｅｃａｌｉｓ、Ｅｎｔｅｒｏｃｏｃｃｕｓ  ｆａｅｃｉｕｍ、Ｅｎｔｅｒｏｃｏｃｃｕｓ  ｆａｅｃａｌｉｓ  Ｎｅｉｓｓｅｒｉａ  ｇｏｎｏｒｒｈｏｅａｅ、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓ、Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ、Ｐａｓｔｅｕｒｅｌｌａ  ｐｅｓｔｉｓ、カンピロバクター属菌種, Campylobacter jejuni, Clostridium spp., Clostridium tetani, Clostridium difficile, Mycobacterium spp., Mycobacterium tuberculosis, M. ｃａｔａｒｒｈａｌｉｓ、Ｋｌｅｂｓｉｅｌｌａ  ｐｎｅｕｍｏｎｉａｅ、トレポネーマ属菌種、ボレリア属菌種、Ｂｏｒｒｅｌｉａ  ｂｕｒｇｄｏｒｆｅｒｉ、レプトスピラ属菌種、Ｈｅｍｏｐｈｉｌｕｓ  ｄｕｃｒｅｙｉ、Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ  ｄｉｐｈｔｈｅｒｉａ、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓ、Ｂｏｒｄｅｔｅｌｌａ  ｐａｒａｐｅｒｔｕｓｓｉｓ、Ｂｏｒｄｅｔｅｌｌａ  ｂｒｏｎｃｈｉｓｅｐｔｉｃａ、赤痢菌属菌種、エーリキア属（Ｅｒｌｉｃｈｉａ）菌s, Rickettsia spp. and N. meningitidis polysaccharide (A, B, C, D, W135, X, Y, Z and 29E) acellular pertussis antigen, modified adenylate cyclase, malaria antigen (RTS, S), splenic anthrax, dengue fever, malaria, From measles, mumps, rubella, BCG, human papillomavirus, Japanese encephalitis, dengue, Zika, Ebola, chikungunya, poliovirus, rotavirus, smallpox, yellow fever, flavivirus, shingles and varicella virus antigens It may further comprise one or more antigens selected from the group consisting of:
</span>
    </p>
    <p num="0155" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１１の実施形態によると、組成物は、以下の少なくとも１つの組合せを含む：<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｈ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｈ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｉ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
            <br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原。
</span>According to an eleventh embodiment of the present disclosure, the composition comprises a combination of at least one of:<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> h) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen;<br class="style-scope patent-text"> e) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> h) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> i) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> <br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen.</span>
    </p>
    <p num="0156" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0157" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0158" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0159" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0160" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、５μｇの用量のＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原を含む。<br class="style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、５μｇの用量のＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原を含む。
</span>Still preferably, 0.5 ml of composition contains a dose of 5 μg of Neisseria meningitidis A saccharide-TT conjugate antigen.<br class="style-scope patent-text"> Still preferably, 0.5 ml of the composition contains a dose of 5 μg Neisseria meningitidis C sugar-CRM197 conjugate antigen.</span>
    </p>
    <p num="0161" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、５μｇの用量のＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原を含む。<br class="style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、５μｇの用量のＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ糖－ＣＲＭ１９７コンジュゲート抗原を含む。
</span>Still preferably, 0.5 ml of the composition contains a dose of 5 μg Neisseria meningitidis Y sugar-CRM197 conjugate antigen.<br class="style-scope patent-text"> Still preferably, 0.5 ml of the composition contains a dose of 5 μg Neisseria meningitidis W saccharide-CRM197 conjugate antigen.</span>
    </p>
    <p num="0162" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、５μｇの用量の  Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原を含む。<br class="style-scope patent-text">
  本開示の第１２の実施形態によると、免疫原性組成物は、以下の少なくとも１つの組合せを含む：<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｃ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｆ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｇ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｅ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｆ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｇ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｈ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｄ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｅ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｆ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｇ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｈ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｅ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｆ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｇ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｈ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｉ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｅ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｆ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｇ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｈ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｉ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｅ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｆ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｇ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｈ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｉ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｊ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｆ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｇ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｈ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｉ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｊ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｆ）ＳａｌｋまたはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｇ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｈ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｉ）全細胞百日咳（ｗＰ）抗原または無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｊ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｋ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）。
</span>Still preferably, a 0.5 ml composition contains a dose of 5 μg Neisseria meningitidis X sugar-TT conjugate antigen.<br class="style-scope patent-text"> According to a twelfth embodiment of the present disclosure, the immunogenic composition comprises a combination of at least one of:<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg), and g) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) a diphtheria toxoid (D) antigen;<br class="style-scope patent-text"> e) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> f) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> g) hepatitis B virus surface antigen (HBsAg), and h) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> d) a diphtheria toxoid (D) antigen;<br class="style-scope patent-text"> e) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> f) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> g) hepatitis B virus surface antigen (HBsAg), and h) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> e) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> f) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> g) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> h) hepatitis B virus surface antigen (HBsAg), and i) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> e) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> f) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> g) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> h) hepatitis B virus surface antigen (HBsAg), and i) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) a rotavirus antigen,<br class="style-scope patent-text"> e) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> f) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> g) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> h) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> i) hepatitis B virus surface antigen (HBsAg), and j) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> f) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> g) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> h) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> i) hepatitis B virus surface antigen (HBsAg), and j) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) a rotavirus antigen,<br class="style-scope patent-text"> f) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> g) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> h) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> i) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> j) hepatitis B virus surface antigen (HBsAg), and k) Haemophilus influenzae type b antigen (Hib).</span>
    </p>
    <p num="0163" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0164" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0165" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0166" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0167" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原を含む。<br class="style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）を含む。
</span>Still preferably, the composition comprises the diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml.<br class="style-scope patent-text"> Still preferably, the composition comprises tetanus toxoid (T) in an amount of 1-30 Lf per 0.5 ml.</span>
    </p>
    <p num="0168" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または１種もしくは複数の変性アデニレートシクラーゼ、０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇ、または線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇを含む無細胞性百日咳（ａＰ）抗原を含む。
</span>
  Still preferably, the composition comprises whole cell pertussis (wP) antigen, or one or more modified adenylate cyclases, in an amount of 1-50 IOU per 0.5 ml, pertussis toxin (PT) per 0.5 ml, 1-50 IU per 0.5 ml. acellular pertussis (aP) antigens containing 50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) 1-20 μg, or fimbrial proteins (FIM1, 2 and 3) 2-25 μg.
</span>
    </p>
    <p num="0169" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）を含む。<br class="style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）を含む。
</span>Still preferably, the composition comprises hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml.<br class="style-scope patent-text"> Still preferably, the composition comprises Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml.</span>
    </p>
    <p num="0170" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原を含む。
</span>
  Still preferably, the composition comprises an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml. include.
</span>
    </p>
    <p num="0171" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原を含み、０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量である。
</span>
  Still preferably, the composition comprises an inactivated poliovirus (IPV) antigen selected from Sabin or Salk strains, with a dose of 1-50 D antigen units (DU) for IPV type 1 and 1 D antigen unit (DU) for IPV type 2 per 0.5 ml. A dose of ˜50 D antigen units (DU), or a dose of 1-50 D antigen units (DU) for IPV type 3.
</span>
    </p>
    <p num="0172" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１３の実施形態によると、免疫原性組成物は、以下の少なくとも１つの組合せを含む：<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｄ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｅ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｆ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｇ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｇ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｅ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｆ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｇ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｈ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｆ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｇ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｈ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｉ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原。
</span>According to a thirteenth embodiment of the present disclosure, the immunogenic composition comprises a combination of at least one of:<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) a rotavirus antigen,<br class="style-scope patent-text"> c) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> d) Shigella spp. antigen,<br class="style-scope patent-text"> e) a Campylobacter jejuni antigen;<br class="style-scope patent-text"> f) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens;<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejuni antigens,<br class="style-scope patent-text"> g) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens;<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejuni antigens,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens;<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) Shigella spp. antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejuni antigens,<br class="style-scope patent-text"> g) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) a rotavirus antigen,<br class="style-scope patent-text"> e) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> f) Shigella spp. antigen,<br class="style-scope patent-text"> g) Campylobacter jejuni antigens,<br class="style-scope patent-text"> h) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) a rotavirus antigen,<br class="style-scope patent-text"> f) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> g) Shigella spp. antigen,<br class="style-scope patent-text"> h) Campylobacter jejuni antigens,<br class="style-scope patent-text"> i) Vibrio cholerae antigen.</span>
    </p>
    <p num="0173" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原を含む。
</span>
  Still preferably, 0.5 ml of composition contains Salmonella enterica serovar typhi ViPs-TT conjugate antigen in a dose range of 1.25-50 μg.
</span>
    </p>
    <p num="0174" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar Paratyphi A OSP-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0175" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar typhimurium saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0176" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、０．５ｍｌの組成物は、１．２５～５０μｇの用量範囲のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原を含み、ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである。
</span>
  Still preferably, 0.5 ml of the composition comprises Salmonella enterica serovar enteritidis saccharide-CP conjugate antigen in a dose range of 1.25-50 μg, wherein CP is either TT or DT or CRM197.
</span>
    </p>
    <p num="0177" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、組成物は、０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原を含む。
</span>
  Still preferably, the composition comprises an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml. include.
</span>
    </p>
    <p num="0178" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態の一態様によると、免疫原性組成物は、炭酸塩、リン酸塩、酢酸塩、ＨＥＰＥＳ、コハク酸塩、ヒスチジン、トリス、硼酸塩、クエン酸塩、酪酸塩、グルコンサン塩および酒石酸塩からなる群から選択される緩衝剤、ならびにリン酸ナトリウムおよび／またはリン酸カリウムを所望のｐＨに到達するように選択された比で含有するリン酸緩衝剤を含むより複雑な有機緩衝剤をさらに含んでもよい。別の例では、緩衝剤は、所望のｐＨに到達するように製剤化されたトリス（ヒドロキシメチル）アミノメタンすなわち「トリス」を含有する。なお別の例では、緩衝剤は、ハンクス塩を含む最小必須培地であり得る。ＨＥＰＥＳ、ピペラジン－Ｎ，Ｎ’－ビス（ＰＩＰＥＳ）および２－エタンスルホン酸（ＭＥＳ）などの他の緩衝液もまた、本開示により想定される。緩衝液は、本開示の免疫原性組成物を安定化するのを助ける。緩衝液の量は、好ましくは、５ｍＭ、６ｍＭ、７ｍＭ、２２ｍＭ、２３ｍＭ、２４ｍＭ、２５ｍＭ、２６ｍＭ、２７ｍＭ、２８ｍＭ、２９ｍＭおよび３０ｍＭから選択される０．１ｍＭ～１００ｍＭの範囲であってもよい。緩衝液の量は、０．１ｍｇ～２．０ｍｇの量であってもよい。
</span>
  According to one aspect of an embodiment, the immunogenic composition comprises carbonate, phosphate, acetate, HEPES, succinate, histidine, tris, borate, citrate, butyrate, gluconate and tartaric acid. More complex organic buffers including buffers selected from the group consisting of salts and phosphate buffers containing sodium phosphate and/or potassium phosphate in ratios selected to reach the desired pH. It may contain further. In another example, the buffer contains tris(hydroxymethyl)aminomethane or "Tris" formulated to reach the desired pH. In yet another example, the buffering agent can be minimal essential medium containing Hank's salts. Other buffers such as HEPES, piperazine-N,N'-bis (PIPES) and 2-ethanesulfonic acid (MES) are also envisioned by the present disclosure. Buffers help stabilize the immunogenic compositions of this disclosure. The amount of buffer may preferably range from 0.1 mM to 100 mM selected from 5 mM, 6 mM, 7 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM and 30 mM. The amount of buffer may be between 0.1 mg and 2.0 mg.
</span>
    </p>
    <p num="0179" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  クエン酸緩衝液は、１．０５～２．６３ｍｇの範囲のクエン酸一水和物（ＣＡＭ）および１．４７～３．６８ｍｇの範囲のクエン酸三ナトリウム無水物（ＴＣＤ）を溶解することによって調製されてもよい。
</span>
  The citrate buffer is prepared by dissolving citric acid monohydrate (CAM) in the range of 1.05-2.63 mg and trisodium citrate anhydrous (TCD) in the range of 1.47-3.68 mg. may be prepared.
</span>
    </p>
    <p num="0180" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、０．１ｍｇ～２．０ｍｇの範囲のトリスまたはクエン酸緩衝液またはヒスチジン緩衝液またはコハク酸緩衝液をさらに含んでもよい。<br class="style-scope patent-text">
  好ましくは、免疫原性組成物は、０．６１ｍｇ～１．５２ｍｇの範囲のトリス緩衝液をさらに含んでもよい。
</span>Preferably, the immunogenic composition may further comprise Tris or citrate buffer or histidine buffer or succinate buffer in the range of 0.1 mg to 2.0 mg.<br class="style-scope patent-text"> Preferably, the immunogenic composition may further comprise Tris buffer in the range of 0.61 mg to 1.52 mg.</span>
    </p>
    <p num="0181" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、１０ｍＭ～２５ｍＭの範囲のクエン酸緩衝液をさらに含んでもよい。<br class="style-scope patent-text">
  好ましくは、免疫原性組成物は、０．７８～１．９４ｍｇの範囲のヒスチジン緩衝液をさらに含んでもよい。
</span>Preferably, the immunogenic composition may further comprise a citrate buffer in the range of 10mM to 25mM.<br class="style-scope patent-text"> Preferably, the immunogenic composition may further comprise a histidine buffer in the range of 0.78-1.94 mg.</span>
    </p>
    <p num="0182" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、０．５９～１．４８ｍｇの範囲のコハク酸緩衝液をさらに含んでもよい。<br class="style-scope patent-text">
  実施形態のなお別の態様によると、免疫原性組成物は、糖、界面活性剤、ポリマー、塩、アミノ酸またはｐＨ調整剤からなる群から選択される薬学的に許容される賦形剤をさらに含んでもよい。
</span>Preferably, the immunogenic composition may further comprise succinate buffer in the range of 0.59-1.48 mg.<br class="style-scope patent-text"> According to yet another aspect of an embodiment, the immunogenic composition further comprises a pharmaceutically acceptable excipient selected from the group consisting of sugars, surfactants, polymers, salts, amino acids or pH modifiers. may contain.</span>
    </p>
    <p num="0183" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  界面活性剤の例には、ポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５、ノニルフェノキシポリエタノール、ｔ－オクチルフェノキシポリエトキシエタノール、オクトキシノール（ｏｘｔｏｘｙｎｏｌ）４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマーなどのイオン性および非イオン性界面活性剤が含まれ得る。
</span>
  Examples of surfactants include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, <figure-callout id="80" label="polysorbate" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">polysorbate</a></figure-callout> 80, polysorbate 85, nonylphenoxypolyethanol, t-octylphenoxypolyethoxyethanol, oxtoxynol 40, nonoxynol-9. , triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamers.
</span>
    </p>
    <p num="0184" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、薬学的に許容される賦形剤としてポリソルベート２０を含んでもよい。<br class="style-scope patent-text">
  ポリマーの例には、デキストラン、カルボキシメチルセルロース、ヒアルロン酸、シクロデキストリンなどが含まれ得る。
</span>Preferably, the immunogenic composition may contain polysorbate 20 as a pharmaceutically acceptable excipient.<br class="style-scope patent-text"> Examples of polymers can include dextran, carboxymethylcellulose, hyaluronic acid, cyclodextrin, and the like.</span>
    </p>
    <p num="0185" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  塩の例には、ＮａＣｌ、ＫＣｌ、ＫＨ<sub class="style-scope patent-text">２</sub>ＰＯ<sub class="style-scope patent-text">４</sub>、Ｎａ<sub class="style-scope patent-text">２</sub>ＨＰＯ<sub class="style-scope patent-text">４</sub>．２Ｈ<sub class="style-scope patent-text">２</sub>Ｏ、ＣａＣｌ<sub class="style-scope patent-text">２</sub>、ＭｇＣｌ<sub class="style-scope patent-text">２</sub>などが含まれ得る。好ましくは、塩は、ＮａＣｌであってもよい。典型的には、塩の量は、１００ｍＭ～２００ｍＭの範囲であってもよい。
</span>Examples of salts include <sub class="style-scope patent-text">NaCl</sub> , <sub class="style-scope patent-text">KCl</sub> , <sub class="style-scope patent-text">KH2PO4</sub> , <sub class="style-scope patent-text">Na2HPO4</sub> . <sub class="style-scope patent-text">2H2O</sub> , <sub class="style-scope patent-text">CaCl2</sub> , <sub class="style-scope patent-text">MgCl2</sub> , and the like may be included. Preferably, the salt may be NaCl. Typically, the amount of salt may range from 100 mM to 200 mM.</span>
    </p>
    <p num="0186" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、１～１０ｍｇの範囲の塩化ナトリウムを含んでもよい。<br class="style-scope patent-text">
  賦形剤としてのアミノ酸の例は、Ｌ－ヒスチジン、リシン、イソロイシン、メチオニン、グリシン、アスパラギン酸、トリシン、アルギニン、ロイシン、グルタミン、アラニン、ペプチド、加水分解タンパク質または血清アルブミンなどのタンパク質の群から選択される。
</span>Preferably, the immunogenic composition may contain sodium chloride in the range of 1-10 mg.<br class="style-scope patent-text"> Examples of amino acids as excipients are selected from the group of proteins such as L-histidine, lysine, isoleucine, methionine, glycine, aspartic acid, tricine, arginine, leucine, glutamine, alanine, peptides, hydrolyzed proteins or serum albumin. be done.</span>
    </p>
    <p num="0187" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、ヒスチジンを含んでもよい。<br class="style-scope patent-text">
  賦形剤としての糖の例は、スクロース、マンニトール、トレハロース、マンノース、ラフィノース、ラクチトール、ラクトビオン酸、グルコース、マルツロース、イソマルツロース、マルトース、ラクトースソルビトール、デキストロース、フルクトース、グリセロールまたはその組合せの群から選択される。
</span>Preferably, the immunogenic composition may contain histidine.<br class="style-scope patent-text"> Examples of sugars as excipients are selected from the group of sucrose, mannitol, trehalose, mannose, raffinose, lactitol, lactobionic acid, glucose, maltulose, isomaltulose, maltose, lactose sorbitol, dextrose, fructose, glycerol or combinations thereof. be done.</span>
    </p>
    <p num="0188" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  好ましくは、免疫原性組成物は、スクロースをさらに含んでもよい。<br class="style-scope patent-text">
  賦形剤としてのポリマーの例は、デキストラン、カルボキシメチルセルロース、ヒアルロン酸、シクロデキストリンの群から選択される。
</span>Preferably, the immunogenic composition may further comprise sucrose.<br class="style-scope patent-text"> Examples of polymers as excipients are selected from the group of dextrans, carboxymethylcellulose, hyaluronic acid, cyclodextrins.</span>
    </p>
    <p num="0189" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、単回用量組成物は、保存剤を含まない。<br class="style-scope patent-text">
  なお好ましくは、多回用量免疫原性組成物は、２－フェノキシエタノール、塩化ベンゼトニウム（フェメロール）、フェノール、ｍ－クレゾール、チオメルサール、ホルムアルデヒド、パラベンエステル（例えば、メチル－、エチル－、プロピル－またはブチル－パラベン）、塩化ベンザルコニウム、ベンジルアルコール、クロロブタノール、ｐ－クロロ－ｍ－クレゾールもしくはベンジルアルコール、またはその組合せからなる群から選択される保存剤をさらに含んでもよい。ワクチン組成物は、単回免疫化のための材料を含んでもよく、または複数回免疫化のための材料を含んでもよい（すなわち、「多回用量」キット）。保存剤の含有は、多回用量構成において好ましい。多回用量組成物中に保存剤を含むことに代えて（またはこれに加えて）、組成物は、材料の除去のための無菌アダプターを有する容器に含有されてもよい。好ましくは、保存剤は、０．１ｍｇ～５０ｍｇ、より好ましくは１～１０ｍｇの範囲の２－フェノキシエタノールであってもよい。
</span>Still preferably, the single dose composition does not contain a preservative.<br class="style-scope patent-text"> Still preferably, the multi-dose immunogenic composition comprises 2-phenoxyethanol, benzethonium chloride (femerol), phenol, m-cresol, thiomersal, formaldehyde, paraben esters (e.g. methyl-, ethyl-, propyl- or butyl- parabens), benzalkonium chloride, benzyl alcohol, chlorobutanol, p-chloro-m-cresol or benzyl alcohol, or a combination thereof. A vaccine composition may contain material for a single immunization or may contain material for multiple immunizations (ie, a "multidose" kit). Inclusion of a preservative is preferred in multiple dose formulations. Alternatively (or in addition) to including a preservative in the multi-dose composition, the composition may be contained in a container having a sterile adapter for removal of the material. Preferably, the preservative may be 2-phenoxyethanol in the range of 0.1 mg to 50 mg, more preferably 1 to 10 mg.</span>
    </p>
    <p num="0190" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態のなお別の態様によると、免疫原性組成物は、所望の投与経路および調製物に応じて補助物質、例えば、湿潤または乳化剤、希釈ｐＨ緩衝剤、ゲル化または増粘添加剤、保存剤、着香料、着色料などをさらに含んでもよい。
</span>
  According to yet another aspect of an embodiment, the immunogenic composition may contain auxiliary substances such as wetting or emulsifying agents, diluent pH buffers, gelling or thickening additives, preservatives, depending on the desired route of administration and preparation. Further agents, flavoring agents, coloring agents, and the like may be included.
</span>
    </p>
    <p num="0191" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態のなお好ましい態様によると、免疫原性組成物は、希釈剤として注射用水をさらに含んでもよい。<br class="style-scope patent-text">
  実施形態のなお別の態様によると、免疫原性組成物は、アルミニウム塩、水酸化アルミニウム、リン酸アルミニウム、ヒドロキシリン酸アルミニウムおよび硫酸アルミニウムカリウムの群から選択されるアジュバントをさらに含んでもよい。
</span>According to a still preferred aspect of the embodiment, the immunogenic composition may further comprise water for injection as a diluent.<br class="style-scope patent-text"> According to yet another aspect of the embodiment, the immunogenic composition may further comprise an adjuvant selected from the group of aluminum salts, aluminum hydroxide, aluminum phosphate, aluminum hydroxyphosphate and aluminum potassium sulfate.</span>
    </p>
    <p num="0192" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態のなお別の態様によると、免疫原性組成物は、油水エマルジョン、ＭＦ－５９、リポソーム、リポ多糖、サポニン、リピドＡ、リピドＡ誘導体、モノホスホリルリピドＡ、３－脱アシル化モノホスホリルリピドＡ、ＡＳ０１、ＡＳ０３、オリゴヌクレオチド、少なくとも１つの非メチル化ＣｐＧおよび／またはリポソームを含むオリゴヌクレオチド、フロイントアジュバント、フロイント完全アジュバント、フロイント不完全アジュバント、ポリマー、ブロックコポリマーを含むポリオキシエチレン－ポリオキシプロピレンコポリマーなどのコポリマー、ポリマーｐ  １００５、ＣＲＬ－８３００アジュバント、ムラミルジペプチド、ＴＬＲ－４アゴニスト、フラゲリン、グラム陰性菌由来のフラゲリン、ＴＬＲ－５アゴニスト、ＴＬＲ－５受容体に結合することが可能なフラゲリンの断片、アルファ－Ｃ－ガラクトシルセラミド、キトサン、インターロイキン－２、ＱＳ－２１、ＩＳＣＯＭＳ、スクアレン混合物（ＳＡＦ－１）、Ｑｕｉｌ  Ａ、コレラ毒素Ｂサブユニット、ポリホスファゼンおよび誘導体、マイコバクテリウム細胞壁調製物、ミコール酸誘導体、非イオン性ブロックコポリマー界面活性剤、ＯＭＶ、ｆＨｂｐ、ステロールおよび脂質とのサポニン組合せからなる群から選択される免疫刺激成分をさらに含んでもよい。
</span>
  According to yet another aspect of an embodiment, the immunogenic composition comprises an oil-water emulsion, MF-59, liposomes, lipopolysaccharide, saponin, lipid A, lipid A derivative, monophosphoryl lipid A, 3-deacylated monophosphoryl Lipid A, AS01, AS03, oligonucleotides, oligonucleotides containing at least one unmethylated CpG and/or liposomes, Freund's adjuvant, Freund's complete adjuvant, Freund's incomplete adjuvant, polymers, polyoxyethylene-polyoxy containing block copolymers Copolymers such as propylene copolymers, polymer p 1005, CRL-8300 adjuvant, muramyl dipeptide, TLR-4 agonists, flagellin, flagellin from Gram-negative bacteria, TLR-5 agonists, capable of binding to TLR-5 receptors fragment of flagellin, alpha-C-galactosylceramide, chitosan, interleukin-2, QS-21, ISCOMS, squalene mixture (SAF-1), Quil A, cholera toxin B subunit, polyphosphazene and derivatives, mycobacterium cell wall The formulation may further comprise an immunostimulatory component selected from the group consisting of mycolic acid derivatives, nonionic block copolymer surfactants, OMVs, fHbp, sterols and saponin combinations with lipids.
</span>
    </p>
    <p num="0193" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態のなお別の態様によると、免疫原性組成物は完全に液体であってもよい。液体調製物の好適な形態には、選択したｐＨに緩衝された溶液、懸濁液、エマルジョン、シロップ、等張水溶液、粘性組成物およびエリキシルが含まれ得る。
</span>
  According to yet another aspect of an embodiment, the immunogenic composition may be entirely liquid. Suitable forms of liquid preparations may include solutions, suspensions, emulsions, syrups, isotonic aqueous solutions, viscous compositions and elixirs buffered at the selected pH.
</span>
    </p>
    <p num="0194" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、免疫原性組成物は、完全に液体であってもよく、２～８℃、２５℃および４０℃で６ヶ月の期間にわたって安定であってもよく、６ヶ月後の遊離多糖体は、１８０～２２０ｋＤａ多糖体について７．５％以下であり、６ヶ月後の遊離多糖体は、３８８／８０／４５ｋＤａ多糖体について１０．５％以下である。
</span>
  Still preferably, the immunogenic composition may be completely liquid and stable at 2-8° C., 25° C. and 40° C. for a period of 6 months, after 6 months the free polysaccharide is 7.5% or less for the 180-220 kDa polysaccharide and the free polysaccharide after 6 months is 10.5% or less for the 388/80/45 kDa polysaccharide.
</span>
    </p>
    <p num="0195" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の免疫原性組成物は、ローション、ゲル、スプレー、軟膏または他の好適な技術を含む経皮調製物の形態であってもよい。経鼻または呼吸器（粘膜）投与が所望される場合（例えば、エアロゾル吸入またはガス注入）、組成物はある形態であり、スクイズスプレーディスペンサー、ポンプディスペンサーまたはエアロゾルディスペンサーによって投与され得る。エアロゾルは、通常、炭化水素による加圧下にある。ポンプディスペンサーは、好ましくは、計量用量または特定の粒径を有する用量を投与できる。溶液、懸濁液およびゲルの形態の場合、一部の実施形態では、免疫原性組成物は、活性成分に加えて大量の水（好ましくは精製水）を含有する。実施形態のなお代替の態様によると、免疫原性組成物は、凍結乾燥またはフリーズドライ組成物であり得る。
</span>
  The immunogenic compositions of this disclosure may be in the form of transdermal preparations including lotions, gels, sprays, ointments or other suitable techniques. When nasal or respiratory (mucosal) administration is desired (eg, by aerosol inhalation or insufflation), compositions may be in a form and administered by a squeeze spray dispenser, a pump dispenser or an aerosol dispenser. Aerosols are usually under pressure with a hydrocarbon. Pump dispensers are preferably capable of administering metered doses or doses having a particular particle size. When in the form of solutions, suspensions, and gels, in some embodiments, immunogenic compositions contain large amounts of water (preferably purified water) in addition to the active ingredient. According to still alternative aspects of embodiments, the immunogenic composition may be a lyophilized or freeze-dried composition.
</span>
    </p>
    <p num="0196" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書で使用される場合、「フリーズドライ」または「凍結乾燥する」または「凍結乾燥」という用語は、凍結乾燥を含み、懸濁液／溶液を凍結し、その後、低圧における昇華によって水を除去するプロセスを指す。本明細書で使用される場合、「昇華」という用語は、組成物が液体になることなく固体状態から気体状態に直接変化する、組成物の物理特性の変化を指す。
</span>
  As used herein, the term "freeze-drying" or "lyophilize" or "lyophilization" includes freeze-drying, freezing the suspension/solution and then removing water by sublimation at low pressure. Refers to the process of removing. As used herein, the term "sublimation" refers to a change in physical properties of a composition in which the composition changes directly from a solid state to a gaseous state without becoming liquid.
</span>
    </p>
    <p num="0197" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  したがって、凍結乾燥免疫原性組成物は、２～８℃で１２～３６ヶ月間、２５℃で２～６ヶ月間、３７℃で１週間～４週間、４２℃で２～７日間、および５５℃で２～７日間、安定であり得る。
</span>
  Thus, the lyophilized immunogenic composition can be stored at 2-8°C for 12-36 months, 25°C for 2-6 months, 37°C for 1-4 weeks, 42°C for 2-7 days, and 55°C. °C for 2-7 days.
</span>
    </p>
    <p num="0198" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態の一態様によると、凍結乾燥免疫原性組成物を再構成するための方法は、凍結乾燥免疫原性組成物を、水溶液、任意選択で食塩水または注射用水（ＷＦＩ）で再構成するステップを含んでもよく、再構成後の免疫原性組成物の最終ｐＨは、ｐＨ６．０～ｐＨ８．０の範囲、より好ましくはｐＨ７．０～ｐＨ８．０の範囲、なおより好ましくはｐＨ７．２～ｐＨ７．９の範囲、最も好ましくはｐＨ７．５～ｐＨ７．９の範囲である。
</span>
  According to one aspect of an embodiment, a method for reconstituting a lyophilized immunogenic composition comprises reconstituting the lyophilized immunogenic composition with an aqueous solution, optionally saline or water for injection (WFI). The final pH of the immunogenic composition after reconstitution is in the range of pH 6.0 to pH 8.0, more preferably in the range of pH 7.0 to pH 8.0, even more preferably pH 7.2. to pH 7.9, most preferably pH 7.5 to pH 7.9.
</span>
    </p>
    <p num="0199" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第９の実施形態によると、免疫原性組成物は、Ｓａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ感染を含む健康状態の発症を低減するまたは防止するための方法であって、免疫学的有効量の免疫原性組成物を、非経口もしくは皮下もしくは皮内、筋肉内もしくは腹腔内もしくは静脈内投与、または注射可能投与、またはインプラントからの持続放出、または点眼もしくは経鼻もしくは直腸もしくは口腔内もしくは膣内、経口もしくは胃内もしくは粘膜もしくは舌下、歯槽もしくは歯肉もしくは嗅覚器もしくは呼吸粘膜投与、または任意の他の免疫化経路を介して、ヒト対象に投与するステップを含む方法における使用のために製剤化されてもよい。
</span>
  According to a ninth embodiment of the present disclosure, the immunogenic composition comprises Salmonella serovar strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. A method for reducing or preventing the onset of a condition comprising an infection with enteritidis, comprising administering an immunologically effective amount of an immunogenic composition parenterally or subcutaneously or intradermally, intramuscularly or intraperitoneally or intravenously. administration, or injectable administration, or sustained release from an implant, or ocular or nasal or rectal or buccal or intravaginal, oral or intragastric or mucosal or sublingual, alveolar or gingival or olfactory or respiratory mucosal administration, or It may be formulated for use in methods comprising administering to a human subject via any other route of immunization.
</span>
    </p>
    <p num="0200" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施形態の好ましい態様によると、免疫原性組成物は、筋肉内経路または皮下を介してヒト対象に投与されてもよい。<br class="style-scope patent-text">
  実施形態の好ましい態様によると、Ｓａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ感染細菌感染に対するワクチン接種のための多糖体－タンパク質コンジュゲートを含む免疫学的有効量の免疫原性組成物は、約１μｇ／０．５ｍｌ以下のＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍまたはＳ．ｅｎｔｅｒｉｔｉｄｉｓの多糖体コンジュゲート～約１００μｇ／０．５ｍｌ以上のＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍまたはＳ．ｅｎｔｅｒｉｔｉｄｉｓの多糖体コンジュゲートであり得る。一部の他の態様では、これは、０．５ｍｌの単回用量当たり約２、３、４、５、６、７、８、９、１０、１５、２０、２５、３０、３５、４０、４５または５０μｇ～約５５、６０、６５、７０、７５、８０、８５、９０または９５μｇであり得る。一部の実施形態では、Ｓａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ感染細菌感染に対するワクチン接種に関する免疫学的有効量は、１μｇ／０．５ｍｌ～５０μｇ／０．５ｍｌであり、より好ましくはＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原は、約５ｕｇ／０．５ｍｌ～約３０ｕｇ／０．５ｍｌの用量範囲で存在し、なおより好ましくは、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原は、約２５ｕｇ／０．５ｍｌの用量で存在する。
</span>According to preferred aspects of embodiments, the immunogenic composition may be administered to a human subject via intramuscular routes or subcutaneously.<br class="style-scope patent-text"> According to a preferred aspect of the embodiment, the Salmonella serovar strain S. typhi, S. paratyphi A, S.; typhimurium and S. An immunologically effective amount of an immunogenic composition comprising a polysaccharide-protein conjugate for vaccination against bacterial infection of Salmonella serovar S. enteritidis is about 1 μg/0.5 ml or less. typhi, S. paratyphi A, S.; typhimurium or S. polysaccharide conjugate of S. enteritidis to about 100 μg/0.5 ml or more of Salmonella serovar strain S. typhi, S. paratyphi A, S.; typhimurium or S. enteritidis polysaccharide conjugate. In some other aspects, it is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 μg to about 55, 60, 65, 70, 75, 80, 85, 90 or 95 μg. In some embodiments, the Salmonella serovar strain S. typhi, S. paratyphi A, S.; typhimurium and S. The immunologically effective amount for vaccination against bacterial infection of Enteritidis is 1 μg/0.5 ml to 50 μg/0.5 ml, more preferably Salmonella enterica serovar typhi saccharide-carrier protein conjugate antigen, Salmonella enterica serovar Paratyphi A saccharide - Carrier protein conjugate antigen, Salmonella enterica serovar typhimurium saccharide-carrier protein conjugate antigen, Salmonella enterica serovar enteritidis saccharide-carrier protein conjugate antigen is present in a dose range of about 5 ug/0.5 ml to about 30 ug/0.5 ml and, even more preferably, Salmonella enterica serovar typhi saccharide-carrier protein conjugate antigen, Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate antigen, Salmonella enterica serovar typhimurium saccharide-carrier protein conjugate antigen, Salmonella serovar enterisenta saccharide-carrier protein conjugate antigen Carrier protein conjugated antigen is present at a dose of approximately 25 ug/0.5 ml.</span>
    </p>
    <p num="0201" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１０の実施形態によると、免疫原性組成物は、中和抗体の製造および防御のために有効な用量で、筋肉内または皮下投与されてもよい。ワクチンは、投与量製剤と適合する方式で、かつチフスおよびＮＴＳ感染に対して予防および／または治療有効であるような量で投与される。本開示の免疫原性組成物は、感染のリスクのある年配者、１０代の者、成人もしくは小児において一次予防剤として投与でき、または感染患者を処置するための二次剤として使用できる。例えば、本明細書で開示される免疫原性組成物は、Ｓａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ感染のリスクのある年配者、１０代の者、成人または２歳未満もしくは２歳を超える小児において使用でき、またはＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍａｎｄＳ．ｅｎｔｅｒｉｔｉｄｉｓ感染患者を処置するための二次剤として使用できる。
</span>
  According to a tenth embodiment of the present disclosure, the immunogenic composition may be administered intramuscularly or subcutaneously at a dose effective for production and protection of neutralizing antibodies. Vaccines are administered in a manner compatible with the dosage formulation and in such amount as is prophylactically and/or therapeutically effective against typhoid and NTS infections. The immunogenic compositions of the present disclosure can be administered as primary prophylaxis in the elderly, teenagers, adults or children at risk of infection, or can be used as secondary agents to treat infected patients. For example, the immunogenic compositions disclosed herein are directed against Salmonella serovar S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. It can be used in the elderly, teenagers, adults or children under or over 2 years of age who are at risk of infection with Salmonella serovar S. enteritidis. typhi, S. paratyphi A, S.; typhimuriumandS. It can be used as a secondary agent to treat patients infected with S. enteritidis.
</span>
    </p>
    <p num="0202" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なおあるいは、ＮＴＳのワクチンは、およそ１２月齢で生じる発症率ピーク前に、２～４月齢の乳児に投与されてもよい。さらに、ワクチンの実施はまた、ＨＩＶに感染した集団を含む可能性があると考えられ、これは、彼らがＮＴＳへの感染リスクが高くなっているからである。先進国では、ＮＴＳワクチンは、非常に高い致死率（最大５０パーセント）を経験する年配者を標的とし得る。小児において、計画された現場実施は、おそらく６、１０および１４週における既存の免疫化拡大計画スケジュールと直接統合され得ることが提案されている。
</span>
  Still alternatively, a vaccine for NTS may be administered to infants aged 2-4 months before the peak incidence occurs at approximately 12 months of age. In addition, it is believed that vaccination practices may also include HIV-infected populations, as they are at increased risk of infection with NTS. In developed countries, NTS vaccines may target the elderly, who experience very high mortality rates (up to 50 percent). In children, it has been proposed that planned field implementation could be directly integrated with existing immunization expansion plan schedules, perhaps at 6, 10 and 14 weeks.
</span>
    </p>
    <p num="0203" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  より好ましくは、免疫原性組成物は、約０．５ｍｌまたは１ｍｌの投与量容積で筋肉内または皮下投与されてもよい。<br class="style-scope patent-text">
  本開示の第１１の実施形態によると、免疫原性組成物は、単回用量バイアルもしくは多回用量バイアル（２回用量または５回用量または１０回用量バイアル）、または多回用量キットとして、または充填済みシリンジとして製剤化され得、前記免疫原性組成物は、単回用量スケジュール、または好ましくは、ワクチン接種の一次過程に、必要であれば１～３年後の後続の時間間隔で投与される１～３分割用量が続く複数回用量スケジュールで投与されてもよい。投与量レジメンはまた、少なくとも一部には、防御免疫を付与するのに必要なブースター用量の必要性に応じて決定される。
</span>More preferably, the immunogenic composition may be administered intramuscularly or subcutaneously in a dosage volume of about 0.5 ml or 1 ml.<br class="style-scope patent-text"> According to an eleventh embodiment of the present disclosure, the immunogenic composition is provided as a single or multi-dose vial (2-dose or 5-dose or 10-dose vials), or as a multi-dose kit, or It may be formulated as a pre-filled syringe, and the immunogenic composition is administered on a single dose schedule or, preferably, at subsequent time intervals after 1-3 years, preferably during the first course of vaccination. may be administered in a multiple dose schedule followed by 1 to 3 divided doses. Dosage regimens are also determined, at least in part, by the need for booster doses necessary to confer protective immunity.</span>
    </p>
    <p num="0204" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお好ましくは、免疫原性組成物は、第１の用量および／または第１の用量の３ヶ月～２年後に投与される第２の用量および／または第２の用量の３ヶ月～２年後に投与される第３の用量からなる１用量もしくは２用量レジメン、または３用量レジメンに従って、年配者、１０代の者、成人または２歳未満もしくは２歳を超える小児のヒト対象に投与するために製剤化されてもよい。
</span>
  Still preferably, the immunogenic composition is administered 3 months to 2 years after the first dose and/or 3 months to 2 years after the first dose and/or 3 months to 2 years after the second dose Formulations for administration to elderly, teenage, adult or pediatric human subjects under the age of 2 or over the age of 2 according to a 1-dose or 2-dose regimen consisting of a third dose administered, or a 3-dose regimen may be changed.
</span>
    </p>
    <p num="0205" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の第１１の実施形態によると、免疫原性組成物は、他の薬物または任意の他のワクチンと同時に投与されてもよい。<br class="style-scope patent-text">
  なお第１１の実施形態の一態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to the eleventh embodiment of the present disclosure, the immunogenic composition may be co-administered with other drugs or any other vaccine.<br class="style-scope patent-text"> According to still an aspect of the eleventh embodiment, the single dose vaccine kit comprises:<br class="style-scope patent-text"> Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> for prophylaxis against typhus caused by Salmonella typhi and Neisseria meningitidis antigens, Neisseria There is no antigenic interference of ViPs-TT by meningitidis antigens, and the vaccine formulations can be administered to children under 2 years of age, teenagers, adults and the elderly with only one injection including the full vaccination schedule. S. sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </p>
    <p num="0206" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお第１１の実施形態の第２の態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスおよびパラチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to still a second aspect of the eleventh embodiment, the single dose vaccine kit comprises:<br class="style-scope patent-text"> Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> d) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a liquid composition for reconstitution of a lyophilized (freeze-dried) immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT with Neisseria meningitidis antigens for prophylaxis against typhoid and paratyphoid fever caused by Neisseria meningitidis antigens; no antigenic interference of OSP antigens, said vaccine formulation, with only one injection comprising a complete vaccination schedule, Including children under 2 years of age, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.</span>
    </p>
    <p num="0207" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお第１１の実施形態の第３の態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
完全液体六価免疫原性組成物：  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される変性アデニレートシクラーゼの１種または複数を含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール（ｏｃｔｙｌｐｈｅｎｏｘｙｐｏｌｙｅｔｈｏｘｅｔｈａｎｏｌ）、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび六価抗原によって引き起こされるチフスに対する予防について、六価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to still a third aspect of the eleventh embodiment, the single dose vaccine kit comprises<br class="style-scope patent-text"> Complete Liquid Hexavalent Immunogenic Composition: a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1 per 0.5 ml an inactivated poliovirus (IPV) antigen selected from Sabin or Salk strains at a dose of ˜50 D antigen units (DU);<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml, and/or c) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or or d) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, <figure-callout id="80" label="polysorbate" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">polysorbate</a></figure-callout> 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxethanol in an amount of 25-500 μg per 0.5 ml. , octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or e)0. 1-10 mg 2-phenoxyethanol per 5 ml, and/or f) Water for Injection (WFI) as appropriate<br class="style-scope patent-text"> and for prophylaxis against typhoid fever caused by Salmonella typhi and hexavalent antigen, the antigenic interference of ViPs-TT by the hexavalent immune composition is The vaccine formulation is effective against S. pneumoniae, including children under 2 years of age, teenagers, adults and the elderly, with only one injection, including the full vaccination schedule. sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </p>
    <p num="0208" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお第１１の実施形態の第４の態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される変性アデニレートシクラーゼの１種または複数を含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび六価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、六価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to still a fourth aspect of the eleventh embodiment, the single dose vaccine kit comprises:<br class="style-scope patent-text"> Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or g) 0 a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, <figure-callout id="80" label="polysorbate" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">polysorbate</a></figure-callout> 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol in an amount of 25-500 μg per 5 ml. -9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or h) 1-10 mg of 2 per 0.5 ml - phenoxyethanol, and/or e) suitable amount of water for injection (WFI)<br class="style-scope patent-text"> A second container may be provided containing a complete liquid immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT by hexavalent antigens for prophylaxis against typhoid and paratyphoid caused by paratyphi and hexavalent antigens; Including children under 2 years of age, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.</span>
    </p>
    <p num="0209" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお第１１の実施形態の第５の態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
完全液体七価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される変性アデニレートシクラーゼの１種または複数を含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび七価抗原によって引き起こされるチフスに対する予防について、七価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to still a fifth aspect of the eleventh embodiment, the single dose vaccine kit comprises<br class="style-scope patent-text"> Complete Liquid Heptavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> for prophylaxis against typhoid fever caused by Salmonella typhi and heptavalent antigen, seven There is no antigenic interference of ViPs-TT by the immunizing composition, and the vaccine formulation can be administered to children under 2 years of age, teenagers, adults and the elderly with only one injection including the complete vaccination schedule. , S. sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </p>
    <p num="0210" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  なお第１１の実施形態の第６の態様によると、単回用量ワクチンキットは、<br class="style-scope patent-text">
完全液体七価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される変性アデニレートシクラーゼの１種または複数を含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備えてもよく、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび七価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、七価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めてＳ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>According to still a sixth aspect of the eleventh embodiment, the single dose vaccine kit comprises:<br class="style-scope patent-text"> Complete Liquid Heptavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride per 0.5 ml, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or or g) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, <figure-callout id="80" label="polysorbate" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">polysorbate</a></figure-callout> 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxy in an amount of 25-500 μg per 0.5 ml Nol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or h) 1 per 0.5 ml ~10 mg of 2-phenoxyethanol, and/or e) a suitable amount of water for injection (WFI)<br class="style-scope patent-text"> A second container may be provided containing a complete liquid immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT by heptavalent antigen for prophylaxis against typhoid and paratyphoid caused by paratyphi and heptavalent antigen; S. cerevisiae, including children under 2 years of age, teenagers, adults and the elderly. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.</span>
    </p>
    <p num="0211" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示の免疫原性組成物を開発するために使用されるＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓには、Ｖｉ多糖体に特異的な「ｔｖｉＢ」遺伝子を有するＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＴＹ２株（Ｇｅｎｅｏｍｂｉｏ  Ｔｅｃｈｎｏｌｏｇｉｅｓ  Ｐｒｉｖａｔｅ  Ｌｉｍｉｔｅｄ、Ｐｕｎｅにより同定され、Ｖｉｌｌｏｏ  Ｐｏｏｎａｗａｌｌａ  Ｍｅｍｏｒｉａｌ  Ｈｏｓｐｉｔａｌ、Ｐｕｎｅにおいてチフスと確認された患者の大便試料から単離された）；Ｓ．ｔｙｐｈｉ：ＡＴＣＣ  １９４３０；Ｃ６５２４（ＮＩＣＥＤ、Ｋｏｌｋａｔａ、Ｉｎｄｉａ）；Ｓ．ｐａｒａｔｙｐｈｉ  Ａ：Ｃｈｒｏｍａｃｈｅｍｉｅ  Ｌａｂｏｒａｔｏｒｙ  Ｐｒｉｖａｔｅ  Ｌｉｍｉｔｅｄ、Ｂａｎｇａｌｏｒｅから獲得したＡＴＣＣ  ９１５０、ＣＭＣＣ５００７３、ＣＭＣＣ５０９７３；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ：ＡＴＣＣ  ４９３１；ＡＴＣＣ  １３０７６；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  Ｒ１１；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  Ｄ２４３５９；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ６１８；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ５０２；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ＩＶ３４５３２１９；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ：Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  ２１９２；ＡＴＣＣ  １４２０８；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  ２１８９；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  Ｄ２３５８０；ＡＴＣＣ１９５８５；ＡＴＣＣ  ７００４０８；（ＬＴ２／ＳＬ１３４（ＳＴ１９））；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  １７７（ＳＴ１９）ＣＤＣ  ６５１６－６０；ＡＴＣＣ  ７００７２０が含まれ得る。さらに、任意の弱毒化Ｓａｌｍｏｎｅｌｌａ血清型株（Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓおよびＳ．ｔｙｐｈｉｍｕｒｉｕｍ）が、本開示の免疫原性組成物の調製に使用されてもよい。
</span>
  The Salmonella serovar strain S. cerevisiae used to develop the immunogenic compositions of the present disclosure. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis includes the Salmonella enterica serovar typhi strain TY2, which has the "tviB" gene specific for the Vi polysaccharide (identified by Geneombio Technologies Private Limited, Pune and confirmed in a stool sample from a Villoo Poonawalla Memorial patient's stool, Pune). (isolated from ); typhi: ATCC 19430; C6524 (NICED, Kolkata, India); paratyphi A: ATCC 9150, CMCC 50073, CMCC 50973 obtained from Chromachemie Laboratory Private Limited, Bangalore; enteritidis: ATCC 4931; ATCC 13076; S. enteritidis R11; enteritidis D24359; enteritidis 618; enteritidis 502; enteritidis IV3453219; typhimurium: S. typhimurium 2192; ATCC 14208; typhimurium 2189; typhimurium D23580; ATCC 19585; ATCC 700408; (LT2/SL134 (ST19)); typhimurium 177 (ST19) CDC 6516-60; ATCC 700720. Additionally, any attenuated Salmonella serotype strain (S. typhi, S. paratyphi A, S. enteritidis and S. typhimurium) may be used in the preparation of immunogenic compositions of the present disclosure.
</span>
    </p>
    <p num="0212" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  国際寄託当局であるＮＣＭＲ－ＮＣＣＳ、Ｐｕｎｅで寄託された、受託番号ＭＣＣ  ０１９３を割当てられたＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ；株名称ＰＤＬ－１。
</span>
  Salmonella enterica serovar typhi assigned accession number MCC 0193, deposited at the International Depository Authority NCMR-NCCS, Pune; strain designation PDL-1.
</span>
    </p>
    <p num="0213" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書で開示される他の実施形態はまた、凍結乾燥（フリーズドライ）免疫原性組成物を含有する第１の容器、および凍結乾燥（フリーズドライ）免疫原性組成物を再構成するための水溶液、任意選択で食塩水またはＷＦＩ（注射用水）を含有する第２の容器を備えるワクチンキットを包含する。
</span>
  Other embodiments disclosed herein also provide a first container containing a lyophilized (freeze-dried) immunogenic composition and a lyophilized (freeze-dried) immunogenic composition for reconstituting the optionally saline or WFI (water for injection).
</span>
    </p>
    <p num="0214" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  特定の実施形態の前述の記載は、現在の知識を適用することによって、誰でも、類概念から逸脱することなくそのような特定の実施形態を種々の用途に容易に修正および／または適合させることができる本明細書の実施形態の一般的性質を完全に明らかにし、したがって、そのような適合および修正は、本開示の実施形態の等価物の意味および範囲内で理解されるべきであり、それが意図される。本明細書で用いられる語法または用語は、説明の目的であり、限定ではないことが理解される。したがって、本明細書の実施形態は好ましい実施形態に関して記載されているが、当業者であれば、本明細書の実施形態が、本明細書に記載される趣旨および範囲内の修正により実施できることを認識するであろう。
</span>
  The foregoing descriptions of the specific embodiments should enable anyone applying current knowledge to readily modify and/or adapt such specific embodiments to various uses without departing from the general conception. fully illuminate the general nature of the embodiments herein, and thus such adaptations and modifications are to be understood within the meaning and range of equivalents of the embodiments of the disclosure, which is intended. It is understood that the phraseology or terminology used herein is for the purpose of description and should not be regarded as limiting. Thus, although the embodiments herein have been described with respect to preferred embodiments, those skilled in the art will appreciate that the embodiments herein can be practiced with modification within the spirit and scope of the description herein. will recognize.
</span>
    </p>
    <p num="0215" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書全体を通して、「含む（ｃｏｍｐｒｉｓｅ）」という語または「含む（ｃｏｍｐｒｉｓｅｓ）」もしくは「含むこと（ｃｏｍｐｒｉｓｉｎｇ）」などの変形は、述べられた要素、整数もしくはステップ、または要素、整数もしくはステップの群を含むことを含意するが、任意の他の要素、整数もしくはステップ、または要素、整数もしくはステップの群を除外することは含意しない。
</span>
  Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" may be used to refer to a stated element, integer or step, or to an element, integer or step. Inclusion of groups, but not exclusion of any other element, integer or step, or group of elements, integers or steps is implied.
</span>
    </p>
    <p num="0216" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  「１つまたは複数の」または「少なくとも１つの」という表現の使用は、その使用により本発明の実施形態において所望の目的または結果の１つまたは複数が実現され得る１つまたは複数の要素または成分または量の使用を示唆する。
</span>
  Use of the phrase "one or more" or "at least one" refers to one or more elements or components whose use can achieve one or more of the desired objectives or results in embodiments of the present invention. Or suggest the use of quantity.
</span>
    </p>
    <p num="0217" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書に含まれている文献、作業、材料、デバイス、物品などに関する議論は、本開示の状況を提示する目的のみである。本出願の優先日より前のいずれかに存在するからといって、これらの事項のいずれかまたはすべてが、先行技術基準の一部を形成する、または本開示の関連する分野の一般技術常識であることを認めるとは理解されない。
</span>
  Discussion of documents, works, materials, devices, articles, etc. contained herein is for the sole purpose of presenting the context of the present disclosure. Any or all of these matters, by virtue of existing anywhere prior to the priority date of this application, do not form part of the prior art reference or are common general knowledge in the field to which this disclosure pertains. It is not understood as acknowledging something.
</span>
    </p>
    <p num="0218" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  様々な物理パラメーター、寸法および量について示される数値は単に近似値であり、これは、本明細書に相反する記述がない限り、物理パラメーター、寸法および量に割当てられた数値よりも高い値が、本発明の範囲内であることを想定する。
</span>
  The numerical values given for the various physical parameters, dimensions and quantities are only approximations, it being understood that, unless stated to the contrary herein, values higher than the numerical values assigned to the physical parameters, dimensions and quantities are It is envisaged to be within the scope of the present invention.
</span>
    </p>
    <p num="0219" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本明細書において好ましい実施形態の特定の特徴が多分に強調されているが、多くの追加の特徴が追加され得ること、および多くの変更が、本開示の原理から逸脱することなく好ましい実施形態においてなされ得ることが認識される。本開示の好ましい実施形態におけるこれらのおよび他の変更は、本開示から当業者には明らかであり、これによって、前述の説明事項が、単に本開示の例示として解釈され、限定としては解釈されないことが明らかに理解されることになる。<br class="style-scope patent-text">
技術的利点：<br class="style-scope patent-text">
  １．  本開示は、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓに対する感染の防御もしくは処置を付与する、またはその臨床症状の発症もしくは進行を防止、改善もしくは遅延するのに有効な、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体をその任意の組合せで含む一価および多価多糖体－タンパク質コンジュゲートワクチンを提供する。
</span>Although certain features of the preferred embodiments have been emphasized to some extent herein, many additional features could be added and many changes could be made in the preferred embodiments without departing from the principles of the disclosure. It is recognized that it can be done. These and other variations in the preferred embodiments of this disclosure will be apparent to those skilled in the art from this disclosure, and hereby the foregoing description should be construed merely as illustrative of this disclosure and not as a limitation. will be clearly understood.<br class="style-scope patent-text"> Technical advantages:<br class="style-scope patent-text"> 1. The present disclosure provides the Salmonella serotype strain S. cerevisiae. typhi, S. paratyphi A, S.; typhimurium and S. Salmonella serovar strain S. enteritidis effective in conferring protection or treatment of infection against, or in preventing, ameliorating or delaying the onset or progression of clinical symptoms thereof. typhi, S. paratyphi A, S.; typhimurium and S. Monovalent and polyvalent polysaccharide-protein conjugate vaccines comprising polysaccharides from S. enteritidis in any combination thereof are provided.</span>
    </p>
    <p num="0220" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  改善された上流、下流およびコンジュゲーションプロセス。<br class="style-scope patent-text">
  ３．  上流発酵培地は、カゼイン消化物／トリプトン、カザミノ酸を含まない。<br class="style-scope patent-text">
  ４．  ｉ）消泡剤、大豆ペプトンおよび酵母抽出物の組合せ、ｉｉ）特定のＤＯ３６～３９％、およびｉｉｉ）浸透圧４００～６００ｍＯｓｍｏｌ／ｋｇ、の使用により、＞５０％の収穫段階多糖体収率の改善をもたらす。
</span>2. Improved upstream, downstream and conjugation processes.<br class="style-scope patent-text"> 3. The upstream fermentation medium does not contain casein digest/tryptone, casamino acids.<br class="style-scope patent-text"> 4. Use of i) a combination of antifoam, soybean peptone and yeast extract, ii) a specified DO of 36-39%, and iii) an osmolality of 400-600 mOsmol/kg resulted in &gt;50% harvest stage polysaccharide yield. bring about improvement.</span>
    </p>
    <p num="0221" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ５．  低エンドトキシン＜１０ＥＵ／μｇ、低タンパク質＜１％および低核酸含有量＜２％の改善された精製方法であって、精製プロセスが、ｉ）動物由来生成物であり、最終生成物中のその残留存在でさえ、規制当局および特定の宗教共同体により許容されない生成物になることがある、デオキシコール酸ナトリウム（ＤＯＣ）を含まず、ｉｉ）Ｔｒｉｔｏｎ  Ｘを含まず、ｉｉｉ）硫酸アンモニウムを含まず、ｉｖ）いかなる吸着剤（ヒドロキシアパタイト、リン酸カルシウムまたはアパタイト）も含まない、精製方法。
</span>
  5. An improved purification method with low endotoxin &lt;10 EU/μg, low protein &lt;1% and low nucleic acid content &lt;2%, wherein the purification process i) is an animal derived product and its residue in the final product Does not contain sodium deoxycholate (DOC), ii) does not contain Triton X, iii) does not contain ammonium sulfate, and iv) does not contain sodium deoxycholate (DOC), which even its presence can result in an unacceptable product by regulatory authorities and certain religious communities. A purification method that does not involve any adsorbents (hydroxyapatite, calcium phosphate or apatite).
</span>
    </p>
    <p num="0222" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ６．  ｉ）Ｐｓ：Ｐｒ：ＥＤＡＣ比が１：１：２であり、ｉｉ）安定性を示す遊離多糖体が＜５％（好ましくは＜３％）であり、遊離タンパク質が＜５％（好ましくは＜４％）である、改善されたコンジュゲーション効率（＞６０％）、改善されたコンジュゲート収率（≧５０％）およびコンジュゲートの安定性。
</span>
  6. i) a Ps:Pr:EDAC ratio of 1:1:2; ii) &lt;5% (preferably &lt;3%) free polysaccharide and &lt;5% (preferably &lt; 4%), improved conjugation efficiency (&gt;60%), improved conjugate yield (≧50%) and conjugate stability.
</span>
    </p>
    <p num="0223" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ７．  ｉ）１２００ｋＤａ～１６００ｋＤａの特有のサイズを有するＶｉ多糖体－タンパク質コンジュゲート、およびｉｉ）コンジュゲーションに使用される多糖体が、１５０～３００ｋＤａ（好ましくは、１５０～２５０ｋＤａ）の平均分子量を有する、ことに帰するコンジュゲートの改善された免疫原性。
</span>
  7. i) a Vi polysaccharide-protein conjugate with a characteristic size of 1200 kDa to 1600 kDa, and ii) the polysaccharide used for conjugation has an average molecular weight of 150 to 300 kDa (preferably 150 to 250 kDa). Improved immunogenicity of the conjugates attributed to
</span>
    </p>
    <p num="0224" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ８．  免疫原性組成物は、２～８℃、２５℃および４０℃で６ヶ月の期間にわたって安定であり、６ヶ月後の遊離多糖体は、１８０～２２０ｋＤａ多糖体について７．５％以下であり、６ヶ月後の遊離多糖体は、３８８／８０／４５ｋＤａ多糖体について１０．５％以下である。
</span>
  8. the immunogenic composition is stable at 2-8° C., 25° C. and 40° C. for a period of 6 months and the free polysaccharide after 6 months is 7.5% or less for the 180-220 kDa polysaccharide; The free polysaccharide after 6 months is less than 10.5% for the 388/80/45 kDa polysaccharide.
</span>
    </p>
    <p num="0225" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ９．  ａ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＤＴ、ｂ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＴＴおよびｃ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＣＲＭ  Ｖｉ  ＴＴなどの二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンを注射されたマウス群は、（非コンジュゲートＶｉ  ＰＳまたは非コンジュゲートＳＩＩＰＬ  Ｏ－ＳＰ  Ａを投与されたマウスと比較して）４倍超高いＩｇＧの誘導を示したため、Ｖｉ  ＴＴおよびＳＩＩＰＬ  Ｏ－ＳＰ  Ａ（ＤＴ／ＴＴ／ＣＲＭ）の組合せを含有する二価ＳＩＩＰＬワクチンの免疫原性の可能性を示している。
</span>
  9. Bivalent (typhoid and paratyphoid) SIIPL such as a) SIIPL Vi PS-TT + SIIPL O-SP A DT, b) SIIPL Vi PS-TT + SIIPL O-SP A TT and c) SIIPL Vi PS-TT + SIIPL O-SP A CRM Vi TT Vaccine-injected mouse groups showed more than 4-fold higher induction of IgG (compared to mice receiving unconjugated Vi PS or unconjugated SIIPL O-SP A), thus Vi TT and SIIPL O - Shows the immunogenic potential of a bivalent SIIPL vaccine containing the combination of SPA (DT/TT/CRM).
</span>
    </p>
    <p num="0226" class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  １０．  最小限の成分がワクチン組成物に含まれる。
</span>
  10. A minimal amount of ingredients is included in the vaccine composition.
</span>
    </p>
    <embodiments-example class="style-scope patent-text">
      <p num="0227" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下の実施例は、本発明の好ましい実施形態を実証するために含まれる。当業者であれば、以下の実施例において開示される組成物および技術は、本発明の実施において良好に機能する、本発明者によって発見された技術を表し、したがって、その実施の好ましい形態を構成すると考えることができることを認識するはずである。しかしながら、当業者は、本開示に照らして、開示される特定の実施形態において多くの変更がなされ得、類似のまたは同様の結果を本発明の趣旨および範囲から逸脱することなくなお得ることができることを認識するべきである。
</span>
  The following examples are included to demonstrate preferred embodiments of the invention. It will be appreciated by those skilled in the art that the compositions and techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus constitute preferred modes of its practice. Then you should recognize that you can think. However, those skilled in the art will appreciate, in light of the present disclosure, that many changes can be made in the particular embodiments disclosed and similar or similar results can still be obtained without departing from the spirit and scope of the invention. should be recognized.
</span>
      </p>
      <p num="0228" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例１：<br class="style-scope patent-text">
Ａ）株：<br class="style-scope patent-text">
  本開示の免疫原性組成物を開発するために使用されるＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓには、Ｖｉ多糖体に特異的な「ｔｖｉＢ」遺伝子を有するＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＴＹ２株（Ｇｅｎｅｏｍｂｉｏ  Ｔｅｃｈｎｏｌｏｇｉｅｓ  Ｐｒｉｖａｔｅ  Ｌｉｍｉｔｅｄ、Ｐｕｎｅにより同定され、Ｖｉｌｌｏｏ  Ｐｏｏｎａｗａｌｌａ  Ｍｅｍｏｒｉａｌ  Ｈｏｓｐｉｔａｌ、Ｐｕｎｅにおいてチフスと確認された患者の大便試料から単離された）；国際寄託当局であるＮＣＭＲ－ＮＣＣＳ、Ｐｕｎｅで寄託された、受託番号ＭＣＣ  ０１９３を割当てられたＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ；株名称ＰＤＬ－１、Ｓ．ｔｙｐｈｉ：ＡＴＣＣ  １９４３０；Ｃ６５２４（ＮＩＣＥＤ、Ｋｏｌｋａｔａ、Ｉｎｄｉａ）；Ｓ．ｐａｒａｔｙｐｈｉ  Ａ：Ｃｈｒｏｍａｃｈｅｍｉｅ  Ｌａｂｏｒａｔｏｒｙ  Ｐｒｉｖａｔｅ  Ｌｉｍｉｔｅｄ、Ｂａｎｇａｌｏｒｅから獲得したＡＴＣＣ  ９１５０、ＣＭＣＣ５００７３、ＣＭＣＣ５０９７３；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ：ＡＴＣＣ  ４９３１；ＡＴＣＣ  １３０７６；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  Ｒ１１；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  Ｄ２４３５９；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ６１８；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ５０２；Ｓ．ｅｎｔｅｒｉｔｉｄｉｓ  ＩＶ３４５３２１９；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ：Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  ２１９２；ＡＴＣＣ  １４２０８；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  ２１８９；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  Ｄ２３５８０；ＡＴＣＣ１９５８５；ＡＴＣＣ  ７００４０８；（ＬＴ２／ＳＬ１３４（ＳＴ１９））；Ｓ．ｔｙｐｈｉｍｕｒｉｕｍ  １７７（ＳＴ１９）ＣＤＣ  ６５１６－６０；ＡＴＣＣ  ７００７２０が含まれ得る。さらに、任意の弱毒化Ｓａｌｍｏｎｅｌｌａ血清型株（Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｅｎｔｅｒｉｔｉｄｉｓおよびＳ．ｔｙｐｈｉｍｕｒｉｕｍ）が、本開示の免疫原性組成物の調製に使用されてもよい。
</span>Example 1:<br class="style-scope patent-text"> A) Strain:<br class="style-scope patent-text"> The Salmonella serovar strain S. cerevisiae used to develop the immunogenic compositions of the present disclosure. typhi, S. paratyphi A, S.; typhimurium and S. enteritidis includes the Salmonella enterica serovar typhi strain TY2, which has the "tviB" gene specific for the Vi polysaccharide (identified by Geneombio Technologies Private Limited, Pune and confirmed in a stool sample from a Villoo Poonawalla Memorial patient's stool, Pune). Salmonella enterica serovar typhi, deposited at the International Depository Authority NCMR-NCCS, Pune, assigned accession number MCC 0193; strain designation PDL-1, S. typhi: ATCC 19430; C6524 (NICED, Kolkata, India); paratyphi A: ATCC 9150, CMCC 50073, CMCC 50973 obtained from Chromachemie Laboratory Private Limited, Bangalore; enteritidis: ATCC 4931; ATCC 13076; S. enteritidis R11; enteritidis D24359; enteritidis 618; enteritidis 502; enteritidis IV3453219; typhimurium: S. typhimurium 2192; ATCC 14208; typhimurium 2189; typhimurium D23580; ATCC 19585; ATCC 700408; (LT2/SL134 (ST19)); typhimurium 177 (ST19) CDC 6516-60; ATCC 700720. Additionally, any attenuated Salmonella serotype strain (S. typhi, S. paratyphi A, S. enteritidis and S. typhimurium) may be used in the preparation of immunogenic compositions of the present disclosure.</span>
      </p>
      <p num="0229" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＷＯ２０１８０３７３６５、ＷＯ２０１９０１６６５４およびＷＯ２０２００７５１８４は、ジフテリアトキソイド（ＤＴ）、破傷風トキソイド（ＴＴ）、不活化全細胞百日咳（ｗＰ）、無細胞性百日咳（ａＰ）、Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ｈｉｂ）および不活化ポリオウイルス（標準用量および低減用量ポリオウイルス）の調製への参照により組み込まれている。
</span>
  WO2018037365, WO2019016654 and WO2020075184 describe diphtheria toxoid (DT), tetanus toxoid (TT), inactivated whole cell pertussis (wP), acellular pertussis (aP), hepatitis B virus surface antigen (HBsAg), Haemophilus influenzae type b Incorporated by reference to the preparation of antigen (Hib) and inactivated poliovirus (standard and reduced dose poliovirus).
</span>
      </p>
      <p num="0230" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＷＯ２０１８０３７３６５は、不活化ポリオウイルスおよび不活化ロタウイルスの調製への参照により組み込まれている。<br class="style-scope patent-text">
  ＷＯ２０１３１１４２６８は、血清型Ａ、Ｃ、Ｗ、ＸおよびＹの髄膜炎菌多糖体抗原の調製への参照により組み込まれている。<br class="style-scope patent-text">
Ｂ）流加プロセスによってＳａｌｍｏｎｅｌｌａ血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を得る方法は、以下のステップを含む：（上流発酵）<br class="style-scope patent-text">
  １）接種および収穫のＳ１段階：<br class="style-scope patent-text">
  細胞バンクバイアルからの０．５ｍＬ培養物を、培地で５ｍＬに希釈し、これからの白金耳培養物を、ＳＣＤＡプレートでストリークし、３６±０．５℃で２８～３２時間インキュベートする。
</span>WO2018037365 is incorporated by reference to the preparation of inactivated poliovirus and inactivated rotavirus.<br class="style-scope patent-text"> WO2013114268 is incorporated by reference to the preparation of serotypes A, C, W, X and Y meningococcal polysaccharide antigens.<br class="style-scope patent-text"> B) Salmonella serovar strain S. cerevisiae was isolated by a fed-batch process. typhi, S. paratyphi A, S.; typhimurium and S. The method of obtaining polysaccharides from P. enteritidis includes the following steps: (upstream fermentation)<br class="style-scope patent-text"> 1) S1 stage of inoculation and harvest:<br class="style-scope patent-text"> A 0.5 mL culture from a cell bank vial is diluted to 5 mL with medium and the loop culture from this is streaked onto SCDA plates and incubated at 36±0.5° C. for 28-32 hours.</span>
      </p>
      <p num="0231" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２）接種および収穫のＳ２段階：<br class="style-scope patent-text">
  Ｓ１段階プレートからの１０個の十分単離されたコロニーを、４０ｍＬ培地を含有するコニカルフラスコに接種する。培養物の光学密度（ＯＤ）が２．５～３．５範囲に達するまで、フラスコを３６±０．５℃および１５０±１０ＲＰＭでインキュベートする。
</span>2) S2 stage of inoculation and harvest:<br class="style-scope patent-text"> Inoculate a conical flask containing 40 mL medium with 10 well-isolated colonies from the S1 stage plate. Flasks are incubated at 36±0.5° C. and 150±10 RPM until the optical density (OD) of the culture reaches the 2.5-3.5 range.</span>
      </p>
      <p num="0232" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ３）接種および収穫のＳ３段階：<br class="style-scope patent-text">
  Ｓ２段階培養物の光学密度（ＯＤ）が２．５～３．５範囲に達したら、４０ｍｌ培養物を８００ｍｌに増大し、それぞれ５つの１Ｌフラスコに１６０ｍｌ内容物を分配する。培養物のＯＤが２．５～３．５範囲に達するまで、フラスコを３６±０．５℃および１５０±１０ｒｐｍでインキュベートする。
</span>3) S3 stage of inoculation and harvest:<br class="style-scope patent-text"> When the optical density (OD) of the S2 staged culture reaches the 2.5-3.5 range, the 40 ml culture is increased to 800 ml and the 160 ml contents are divided into five 1 L flasks each. Flasks are incubated at 36±0.5° C. and 150±10 rpm until the OD of the culture reaches the 2.5-3.5 range.</span>
      </p>
      <p num="0233" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ４）接種および収穫のＳ４段階（２０Ｌ発酵槽）：<br class="style-scope patent-text">
  Ｓ３段階培養物のＯＤが２．５～３．５範囲に達したら、５つすべてのフラスコの培養物を元種用ボトルアセンブリにプールし、２０Ｌ発酵槽中に接種する。以下のパラメーターを使用して、発酵を継続する。
</span>4) S4 stage of inoculation and harvest (20L fermentor):<br class="style-scope patent-text"> When the OD of the S3 stage culture reaches the 2.5-3.5 range, pool the cultures from all five flasks into the original seed bottle assembly and inoculate into the 20 L fermentor. Fermentation is continued using the following parameters.</span>
      </p>
      <p num="0234" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  発酵プロセスパラメーター：
</span>
  Fermentation process parameters:
</span>
      </p>
      <p num="0235" class="style-scope patent-text">
        <tables num="1" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/77/92/8b/f22973ec4c8b68/2022546763000001.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000001.jpg" he="85" wi="110" width="440" height="340" alt="Figure 2022546763000001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/77/92/8b/f22973ec4c8b68/2022546763000001.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/77/92/8b/f22973ec4c8b68/2022546763000001.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000001.jpg" he="85" wi="110" width="440" height="340" alt="Figure 2022546763000001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/77/92/8b/f22973ec4c8b68/2022546763000001.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0236" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ３時間目以降に培地の供給を開始し、ＯＤに比例して増加させる。発酵を１３～１５時間継続する。<br class="style-scope patent-text">
  ５）Ｓ４段階のホルマリン不活化：<br class="style-scope patent-text">
  Ｓ４段階が完了した後、ホルムアルデヒド溶液を発酵槽に添加して、最終濃度を０．５～１．０％にし、培養物を３６℃±２℃で８～１０時間インキュベートする。
</span>Begin feeding medium after 3 hours and increase proportionally to the OD. Fermentation is continued for 13-15 hours.<br class="style-scope patent-text"> 5) S4 stage formalin inactivation:<br class="style-scope patent-text"> After the S4 stage is complete, formaldehyde solution is added to the fermentor to a final concentration of 0.5-1.0% and the culture is incubated at 36°C ± 2°C for 8-10 hours.</span>
      </p>
      <p num="0237" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ６）遠心による細胞分離：<br class="style-scope patent-text">
  不活化ステップが完了した後、遠心によりブロスを清澄化し、上清を収集する。<br class="style-scope patent-text">
  以下のパラメーターを使用して遠心を実施する。
</span>6) Cell separation by centrifugation:<br class="style-scope patent-text"> After the inactivation step is complete, the broth is clarified by centrifugation and the supernatant is collected.<br class="style-scope patent-text"> Centrifugation is performed using the following parameters.</span>
      </p>
      <p num="0238" class="style-scope patent-text">
        <tables num="2" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a6/38/79/37da7fca158df7/2022546763000002.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000002.jpg" he="53" wi="103" width="412" height="212" alt="Figure 2022546763000002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a6/38/79/37da7fca158df7/2022546763000002.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a6/38/79/37da7fca158df7/2022546763000002.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000002.jpg" he="53" wi="103" width="412" height="212" alt="Figure 2022546763000002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a6/38/79/37da7fca158df7/2022546763000002.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0239" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ７）深層ろ過による清澄化：<br class="style-scope patent-text">
  遠心が終了した後、上清を、デプスフィルターを使用してろ過する。<br class="style-scope patent-text">
  ８）０．２μろ過：<br class="style-scope patent-text">
  深層ろ過後、ろ液を０．２μろ過に供する。<br class="style-scope patent-text">
Ｂ１．  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓの増殖のための培地最適化。
</span>7) Clarification by depth filtration:<br class="style-scope patent-text"> After centrifugation is finished, the supernatant is filtered using a depth filter.<br class="style-scope patent-text"> 8) 0.2μ filtration:<br class="style-scope patent-text"> After depth filtration, the filtrate is subjected to 0.2μ filtration.<br class="style-scope patent-text"> B1. Salmonella typhi, S. paratyphi A, S.; typhimurium and S. Media optimization for growth of C. enteritidis.</span>
      </p>
      <p num="0240" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下の実験を、培地最適化およびバッチパラメーターのために実施した。<br class="style-scope patent-text">
  実験番号：０１  －  グラム陰性微生物の増殖に広く使用されているため、実験にＦｒａｎｔｚ培地を選択し、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉの増殖について評価した。Ｆｒａｎｔｚ培地を、元種の発育および発酵のために使用した。炭素源としてグルコースを供給培地中に構成した。
</span>The following experiments were performed for media optimization and batch parameters.<br class="style-scope patent-text"> Experiment No: 01—Frantz medium was chosen for the experiment because it is widely used for the growth of Gram-negative microorganisms and was evaluated for the growth of Salmonella Typhi. Frantz medium was used for the growth and fermentation of the original seed. Glucose was constituted in the feed medium as a carbon source.</span>
      </p>
      <p num="0241" class="style-scope patent-text">
        <tables num="3" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fa/8c/01/09c5115da8662c/2022546763000003.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000003.jpg" he="53" wi="102" width="408" height="212" alt="Figure 2022546763000003" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fa/8c/01/09c5115da8662c/2022546763000003.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fa/8c/01/09c5115da8662c/2022546763000003.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000003.jpg" he="53" wi="102" width="408" height="212" alt="Figure 2022546763000003" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fa/8c/01/09c5115da8662c/2022546763000003.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0242" class="style-scope patent-text">
        <tables num="4" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d2/f3/7b/8a668423200819/2022546763000004.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000004.jpg" he="54" wi="106" width="424" height="216" alt="Figure 2022546763000004" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d2/f3/7b/8a668423200819/2022546763000004.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d2/f3/7b/8a668423200819/2022546763000004.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000004.jpg" he="54" wi="106" width="424" height="216" alt="Figure 2022546763000004" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d2/f3/7b/8a668423200819/2022546763000004.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0243" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  元種を使い捨てフラスコ（１２５ｍｌおよび５００ｍｌ）で発育させ、２Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００、２５％溶存酸素（ＤＯ）および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  The original seed was grown in disposable flasks (125 ml and 500 ml) and inoculated into 2 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00, 25% dissolved oxygen (DO) and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0244" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0245" class="style-scope patent-text">
        <tables num="5" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/13/54/a6/692a5ec520ae4d/2022546763000005.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000005.jpg" he="133" wi="88" width="352" height="532" alt="Figure 2022546763000005" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/13/54/a6/692a5ec520ae4d/2022546763000005.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/13/54/a6/692a5ec520ae4d/2022546763000005.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000005.jpg" he="133" wi="88" width="352" height="532" alt="Figure 2022546763000005" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/13/54/a6/692a5ec520ae4d/2022546763000005.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0246" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：Ｆｒａｎｔｚ培地は、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖を限られた程度に支持することが見出された。培地のさらなる最適化が必要であった。<br class="style-scope patent-text">
  実験番号：０２  －  酵母抽出物を発酵および供給培地に添加して、細胞の増殖を支持した。
</span>Conclusion: Frantz medium was found to support the growth of Salmonella typhi microorganisms to a limited extent. Further optimization of the medium was required.<br class="style-scope patent-text"> Experiment No: 02 - Yeast extract was added to fermentation and feed media to support cell growth.</span>
      </p>
      <p num="0247" class="style-scope patent-text">
        <tables num="6" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e0/82/f8/131689133bf2a5/2022546763000006.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000006.jpg" he="65" wi="134" width="536" height="260" alt="Figure 2022546763000006" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e0/82/f8/131689133bf2a5/2022546763000006.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e0/82/f8/131689133bf2a5/2022546763000006.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000006.jpg" he="65" wi="134" width="536" height="260" alt="Figure 2022546763000006" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e0/82/f8/131689133bf2a5/2022546763000006.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0248" class="style-scope patent-text">
        <tables num="7" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/68/38/06d9163d37c927/2022546763000007.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000007.jpg" he="64" wi="115" width="460" height="256" alt="Figure 2022546763000007" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/68/38/06d9163d37c927/2022546763000007.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/68/38/06d9163d37c927/2022546763000007.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000007.jpg" he="64" wi="115" width="460" height="256" alt="Figure 2022546763000007" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/68/38/06d9163d37c927/2022546763000007.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0249" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：<br class="style-scope patent-text">
  元種を使い捨てフラスコ（１２５ｍｌおよび５００ｍｌ）で発育させ、２Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００、２５％溶存酸素（ＤＯ）および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>procedure:<br class="style-scope patent-text"> The original seed was grown in disposable flasks (125 ml and 500 ml) and inoculated into 2 L fermentors. After inoculation, fermentation was carried out in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00, 25% dissolved oxygen (DO) and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.</span>
      </p>
      <p num="0250" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0251" class="style-scope patent-text">
        <tables num="8" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bc/bb/ec/ea11828168c0d5/2022546763000008.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000008.jpg" he="134" wi="89" width="356" height="536" alt="Figure 2022546763000008" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bc/bb/ec/ea11828168c0d5/2022546763000008.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bc/bb/ec/ea11828168c0d5/2022546763000008.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000008.jpg" he="134" wi="89" width="356" height="536" alt="Figure 2022546763000008" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bc/bb/ec/ea11828168c0d5/2022546763000008.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0252" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：酵母抽出物の添加は、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖を限られた程度に支持することが見出された。培地のさらなる最適化が必要であった。<br class="style-scope patent-text">
  実験番号：０３  －  大豆ペプトンを発酵および供給培地に添加して、細胞の増殖を支持した。
</span>Conclusion: Addition of yeast extract was found to support the growth of Salmonella typhi microorganisms to a limited extent. Further optimization of the medium was required.<br class="style-scope patent-text"> Experiment #: 03 - Soy peptone was added to the fermentation and feed media to support cell growth.</span>
      </p>
      <p num="0253" class="style-scope patent-text">
        <tables num="9" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/90/0b/619ee7529b2d3a/2022546763000009.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000009.jpg" he="72" wi="117" width="468" height="288" alt="Figure 2022546763000009" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/90/0b/619ee7529b2d3a/2022546763000009.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/90/0b/619ee7529b2d3a/2022546763000009.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000009.jpg" he="72" wi="117" width="468" height="288" alt="Figure 2022546763000009" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/90/0b/619ee7529b2d3a/2022546763000009.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0254" class="style-scope patent-text">
        <tables num="10" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/56/e8/cd/f0420c371f6cee/2022546763000010.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000010.jpg" he="73" wi="114" width="456" height="292" alt="Figure 2022546763000010" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/56/e8/cd/f0420c371f6cee/2022546763000010.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/56/e8/cd/f0420c371f6cee/2022546763000010.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000010.jpg" he="73" wi="114" width="456" height="292" alt="Figure 2022546763000010" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/56/e8/cd/f0420c371f6cee/2022546763000010.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0255" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：<br class="style-scope patent-text">
  元種を使い捨てフラスコ（１２５ｍｌおよび５００ｍｌ）で発育させ、２Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００、２５％溶存酸素（ＤＯ）および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>procedure:<br class="style-scope patent-text"> The original seed was grown in disposable flasks (125 ml and 500 ml) and inoculated into 2 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00, 25% dissolved oxygen (DO) and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.</span>
      </p>
      <p num="0256" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0257" class="style-scope patent-text">
        <tables num="11" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/93/94/bb/fafe855af09dc3/2022546763000011.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000011.jpg" he="137" wi="85" width="340" height="548" alt="Figure 2022546763000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/93/94/bb/fafe855af09dc3/2022546763000011.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/93/94/bb/fafe855af09dc3/2022546763000011.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000011.jpg" he="137" wi="85" width="340" height="548" alt="Figure 2022546763000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/93/94/bb/fafe855af09dc3/2022546763000011.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0258" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：大豆ペプトンの添加は、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖を支持することが見出された。製造のためのバッチパラメーターの最適化が必要であった。<br class="style-scope patent-text">
  実験番号：０４  －  細胞増殖の改善のために、消泡剤Ｃｔｏｂｅを消泡剤Ｓｔｒｕｋｔｏｌに置き換えた。
</span>Conclusion: Soy peptone addition was found to support the growth of Salmonella typhi microorganisms. Optimization of batch parameters for manufacturing was required.<br class="style-scope patent-text"> Experiment No: 04 - The antifoam Ctobe was replaced with the antifoam Struktol for improved cell growth.</span>
      </p>
      <p num="0259" class="style-scope patent-text">
        <tables num="12" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/31/e9/3a7f0f7a3bf810/2022546763000012.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000012.jpg" he="73" wi="115" width="460" height="292" alt="Figure 2022546763000012" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/31/e9/3a7f0f7a3bf810/2022546763000012.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/31/e9/3a7f0f7a3bf810/2022546763000012.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000012.jpg" he="73" wi="115" width="460" height="292" alt="Figure 2022546763000012" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/31/e9/3a7f0f7a3bf810/2022546763000012.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0260" class="style-scope patent-text">
        <tables num="13" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/93/a0/19/f388f55a4bbc1e/2022546763000013.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000013.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000013" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/93/a0/19/f388f55a4bbc1e/2022546763000013.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/93/a0/19/f388f55a4bbc1e/2022546763000013.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000013.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000013" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/93/a0/19/f388f55a4bbc1e/2022546763000013.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0261" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：<br class="style-scope patent-text">
  元種を使い捨てフラスコ（１２５ｍｌおよび５００ｍｌ）で発育させ、２Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００、２５％溶存酸素（ＤＯ）および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>procedure:<br class="style-scope patent-text"> The original seed was grown in disposable flasks (125 ml and 500 ml) and inoculated into 2 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00, 25% dissolved oxygen (DO) and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.</span>
      </p>
      <p num="0262" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0263" class="style-scope patent-text">
        <tables num="14" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/61/13/20/8fd22a51924db2/2022546763000014.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000014.jpg" he="136" wi="80" width="320" height="544" alt="Figure 2022546763000014" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/61/13/20/8fd22a51924db2/2022546763000014.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/61/13/20/8fd22a51924db2/2022546763000014.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000014.jpg" he="136" wi="80" width="320" height="544" alt="Figure 2022546763000014" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/61/13/20/8fd22a51924db2/2022546763000014.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0264" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：消泡剤Ｃの消泡剤Ｓｔｒｕｋｔｏｌへの置き換えは、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖を改善することが見出された。<br class="style-scope patent-text">
  実験番号：０５  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>Conclusion: Replacing antifoam C with antifoam Struktol was found to improve the growth of Salmonella typhi microorganisms.<br class="style-scope patent-text"> Experiment No.: 05 - The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 20L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.</span>
      </p>
      <p num="0265" class="style-scope patent-text">
        <tables num="15" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/df/79/c0/3d760795e09930/2022546763000015.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000015.jpg" he="65" wi="111" width="444" height="260" alt="Figure 2022546763000015" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/df/79/c0/3d760795e09930/2022546763000015.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/df/79/c0/3d760795e09930/2022546763000015.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000015.jpg" he="65" wi="111" width="444" height="260" alt="Figure 2022546763000015" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/df/79/c0/3d760795e09930/2022546763000015.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0266" class="style-scope patent-text">
        <tables num="16" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/46/91/21/50520bf2feee6f/2022546763000016.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000016.jpg" he="73" wi="122" width="488" height="292" alt="Figure 2022546763000016" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/46/91/21/50520bf2feee6f/2022546763000016.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/46/91/21/50520bf2feee6f/2022546763000016.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000016.jpg" he="73" wi="122" width="488" height="292" alt="Figure 2022546763000016" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/46/91/21/50520bf2feee6f/2022546763000016.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0267" class="style-scope patent-text">
        <tables num="17" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/5b/5f/e85e6f3436a09a/2022546763000017.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000017.jpg" he="72" wi="122" width="488" height="288" alt="Figure 2022546763000017" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/5b/5f/e85e6f3436a09a/2022546763000017.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/5b/5f/e85e6f3436a09a/2022546763000017.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000017.jpg" he="72" wi="122" width="488" height="288" alt="Figure 2022546763000017" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/5b/5f/e85e6f3436a09a/2022546763000017.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0268" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0269" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0270" class="style-scope patent-text">
        <tables num="18" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/5f/d1/538600dc737aaf/2022546763000018.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000018.jpg" he="138" wi="82" width="328" height="552" alt="Figure 2022546763000018" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/5f/d1/538600dc737aaf/2022546763000018.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/5f/d1/538600dc737aaf/2022546763000018.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000018.jpg" he="138" wi="82" width="328" height="552" alt="Figure 2022546763000018" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/5f/d1/538600dc737aaf/2022546763000018.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0271" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：観察から、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖のために、この実験の実験設定点の表において言及したパラメーターの最適化が必要であったことが結論された。
</span>
  Conclusion: From the observations it was concluded that the growth of Salmonella typhi microorganisms required optimization of the parameters mentioned in the experimental setpoint table of this experiment.
</span>
      </p>
      <p num="0272" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：０６  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>
  Experiment No.: 06 - The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 20L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.
</span>
      </p>
      <p num="0273" class="style-scope patent-text">
        <tables num="19" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/dc/dd/e48062a11a8613/2022546763000019.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000019.jpg" he="63" wi="99" width="396" height="252" alt="Figure 2022546763000019" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/dc/dd/e48062a11a8613/2022546763000019.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/eb/dc/dd/e48062a11a8613/2022546763000019.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000019.jpg" he="63" wi="99" width="396" height="252" alt="Figure 2022546763000019" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/eb/dc/dd/e48062a11a8613/2022546763000019.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0274" class="style-scope patent-text">
        <tables num="20" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2d/cd/c0/b5b3a51f43ef48/2022546763000020.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000020.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000020" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2d/cd/c0/b5b3a51f43ef48/2022546763000020.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2d/cd/c0/b5b3a51f43ef48/2022546763000020.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000020.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000020" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2d/cd/c0/b5b3a51f43ef48/2022546763000020.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0275" class="style-scope patent-text">
        <tables num="21" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/93/f0/0c43788ee8122d/2022546763000021.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000021.jpg" he="75" wi="115" width="460" height="300" alt="Figure 2022546763000021" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/93/f0/0c43788ee8122d/2022546763000021.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/93/f0/0c43788ee8122d/2022546763000021.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000021.jpg" he="75" wi="115" width="460" height="300" alt="Figure 2022546763000021" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/93/f0/0c43788ee8122d/2022546763000021.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0276" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0277" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0278" class="style-scope patent-text">
        <tables num="22" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e5/8f/d9/1365c233002904/2022546763000022.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000022.jpg" he="138" wi="82" width="328" height="552" alt="Figure 2022546763000022" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e5/8f/d9/1365c233002904/2022546763000022.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e5/8f/d9/1365c233002904/2022546763000022.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000022.jpg" he="138" wi="82" width="328" height="552" alt="Figure 2022546763000022" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e5/8f/d9/1365c233002904/2022546763000022.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0279" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：観察から、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖のために、この実験の実験設定点の表において言及したパラメーターの最適化が必要であったことが結論された。
</span>
  Conclusion: From the observations it was concluded that the growth of Salmonella typhi microorganisms required optimization of the parameters mentioned in the experimental setpoint table of this experiment.
</span>
      </p>
      <p num="0280" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：０７  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>
  Experiment No: 07 - The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 20L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.
</span>
      </p>
      <p num="0281" class="style-scope patent-text">
        <tables num="23" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a1/d9/0e/5c13b62d8ba378/2022546763000023.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000023.jpg" he="68" wi="101" width="404" height="272" alt="Figure 2022546763000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a1/d9/0e/5c13b62d8ba378/2022546763000023.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a1/d9/0e/5c13b62d8ba378/2022546763000023.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000023.jpg" he="68" wi="101" width="404" height="272" alt="Figure 2022546763000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a1/d9/0e/5c13b62d8ba378/2022546763000023.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0282" class="style-scope patent-text">
        <tables num="24" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/5d/dd/892feed75c409b/2022546763000024.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000024.jpg" he="72" wi="114" width="456" height="288" alt="Figure 2022546763000024" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/5d/dd/892feed75c409b/2022546763000024.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7e/5d/dd/892feed75c409b/2022546763000024.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000024.jpg" he="72" wi="114" width="456" height="288" alt="Figure 2022546763000024" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7e/5d/dd/892feed75c409b/2022546763000024.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0283" class="style-scope patent-text">
        <tables num="25" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/56/72/fe91f78ac42a8a/2022546763000025.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000025.jpg" he="72" wi="119" width="476" height="288" alt="Figure 2022546763000025" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/56/72/fe91f78ac42a8a/2022546763000025.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/cd/56/72/fe91f78ac42a8a/2022546763000025.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000025.jpg" he="72" wi="119" width="476" height="288" alt="Figure 2022546763000025" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/cd/56/72/fe91f78ac42a8a/2022546763000025.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0284" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0285" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0286" class="style-scope patent-text">
        <tables num="26" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c7/0a/e0/bf0153de157a24/2022546763000026.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000026.jpg" he="134" wi="77" width="308" height="536" alt="Figure 2022546763000026" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c7/0a/e0/bf0153de157a24/2022546763000026.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c7/0a/e0/bf0153de157a24/2022546763000026.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000026.jpg" he="134" wi="77" width="308" height="536" alt="Figure 2022546763000026" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c7/0a/e0/bf0153de157a24/2022546763000026.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0287" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：観察から、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖のために、この実験の実験設定点の表において言及したパラメーターの最適化が必要であったことが結論された。
</span>
  Conclusion: From the observations it was concluded that the growth of Salmonella typhi microorganisms required optimization of the parameters mentioned in the experimental setpoint table of this experiment.
</span>
      </p>
      <p num="0288" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：０８  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>
  Experiment No.: 08 - The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 20L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.
</span>
      </p>
      <p num="0289" class="style-scope patent-text">
        <tables num="27" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/6d/1d/9446f946987d10/2022546763000027.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000027.jpg" he="61" wi="96" width="384" height="244" alt="Figure 2022546763000027" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/6d/1d/9446f946987d10/2022546763000027.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/6d/1d/9446f946987d10/2022546763000027.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000027.jpg" he="61" wi="96" width="384" height="244" alt="Figure 2022546763000027" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/6d/1d/9446f946987d10/2022546763000027.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0290" class="style-scope patent-text">
        <tables num="28" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2b/e0/5c/bffd5abe1c4c05/2022546763000028.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000028.jpg" he="71" wi="116" width="464" height="284" alt="Figure 2022546763000028" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2b/e0/5c/bffd5abe1c4c05/2022546763000028.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2b/e0/5c/bffd5abe1c4c05/2022546763000028.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000028.jpg" he="71" wi="116" width="464" height="284" alt="Figure 2022546763000028" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2b/e0/5c/bffd5abe1c4c05/2022546763000028.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0291" class="style-scope patent-text">
        <tables num="29" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/9e/67/147428b2ae9894/2022546763000029.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000029.jpg" he="72" wi="115" width="460" height="288" alt="Figure 2022546763000029" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/9e/67/147428b2ae9894/2022546763000029.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/9e/67/147428b2ae9894/2022546763000029.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000029.jpg" he="72" wi="115" width="460" height="288" alt="Figure 2022546763000029" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/9e/67/147428b2ae9894/2022546763000029.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0292" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0293" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0294" class="style-scope patent-text">
        <tables num="30" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/52/d7/56/88e9c7963c43b0/2022546763000030.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000030.jpg" he="137" wi="80" width="320" height="548" alt="Figure 2022546763000030" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/52/d7/56/88e9c7963c43b0/2022546763000030.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/52/d7/56/88e9c7963c43b0/2022546763000030.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000030.jpg" he="137" wi="80" width="320" height="548" alt="Figure 2022546763000030" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/52/d7/56/88e9c7963c43b0/2022546763000030.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0295" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：観察から、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖のために、この実験の実験設定点の表において言及したパラメーターの最適化が必要であったことが結論された。
</span>
  Conclusion: From the observations it was concluded that the growth of Salmonella typhi microorganisms required optimization of the parameters mentioned in the experimental setpoint table of this experiment.
</span>
      </p>
      <p num="0296" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：０９  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>
  Experiment No.: 09 - The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 20L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.
</span>
      </p>
      <p num="0297" class="style-scope patent-text">
        <tables num="31" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/8b/71/ae9cbae77c3738/2022546763000031.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000031.jpg" he="65" wi="99" width="396" height="260" alt="Figure 2022546763000031" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/8b/71/ae9cbae77c3738/2022546763000031.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/8b/71/ae9cbae77c3738/2022546763000031.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000031.jpg" he="65" wi="99" width="396" height="260" alt="Figure 2022546763000031" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/8b/71/ae9cbae77c3738/2022546763000031.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0298" class="style-scope patent-text">
        <tables num="32" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b1/4f/de/8aaef75f19a7bb/2022546763000032.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000032.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000032" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b1/4f/de/8aaef75f19a7bb/2022546763000032.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b1/4f/de/8aaef75f19a7bb/2022546763000032.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000032.jpg" he="73" wi="116" width="464" height="292" alt="Figure 2022546763000032" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b1/4f/de/8aaef75f19a7bb/2022546763000032.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0299" class="style-scope patent-text">
        <tables num="33" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4f/44/eb/dd297bb8e6397b/2022546763000033.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000033.jpg" he="72" wi="117" width="468" height="288" alt="Figure 2022546763000033" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4f/44/eb/dd297bb8e6397b/2022546763000033.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4f/44/eb/dd297bb8e6397b/2022546763000033.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000033.jpg" he="72" wi="117" width="468" height="288" alt="Figure 2022546763000033" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4f/44/eb/dd297bb8e6397b/2022546763000033.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0300" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0301" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0302" class="style-scope patent-text">
        <tables num="34" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0b/3c/1c/ae5aea3d8195c5/2022546763000034.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000034.jpg" he="135" wi="85" width="340" height="540" alt="Figure 2022546763000034" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0b/3c/1c/ae5aea3d8195c5/2022546763000034.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0b/3c/1c/ae5aea3d8195c5/2022546763000034.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000034.jpg" he="135" wi="85" width="340" height="540" alt="Figure 2022546763000034" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0b/3c/1c/ae5aea3d8195c5/2022546763000034.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0303" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：観察から、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ微生物の増殖のために、この実験の実験設定点の表において言及したパラメーターの最適化が必要であったことが結論された。
</span>
  Conclusion: From the observations it was concluded that the growth of Salmonella typhi microorganisms required optimization of the parameters mentioned in the experimental setpoint table of this experiment.
</span>
      </p>
      <p num="0304" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：１０  －  ２０Ｌ規模のバッチにおいて以下の発酵パラメーターでＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉの増殖パターンを研究した。Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉのバッチについて、好適なパラメーターを定義した。溶存酸素および浸透圧は、実験設定点付近に制御した。
</span>
  Experiment No.: The growth pattern of Salmonella typhi was studied with the following fermentation parameters in 10-20 L scale batches. Suitable parameters were defined for a batch of Salmonella typhi. Dissolved oxygen and osmolarity were controlled near the experimental set points.
</span>
      </p>
      <p num="0305" class="style-scope patent-text">
        <tables num="35" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e3/be/0d/86a223c9d5bac9/2022546763000035.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000035.jpg" he="67" wi="101" width="404" height="268" alt="Figure 2022546763000035" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e3/be/0d/86a223c9d5bac9/2022546763000035.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e3/be/0d/86a223c9d5bac9/2022546763000035.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000035.jpg" he="67" wi="101" width="404" height="268" alt="Figure 2022546763000035" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e3/be/0d/86a223c9d5bac9/2022546763000035.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0306" class="style-scope patent-text">
        <tables num="36" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4a/b3/3a/fd1995f61713dc/2022546763000036.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000036.jpg" he="72" wi="118" width="472" height="288" alt="Figure 2022546763000036" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4a/b3/3a/fd1995f61713dc/2022546763000036.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4a/b3/3a/fd1995f61713dc/2022546763000036.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000036.jpg" he="72" wi="118" width="472" height="288" alt="Figure 2022546763000036" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4a/b3/3a/fd1995f61713dc/2022546763000036.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0307" class="style-scope patent-text">
        <tables num="37" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4b/62/3e/35d04deaa0980d/2022546763000037.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000037.jpg" he="71" wi="117" width="468" height="284" alt="Figure 2022546763000037" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4b/62/3e/35d04deaa0980d/2022546763000037.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4b/62/3e/35d04deaa0980d/2022546763000037.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000037.jpg" he="71" wi="117" width="468" height="284" alt="Figure 2022546763000037" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4b/62/3e/35d04deaa0980d/2022546763000037.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0308" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  手順：元種を使い捨てフラスコ（２５０ｍｌおよび１Ｌ）で発育させ、２０Ｌ発酵槽に接種した。接種後、発酵を、流加モードで実施した。供給物を発酵槽に添加して、Ｓａｌｍｏｎｅｌｌａ  Ｔｙｐｈｉ微生物の増殖を支持した。バッチを、３６℃の温度、ｐＨ７．００および１５０～５００ＲＰＭ撹拌（ＤＯを維持するカスケードモード）で操作した。消泡剤を断続的に添加して、発酵の間の発泡を制御した。
</span>
  Procedure: The original seed was grown in disposable flasks (250 ml and 1 L) and inoculated into 20 L fermentors. After inoculation, fermentation was performed in fed-batch mode. Feed was added to the fermentor to support the growth of Salmonella Typhi microorganisms. The batch was operated at a temperature of 36° C., pH 7.00 and 150-500 RPM agitation (cascade mode to maintain DO). Antifoam was added intermittently to control foaming during fermentation.
</span>
      </p>
      <p num="0309" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：
</span>
  observation:
</span>
      </p>
      <p num="0310" class="style-scope patent-text">
        <tables num="38" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7d/77/f0/b66002c38c59fc/2022546763000038.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000038.jpg" he="135" wi="83" width="332" height="540" alt="Figure 2022546763000038" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7d/77/f0/b66002c38c59fc/2022546763000038.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7d/77/f0/b66002c38c59fc/2022546763000038.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000038.jpg" he="135" wi="83" width="332" height="540" alt="Figure 2022546763000038" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7d/77/f0/b66002c38c59fc/2022546763000038.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0311" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：
</span>
  Conclusion:
</span>
      </p>
      <p num="0312" class="style-scope patent-text">
        <tables num="39" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/41/d8/1b/cc762fbbca46ec/2022546763000039.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000039.jpg" he="112" wi="163" width="652" height="448" alt="Figure 2022546763000039" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/41/d8/1b/cc762fbbca46ec/2022546763000039.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/41/d8/1b/cc762fbbca46ec/2022546763000039.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000039.jpg" he="112" wi="163" width="652" height="448" alt="Figure 2022546763000039" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/41/d8/1b/cc762fbbca46ec/2022546763000039.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0313" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  培養の間、消泡剤Ｊ６７３  ＳＴＲＵＫＴＯＬ、４０～７０ｇ／Ｌの範囲の大豆ペプトンＤｉｆｃｏ（商標）Ｓｅｌｅｃｔ  Ｐｈｙｔｏｎｅ（商標）ＵＦおよび４０～７０ｇ／Ｌの範囲の酵母抽出物Ｄｉｆｃｏ（商標）Ｙｅａｓｔ  Ｅｘｔｒａｃｔ、ＵＦの組合せの使用を含む流加プロセスによる、サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体の高収率収穫を得るための培養の流加モードの結果、収率が改善し（１００～７００ｍｇ／Ｌ）、発酵パラメーターは、６．７～７．１の範囲に維持されたｐＨ、３４．０～３８．０℃の範囲で維持された温度、３６～３９％に維持された溶存酸素レベル、１５０～５００に維持された撹拌（ｒｐｍ）および４００～６００ｍＯｓｍｏｌ／ｋｇの浸透圧で構成される。
</span>
  During cultivation, defoamer J673 STRUKTOL, soy peptone Difco™ Select Phytone™ UF ranging from 40 to 70 g/L and yeast extract Difco™ Yeast Extract, UF ranging from 40 to 70 g/L. Salmonella serotype strain S. cerevisiae by a fed-batch process involving the use of combinations typhi, S. paratyphi A, S.; typhimurium and S. The fed-batch mode of cultivation to obtain a high-yield harvest of polysaccharides from enteritidis resulted in improved yields (100-700 mg/L) and fermentation parameters were maintained in the range of 6.7-7.1. pH maintained in the range of 34.0-38.0° C., dissolved oxygen level maintained at 36-39%, agitation (rpm) maintained at 150-500 and 400-600 mOsmol/kg. Consists of osmotic pressure.
</span>
      </p>
      <p num="0314" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例２：<br class="style-scope patent-text">
Ｃ）サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を精製する方法（下流精製）<br class="style-scope patent-text">
Ｃ１）ＶｉＰｓ発酵収穫物を、以下の下流精製ステップに供して、所望の品質のＶｉ多糖体（ＶｉＰｓ）を得た：<br class="style-scope patent-text">
  ｎ）約０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）による細菌莢膜多糖体収穫物の清澄化、<br class="style-scope patent-text">
  ｏ）接線流限外ろ過（ＴＦＦ）による濃縮および１００ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換（５ｍＭ  ＥＤＴＡを含有する２０ｍＭトリス緩衝液ｐＨ７．５）、<br class="style-scope patent-text">
  ｐ）タンパク質、核酸およびリポ多糖の変性のための、ＳＤＳ（２０％ＳＤＳ原液投入量）、エチレンジアミン四酢酸（ＥＤＴＡ）（４～１０ｍＭ）および酢酸ナトリウム（５％～１０％）による処理、<br class="style-scope patent-text">
  ｑ）エタノール沈殿（４０％～７０％）、<br class="style-scope patent-text">
  ｒ）遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｓ）過剰な洗剤の除去のための２Ｍ塩化カリウム（ＫＣｌ）による処理に続いて、遠心および約０．２μＭの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｔ）接線流ろ過（ＴＦＦ）による濃縮および３０ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｕ）ＣＴＡＢ（１２％ＣＴＡＢ原液投入量）によるＰＳの選択的沈殿、<br class="style-scope patent-text">
  ｖ）遠心および約０．４５マイクロメートル～約０．２マイクロメートルの孔径を有する少なくとも１つの清澄化フィルターを通したダイレクトフローろ過（ＤＦＦ）によるろ過、<br class="style-scope patent-text">
  ｗ）１Ｍ  ＮａＣｌ（０．１Ｍ～２Ｍ）の存在下、６０％エタノール（５０％～７０％）でペレットを洗浄することによるタンパク質および核酸不純物の除去、<br class="style-scope patent-text">
  ｘ）６０％エタノール（＜７５％ＯＲ＞９５％）を利用することによる多糖体の選択的沈殿、<br class="style-scope patent-text">
  ｙ）多糖体をＷＦＩまたは１Ｍ  ＮａＣｌに溶解し、接線流ろ過（ＴＦＦ）による濃縮および３０ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換に供するステップ、ならびに<br class="style-scope patent-text">
  ｚ）滅菌条件下、約０．２マイクロメートルの孔径を有する少なくとも１つの滅菌フィルターを通した滅菌ろ過および≦－２０℃での保存。<br class="style-scope patent-text">
Ｃ２）リポ多糖（ＬＰＳ）発酵収穫物のＳａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉ  Ｏ特異的多糖体（ＯＳＰ）を以下の下流精製ステップに供して、Ｓａｌｍｏｎｅｌｌａ  Ｐａｒａｔｙｐｈｉ  Ａリポ多糖体（ＬＰＳ）から所望の品質のＯ特異的多糖体を得た：<br class="style-scope patent-text">
  ｒ）７０００ｒｐｍ、４℃で３０分間遠心し、細胞ペレット（約１Ｋｇ）を収集し、上清および細胞ペレットを１５Ｌの１Ｍ  ＮａＣｌに懸濁し、室温で１時間撹拌するステップ、<br class="style-scope patent-text">
  ｓ）接線流限外ろ過（ＴＦＦ）による濃縮、ならびに０．４５μｍ  Ｐｒｏｓｔａｋカセットおよび３０ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｔ）９０℃の温度で１８０分間の、１％酢酸（ｐＨ約２．８～３．０）によるＬＰＳの酸加水分解、<br class="style-scope patent-text">
  ｕ）混合物の室温（ＲＴ）への冷却、および７０００ｒｐｍ、２５℃で４５分間の遠心による不純沈殿物の除去、<br class="style-scope patent-text">
  ｖ）上清をガラスボトルに中和収集し、アンモニア水によりｐＨ７．０に中和するステップ、<br class="style-scope patent-text">
  ｗ）約０．４５および約０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）による清澄化、<br class="style-scope patent-text">
  ｘ）デオキシコール酸ナトリウムストック溶液を添加して、１％の最終濃度にし、３０℃の温度で撹拌しながら、３０分間インキュベートし、酢酸によりｐＨを２．０に調節し、３０℃で撹拌しながら、１５分間インキュベートするステップ、<br class="style-scope patent-text">
  ｙ）７０００ｒｐｍ、２５℃で４５分間の遠心、<br class="style-scope patent-text">
  ｚ）約０．４５および約０．２マイクロメートルの孔径を有する少なくとも１つの膜を通したダイレクトフローろ過（ＤＦＦ）、<br class="style-scope patent-text">
  ａａ）接線流ろ過（ＴＦＦ）による濃縮および１０ｋＤａ分画分子量（ＭＷＣＯ）を有する膜を使用した透析ろ過（ＤＦ）による緩衝液交換、<br class="style-scope patent-text">
  ｂｂ）滅菌条件下、約０．２マイクロメートルの孔径を有する少なくとも１つの滅菌フィルターを通した滅菌ろ過により精製Ｏ特異的多糖体（ＯＳＰ）を得るステップ。
</span>Example 2:<br class="style-scope patent-text"> C) Salmonella serotype strain S . typhi, S. paratyphi A, S.; typhimurium and S. Method for purifying polysaccharides from enteritidis (downstream purification)<br class="style-scope patent-text"> C1) The ViPs fermentation harvest was subjected to the following downstream purification steps to obtain the desired quality of Vi polysaccharides (ViPs):<br class="style-scope patent-text"> n) clarification of the bacterial capsular polysaccharide harvest by direct flow filtration (DFF) through at least one membrane having a pore size of about 0.2 micrometers;<br class="style-scope patent-text"> o) concentration by tangential flow ultrafiltration (TFF) and buffer exchange (20 mM Tris buffer pH 7.5 containing 5 mM EDTA) by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 100 kDa;<br class="style-scope patent-text"> p) treatment with SDS (20% SDS stock solution input), ethylenediaminetetraacetic acid (EDTA) (4-10 mM) and sodium acetate (5%-10%) for denaturation of proteins, nucleic acids and lipopolysaccharides;<br class="style-scope patent-text"> q) ethanol precipitation (40%-70%),<br class="style-scope patent-text"> r) centrifugation and filtration by direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.2 μM;<br class="style-scope patent-text"> s) treatment with 2M potassium chloride (KCl) for removal of excess detergent, followed by centrifugation and filtration by direct flow filtration (DFF) through at least one clarification filter with a pore size of about 0.2 μM;<br class="style-scope patent-text"> t) concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 30 kDa;<br class="style-scope patent-text"> u) selective precipitation of PS by CTAB (12% CTAB stock solution input);<br class="style-scope patent-text"> v) filtration by centrifugation and direct flow filtration (DFF) through at least one clarification filter having a pore size of about 0.45 micrometers to about 0.2 micrometers;<br class="style-scope patent-text"> w) removal of protein and nucleic acid impurities by washing the pellet with 60% ethanol (50%-70%) in the presence of 1M NaCl (0.1M-2M);<br class="style-scope patent-text"> x) selective precipitation of polysaccharides by utilizing 60% ethanol (&lt;75% OR&gt;95%);<br class="style-scope patent-text"> y) dissolving the polysaccharide in WFI or 1 M NaCl and subjecting it to concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 30 kDa, and z ) Sterile filtration through at least one sterile filter with a pore size of about 0.2 micrometers under sterile conditions and storage at ≤ -20°C.<br class="style-scope patent-text"> C2) Salmonella paratyphi O-specific polysaccharide (OSP) of lipopolysaccharide (LPS) fermentation harvest is subjected to the following downstream purification steps to obtain desired quality O-specific polysaccharide from Salmonella Paratyphi A lipopolysaccharide (LPS) got:<br class="style-scope patent-text"> r) centrifuging at 7000 rpm for 30 minutes at 4° C., collecting the cell pellet (approximately 1 Kg), suspending the supernatant and cell pellet in 15 L of 1 M NaCl and stirring for 1 hour at room temperature;<br class="style-scope patent-text"> s) concentration by tangential flow ultrafiltration (TFF) and buffer exchange by diafiltration (DF) using a 0.45 μm Prostak cassette and a membrane with a molecular weight cutoff (MWCO) of 30 kDa;<br class="style-scope patent-text"> t) acid hydrolysis of LPS with 1% acetic acid (pH about 2.8-3.0) at a temperature of 90° C. for 180 minutes;<br class="style-scope patent-text"> u) cooling the mixture to room temperature (RT) and removing the impure precipitate by centrifugation at 7000 rpm, 25° C. for 45 min;<br class="style-scope patent-text"> v) Neutralize and collect the supernatant in a glass bottle and neutralize to pH 7.0 with aqueous ammonia;<br class="style-scope patent-text"> w) clarification by direct flow filtration (DFF) through at least one membrane having a pore size of about 0.45 and about 0.2 micrometers;<br class="style-scope patent-text"> x) Add sodium deoxycholate stock solution to a final concentration of 1%, incubate for 30 minutes with stirring at a temperature of 30°C, adjust the pH to 2.0 with acetic acid and stir at 30°C. incubating for 15 minutes while<br class="style-scope patent-text"> y) centrifugation at 7000 rpm, 25° C. for 45 minutes;<br class="style-scope patent-text"> z) direct flow filtration (DFF) through at least one membrane having a pore size of about 0.45 and about 0.2 micrometers;<br class="style-scope patent-text"> aa) concentration by tangential flow filtration (TFF) and buffer exchange by diafiltration (DF) using a membrane with a molecular weight cutoff (MWCO) of 10 kDa;<br class="style-scope patent-text"> bb) obtaining purified O-specific polysaccharide (OSP) by sterile filtration through at least one sterile filter having a pore size of about 0.2 micrometer under sterile conditions.</span>
      </p>
      <p num="0315" class="style-scope patent-text">
        <tables num="40-1" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/a4/9a/f36c687204c3bc/2022546763000040.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000040.jpg" he="225" wi="168" width="672" height="900" alt="Figure 2022546763000040" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/a4/9a/f36c687204c3bc/2022546763000040.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/a4/9a/f36c687204c3bc/2022546763000040.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000040.jpg" he="225" wi="168" width="672" height="900" alt="Figure 2022546763000040" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/a4/9a/f36c687204c3bc/2022546763000040.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0316" class="style-scope patent-text">
        <tables num="40-2" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/79/73/1d/096d5396cbd9f2/2022546763000041.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000041.jpg" he="220" wi="168" width="672" height="880" alt="Figure 2022546763000041" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/79/73/1d/096d5396cbd9f2/2022546763000041.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/79/73/1d/096d5396cbd9f2/2022546763000041.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000041.jpg" he="220" wi="168" width="672" height="880" alt="Figure 2022546763000041" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/79/73/1d/096d5396cbd9f2/2022546763000041.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0317" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結果および解釈：
</span>
  Results and Interpretation:
</span>
      </p>
      <p num="0318" class="style-scope patent-text">
        <tables num="41" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/e4/e0/c205511e31d4f3/2022546763000042.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000042.jpg" he="179" wi="167" width="668" height="716" alt="Figure 2022546763000042" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/e4/e0/c205511e31d4f3/2022546763000042.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/af/e4/e0/c205511e31d4f3/2022546763000042.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000042.jpg" he="179" wi="167" width="668" height="716" alt="Figure 2022546763000042" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/af/e4/e0/c205511e31d4f3/2022546763000042.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0319" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｖｉ  ＰＳ精製の改善された方法は、操作の容易さ、および以下のいくつかの他の利点の両方の点で明らかな利点を有する。<br class="style-scope patent-text">
  ・  酢酸ナトリウム（２％）に対して酢酸ナトリウム（６％）を使用した場合、改善された多糖体精製（回収率、Ｏアセチル、エンドトキシン、タンパク質、核酸含有量、多分散性、粘度の点で）<br class="style-scope patent-text">
  酢酸ナトリウム（６％）を使用した場合の値<br class="style-scope patent-text">
    ＤＳＰ％回収率  －  ５０％<br class="style-scope patent-text">
    Ｐｓ粘度  －  データなし<br class="style-scope patent-text">
    Ｐｓ多分散度  －  データなし<br class="style-scope patent-text">
    Ｏアセチル  －  ２．９ｍｍｏｌ／ｇｍＰＳ<br class="style-scope patent-text">
  酢酸ナトリウム（２％）を使用した場合の値<br class="style-scope patent-text">
    ＤＳＰ％回収率  －  ４０％<br class="style-scope patent-text">
    Ｐｓ粘度  －  データなし<br class="style-scope patent-text">
    Ｐｓ多分散度  －  データなし<br class="style-scope patent-text">
  Ｏアセチル  －  ２．６ｍｍｏｌ／ｇｍＰＳ<br class="style-scope patent-text">
  酢酸ナトリウムは核酸と反応する。酢酸ナトリウムは、Ｎａ＋と（ＣＨ３ＣＯＯ）－に解離する。正電荷ナトリウムイオンは、核酸の負電荷ＰＯ３－を中和し、したがって、核酸の沈殿を助ける。そのため、より高濃度、すなわち６％の酢酸ナトリウムは、核酸のような宿主細胞不純物を効果的に沈殿させる。
</span>The improved method of Vi PS purification has clear advantages both in terms of ease of operation and some other advantages as follows.<br class="style-scope patent-text"> - Improved polysaccharide purification (in terms of recovery, O-acetyl, endotoxin, protein, nucleic acid content, polydispersity, viscosity) when using sodium acetate (6%) versus sodium acetate (2%) )<br class="style-scope patent-text"> Values with Sodium Acetate (6%) DSP % Recovery - 50%<br class="style-scope patent-text"> Ps viscosity - no data Ps polydispersity - no data O acetyl - 2.9 mmol/gmPS<br class="style-scope patent-text"> Values with Sodium Acetate (2%) DSP % Recovery - 40%<br class="style-scope patent-text"> Ps viscosity - no data Ps polydispersity - no data O acetyl - 2.6 mmol/gmPS<br class="style-scope patent-text"> Sodium acetate reacts with nucleic acids. Sodium acetate dissociates into Na+ and (CH3COO)-. Positively charged sodium ions neutralize the negative charge PO3- of nucleic acids and thus aid in nucleic acid precipitation. Therefore, a higher concentration of sodium acetate, ie 6%, effectively precipitates host cell impurities such as nucleic acids.</span>
      </p>
      <p num="0320" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  ＣＴＡＢ（０．５、１％）に対してＣＴＡＢ（３％）の改善された多糖体精製（回収率、Ｏアセチル、エンドトキシン、タンパク質、核酸含有量、多分散性、粘度の点で）。ＣＴＡＢは、アミンベースのカチオン性４級界面活性剤である。ＣＴＡＢはアニオン性多糖体と相互作用（イオン性相互作用）し、次いで、その溶解度が減少するため、ＣＴＡＢは、溶液から多糖体を沈殿させる。そのため、より高濃度のＣＴＡＢ（２％）は、より大量の多糖体を常に沈殿させ、これにより、より高い収率が得られ、タンパク質不純物の除去は追加の利点である。
</span>
  • Improved polysaccharide purification of CTAB (3%) versus CTAB (0.5, 1%) (in terms of recovery, O-acetyl, endotoxin, protein, nucleic acid content, polydispersity, viscosity). CTAB is an amine-based cationic quaternary surfactant. Because CTAB interacts with anionic polysaccharides (ionic interactions) and then decreases their solubility, CTAB precipitates polysaccharides out of solution. Therefore, higher concentrations of CTAB (2%) consistently precipitate larger amounts of polysaccharide, which leads to higher yields, and removal of protein impurities is an added benefit.
</span>
      </p>
      <p num="0321" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  ＤＯＣベースのプロセスに対してＤＯＣを用いない現在のプロセスでの改善された多糖体精製（回収率、Ｏアセチル、エンドトキシン、タンパク質、核酸含有量、多分散性、粘度の点で）。
</span>
  • Improved polysaccharide purification (in terms of recovery, O-acetyl, endotoxin, protein, nucleic acid content, polydispersity, viscosity) in current processes without DOC versus DOC-based processes.
</span>
      </p>
      <p num="0322" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＤＯＣプロセスを用いない改善された方法の利点<br class="style-scope patent-text">
  １．  規制の問題：ＤＯＣは、動物由来の成分であり、ＨＡＬＡＬ遵守ではない。ＤＯＣは、世界中全体で単一のベンダーにより製造および供給されている一方、ＳＤＳは、合成洗剤であり、ＨＡＬＡＬ認証されており、世界でいくつかの供給業者が利用できる。
</span>Advantages of improved method without DOC process1. Regulatory Issues: DOC is an animal derived ingredient and not HALAL compliant. DOC is manufactured and supplied by a single vendor worldwide, while SDS is a synthetic detergent, is HALAL certified and is available from several suppliers worldwide.</span>
      </p>
      <p num="0323" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  機能の問題：ＤＯＣは化学組成に影響することなくエンドトキシンを分解し、洗剤が除去されると、エンドトキシンがその生物活性を取り戻す一方、ＳＤＳは、その両親媒性およびより高い凝集数に起因して、タンパク質を良好に変性および可溶化し、また、エンドトキシンをそのモノマー単位に不可逆的に破壊する。
</span>
  2. Functional Issues: DOC degrades endotoxin without affecting its chemical composition, and endotoxin regains its biological activity when the detergent is removed, whereas SDS, due to its amphiphilicity and higher aggregation number, , denatures and solubilizes proteins well and irreversibly breaks down endotoxin into its monomeric units.
</span>
      </p>
      <p num="0324" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  動物由来成分であるデオキシコール酸ナトリウム（ＤＯＣ）またはフェノールを使用することなく開発されたＶｉ  ＰＳ精製の新しい改善された方法。タンパク質、核酸およびリポ多糖のような宿主細胞不純物が、酢酸ナトリウム（６％）、ドデシル硫酸ナトリウム（２％）およびエタノール（４０％）を使用することによる初期ステップ、ならびに様々なステップにおける濃縮および３０ｋＤａ分画膜を使用する透析ろ過で除去され、次いで、多糖体がカチオン性洗剤ＣＴＡＢによって沈殿され、研磨精製ステップを実施して精製Ｖｉ多糖体のより高収率を実現する多糖体の逆精製に基づく改善された方法は、ＷＨＯ仕様書を満たしている。
</span>
  • A new and improved method of Vi PS purification developed without the use of animal-derived components sodium deoxycholate (DOC) or phenol. Host cell contaminants such as proteins, nucleic acids and lipopolysaccharides were removed from the initial step by using sodium acetate (6%), sodium dodecyl sulfate (2%) and ethanol (40%), and enrichment and 30 kDa in various steps. After removal by diafiltration using a fractionating membrane, the polysaccharide was then precipitated by the cationic detergent CTAB and an abrasive purification step was performed to achieve a higher yield of purified Vi polysaccharide. The improved method based on meets WHO specifications.
</span>
      </p>
      <p num="0325" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  精製方法の結果、所望のＯ－アセチルレベル（２．０ｍｍｏｌ超／多糖体１ｇ）を有する約４０％～６５％の高い回収率、４００～４０００ｍｇ／Ｌの範囲の精製Ｖｉ多糖体収率がもたらされ、平均分子量は４０～４００ｋＤａの範囲であることが見出され、１％未満のタンパク質／ペプチド、２％未満の核酸、多糖体（ＰＳ）１μｇ当たり１００ＥＵ未満のエンドトキシンを含有し、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に５０％超のＰＳが溶出する）がもたらされる。
</span>
  - Purification methods resulted in high recovery of about 40%-65% with desired O-acetyl levels (&gt;2.0 mmol/g polysaccharide), purified Vi polysaccharide yields in the range of 400-4000 mg/L. and was found to have an average molecular weight in the range of 40-400 kDa, containing less than 1% protein/peptide, less than 2% nucleic acid, less than 100 EU endotoxin per μg of polysaccharide (PS), a molecule A size distribution (more than 50% of PS elutes before reaching a distribution coefficient (KD) of 0.25) is provided.
</span>
      </p>
      <p num="0326" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  Ｏ特異的多糖体（ＯＳＰ）精製方法の結果、エンドトキシン（ＰＳ  １μｇ当たり＜１００ＥＵのエンドトキシン）、タンパク質（＜１％）および核酸（＜２％）不純物の大幅な低減、好適には４０％～６５％の範囲のより高い莢膜多糖体回収率と共に、所望のＯ－アセチルレベル（＞２．０ｍｍｏｌ／多糖体１ｇ）、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に＞５０％のＰＳが溶出する）がもたらされ、精製Ｏ－特異的多糖体（ＯＳＰ）の平均分子量は、４０～２００ｋＤａの範囲であることが見出された。
</span>
  O-specific polysaccharide (OSP) purification methods result in significant reductions in endotoxin (&lt;100 EU endotoxin per μg of PS), protein (&lt;1%) and nucleic acid (&lt;2%) impurities, preferably from 40% to Desired O-acetyl levels (&gt;2.0 mmol/g polysaccharide), molecular size distributions (&gt;0.25 before reaching a distribution coefficient (KD) of 0.25), along with higher capsular polysaccharide recoveries in the range of 65%. 50% PS elutes) and the average molecular weight of the purified O-specific polysaccharide (OSP) was found to range from 40-200 kDa.
</span>
      </p>
      <p num="0327" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例３：<br class="style-scope patent-text">
Ｄ）サルモネラ菌血清型株Ｓ．ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を担体タンパク質にコンジュゲートする方法。
</span>Example 3:<br class="style-scope patent-text"> D) Salmonella serotype strain S . typhi, S. paratyphi A, S.; typhimurium and S. A method of conjugating a polysaccharide from enteritidis to a carrier protein.</span>
      </p>
      <p num="0328" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ  Ｖｉ多糖体とコンジュゲートするために使用する担体タンパク質は、破傷風トキソイドである。Ｓ．ｐａｒａｔｙｐｈｉ  Ａ、Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を、破傷風トキソイド（ＴＴ）、ジフテリアトキソイド（ＤＴ）またはＣＲＭ１９７から選択される担体タンパク質に個々にコンジュゲートする。
</span>
  The carrier protein used to conjugate the Salmonella typhi Vi polysaccharide is tetanus toxoid. S. paratyphi A, S.; typhimurium and S. polysaccharides from S. enteritidis are individually conjugated to a carrier protein selected from tetanus toxoid (TT), diphtheria toxoid (DT) or CRM197.
</span>
      </p>
      <p num="0329" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＣＲＭ１９７は、Ｐｆｅｎｅｘ  ＵＳＡからのＰｓｅｕｄｏｍｏｎａｓ  ｆｌｕｏｒｅｓｃｅｎｓの組換え株ＣＳ４６３－００３（ＭＢ１０１）から獲得される。
</span>
  According to the present disclosure, CRM197 is obtained from Pseudomonas fluorescens recombinant strain CS463-003 (MB101) from Pfenex USA.
</span>
      </p>
      <p num="0330" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＴＴは、Ｃｅｎｔｒａｌ  ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）、Ｎａｔｉｏｎａｌ  Ｃｏｎｔｒｏｌ  Ａｕｔｈｏｒｉｔｙ、Ｋａｓａｕｌｉ、Ｈｉｍａｃｈａｌ  Ｐｒａｄｅｓｈ、Ｉｎｄｉａから得たＣｌｏｓｔｒｉｄｉｕｍ  Ｔｅｔａｎｉ（Ｈａｒｖａｒｄ  Ｎｏ４９２０５）から獲得される。Ｃｅｎｔｒａｌ  ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）は、この株をＮＶＩ、Ｎｅｔｈｅｒｌａｎｄから獲得した。
</span>
  According to the present disclosure, TT is obtained from Clostridium Tetani obtained from the Central Research Institute (CRI), National Control Authority, Kasauli, Himachal Pradesh, India (Harvard No 49205). The Central Research Institute (CRI) obtained this strain from NVI, Netherlands.
</span>
      </p>
      <p num="0331" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  本開示によると、ＤＴは、Ｃｅｎｔｒａｌ  Ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）、Ｎａｔｉｏｎａｌ  Ｃｏｎｔｒｏｌ  Ａｕｔｈｏｒｉｔｙ、Ｋａｓａｕｌｉ、Ｈｉｍａｃｈａｌ  Ｐｒａｄｅｓｈ、Ｉｎｄｉａから得られるＣｏｒｎｙｎｅｂａｃｔｅｒｉｕｍ  ｄｉｐｈｔｈｅｒｉａｅ  Ｐａｒｋ－Ｗｉｌｌｉａｍｓ  Ｎｕｍｂｅｒ  ８株の培養物から製造する。Ｃｅｎｔｒａｌ  ｒｅｓｅａｒｃｈ  Ｉｎｓｔｉｔｕｔｅ（ＣＲＩ）は、この株をＷｅｌｌｃｏｍｅ  Ｒｅｓｅａｒｃｈ  Ｌａｂｏｒａｔｏｒｉｅｓから獲得した。<br class="style-scope patent-text">
Ｄ１）カルボジイミド化学を使用した一価Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉコンジュゲートの調製：<br class="style-scope patent-text">
ステップ１：ＴＴの濃縮および誘導体化<br class="style-scope patent-text">
  手順：<br class="style-scope patent-text">
  ａ）ＧＦＣ精製ＴＴ（モノマー含有量９０％超）を、１０ｋＤａ膜を使用して濃縮して、１２ｍｇ／ｍｌ以上のタンパク質濃度に到達させた（Ｌｏｗｒｙアッセイ）。
</span>According to the present disclosure, DT is produced from a culture of Cornynebacterium diphtheriae Park-<figure-callout id="8" label="Williams Number" filenames="2022546763000111.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Williams Number</a></figure-callout> 8 strain obtained from the Central Research Institute (CRI), National Control Authority, Kasauli, Himachal Pradesh, India. The Central Research Institute (CRI) obtained this strain from Wellcome Research Laboratories.<br class="style-scope patent-text"> D1) Preparation of monovalent Salmonella typhi conjugates using carbodiimide chemistry:<br class="style-scope patent-text"> Step 1: Enrichment and Derivatization of TT Procedure:<br class="style-scope patent-text"> a) GFC-purified TT (&gt;90% monomer content) was concentrated using a 10 kDa membrane to reach a protein concentration &gt;12 mg/ml (Lowry assay).</span>
      </p>
      <p num="0332" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｂ）誘導体化比を、以下に示す通り使用し、これに従って必要な量を計算した。<br class="style-scope patent-text">
  Ｐｒ：ＡＤＨ：ＥＤＣは、１：６．０：１<br class="style-scope patent-text">
  誘導体化規模：１３ｇｍ<br class="style-scope patent-text">
  ｃ）濃縮ＴＴ（０．９％ＮａＣｌ中）、１Ｍ  ＭＥＳ  ｐＨ６．０、ＡＤＨ溶液（０．１Ｍ  ＭＥＳ  ｐＨ６．０に溶解）およびＥＤＣ溶液（０．１Ｍ  ＭＥＳ  ｐＨ６．０に溶解）を、順次添加し、０．１Ｍ  ＭＥＳ緩衝液ｐＨ６．０の添加により最終必要容積にした。反応における最終Ｐｒ濃度は、約４．５ｍｇ／ｍｌであった。
</span>b) The derivatization ratio was used as indicated below and the required amount was calculated accordingly.<br class="style-scope patent-text"> Pr:ADH:EDC is 1:6.0:1<br class="style-scope patent-text"> Derivatization scale: 13 gm<br class="style-scope patent-text"> c) Concentrated TT (in 0.9% NaCl), 1 M MES pH 6.0, ADH solution (dissolved in 0.1 M MES pH 6.0) and EDC solution (dissolved in 0.1 M MES pH 6.0) added sequentially and brought to final required volume by addition of 0.1 M MES buffer pH 6.0. The final Pr concentration in the reaction was approximately 4.5 mg/ml.</span>
      </p>
      <p num="0333" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｄ）反応混合物を撹拌し、ｐＨ５．９０で約１時間継続した。次いで、ＥＤＴＡ  ｐＨ８．０を含有する０．１Ｍリン酸緩衝液を使用してｐＨを７．５超に調節することによって、誘導体化反応をクエンチした。
</span>
  d) The reaction mixture was stirred and continued at pH 5.90 for about 1 hour. The derivatization reaction was then quenched by adjusting the pH above 7.5 using 0.1 M phosphate buffer containing EDTA pH 8.0.
</span>
      </p>
      <p num="0334" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｅ）クエンチした反応混合物を、２２容積を使用する１０ｍＭリン酸緩衝液、続いて、少なくとも１２容積の０．１Ｍ  ＭＥＳ緩衝液ｐＨ６．０に対して１０ｋＤａ分画膜を使用して、透析ろ過にかけて、未反応部分および他の残留物を除去した。
</span>
  e) The quenched reaction mixture was subjected to diafiltration using 22 volumes of 10 mM phosphate buffer followed by at least 12 volumes of 0.1 M MES buffer pH 6.0 using a 10 kDa cutoff membrane. , unreacted moieties and other residues were removed.
</span>
      </p>
      <p num="0335" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｆ）誘導体化試料を、Ｌｏｗｒｙアッセイによって総Ｐｒ濃度、および比色分析（ＴＮＢＳ）アッセイによって誘導体化度値について分析した。<br class="style-scope patent-text">
  結果：<br class="style-scope patent-text">
  Ｌｏｗｒｙアッセイによる誘導体化Ｐｒ濃度：１５ｍｇ／ｍｌ<br class="style-scope patent-text">
  誘導体化度値（ＤＯＡ）：１９<br class="style-scope patent-text">
  パーセンテージ回収率：約７５％<br class="style-scope patent-text">
ステップ２：Ｖｉ  ＰｓのコンジュゲーションからＴＴの誘導体化<br class="style-scope patent-text">
  手順：<br class="style-scope patent-text">
  Ｖｉ  ＰＳ誘導体化ＴＴコンジュゲーションを、カルボジイミド化学を使用して実施した。
</span>f) Derivatized samples were analyzed for total Pr concentration by Lowry assay and degree of derivatization value by colorimetric (TNBS) assay.<br class="style-scope patent-text"> result:<br class="style-scope patent-text"> Derivatized Pr concentration by Lowry assay: 15 mg/ml<br class="style-scope patent-text"> Degree of derivatization value (DOA): 19<br class="style-scope patent-text"> Percentage recovery: about 75%<br class="style-scope patent-text"> Step 2: Derivatization of TT from conjugation of Vi Ps Procedure:<br class="style-scope patent-text"> Vi PS derivatized TT conjugation was performed using carbodiimide chemistry.</span>
      </p>
      <p num="0336" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下のＰＳおよびＰｒのパラメーターをコンジュゲーションに使用した。<br class="style-scope patent-text">
  ａ．  Ｐｓ：Ｐｒ：ＥＤＣ：：１：０．９：１．７５（ＰｒおよびＥＤＣについて＋０．５）のコンジュゲーション反応の比を使用した。コンジュゲーション規模１０ｇｍ。
</span>The following PS and Pr parameters were used for conjugation.<br class="style-scope patent-text"> a. A conjugation reaction ratio of Ps:Pr:EDC::1:0.9:1.75 (+0.5 for Pr and EDC) was used. Conjugation scale 10 gm.</span>
      </p>
      <p num="0337" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｂ．  ＰＳの必要なバッチ容積を滅菌済みガラスボトルに添加した。<br class="style-scope patent-text">
  ｃ．  １Ｍ  ＭＥＳ緩衝液ｐＨ６．０（原緩衝液）を、測定容積のＰＳに添加して、０．１Ｍ  ＭＥＳ濃度に到達させた。
</span>b. The required batch volume of PS was added to a sterilized glass bottle.<br class="style-scope patent-text"> c. 1M MES buffer pH 6.0 (stock buffer) was added to a measured volume of PS to reach a 0.1M MES concentration.</span>
      </p>
      <p num="0338" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｄ．  混合物を、均質な混合のために約１００ｒｐｍで撹拌した。<br class="style-scope patent-text">
  ｅ．  次いで、測定容積の誘導体化ＴＴをＰｓ含有ボトルに添加した。<br class="style-scope patent-text">
  ｆ．  ＴＴの添加直後に、新しく調製したＥＤＣ（０．１Ｍ  ＭＥＳ緩衝液ｐＨ６．０に溶解）を上記反応に添加した。
</span>d. The mixture was stirred at approximately 100 rpm for homogeneous mixing.<br class="style-scope patent-text"> e. A measured volume of derivatized TT was then added to the Ps-containing bottle.<br class="style-scope patent-text"> f. Freshly prepared EDC (dissolved in 0.1 M MES buffer pH 6.0) was added to the reaction immediately after the addition of TT.</span>
      </p>
      <p num="0339" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｇ．  ｐＨを観察し、記録した（ｐＨ６．０＋０．５）。<br class="style-scope patent-text">
  ｈ．  試料を、ＳＥ－ＨＰＬＣを使用して異なる時間間隔で分析した。コンジュゲーション変換パーセンテージおよびタンパク質消費をモニタリングした。
</span>g. The pH was observed and recorded (pH 6.0+0.5).<br class="style-scope patent-text"> h. Samples were analyzed at different time intervals using SE-HPLC. Conjugation conversion percentage and protein consumption were monitored.</span>
      </p>
      <p num="0340" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｉ．  ＜９０％タンパク質が消費されたら、ＥＤＴＡを含有する０．１Ｍリン酸緩衝液を使用してｐＨを７．５に上昇させることによって、反応を１．４５時間後にクエンチした。
</span>
  i. When &lt;90% protein was consumed, the reaction was quenched after 1.45 hours by raising the pH to 7.5 using 0.1 M phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0341" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｊ．  クエンチした反応混合物を、さらなる使用まで２～８℃で保存した。<br class="style-scope patent-text">
ステップ３：クエンチしたＶｉ－ＴＴコンジュゲートの精製<br class="style-scope patent-text">
  クエンチしたコンジュゲートの精製を、以下のパラメーターを使用して、未反応Ｐｓ、未反応Ｐｒ、他の残留物を除去するために実施した２つの方法によって実施した。<br class="style-scope patent-text">
１．  限外ろ過法：<br class="style-scope patent-text">
  以下のパラメーターを透析ろ過のために使用した。
</span>j. The quenched reaction mixture was stored at 2-8°C until further use.<br class="style-scope patent-text"> Step 3: Purification of the quenched Vi-TT conjugate Purification of the quenched conjugate was performed in two ways to remove unreacted Ps, unreacted Pr and other residues using the following parameters conducted by<br class="style-scope patent-text"> 1. Ultrafiltration method:<br class="style-scope patent-text"> The following parameters were used for diafiltration.</span>
      </p>
      <p num="0342" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
    透析ろ過規模：８．５ｇｍ<br class="style-scope patent-text">
    Ｄ／Ｆの間のＰｓ濃度：約２ｍｇ／ｍｌ<br class="style-scope patent-text">
    分画膜：３００ｋＤａ<br class="style-scope patent-text">
    膜製造：Ｐａｌｌ<br class="style-scope patent-text">
    膜面積：２．５ｍ<sup class="style-scope patent-text">２</sup>
               <br class="style-scope patent-text">
    使用した緩衝液Ａ：１０ｍＭ  ＰＢＳ最小２５容積<br class="style-scope patent-text">
    使用した緩衝液Ｂ：０．９％ＮａＣｌ  ３０容積。
</span>Diafiltration Scale: 8.5gm<br class="style-scope patent-text"> Ps concentration during D/F: about 2mg/ml<br class="style-scope patent-text"> Fractionation membrane: 300 kDa<br class="style-scope patent-text"> Membrane Manufacture: Pall<br class="style-scope patent-text"> Membrane area: <sup class="style-scope patent-text">2.5m2</sup> <br class="style-scope patent-text"> Buffer A used: minimum 25 volumes of 10 mM PBS Buffer B used: 30 volumes of 0.9% NaCl.</span>
      </p>
      <p num="0343" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
    最終容積：６．５Ｌ<br class="style-scope patent-text">
  精製コンジュゲートを、０．２μＭフィルターを使用してろ過した。<br class="style-scope patent-text">
２．  ゲルろ過クロマトグラフィー：<br class="style-scope patent-text">
  クエンチしたコンジュゲート約１．５ｇｍを、０．１ｍ２  ３００ｋＤａ分画膜で約２～４ｍｇ／ｍｌに濃縮した。ゲルろ過クロマトグラフィーを使用して未結合ＰＳ、未結合ＴＴおよび残留ＥＤＣを除去し、コンジュゲート精製を実施した。
</span>Final volume: 6.5L<br class="style-scope patent-text"> Purified conjugate was filtered using a 0.2 μM filter.<br class="style-scope patent-text"> 2. Gel filtration chromatography:<br class="style-scope patent-text"> Approximately 1.5 gm of quenched conjugate was concentrated to approximately 2-4 mg/ml on a 0.1 <figure-callout id="300" label="m2" filenames="2022546763000107.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">m2</a></figure-callout> 300 kDa fractionation membrane. Conjugate purification was performed using gel filtration chromatography to remove unbound PS, unbound TT and residual EDC.</span>
      </p>
      <p num="0344" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２回の別々のＧＦＣ実行を、同じ精製のパラメーターで実施した。<br class="style-scope patent-text">
  精製のために以下のクロマトグラフィー条件を使用した。
</span>Two separate GFC runs were performed with the same purification parameters.<br class="style-scope patent-text"> The following chromatographic conditions were used for purification.</span>
      </p>
      <p num="0345" class="style-scope patent-text">
        <tables num="42" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/18/44/fd/319e74bca31e5b/2022546763000043.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000043.jpg" he="98" wi="153" width="612" height="392" alt="Figure 2022546763000043" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/18/44/fd/319e74bca31e5b/2022546763000043.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/18/44/fd/319e74bca31e5b/2022546763000043.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000043.jpg" he="98" wi="153" width="612" height="392" alt="Figure 2022546763000043" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/18/44/fd/319e74bca31e5b/2022546763000043.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0346" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  １  収集した合計２７個の画分（各１００ｍｌ）を、ＳＥ－ＨＰＬＣで分析し、クロマトグラフィープロファイルに基づいて一緒にプールした。<br class="style-scope patent-text">
  ２  画分を、Ｐｓ含有量についてＨＰＡＤ法によって、Ｐｒ含有量についてＬｏｗｒｙ法によって、％遊離ＰｓについてＤＯＣ－ＨＰＡＤ法によって、分析した。
</span>1 A total of 27 fractions (100 ml each) collected were analyzed by SE-HPLC and pooled together based on the chromatographic profile.<br class="style-scope patent-text"> 2 fractions were analyzed for Ps content by the HPAD method, for Pr content by the Lowry method and for % free Ps by the DOC-HPAD method.</span>
      </p>
      <p num="0347" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ３  分析に基づいて画分をプールし（１～２３個）、０．２２μＭフィルターを使用してろ過した。<br class="style-scope patent-text">
  ４  試料を、Ｐｓ含有量、Ｐｒ含有量および遊離Ｐｓ分析、ならびにエンドトキシン、Ｏアセチル含有量、無菌性、ｐＨ値およびエンドトキシン分析について分析した。
</span>3 Based on analysis, fractions were pooled (1-23) and filtered using a 0.22 μM filter.<br class="style-scope patent-text"> 4 Samples were analyzed for Ps content, Pr content and free Ps analysis, as well as endotoxin, O-acetyl content, sterility, pH value and endotoxin analysis.</span>
      </p>
      <p num="0348" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結果および解釈：
</span>
  Results and Interpretation:
</span>
      </p>
      <p num="0349" class="style-scope patent-text">
        <tables num="43" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6d/a6/d8/19f97ca4c1c021/2022546763000044.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000044.jpg" he="79" wi="166" width="664" height="316" alt="Figure 2022546763000044" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6d/a6/d8/19f97ca4c1c021/2022546763000044.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6d/a6/d8/19f97ca4c1c021/2022546763000044.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000044.jpg" he="79" wi="166" width="664" height="316" alt="Figure 2022546763000044" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6d/a6/d8/19f97ca4c1c021/2022546763000044.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0350" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  比較用コンジュゲーションプロセスデータ－コンジュゲーション効率の改善、コンジュゲート収率の改善およびＳＩＩＰＬチフスコンジュゲートの安定性（遊離Ｐｓ、遊離Ｐｒ）（Ｐｓ：Ｐｒ：ＥＤＡＣ比は、他のＰｓ：Ｐｒ：ＥＤＡＣ比に対して１：１：２である）。
</span>
  Comparative Conjugation Process Data—Improved Conjugation Efficiency, Improved Conjugate Yield and SIIPL Typhoid Conjugate Stability (Free Ps, Free Pr) ratio is 1:1:2).
</span>
      </p>
      <p num="0351" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション効率の改善：９０％超のコンジュゲーション変換パーセンテージが観察された。<br class="style-scope patent-text">
  コンジュゲート収率の改善：様々なコンジュゲーション精製規模で異なる方法、すなわち、限外ろ過法およびゲルろ過法を使用して精製を実施し、回収率は４０～８７％であった。
</span>Improved conjugation efficiency: Conjugation conversion percentages greater than 90% were observed.<br class="style-scope patent-text"> Improved Conjugate Yield: Purification was performed using different methods, ie, ultrafiltration and gel filtration, at various scales of conjugation purification with recoveries ranging from 40-87%.</span>
      </p>
      <p num="0352" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｖｉ－ＴＴコンジュゲーションについて、１：１．５：１．２、１：０．９：２、１：０．９：１．７５、１：０．８：１．８：、１：０．７：１．８、１：０．９：０．６、１：０．９：１および１：０．７：１．５に対して１：１：２の比を使用し、１．５ＥＤＣのより低タンパク質により、最適コンジュゲーション変換率（％）を得ることができることが見出された。
</span>
  For Vi-TT conjugation, 1:1.5:1.2, 1:0.9:2, 1:0.9:1.75, 1:0.8:1.8:, 1:0. 1:1:2 ratios were used for 7:1.8, 1:0.9:0.6, 1:0.9:1 and 1:0.7:1.5 and 1.5 EDC It was found that the optimal conjugation conversion (%) can be obtained with a lower protein of .
</span>
      </p>
      <p num="0353" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  様々なサイズのＶｉ  Ｐｓが、ＡＤＨ活性化ＴＴとコンジュゲートし得ることが見出された。<br class="style-scope patent-text">
  異なる精製技術でより低ｐＨにおいて使用したＰｓ：Ｐｒ：ＥＤＣ：：１：０．７：１．８、１：０．８：１．８、１：０．９：２および１：１：２のような異なる比により、０．５超のＰＳ／Ｐｒ比、より低い遊離ｐｓと共にコンジュゲートの良好な回収率がもたらされる。<br class="style-scope patent-text">
Ｄ２）一価Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉコンジュゲートの調製：<br class="style-scope patent-text">
  ２種類のコンジュゲーション化学（シアニル化およびカルボジイミド化学）を、担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのパラチフスＯＳＰのコンジュゲーションに適用した。<br class="style-scope patent-text">
１）シアニル化化学に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのパラチフスＯＳＰのコンジュゲーション<br class="style-scope patent-text">
  Ａ）カルボジイミド化学を使用したジフテリアトキソイド（ＤＴ）の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮ＯＳＰとのコンジュゲーション<br class="style-scope patent-text">
  Ｂ）カルボジイミド化学を使用した、ＣＲＭ１９７、破傷風トキソイド（ＴＴ）の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮ＯＳＰとのコンジュゲーション<br class="style-scope patent-text">
  Ｃ）カルボジイミド化学を使用した破傷風トキソイド（ＴＴ）の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮ＯＳＰとのコンジュゲーション<br class="style-scope patent-text">
１Ａ）ジフテリアトキソイドを担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製。<br class="style-scope patent-text">
１）タンパク質誘導体化：<br class="style-scope patent-text">
  高モノマージフテリアトキソイド（ＤＴ）を、１０ｋＤａ膜で（１０～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>It was found that Vi Ps of various sizes can conjugate with ADH-activated TT.<br class="style-scope patent-text"> Ps:Pr:EDC::1:0.7:1.8, 1:0.8:1.8, 1:0.9:2 and 1:1:2 used at lower pH in different purification techniques A PS/Pr ratio greater than 0.5, resulting in good recovery of the conjugate with lower free ps.<br class="style-scope patent-text"> D2) Preparation of monovalent Salmonella paratyphi conjugates:<br class="style-scope patent-text"> Two types of conjugation chemistry (cyanylation and carbodiimide chemistry) were applied for the conjugation of Paratyphi OSP to the carrier proteins diphtheria toxoid (DT), CRM197 and tetanus toxoid (TT).<br class="style-scope patent-text"> 1) Conjugation of Paratyphoid OSP to carrier proteins Diphtheria Toxoid (DT), CRM197 and Tetanus Toxoid (TT) based on cyanylation chemistry A) Derivatization of Diphtheria Toxoid (DT) using carbodiimide chemistry (addition of linker ADH) and conjugation with enriched OSP using cyanylation chemistry B) Derivatization of CRM197, tetanus toxoid (TT) using carbodiimide chemistry (attachment of linker ADH) and conjugation with enriched OSP using cyanylation chemistry C) Derivatization of tetanus toxoid (TT) using carbodiimide chemistry (addition of linker ADH) and conjugation with enriched OSP using cyanylation chemistry 1A) S. cerevisiae using diphtheria toxoid as carrier protein. Preparation of Paratyphi conjugates.<br class="style-scope patent-text"> 1) Protein derivatization:<br class="style-scope patent-text"> High monomeric diphtheria toxoid (DT) was concentrated (10-20 mg/ml) with a 10 kDa membrane and analyzed for protein content.</span>
      </p>
      <p num="0354" class="style-scope patent-text">
        <tables num="44" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a5/3f/6c/8d46c81fd6b17e/2022546763000045.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000045.jpg" he="28" wi="156" width="624" height="112" alt="Figure 2022546763000045" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a5/3f/6c/8d46c81fd6b17e/2022546763000045.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a5/3f/6c/8d46c81fd6b17e/2022546763000045.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000045.jpg" he="28" wi="156" width="624" height="112" alt="Figure 2022546763000045" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a5/3f/6c/8d46c81fd6b17e/2022546763000045.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0355" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＤＴに、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：１０でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：５．８に溶解）、および重量比１：１でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：５．８に溶解）を添加した。反応を、ｐＨ５．８で約１時間継続し、次いで、反応混合物を、５０ｍＭ  ホウ酸緩衝液ｐＨ９．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。
</span>
  To concentrated DT was added freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) at a weight ratio of 1:10 (75-100 mg/ml dissolved in 100 mM MES buffer pH: 5.8), and a weight ratio of 1:10. 1 EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 5.8) was added. The reaction was continued at pH 5.8 for about 1 hour, then the reaction mixture was subjected to diafiltration with 10 kDa TFF in 50 mM borate buffer pH 9.0 to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.
</span>
      </p>
      <p num="0356" class="style-scope patent-text">
        <tables num="45" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/a2/95/93515b96553726/2022546763000046.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000046.jpg" he="33" wi="101" width="404" height="132" alt="Figure 2022546763000046" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/a2/95/93515b96553726/2022546763000046.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/a2/95/93515b96553726/2022546763000046.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000046.jpg" he="33" wi="101" width="404" height="132" alt="Figure 2022546763000046" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/a2/95/93515b96553726/2022546763000046.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0357" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２）Ｓ．Ｐａｒａｔｙｐｈｉ  Ａ多糖体（ＯＳＰ）およびＡＤＨ誘導体化ＤＴのコンジュゲーション：<br class="style-scope patent-text">
  １－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）比を変化させることによって２つの実験を実施した。
</span>2) S. Conjugation of Paratyphi A polysaccharide (OSP) and ADH-derivatized DT:<br class="style-scope patent-text"> Two experiments were performed by varying the 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP) ratio.</span>
      </p>
      <p num="0358" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：１  －  ＯＳＰを１０ｋＤａ膜で濃縮して、（１０～１５ｍｇ／ｍｌ）の濃度に到達させた。
</span>
  Run number: 1 - OSP was concentrated on a 10 kDa membrane to reach a concentration of (10-15 mg/ml).
</span>
      </p>
      <p num="0359" class="style-scope patent-text">
        <tables num="46" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8b/d4/b5/32b7f6d4d32dd4/2022546763000047.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000047.jpg" he="32" wi="129" width="516" height="128" alt="Figure 2022546763000047" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8b/d4/b5/32b7f6d4d32dd4/2022546763000047.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8b/d4/b5/32b7f6d4d32dd4/2022546763000047.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000047.jpg" he="32" wi="129" width="516" height="128" alt="Figure 2022546763000047" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8b/d4/b5/32b7f6d4d32dd4/2022546763000047.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0360" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．３）。
</span>
  To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP is 1:0.8:1.3).
</span>
      </p>
      <p num="0361" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0362" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１：多糖体、タンパク質およびコンジュゲートの比較（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．３）を参照<br class="style-scope patent-text">
３）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅａｒｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣｌ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集した。画分２～９を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>See Figure 1: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.3) 3) Conjugate purification by GFC: Using GFC resin (Tyopearl HW65F), 40 cm A Column XK16/70 was prepared at floor level. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/hr, the conjugate was loaded onto the column and fractions were collected at 1 minute intervals. Fractions 2-9 were pooled according to the HPLC profile. The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0363" class="style-scope patent-text">
        <tables num="47" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/8b/47/d9872138b9aced/2022546763000048.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000048.jpg" he="30" wi="159" width="636" height="120" alt="Figure 2022546763000048" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/8b/47/d9872138b9aced/2022546763000048.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/8b/47/d9872138b9aced/2022546763000048.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000048.jpg" he="30" wi="159" width="636" height="120" alt="Figure 2022546763000048" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/8b/47/d9872138b9aced/2022546763000048.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0364" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図２：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．３）のクロマトグラムを参照。<br class="style-scope patent-text">
  実験番号：２  －<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．１で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．１）。
</span>See Figure 2: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:0.8:1.3).<br class="style-scope patent-text"> Experiment number: 2 -<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.1. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP is 1:0.8:1.1).</span>
      </p>
      <p num="0365" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0366" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図３：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．１）の比較を参照。<br class="style-scope patent-text">
  ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅａｒｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣＬ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣＬを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集した。画分２～８を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>See Figure 3: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.1).<br class="style-scope patent-text"> Conjugate purification by GFC: GFC resin (Tyopearl HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/h, the conjugate was loaded onto the column and fractions were collected at 1 minute intervals. Fractions 2-8 were pooled according to the HPLC profile. The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0367" class="style-scope patent-text">
        <tables num="48" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5b/7b/0e/3d0206e51a103c/2022546763000049.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000049.jpg" he="31" wi="150" width="600" height="124" alt="Figure 2022546763000049" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5b/7b/0e/3d0206e51a103c/2022546763000049.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5b/7b/0e/3d0206e51a103c/2022546763000049.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000049.jpg" he="31" wi="150" width="600" height="124" alt="Figure 2022546763000049" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5b/7b/0e/3d0206e51a103c/2022546763000049.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0368" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図４：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．１）のクロマトグラムを参照。<br class="style-scope patent-text">
  結論：ＡＤＨ誘導体化ＤＴを使用したＰａｒａｔｙｐｈｉ  Ａ  ＰＳのコンジュゲーションは成功し、ＰＳ／ＰＲ比は、満足のいくものであった。<br class="style-scope patent-text">
１Ｂ．  ＣＲＭ１９７を担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製<br class="style-scope patent-text">
１）タンパク質誘導体化：製造部門（ＳＩＩＰＬ）から受け取った交差反応変異体（ＣＲＭ１９７）を誘導体化に用いた。
</span>See Figure 4: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP 1:0.8:1.1).<br class="style-scope patent-text"> Conclusion: The conjugation of Paratyphi A PS using ADH-derivatized DT was successful and the PS/PR ratio was satisfactory.<br class="style-scope patent-text"> 1B. S. cerevisiae using CRM197 as a carrier protein. Preparation of Paratyphi conjugates 1) Protein derivatization: A cross-reacting mutant (CRM197) received from the manufacturing department (SIIPL) was used for derivatization.</span>
      </p>
      <p num="0369" class="style-scope patent-text">
        <tables num="49" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0a/72/57/54415b7314502b/2022546763000050.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000050.jpg" he="28" wi="156" width="624" height="112" alt="Figure 2022546763000050" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0a/72/57/54415b7314502b/2022546763000050.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0a/72/57/54415b7314502b/2022546763000050.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000050.jpg" he="28" wi="156" width="624" height="112" alt="Figure 2022546763000050" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0a/72/57/54415b7314502b/2022546763000050.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0370" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＣＲＭ１９７に、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：３．５でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．５に溶解）、および重量比１：０．２５でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．５に溶解）を添加した。５％Ｔｗｅｅｎ  ８０を添加した。１００ｍＭ  ＭＥＳ緩衝液を使用して、３～４ｍｇ／ｍｌの最終濃度に到達する最終反応容積にし、反応をｐＨ６．５で約３時間継続し、次いで、反応混合物を、５０ｍＭホウ酸緩衝液および０．００５％Ｔｗｅｅｎ  ８０  ｐＨ９．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。
</span>
  To concentrated CRM197, freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) (75-100 mg/ml dissolved in 100 mM MES buffer pH: 6.5) at a weight ratio of 1:3.5, and EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 6.5) was added at 1:0.25. 5<figure-callout id="80" label="% Tween" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 80 was added. 100 mM MES buffer was used to make up the final reaction volume to reach a final concentration of 3-4 mg/ml, the reaction was continued at pH 6.5 for about 3 hours, then the reaction mixture was added to 50 mM borate buffer and 0.5 mg/ml. Diafiltration with 10 kDa TFF in .005<figure-callout id="80" label="% Tween" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 80 pH 9.0 was performed to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.
</span>
      </p>
      <p num="0371" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  アッセイの簡単な説明または参照：タンパク質含有量を、ＢＣＡ（ビシンコニン酸）アッセイによって測定した。
</span>
  Assay brief description or reference: Protein content was measured by the BCA (bicinchoninic acid) assay.
</span>
      </p>
      <p num="0372" class="style-scope patent-text">
        <tables num="50" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/38/6c/5d4dbc4605b23e/2022546763000051.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000051.jpg" he="29" wi="119" width="476" height="116" alt="Figure 2022546763000051" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/38/6c/5d4dbc4605b23e/2022546763000051.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/38/6c/5d4dbc4605b23e/2022546763000051.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000051.jpg" he="29" wi="119" width="476" height="116" alt="Figure 2022546763000051" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/38/6c/5d4dbc4605b23e/2022546763000051.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0373" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２）Ｓ．Ｐａｒａｔｙｐｈｉ  Ａ多糖体（ＯＳＰ）およびＡＤＨ誘導体化ＣＲＭ１９７のコンジュゲーション：<br class="style-scope patent-text">
  ＤＳＰから受け取ったＯＳＰを１０ｋＤａ膜で濃縮して、（１０～１５ｍｇ／ｍｌ）の濃度に到達させた。
</span>2) S. Conjugation of Paratyphi A polysaccharide (OSP) and ADH-derivatized CRM197:<br class="style-scope patent-text"> OSP received from DSP was concentrated on a 10 kDa membrane to reach a concentration of (10-15 mg/ml).</span>
      </p>
      <p num="0374" class="style-scope patent-text">
        <tables num="51" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e0/0e/1d/41f55e5097a62b/2022546763000052.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000052.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000052" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e0/0e/1d/41f55e5097a62b/2022546763000052.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e0/0e/1d/41f55e5097a62b/2022546763000052.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000052.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000052" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e0/0e/1d/41f55e5097a62b/2022546763000052.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0375" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：１で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）。
</span>
  To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:1 (PS:PR:CPIP is 1:1:1.3).
</span>
      </p>
      <p num="0376" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0377" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図５および６：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）の比較を参照。<br class="style-scope patent-text">
３）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣＬ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集し、画分２～７を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>See Figures 5 and 6: Comparison of polysaccharide, protein and conjugate (PS:PR:CPIP is 1:1:1.3).<br class="style-scope patent-text"> 3) Conjugate purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/h, the conjugate was loaded onto the column, fractions were collected at 1 minute intervals and fractions 2-7 were pooled according to the profile on HPLC. . The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0378" class="style-scope patent-text">
        <tables num="52" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8a/73/77/eeefef533400d4/2022546763000053.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000053.jpg" he="29" wi="145" width="580" height="116" alt="Figure 2022546763000053" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8a/73/77/eeefef533400d4/2022546763000053.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8a/73/77/eeefef533400d4/2022546763000053.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000053.jpg" he="29" wi="145" width="580" height="116" alt="Figure 2022546763000053" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8a/73/77/eeefef533400d4/2022546763000053.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0379" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図７：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）のクロマトグラムを参照。<br class="style-scope patent-text">
  結論：ＡＤＨ誘導体化ＣＲＭ１９７を使用したＰａｒａｔｙｐｈｉ  Ａ  ＰＳのコンジュゲーションは成功し、ＰＳ／ＰＲ比は、満足のいくものであった。<br class="style-scope patent-text">
１Ｃ）破傷風トキソイドを担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製：<br class="style-scope patent-text">
１）タンパク質誘導体化：製造部門（ＳＩＩＰＬ）から受け取った高モノマー破傷風トキソイド（ＴＴ）を、３０ｋＤａ膜で（１５～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>See Figure 7: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:1:1.3).<br class="style-scope patent-text"> Conclusion: The conjugation of Paratyphi A PS using ADH-derivatized CRM197 was successful and the PS/PR ratio was satisfactory.<br class="style-scope patent-text"> 1C) S. cerevisiae using tetanus toxoid as a carrier protein. Preparation of Paratyphi conjugates:<br class="style-scope patent-text"> 1) Protein derivatization: High monomeric tetanus toxoid (TT) received from the manufacturing department (SIIPL) was concentrated (15-20 mg/ml) with a 30 kDa membrane and analyzed for protein content.</span>
      </p>
      <p num="0380" class="style-scope patent-text">
        <tables num="53" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/13/2b/67/240d5a4abdd40c/2022546763000054.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000054.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000054" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/13/2b/67/240d5a4abdd40c/2022546763000054.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/13/2b/67/240d5a4abdd40c/2022546763000054.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000054.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000054" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/13/2b/67/240d5a4abdd40c/2022546763000054.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0381" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＴＴに、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：１０でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．０に溶解）、および重量比１：１でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．０に溶解）を添加した。反応をｐＨ６．０で約１時間継続し、次いで、反応混合物を、１０ｍＭリン酸緩衝液ｐＨ７．２中３０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。
</span>
  To concentrated TT, freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) (75-100 mg/ml dissolved in 100 mM MES buffer pH: 6.0) at a weight ratio of 1:10, and a weight ratio of 1:10. EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 6.0) was added at 1. The reaction was continued at pH 6.0 for about 1 hour, then the reaction mixture was subjected to diafiltration with 30 kDa TFF in 10 mM phosphate buffer pH 7.2 to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.
</span>
      </p>
      <p num="0382" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  アッセイの簡単な説明または参照：タンパク質含有量を、Ｌｏｗｒｙアッセイによって測定した。
</span>
  Assay brief description or reference: Protein content was measured by the Lowry assay.
</span>
      </p>
      <p num="0383" class="style-scope patent-text">
        <tables num="54" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/04/3c/078da52e2ea573/2022546763000055.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000055.jpg" he="29" wi="97" width="388" height="116" alt="Figure 2022546763000055" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/04/3c/078da52e2ea573/2022546763000055.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c5/04/3c/078da52e2ea573/2022546763000055.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000055.jpg" he="29" wi="97" width="388" height="116" alt="Figure 2022546763000055" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c5/04/3c/078da52e2ea573/2022546763000055.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0384" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２）Ｓ．Ｐａｒａｔｙｐｈｉ  Ａ多糖体（ＯＳＰ）およびＡＤＨ誘導体化ＴＴのコンジュゲーション：<br class="style-scope patent-text">
  ＤＳＰチームから受け取ったＯＳＰを１０ｋＤａ膜で濃縮して、（１０－１３ｍｇ／ｍｌ）の濃度に到達させた。
</span>2) S. Conjugation of Paratyphi A polysaccharide (OSP) and ADH-derivatized TT:<br class="style-scope patent-text"> OSP received from the DSP team was concentrated on a 10 kDa membrane to reach a concentration of (10-13 mg/ml).</span>
      </p>
      <p num="0385" class="style-scope patent-text">
        <tables num="55" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/87/01/e4/409955d59e4587/2022546763000056.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000056.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000056" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/87/01/e4/409955d59e4587/2022546763000056.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/87/01/e4/409955d59e4587/2022546763000056.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000056.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000056" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/87/01/e4/409955d59e4587/2022546763000056.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0386" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  １－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）比を変化させることによって２つの実験を実施した。<br class="style-scope patent-text">
  実験番号：１<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．２５で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：  ＰＲ：  ＣＰＩＰは、１：０．８：１．２５）。
</span>Two experiments were performed by varying the 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP) ratio.<br class="style-scope patent-text"> Experiment number: 1<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.25. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP was 1:0.8:1.25).</span>
      </p>
      <p num="0387" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0388" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図８：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．８：１．２５）の比較を参照。<br class="style-scope patent-text">
３）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭ  トリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>See Figure 8: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP 1:0.8:1.25).<br class="style-scope patent-text"> 3) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0389" class="style-scope patent-text">
        <tables num="56" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a5/15/76/169262a8864ec1/2022546763000057.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000057.jpg" he="29" wi="160" width="640" height="116" alt="Figure 2022546763000057" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a5/15/76/169262a8864ec1/2022546763000057.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a5/15/76/169262a8864ec1/2022546763000057.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000057.jpg" he="29" wi="160" width="640" height="116" alt="Figure 2022546763000057" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a5/15/76/169262a8864ec1/2022546763000057.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0390" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図９：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．２５）のクロマトグラムを参照<br class="style-scope patent-text">
  実験番号：２<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．９で添加した（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．９：１．３）。
</span>Figure 9: See chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP is 1:0.8:1.25) Run number: 2<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.9 (PS:PR:CPIP 1:0.9:1.3).</span>
      </p>
      <p num="0391" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0392" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１０：多糖体、タンパク質およびコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ１：０．９：１．３）の比較を参照。<br class="style-scope patent-text">
３）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>See Figure 10: Comparison of polysaccharides, proteins and conjugates (PS:PR:CPIP1:0.9:1.3).<br class="style-scope patent-text"> 3) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0393" class="style-scope patent-text">
        <tables num="57" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bb/0a/63/a971ed654ae40b/2022546763000058.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000058.jpg" he="28" wi="146" width="584" height="112" alt="Figure 2022546763000058" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bb/0a/63/a971ed654ae40b/2022546763000058.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bb/0a/63/a971ed654ae40b/2022546763000058.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000058.jpg" he="28" wi="146" width="584" height="112" alt="Figure 2022546763000058" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bb/0a/63/a971ed654ae40b/2022546763000058.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0394" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１１：ＧＦＣ精製ＯＳＰ－ＤＴ  ＡＤＨコンジュゲート（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．９：１．３）のクロマトグラムを参照。<br class="style-scope patent-text">
  結論：ＡＤＨ誘導体化ＴＴを使用したＰａｒａｔｙｐｈｉ  Ａ  ＰＳのコンジュゲーションは成功し、２つの異なる種類の透析ろ過方策を適用し、いずれのプロセスも満足のいくＰＳ／Ｐｒ比をもたらした。<br class="style-scope patent-text">
２）カルボジイミド化学に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのパラチフスＯＳＰのコンジュゲーション<br class="style-scope patent-text">
  Ａ）シアニル化化学を使用した濃縮ＯＳＰの誘導体化（リンカーＡＤＨの付加）およびカルボジイミド化学を使用した破傷風トキソイド（ＴＴ）とのコンジュゲーション。
</span>See Figure 11: Chromatogram of GFC-purified OSP-DT ADH conjugate (PS:PR:CPIP 1:0.9:1.3).<br class="style-scope patent-text"> Conclusions: Conjugation of Paratyphi A PS using ADH-derivatized TT was successful, applying two different types of diafiltration strategies, both processes yielding satisfactory PS/Pr ratios.<br class="style-scope patent-text"> 2) Conjugation of paratyphoid OSP to carrier proteins Diphtheria toxoid (DT), CRM197 and Tetanus toxoid (TT) based on carbodiimide chemistry A) Derivatization of concentrated OSP using cyanylation chemistry (addition of linker ADH) and carbodiimide chemistry conjugation with tetanus toxoid (TT) using</span>
      </p>
      <p num="0395" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｂ）シアニル化化学を使用した濃縮ＯＳＰの誘導体化（リンカーＡＤＨの付加）およびカルボジイミド化学を使用したジフテリアトキソイド（ＤＴ）とのコンジュゲーション。<br class="style-scope patent-text">
  Ｃ）シアニル化化学を使用した濃縮ＯＳＰの誘導体化（リンカーＡＤＨの付加）およびカルボジイミド化学を使用したＣＲＭ１９７とのコンジュゲーション。<br class="style-scope patent-text">
２Ａ）破傷風トキソイドを担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製。<br class="style-scope patent-text">
１）多糖体誘導体化：ＤＳＰチームから受け取ったＯＳＰを１０ｋＤａ膜で濃縮して、（１０－１３ｍｇ／ｍｌ）の濃度に到達させた。
</span>B) Derivatization of enriched OSP using cyanylation chemistry (addition of linker ADH) and conjugation with diphtheria toxoid (DT) using carbodiimide chemistry.<br class="style-scope patent-text"> C) Derivatization of enriched OSP using cyanylation chemistry (addition of linker ADH) and conjugation with CRM197 using carbodiimide chemistry.<br class="style-scope patent-text"> 2A) S. cerevisiae using tetanus toxoid as a carrier protein. Preparation of Paratyphi conjugates.<br class="style-scope patent-text"> 1) Polysaccharide derivatization: OSP received from the DSP team was concentrated on a 10 kDa membrane to reach a concentration of (10-13 mg/ml).</span>
      </p>
      <p num="0396" class="style-scope patent-text">
        <tables num="58" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d2/ca/2e/acd216cab6004b/2022546763000059.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000059.jpg" he="29" wi="123" width="492" height="116" alt="Figure 2022546763000059" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d2/ca/2e/acd216cab6004b/2022546763000059.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d2/ca/2e/acd216cab6004b/2022546763000059.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000059.jpg" he="29" wi="123" width="492" height="116" alt="Figure 2022546763000059" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d2/ca/2e/acd216cab6004b/2022546763000059.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0397" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：０．７で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、アジピン酸ジヒドラジド（ＡＤＨ）（０．５Ｍ重炭酸ナトリウム緩衝液ｐＨ：８．０に７５～１００ｍｇ／ｍｌで溶解）を重量比１：１０で添加した（ＰＳ：ＡＤＨ：ＣＰＩＰ  １：１０：０．７）。反応をｐＨ９．５で約２時間継続し、２Ｍグリシン１０を使用してクエンチし、次いで、反応混合物を、１００ｍＭ  ＭＥＳ緩衝液ｐＨ６．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を多糖体含有量について分析した。
</span>
  To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:0.7. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Adipic acid dihydrazide (ADH) (dissolved at 75-100 mg/ml in 0.5 M sodium bicarbonate buffer pH: 8.0) was then added at a weight ratio of 1:10 (PS:ADH:CPIP 1:10: 0.7). The reaction was continued at pH 9.5 for approximately 2 hours, quenched using 2M glycine 10, then the reaction mixture was subjected to diafiltration with 10 kDa TFF in 100 mM MES buffer pH 6.0 to remove residuals and unreacted components. Removed. The final sample was analyzed for polysaccharide content.
</span>
      </p>
      <p num="0398" class="style-scope patent-text">
        <tables num="59" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1b/51/64/1d38b44d49af22/2022546763000060.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000060.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000060" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1b/51/64/1d38b44d49af22/2022546763000060.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1b/51/64/1d38b44d49af22/2022546763000060.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000060.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000060" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1b/51/64/1d38b44d49af22/2022546763000060.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0399" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２）タンパク質調製：製造部門（ＳＩＩＰＬ）から受け取った高モノマー破傷風トキソイド（ＴＴ）を、３０ｋＤａ膜で（１０～１５ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>
2) Protein preparation: High monomeric tetanus toxoid (TT) received from the manufacturing department (SIIPL) was concentrated to (10-15 mg/ml) with a 30 kDa membrane and analyzed for protein content.
</span>
      </p>
      <p num="0400" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  アッセイの簡単な説明または参照：タンパク質含有量を、Ｌｏｗｒｙアッセイによって測定した。
</span>
  Assay brief description or reference: Protein content was measured by the Lowry assay.
</span>
      </p>
      <p num="0401" class="style-scope patent-text">
        <tables num="60" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f9/4c/8d/a5b2505d3a20b6/2022546763000061.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000061.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000061" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f9/4c/8d/a5b2505d3a20b6/2022546763000061.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f9/4c/8d/a5b2505d3a20b6/2022546763000061.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000061.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000061" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f9/4c/8d/a5b2505d3a20b6/2022546763000061.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0402" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３）ＡＤＨ誘導体化Ｓ．Ｐａｒａｔｙｐｈｉ  Ａ  多糖体（ＯＳＰ）および濃縮ＴＴのコンジュゲーション：異なる温度で２つの実験を実施して、Ｐｒ変換を確認した。<br class="style-scope patent-text">
  実験番号：１<br class="style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．９で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、６℃の温度で、継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．９：０．８６）。
</span>3) ADH-derivatized S. Conjugation of Paratyphi A polysaccharide (OSP) and enriched TT: Two experiments were performed at different temperatures to confirm Pr conversion.<br class="style-scope patent-text"> Experiment number: 1<br class="style-scope patent-text"> ADH-derivatized PS was spiked with protein 1:0.9 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (3040 mg/ml in 100 mM MES buffer). solution) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 6° C. (PS:PR:EDC ratio 1:0.9:0.86).</span>
      </p>
      <p num="0403" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。２３時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 23 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0404" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１２：コンジュゲーション反応の進行を示すクロマトグラム（２３時間の時点で反応をクエンチ）を参照。<br class="style-scope patent-text">
４）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>See Figure 12: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 23 hours).<br class="style-scope patent-text"> 4) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0405" class="style-scope patent-text">
        <tables num="61" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/7a/12/5d5102c39bd0e0/2022546763000062.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000062.jpg" he="29" wi="149" width="596" height="116" alt="Figure 2022546763000062" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/7a/12/5d5102c39bd0e0/2022546763000062.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/7a/12/5d5102c39bd0e0/2022546763000062.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000062.jpg" he="29" wi="149" width="596" height="116" alt="Figure 2022546763000062" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/7a/12/5d5102c39bd0e0/2022546763000062.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0406" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：２<br class="style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．９で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、１０℃の温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．９：０．８６）。
</span>Experiment number: 2<br class="style-scope patent-text"> ADH-derivatized PS was spiked with protein at 1:0.9 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 10° C. (PS:PR:EDC ratio 1:0.9:0.86).</span>
      </p>
      <p num="0407" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。４時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 4 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0408" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１３：コンジュゲーション反応の進行を示すクロマトグラムを参照。<br class="style-scope patent-text">
４）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣｌ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集し、画分２～１０を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>See Figure 13: Chromatogram showing the progress of the conjugation reaction.<br class="style-scope patent-text"> 4) Conjugate purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/h, the conjugate was loaded onto the column, fractions were collected at 1 minute intervals and fractions 2-10 were pooled according to the profile on HPLC. . The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0409" class="style-scope patent-text">
        <tables num="62" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2b/d7/86/385653996ec17c/2022546763000063.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000063.jpg" he="28" wi="137" width="548" height="112" alt="Figure 2022546763000063" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2b/d7/86/385653996ec17c/2022546763000063.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/2b/d7/86/385653996ec17c/2022546763000063.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000063.jpg" he="28" wi="137" width="548" height="112" alt="Figure 2022546763000063" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/2b/d7/86/385653996ec17c/2022546763000063.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0410" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：逆コンジュゲーション化学を使用して（ＰＳを活性化する）、温度を６℃から１０℃に上昇させることによって、ＡＤＨ誘導体化Ｐａｒａｔｙｐｈｉ  Ａ  ＰＳおよび濃縮ＴＴのコンジュゲーションは成功した。反応のコンジュゲーション速度は増加し、ＰＳ／Ｐｒ比は、いずれの反応においても非常に低かった。<br class="style-scope patent-text">
２Ｂ）ジフテリアトキソイドを担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製。<br class="style-scope patent-text">
１）多糖体誘導体化：ＤＳＰチームから受け取ったＯＳＰを１０ｋＤａ膜で濃縮して、（１０～１３ｍｇ／ｍｌ）の濃度に到達させた。
</span>Conclusion: Using reverse conjugation chemistry (which activates PS), the conjugation of ADH-derivatized Paratyphi A PS and enriched TT was successful by increasing the temperature from 6°C to 10°C. The conjugation rate of the reactions increased and the PS/Pr ratio was very low in all reactions.<br class="style-scope patent-text"> 2B) S. cerevisiae using diphtheria toxoid as a carrier protein. Preparation of Paratyphi conjugates.<br class="style-scope patent-text"> 1) Polysaccharide derivatization: OSP received from the DSP team was concentrated on a 10 kDa membrane to reach a concentration of (10-13 mg/ml).</span>
      </p>
      <p num="0411" class="style-scope patent-text">
        <tables num="63" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8a/40/6e/1c6bab69cbd3b0/2022546763000064.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000064.jpg" he="29" wi="123" width="492" height="116" alt="Figure 2022546763000064" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8a/40/6e/1c6bab69cbd3b0/2022546763000064.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/8a/40/6e/1c6bab69cbd3b0/2022546763000064.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000064.jpg" he="29" wi="123" width="492" height="116" alt="Figure 2022546763000064" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/8a/40/6e/1c6bab69cbd3b0/2022546763000064.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0412" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中０．１１４ｍｇ／ｍｌ）を、重量比１：０．７で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、アジピン酸ジヒドラジド（ＡＤＨ）（０．５Ｍ重炭酸ナトリウム緩衝液ｐＨ：８．０に７５～１００ｍｇ／ｍｌで溶解）を重量比１：１０で添加した（ＰＳ：ＡＤＨ：ＣＰＩＰは、１：１０：０．７）。反応をｐＨ９．５で約２時間継続し、２Ｍグリシン１０を使用してクエンチし、次いで、反応混合物を、１００ｍＭ  ＭＥＳ緩衝液ｐＨ６．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を多糖体含有量について分析した。
</span>
  To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (0.114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:0.7. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Adipic acid dihydrazide (ADH) (dissolved at 75-100 mg/ml in 0.5 M sodium bicarbonate buffer pH: 8.0) was then added at a weight ratio of 1:10 (PS:ADH:CPIP is 1: 10:0.7). The reaction was continued at pH 9.5 for approximately 2 hours, quenched using 2M glycine 10, then the reaction mixture was subjected to diafiltration with 10 kDa TFF in 100 mM MES buffer pH 6.0 to remove residuals and unreacted components. Removed. The final sample was analyzed for polysaccharide content.
</span>
      </p>
      <p num="0413" class="style-scope patent-text">
        <tables num="64" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/da/eb/43/c20bf5167fda10/2022546763000065.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000065.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000065" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/da/eb/43/c20bf5167fda10/2022546763000065.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/da/eb/43/c20bf5167fda10/2022546763000065.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000065.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000065" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/da/eb/43/c20bf5167fda10/2022546763000065.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0414" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
２）タンパク質調製：製造部門（ＳＩＩＰＬ）から受け取った高モノマージフテリアトキソイド（ＤＴ）を、１０ｋＤａ膜で（１０～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>
2) Protein preparation: High monomeric diphtheria toxoid (DT) received from the manufacturing department (SIIPL) was concentrated (10-20 mg/ml) with a 10 kDa membrane and analyzed for protein content.
</span>
      </p>
      <p num="0415" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  アッセイの簡単な説明または参照：タンパク質含有量を、Ｌｏｗｒｙアッセイによって測定した。
</span>
  Assay brief description or reference: Protein content was measured by the Lowry assay.
</span>
      </p>
      <p num="0416" class="style-scope patent-text">
        <tables num="65" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/79/98/11/b4fb9ceffea0d3/2022546763000066.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000066.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000066" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/79/98/11/b4fb9ceffea0d3/2022546763000066.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/79/98/11/b4fb9ceffea0d3/2022546763000066.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000066.jpg" he="29" wi="122" width="488" height="116" alt="Figure 2022546763000066" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/79/98/11/b4fb9ceffea0d3/2022546763000066.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0417" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
３）ＡＤＨ誘導体化Ｓ．Ｐａｒａｔｙｐｈｉ  Ａ多糖体（ＯＳＰ）および濃縮ＤＴのコンジュゲーション：ＴＴコンジュゲートと同じ条件をＤＴに適用して、Ｐｒ変換を確認した。
</span>
3) ADH-derivatized S. Conjugation of Paratyphi A polysaccharide (OSP) and enriched DT: The same conditions as for TT conjugate were applied to DT to confirm Pr conversion.
</span>
      </p>
      <p num="0418" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：１<br class="style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．８で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、６度の温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．８：０．８６）。
</span>Experiment number: 1<br class="style-scope patent-text"> ADH-derivatized PS was spiked with protein 1:0.8 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 6 degrees (PS:PR:EDC ratio 1:0.8:0.86).</span>
      </p>
      <p num="0419" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。２０時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 20 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0420" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１４：コンジュゲーション反応の進行を示すクロマトグラム（２０時間の時点で反応をクエンチ）を参照。<br class="style-scope patent-text">
４）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣｌ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集し、画分２～１２を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>See Figure 14: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 20 hours).<br class="style-scope patent-text"> 4) Conjugate purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/hr, the conjugate was loaded onto the column, fractions were collected at 1 minute intervals, and fractions 2-12 were pooled according to the HPLC profile. . The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0421" class="style-scope patent-text">
        <tables num="66" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/88/0e/04/910f925f57b306/2022546763000067.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000067.jpg" he="28" wi="149" width="596" height="112" alt="Figure 2022546763000067" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/88/0e/04/910f925f57b306/2022546763000067.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/88/0e/04/910f925f57b306/2022546763000067.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000067.jpg" he="28" wi="149" width="596" height="112" alt="Figure 2022546763000067" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/88/0e/04/910f925f57b306/2022546763000067.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0422" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１５：精製コンジュゲート（プールした画分）を示すクロマトグラムを参照。<br class="style-scope patent-text">
  実験番号：２<br class="style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：１．０で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．９で添加した。反応を、ｐＨ６．０、１０℃の、温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：１．０：０．９）。
</span>See Figure 15: Chromatogram showing purified conjugate (pooled fractions).<br class="style-scope patent-text"> Experiment number: 2<br class="style-scope patent-text"> ADH-derivatized PS was spiked with protein 1:1.0 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.9. The reaction was continued at pH 6.0 and a temperature of 10° C. (PS:PR:EDC ratio 1:1.0:0.9).</span>
      </p>
      <p num="0423" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。４時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 4 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0424" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１６：コンジュゲーション反応の進行を示すクロマトグラム（４時間の時点で反応をクエンチ）を参照。<br class="style-scope patent-text">
４）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>See Figure 16: Chromatogram showing the progress of the conjugation reaction (reaction quenched at 4 hours).<br class="style-scope patent-text"> 4) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0425" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  図１７：精製コンジュゲートを示すクロマトグラムを参照。
</span>
  Figure 17: See chromatogram showing purified conjugate.
</span>
      </p>
      <p num="0426" class="style-scope patent-text">
        <tables num="67" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/65/b8/e2/3af2cd83c0612f/2022546763000068.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000068.jpg" he="29" wi="137" width="548" height="116" alt="Figure 2022546763000068" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/65/b8/e2/3af2cd83c0612f/2022546763000068.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/65/b8/e2/3af2cd83c0612f/2022546763000068.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000068.jpg" he="29" wi="137" width="548" height="116" alt="Figure 2022546763000068" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/65/b8/e2/3af2cd83c0612f/2022546763000068.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0427" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：カルボジイミド化学を使用したＡＤＨ誘導体化Ｐａｒａｔｙｐｈｉ  Ａ  ＰＳのコンジュゲーションは、濃縮ＤＴを使用して成功した。コンジュゲーション反応の速度は、温度の上昇によって増加したが、ＰＳ／Ｐｒ比は、いずれの実験においても低かった。<br class="style-scope patent-text">
Ｄ３）サルモネラ菌血清型株Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ由来の多糖体を、破傷風トキソイド（ＴＴ）、ジフテリアトキソイド（ＤＴ）またはＣＲＭ１９７から選択される担体タンパク質にコンジュゲートする方法。<br class="style-scope patent-text">
１）シアニル化化学に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体のコンジュゲーション<br class="style-scope patent-text">
  Ａ）カルボジイミド化学を使用したジフテリアトキソイド（ＤＴ）の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体とのコンジュゲーション。
</span>Conclusion: Conjugation of ADH-derivatized Paratyphi A PS using carbodiimide chemistry was successful using concentrated DT. The rate of the conjugation reaction increased with increasing temperature, but the PS/Pr ratio was low in all experiments.<br class="style-scope patent-text"> D3) Salmonella serotype strain S. typhimurium and S. A method of conjugating a polysaccharide from enteritidis to a carrier protein selected from tetanus toxoid (TT), diphtheria toxoid (DT) or CRM197.<br class="style-scope patent-text"> 1) S. cerevisiae to carrier proteins diphtheria toxoid (DT), CRM197 and tetanus toxoid (TT) based on cyanylation chemistry. typhimurium and S. Conjugation of polysaccharides of A. enteritidis A) Derivatization of diphtheria toxoid (DT) using carbodiimide chemistry (addition of linker ADH) and enrichment of S. enteritidis using cyanylation chemistry. typhimurium and S. conjugation with S. enteritidis polysaccharides.</span>
      </p>
      <p num="0428" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｂ）カルボジイミド化学を使用した、ＣＲＭ１９７の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓとのコンジュゲーション。
</span>
  B) Derivatization of CRM197 using carbodiimide chemistry (addition of linker ADH) and enrichment S. cerevisiae using cyanylation chemistry. typhimurium and S. conjugation with enteritidis.
</span>
      </p>
      <p num="0429" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｃ）カルボジイミド化学を使用した破傷風トキソイド（ＴＴ）の誘導体化（リンカーＡＤＨの付加）およびシアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓとのコンジュゲーション。
</span>
  C) Derivatization of tetanus toxoid (TT) using carbodiimide chemistry (addition of linker ADH) and enriched S. cerevisiae using cyanylation chemistry. typhimurium and S. conjugation with enteritidis.
</span>
      </p>
      <p num="0430" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｄ）多糖体または担体タンパク質の誘導体化なしのシアニル化化学（ＣＰＰＴ）に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのパラチフスＯＳＰのコンジュゲーション。
</span>
  D) Conjugation of Paratyphi OSP to the carrier proteins diphtheria toxoid (DT), CRM197 and tetanus toxoid (TT) based on cyanylation chemistry (CPPT) without polysaccharide or carrier protein derivatization.
</span>
      </p>
      <p num="0431" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  従った手順：<br class="style-scope patent-text">
Ａ）ジフテリアトキソイド（ＤＴ）を担体タンパク質として使用したＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体コンジュゲートの調製。<br class="style-scope patent-text">
１）タンパク質誘導体化：<br class="style-scope patent-text">
  高モノマージフテリアトキソイド（ＤＴ）を、１０ｋＤａ膜で（１０～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>Steps I followed:<br class="style-scope patent-text"> A) S. cerevisiae using diphtheria toxoid (DT) as a carrier protein. typhimurium and S. Preparation of enteritidis polysaccharide conjugates.<br class="style-scope patent-text"> 1) Protein derivatization:<br class="style-scope patent-text"> High monomeric diphtheria toxoid (DT) was concentrated (10-20 mg/ml) with a 10 kDa membrane and analyzed for protein content.</span>
      </p>
      <p num="0432" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＤＴに、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：１０でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：５．８に溶解）、および重量比１：１でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：５．８に溶解）を添加した。反応をｐＨ５．８で約１時間継続し、次いで、反応混合物を、５０ｍＭホウ酸緩衝液ｐＨ９．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。<br class="style-scope patent-text">
２）Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体（ＰＳ）ならびにＡＤＨ誘導体化ＤＴのコンジュゲーション：<br class="style-scope patent-text">
  １－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）比を変化させることによって２つの実験を実施した。
</span>To concentrated DT was added freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) at a weight ratio of 1:10 (75-100 mg/ml dissolved in 100 mM MES buffer pH: 5.8), and a weight ratio of 1:10. 1 EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 5.8) was added. The reaction was continued at pH 5.8 for about 1 hour, then the reaction mixture was subjected to diafiltration with 10 kDa TFF in 50 mM borate buffer pH 9.0 to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.<br class="style-scope patent-text"> 2) S. typhimurium and S. conjugation of A. enteritidis polysaccharide (PS) as well as ADH-derivatized DT:<br class="style-scope patent-text"> Two experiments were performed by varying the 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP) ratio.</span>
      </p>
      <p num="0433" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：１  －  Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体を１０ｋＤａ膜で濃縮して、（１０～１５ｍｇ／ｍｌ）の濃度に到達させた。<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．３）。
</span>Experiment number: 1-S. typhimurium and S. enteritidis polysaccharide was concentrated on a 10 kDa membrane to reach a concentration of (10-15 mg/ml).<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP is 1:0.8:1.3).</span>
      </p>
      <p num="0434" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。<br class="style-scope patent-text">
３）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅａｒｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣｌ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集した。最終プール画分をろ過し、分析に送った。
</span>Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.<br class="style-scope patent-text"> 3) Conjugate purification by GFC: GFC resin (Tyopearl HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/hr, the conjugate was loaded onto the column and fractions were collected at 1 minute intervals. The final pooled fractions were filtered and sent for analysis.</span>
      </p>
      <p num="0435" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：２<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．１で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．１）。
</span>Experiment number: 2<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.1. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP is 1:0.8:1.1).</span>
      </p>
      <p num="0436" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.
</span>
      </p>
      <p num="0437" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＧＦＣによるコンジュゲート精製：  ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣＬ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣＬを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集した。最終プール画分をろ過し、分析に送った。
</span>
  Conjugate Purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/h, the conjugate was loaded onto the column and fractions were collected at 1 minute intervals. The final pooled fractions were filtered and sent for analysis.
</span>
      </p>
      <p num="0438" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：ＡＤＨ誘導体化ＤＴを使用したＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体のコンジュゲーションは成功し、ＰＳ／ＰＲ比は、満足のいくものであった。<br class="style-scope patent-text">
Ｂ．ＣＲＭ１９７を担体タンパク質として使用したＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体コンジュゲートの調製<br class="style-scope patent-text">
１）タンパク質誘導体化：製造部門（ＳＩＩＰＬ）から受け取った交差反応変異体（ＣＲＭ１９７）を誘導体化に利用した。
</span>Conclusion: S. cerevisiae using ADH-derivatized DT typhimurium and S. The conjugation of the S. enteritidis polysaccharide was successful and the PS/PR ratio was satisfactory.<br class="style-scope patent-text"> B. S. cerevisiae using CRM197 as a carrier protein. typhimurium and S. enteritidis polysaccharide conjugate preparation 1) Protein derivatization: A cross-reacting mutant (CRM197) received from the manufacturing department (SIIPL) was utilized for derivatization.</span>
      </p>
      <p num="0439" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＣＲＭ１９７に、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：３．５でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．５に溶解）、および重量比１：０．２５でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．５に溶解）を添加した。５％Ｔｗｅｅｎ  ８０を添加した。１００ｍＭ  ＭＥＳ緩衝液を使用して３～４ｍｇ／ｍｌの最終濃度に到達する最終反応容積にし、反応をｐＨ６．５で約３時間継続し、次いで、反応混合物を、５０ｍＭホウ酸緩衝液および０．００５％Ｔｗｅｅｎ  ８０  ｐＨ９．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。<br class="style-scope patent-text">
２）Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体（ＰＳ）ならびにＡＤＨ誘導体化ＣＲＭ１９７のコンジュゲーション：<br class="style-scope patent-text">
  ＤＳＰから受け取ったＰＳを１０ｋＤａ膜で濃縮して、（１０～１５ｍｇ／ｍｌ）の濃度に到達させた。
</span>To concentrated CRM197, freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) (75-100 mg/ml dissolved in 100 mM MES buffer pH: 6.5) at a weight ratio of 1:3.5, and EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 6.5) was added at 1:0.25. 5<figure-callout id="80" label="% Tween" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 80 was added. 100 mM MES buffer was used to make up the final reaction volume to reach a final concentration of 3-4 mg/ml, the reaction was continued at pH 6.5 for about 3 hours, then the reaction mixture was added to 50 mM borate buffer and 0.5 mg/ml. Diafiltration with 10 kDa TFF in 005<figure-callout id="80" label="% Tween" filenames="2022546763000098.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 80 pH 9.0 was performed to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.<br class="style-scope patent-text"> 2) S. typhimurium and S. Conjugation of enteritidis polysaccharide (PS) as well as ADH-derivatized CRM197:<br class="style-scope patent-text"> PS received from DSP was concentrated on a 10 kDa membrane to reach a concentration of (10-15 mg/ml).</span>
      </p>
      <p num="0440" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：１で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：１：１．３）。
</span>
  To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:1 (PS:PR:CPIP is 1:1:1.3).
</span>
      </p>
      <p num="0441" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。<br class="style-scope patent-text">
３）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣＬ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣＬを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集し、最終プール画分をろ過し、分析に送った。
</span>Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.<br class="style-scope patent-text"> 3) Conjugate purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/hr, the conjugate was loaded onto the column, fractions were collected at 1 minute intervals and the final pooled fraction was filtered and sent for analysis.</span>
      </p>
      <p num="0442" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：ＡＤＨ誘導体化ＣＲＭ１９７を使用したＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓＰＳのコンジュゲーションは成功し、ＰＳ／ＰＲ比は、満足のいくものであった。<br class="style-scope patent-text">
Ｃ）破傷風トキソイドを担体タンパク質として使用したＳ．Ｐａｒａｔｙｐｈｉコンジュゲートの調製：<br class="style-scope patent-text">
１）タンパク質誘導体化：製造部門（ＳＩＩＰＬ）から受け取った高モノマー破傷風トキソイド（ＴＴ）を、３０ｋＤａ膜で（１５～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。濃縮ＴＴに、新たに調製した１Ｍ  ＭＥＳ緩衝液、重量比１：１０でアジピン酸ジヒドラジド（ＡＤＨ）（７５～１００ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．０に溶解）、および重量比１：１でＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（３０～４０ｍｇ／ｍｌで１００ｍＭ  ＭＥＳ緩衝液ｐＨ：６．０に溶解）を添加した。反応をｐＨ６．０で約１時間継続し、次いで、反応混合物を、１０ｍＭリン酸緩衝液ｐＨ７．２中３０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を、タンパク質含有量および誘導体化度について分析した。<br class="style-scope patent-text">
２）Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体（ＰＳ）ならびにＡＤＨ誘導体化ＴＴのコンジュゲーション：<br class="style-scope patent-text">
  ＤＳＰチームから受け取ったＯＳＰを１０ｋＤａ膜で濃縮して、（１０～１３ｍｇ／ｍｌ）の濃度に到達させた。
</span>Conclusion: S. cerevisiae using ADH-derivatized CRM197. typhimurium and S. The conjugation of P. enteritidis PS was successful and the PS/PR ratio was satisfactory.<br class="style-scope patent-text"> C) S. cerevisiae using tetanus toxoid as carrier protein. Preparation of Paratyphi conjugates:<br class="style-scope patent-text"> 1) Protein derivatization: High monomeric tetanus toxoid (TT) received from the manufacturing department (SIIPL) was concentrated (15-20 mg/ml) with a 30 kDa membrane and analyzed for protein content. To concentrated TT, freshly prepared 1 M MES buffer, adipic acid dihydrazide (ADH) (75-100 mg/ml dissolved in 100 mM MES buffer pH: 6.0) at a weight ratio of 1:10, and a weight ratio of 1:10. EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml dissolved in 100 mM MES buffer pH: 6.0) was added at 1. The reaction was continued at pH 6.0 for about 1 hour, then the reaction mixture was subjected to diafiltration with 30 kDa TFF in 10 mM phosphate buffer pH 7.2 to remove residuals and unreacted components. Final samples were analyzed for protein content and degree of derivatization.<br class="style-scope patent-text"> 2) S. typhimurium and S. conjugation of polysaccharide enteritidis (PS) as well as ADH-derivatized TT:<br class="style-scope patent-text"> OSP received from the DSP team was concentrated on a 10 kDa membrane to reach a concentration of (10-13 mg/ml).</span>
      </p>
      <p num="0443" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  １－シアノ－４－ピロリジノピリジニウム  テトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）比を変化させることによって２つの実験を実施した。<br class="style-scope patent-text">
  実験番号：１<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．２５で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．８で添加した（ＰＳ：ＰＲ：ＣＰＩＰは、１：０．８：１．２５）。
</span>Two experiments were performed by varying the 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP) ratio.<br class="style-scope patent-text"> Experiment number: 1<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.25. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.8 (PS:PR:CPIP was 1:0.8:1.25).</span>
      </p>
      <p num="0444" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。<br class="style-scope patent-text">
３）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.<br class="style-scope patent-text"> 3) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0445" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実験番号：２<br class="style-scope patent-text">
  濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：１．３で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、タンパク質を重量比１：０．９で添加した（ＰＳ：ＰＲ：ＣＰＩＰ  １：０．９：１．３）。
</span>Experiment number: 2<br class="style-scope patent-text"> To the concentrated PS was added 0.9% NaCl and freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:1.3. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Protein was then added at a weight ratio of 1:0.9 (PS:PR:CPIP 1:0.9:1.3).</span>
      </p>
      <p num="0446" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。３～４時間後、２ＭグリシンをＰＳの重量の１０倍重量添加することによって、反応をクエンチした。<br class="style-scope patent-text">
３）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 3-4 hours, the reaction was quenched by adding 10 times the weight of PS of 2M glycine.<br class="style-scope patent-text"> 3) Conjugate purification by ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0447" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：ＡＤＨ誘導体化ＴＴを使用したＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体（ＰＳ）のコンジュゲーションは成功し、２つの異なる種類の透析ろ過方策を適用し、いずれのプロセスも満足のいくＰＳ／Ｐｒ比をもたらした。<br class="style-scope patent-text">
２）カルボジイミド化学に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体のコンジュゲーション<br class="style-scope patent-text">
  Ａ）シアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体の誘導体化（リンカーＡＤＨの付加）、ならびにカルボジイミド化学を使用した破傷風トキソイド（ＴＴ）とのコンジュゲーション。
</span>Conclusion: S. cerevisiae using ADH-derivatized TT. typhimurium and S. The conjugation of the S. enteritidis polysaccharide (PS) was successful, applying two different types of diafiltration strategies, both processes yielding satisfactory PS/Pr ratios.<br class="style-scope patent-text"> 2) S. cerevisiae to carrier proteins diphtheria toxoid (DT), CRM197 and tetanus toxoid (TT) based on carbodiimide chemistry. typhimurium and S. Conjugation of Polysaccharides of Enteritidis A) Enriched S. enteritidis using cyanylation chemistry. typhimurium and S. Derivatization of the enteritidis polysaccharide (addition of linker ADH) and conjugation with tetanus toxoid (TT) using carbodiimide chemistry.</span>
      </p>
      <p num="0448" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｂ）シアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体の誘導体化（リンカーＡＤＨの付加）、ならびにカルボジイミド化学を使用したジフテリアトキソイド（ＤＴ）とのコンジュゲーション。
</span>
  B) Enriched S.I. using cyanylation chemistry. typhimurium and S. Derivatization of the enteritidis polysaccharide (addition of linker ADH) and conjugation with diphtheria toxoid (DT) using carbodiimide chemistry.
</span>
      </p>
      <p num="0449" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｃ）シアニル化化学を使用した濃縮Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体の誘導体化（リンカーＡＤＨの付加）、ならびにカルボジイミド化学を使用したＣＲＭ１９７とのコンジュゲーション。
</span>
  C) Enriched S.I. using cyanylation chemistry typhimurium and S. Derivatization of the enteritidis polysaccharide (addition of linker ADH) and conjugation with CRM197 using carbodiimide chemistry.
</span>
      </p>
      <p num="0450" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｄ）多糖体または担体タンパク質の誘導体化なしのカルボジイミド化学（ＥＤＡＣ）に基づく担体タンパク質ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７および破傷風トキソイド（ＴＴ）へのパラチフスＯＳＰのコンジュゲーション。
</span>
  D) Conjugation of Paratyphi OSP to the carrier proteins diphtheria toxoid (DT), CRM197 and tetanus toxoid (TT) based on carbodiimide chemistry (EDAC) without polysaccharide or carrier protein derivatization.
</span>
      </p>
      <p num="0451" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  従った手順：<br class="style-scope patent-text">
１）多糖体（ＰＳ）誘導体化：受け取ったＳ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体を１０ｋＤａ膜で濃縮して、（１０～１３ｍｇ／ｍｌ）の濃度に到達させた。濃縮ＰＳに、０．９％ＮａＣｌを添加し、新たに調製したＣＰＩＰ溶液（アセトニトリル中１１４ｍｇ／ｍｌ）を、重量比１：０．５～１：２（１：０．７）で多糖体に添加した。２．５Ｍ  ＮａＯＨによりｐＨを直ちに９．５にシフトし、最大３分間保持した。次いで、アジピン酸ジヒドラジド（ＡＤＨ）（０．５Ｍ重炭酸ナトリウム緩衝液ｐＨ：８．０に７５～１００ｍｇ／ｍｌで溶解）を重量比１：１０で添加した（ＰＳ：ＡＤＨ：ＣＰＩＰは、１：２：０．７～１：１０：０．７）。反応をｐＨ９．５で約２時間継続し、２Ｍグリシン１０を使用してクエンチし、次いで、反応混合物を、１００ｍＭ  ＭＥＳ緩衝液ｐＨ６．０中１０ｋＤａ  ＴＦＦで透析ろ過にかけて、残留物および未反応成分を除去した。最終試料を多糖体含有量について分析した。<br class="style-scope patent-text">
２）タンパク質調製：<br class="style-scope patent-text">
  ２Ａ）タンパク質調製：製造部門（ＳＩＩＰＬ）から受け取った高モノマー破傷風トキソイド（ＴＴ）を、３０ｋＤａ膜で（１０～１５ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>Steps I followed:<br class="style-scope patent-text"> 1) Polysaccharide (PS) derivatization: the received S. typhimurium and S. enteritidis polysaccharide was concentrated on a 10 kDa membrane to reach a concentration of (10-13 mg/ml). To the concentrated PS was added 0.9% NaCl and a freshly prepared CPIP solution (114 mg/ml in acetonitrile) was added to the polysaccharide at a weight ratio of 1:0.5-1:2 (1:0.7). added. The pH was immediately shifted to 9.5 with 2.5 M NaOH and held for a maximum of 3 minutes. Adipic acid dihydrazide (ADH) (dissolved at 75-100 mg/ml in 0.5 M sodium bicarbonate buffer pH: 8.0) was then added at a weight ratio of 1:10 (PS:ADH:CPIP is 1: 2:0.7 to 1:10:0.7). The reaction was continued at pH 9.5 for approximately 2 hours, quenched using 2M glycine 10, then the reaction mixture was subjected to diafiltration with 10 kDa TFF in 100 mM MES buffer pH 6.0 to remove residuals and unreacted components. Removed. The final sample was analyzed for polysaccharide content.<br class="style-scope patent-text"> 2) Protein preparation:<br class="style-scope patent-text"> 2A) Protein preparation: High monomeric tetanus toxoid (TT) received from the manufacturing department (SIIPL) was concentrated (10-15 mg/ml) with a 30 kDa membrane and analyzed for protein content.</span>
      </p>
      <p num="0452" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２Ｂ）タンパク質調製：製造部門（ＳＩＩＰＬ）から受け取った高モノマージフテリアトキソイド（ＤＴ）を、３０ｋＤａ膜で（１０～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。
</span>
  2B) Protein preparation: High monomeric diphtheria toxoid (DT) received from the manufacturing department (SIIPL) was concentrated (10-20 mg/ml) on a 30 kDa membrane and analyzed for protein content.
</span>
      </p>
      <p num="0453" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２Ｃ）タンパク質調製：製造部門（ＳＩＩＰＬ）から受け取った高モノマーＣＲＭ１９７を、３０ｋＤａ膜で（１０～２０ｍｇ／ｍｌ）に濃縮し、タンパク質含有量について分析した。<br class="style-scope patent-text">
３）コンジュゲーション<br class="style-scope patent-text">
  ３Ａ）ＡＤＨ誘導体化Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体ならびに濃縮ＴＴのコンジュゲーション：<br class="style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．９で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、６℃の温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．９：０．８６）。
</span>2C) Protein preparation: High monomeric CRM197 received from the manufacturing department (SIIPL) was concentrated to (10-20 mg/ml) with a 30 kDa membrane and analyzed for protein content.<br class="style-scope patent-text"> 3) Conjugation 3A) ADH-derivatized S. typhimurium and S. Conjugation of enteritidis polysaccharide as well as enriched TT:<br class="style-scope patent-text"> ADH-derivatized PS was spiked with protein at 1:0.9 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 6° C. (PS:PR:EDC ratio 1:0.9:0.86).</span>
      </p>
      <p num="0454" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。２３時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 23 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0455" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ３Ｂ）ＡＤＨ誘導体化Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体ならびに濃縮ＤＴのコンジュゲーション：ＴＴコンジュゲートと同じ条件をＤＴに適用して、Ｐｒ変換を確認した。
</span>
  3B) ADH-derivatized S. typhimurium and S. conjugation of C. enteritidis polysaccharide as well as enriched DT: The same conditions as for the TT conjugate were applied to DT to confirm Pr conversion.
</span>
      </p>
      <p num="0456" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．８で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、６℃の温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．８：０．８６）。
</span>
  ADH-derivatized PS was spiked with protein 1:0.8 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 6° C. (PS:PR:EDC ratio 1:0.8:0.86).
</span>
      </p>
      <p num="0457" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。２０時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。
</span>
  Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 20 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.
</span>
      </p>
      <p num="0458" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ３Ｃ）ＡＤＨ誘導体化Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体ならびに濃縮ＣＲＭ１９７のコンジュゲーション：ＴＴおよびＤＴコンジュゲートと同じ条件をＣＲＭ１９７に適用して、Ｐｒ変換を確認した。
</span>
  3C) ADH-derivatized S. typhimurium and S. conjugation of C. enteritidis polysaccharide and enriched CRM197: The same conditions as the TT and DT conjugates were applied to CRM197 to confirm Pr conversion.
</span>
      </p>
      <p num="0459" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＡＤＨ誘導体化ＰＳに、タンパク質を重量で１：０．８で、および新たに調製したＥＤＡＣ（１－エチル－３－（３－ジメチル－アミノプロピル）カルボジイミド）（１００ｍＭ  ＭＥＳ緩衝液中３０～４０ｍｇ／ｍｌで溶解）を重量比１：０．８６で添加した。反応を、ｐＨ６．０、６℃の温度で継続した（ＰＳ：ＰＲ：ＥＤＣ比は、１：０．８：０．８６）。
</span>
  ADH-derivatized PS was spiked with protein 1:0.8 by weight and freshly prepared EDAC (1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide) (30-40 mg/ml in 100 mM MES buffer). ml) was added at a weight ratio of 1:0.86. The reaction was continued at pH 6.0 and a temperature of 6° C. (PS:PR:EDC ratio 1:0.8:0.86).
</span>
      </p>
      <p num="0460" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＰＢＳを移動相とし、流速１ｍｌ／分でＳｈｏｄｅｘカラムＳＢ－８０４  ＨＱおよびＳＢ－８０５  ＨＱを連続的に使用して、タンパク質変換をモニタリングした。２０時間後、ＥＤＴＡを含有する１００ｍＭリン酸緩衝液を添加することによって、反応をクエンチした。<br class="style-scope patent-text">
４）コンジュゲート精製<br class="style-scope patent-text">
  ４Ａ）限外ろ過によるコンジュゲート精製：クエンチしたコンジュゲートを、１０ｍＭ  ＰＢＳ  ｐＨ７．２、続いて、１０ｍＭトリス緩衝液ｐＨ７．２中３００ｋＤａ  ＴＦＦ膜透析ろ過によって精製した。最終濃縮試料を分析に送った。
</span>Protein conversion was monitored using Shodex columns SB-804 HQ and SB-805 HQ sequentially with PBS as the mobile phase and a flow rate of 1 ml/min. After 20 hours, the reaction was quenched by adding 100 mM phosphate buffer containing EDTA.<br class="style-scope patent-text"> 4) Conjugate Purification 4A) Conjugate Purification by Ultrafiltration: The quenched conjugate was purified by 10 mM PBS pH 7.2 followed by 300 kDa TFF membrane diafiltration in 10 mM Tris buffer pH 7.2. A final concentrated sample was sent for analysis.</span>
      </p>
      <p num="0461" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ４Ｂ）ＧＦＣによるコンジュゲート精製：ＧＦＣ樹脂（Ｔｙｏｐｅｒａｌ  ＨＷ６５Ｆ）を使用し、４０ｃｍの床高さでＣｏｌｕｍｎ  ＸＫ１６／７０を準備した。カラムを１００ｃｍ／時の流速で充填して安定させ、１Ｍ  ＮａＣｌ  １％のカラム容積を通過させて、充填カラムの完全性を評価した。０．９％ＮａＣｌを３０ｃｍ／時で使用してカラムを平衡にし、コンジュゲートをカラムに投入し、画分を１分間隔で収集し、画分２～１２を、ＨＰＬＣでのプロファイルに従ってプールした。最終プール画分をろ過し、分析に送った。
</span>
  4B) Conjugate purification by GFC: GFC resin (Tyoperal HW65F) was used and Column XK16/70 was prepared with a bed height of 40 cm. The column was packed and stabilized at a flow rate of 100 cm/hr and passed through a column volume of 1 M NaCl 1% to assess the integrity of the packed column. The column was equilibrated using 0.9% NaCl at 30 cm/hr, the conjugate was loaded onto the column, fractions were collected at 1 minute intervals, and fractions 2-12 were pooled according to the HPLC profile. . The final pooled fractions were filtered and sent for analysis.
</span>
      </p>
      <p num="0462" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：逆コンジュゲーション化学を使用して（ＰＳを活性化する）、温度を６から１０℃に上昇させることによって、ＡＤＨ誘導体化Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体ならびに濃縮ＴＴ、ＤＴおよびＣＲＭ１９７のコンジュゲーションは成功した。反応のコンジュゲーション速度は増加し、ＰＳ／Ｐｒ比は、すべての反応において非常に低かった。
</span>
  Conclusion: Using reverse conjugation chemistry (which activates PS) and increasing the temperature from 6 to 10°C, ADH-derivatized S. typhimurium and S. enteritidis polysaccharide and enriched TT, DT and CRM197 were successfully conjugated. The conjugation rates of the reactions increased and the PS/Pr ratios were very low in all reactions.
</span>
      </p>
      <p num="0463" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  カルボジイミド化学を使用したＡＤＨ誘導体化Ｓ．ｔｙｐｈｉｍｕｒｉｕｍおよびＳ．ｅｎｔｅｒｉｔｉｄｉｓ多糖体ならびに濃縮ＴＴ、ＤＴおよびＣＲＭ１９７のコンジュゲーションは成功した。コンジュゲーション反応の速度は、温度の上昇によって増加したが、ＰＳ／Ｐｒ比は、いずれの実験においても低かった。
</span>
  ADH derivatization using carbodiimide chemistry. typhimurium and S. enteritidis polysaccharide and enriched TT, DT and CRM197 were successfully conjugated. The rate of the conjugation reaction increased with increasing temperature, but the PS/Pr ratio was low in all experiments.
</span>
      </p>
      <p num="0464" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例４：免疫原性組成物
</span>
  Example 4: Immunogenic composition
</span>
      </p>
      <p num="0465" class="style-scope patent-text">
        <tables num="68" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ed/76/8a/c329b5599579c5/2022546763000069.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000069.jpg" he="197" wi="164" width="656" height="788" alt="Figure 2022546763000069" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ed/76/8a/c329b5599579c5/2022546763000069.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ed/76/8a/c329b5599579c5/2022546763000069.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000069.jpg" he="197" wi="164" width="656" height="788" alt="Figure 2022546763000069" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ed/76/8a/c329b5599579c5/2022546763000069.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0466" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  単回用量は、保存剤２－フェノキシエタノールを含まない。<br class="style-scope patent-text">
  多回用量組成物は、２－フェノキシエタノール  －  ５ｍｇ（１～１０ｍｇ）をさらに含んでもよい。
</span>Single doses do not contain the preservative 2-phenoxyethanol.<br class="style-scope patent-text"> The multi-dose composition may further comprise 2-phenoxyethanol-5 mg (1-10 mg).</span>
      </p>
      <p num="0467" class="style-scope patent-text">
        <tables num="69" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/fc/2a/e35be8cacbd2cc/2022546763000070.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000070.jpg" he="153" wi="169" width="676" height="612" alt="Figure 2022546763000070" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/fc/2a/e35be8cacbd2cc/2022546763000070.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/fc/2a/e35be8cacbd2cc/2022546763000070.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000070.jpg" he="153" wi="169" width="676" height="612" alt="Figure 2022546763000070" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/fc/2a/e35be8cacbd2cc/2022546763000070.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0468" class="style-scope patent-text">
        <tables num="70" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b8/79/d7/e975579d94a316/2022546763000071.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000071.jpg" he="120" wi="168" width="672" height="480" alt="Figure 2022546763000071" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b8/79/d7/e975579d94a316/2022546763000071.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b8/79/d7/e975579d94a316/2022546763000071.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000071.jpg" he="120" wi="168" width="672" height="480" alt="Figure 2022546763000071" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b8/79/d7/e975579d94a316/2022546763000071.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0469" class="style-scope patent-text">
        <tables num="71" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0c/27/27/7c49a09e830a30/2022546763000072.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000072.jpg" he="103" wi="168" width="672" height="412" alt="Figure 2022546763000072" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0c/27/27/7c49a09e830a30/2022546763000072.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0c/27/27/7c49a09e830a30/2022546763000072.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000072.jpg" he="103" wi="168" width="672" height="412" alt="Figure 2022546763000072" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0c/27/27/7c49a09e830a30/2022546763000072.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0470" class="style-scope patent-text">
        <tables num="72" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3d/66/c3/505b88edbc0f59/2022546763000073.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000073.jpg" he="250" wi="133" width="532" height="1000" alt="Figure 2022546763000073" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3d/66/c3/505b88edbc0f59/2022546763000073.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3d/66/c3/505b88edbc0f59/2022546763000073.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000073.jpg" he="250" wi="133" width="532" height="1000" alt="Figure 2022546763000073" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3d/66/c3/505b88edbc0f59/2022546763000073.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0471" class="style-scope patent-text">
        <tables num="73" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/44/99/0b/28c62b81aee181/2022546763000074.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000074.jpg" he="246" wi="137" width="548" height="984" alt="Figure 2022546763000074" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/44/99/0b/28c62b81aee181/2022546763000074.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/44/99/0b/28c62b81aee181/2022546763000074.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000074.jpg" he="246" wi="137" width="548" height="984" alt="Figure 2022546763000074" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/44/99/0b/28c62b81aee181/2022546763000074.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0472" class="style-scope patent-text">
        <tables num="74" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e2/bc/af/f4fb690fc0fb76/2022546763000075.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000075.jpg" he="246" wi="129" width="516" height="984" alt="Figure 2022546763000075" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e2/bc/af/f4fb690fc0fb76/2022546763000075.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e2/bc/af/f4fb690fc0fb76/2022546763000075.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000075.jpg" he="246" wi="129" width="516" height="984" alt="Figure 2022546763000075" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e2/bc/af/f4fb690fc0fb76/2022546763000075.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0473" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、上に開示される組成物のｐＨを水酸化ナトリウム／炭酸ナトリウムにより約６．０～７．０に調節し、生理食塩水（０．９％）を添加することによって容積をなす。<br class="style-scope patent-text">
  以下の保存剤の組合せの１つをさらに含んでもよい。
</span>Additionally, the pH of the composition disclosed above is adjusted to about 6.0-7.0 with sodium hydroxide/sodium carbonate and made up to volume by adding saline (0.9%).<br class="style-scope patent-text"> It may further include one of the following preservative combinations.</span>
      </p>
      <p num="0474" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、<br class="style-scope patent-text">
  ｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベン、または<br class="style-scope patent-text">
  ｉｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン、または<br class="style-scope patent-text">
  ｉｖ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベンおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン。
</span>i. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v),<br class="style-scope patent-text"> ii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v), or iii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and propylparaben in an amount of 0.05-0.2 mg per 0.5 ml (w/v), or iv. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v), methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v) and 0.05-0.5 mg per 0.5 ml. Propylparaben in an amount of 2 mg (w/v).</span>
      </p>
      <p num="0475" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  低減用量ＩＰＶ、Ｄ、Ｔ、ＨｅｐＢ、ＶｉＰｓ－ＴＴ、ＯＳＰコンジュゲート、無細胞性百日咳およびＨｉｂ抗原を含む組合せワクチン組成物は、無毒化（特に遺伝子的または化学的に無毒化した）形態のボルデテラ毒素、特に百日咳トキソイド、糸状ヘマグルチニン、パータクチン、またはフィムブリエから選択される無細胞性百日咳抗原、特に、０．５ｍｌ当たり、百日咳トキソイド：１～５０マイクログラム（より詳細には８μｇ）、糸状ヘマグルチニン：１～５０マイクログラム（より詳細には８μｇ）、パータクチン：１～２０マイクログラム（より詳細には２．５μｇ）、任意選択で、フィムブリエ：２～２５マイクログラムを含んでもよい。
</span>
  A combination vaccine composition comprising reduced dose IPV, D, T, HepB, ViPs-TT, OSP conjugates, acellular pertussis and Hib antigens is a detoxified (particularly genetically or chemically detoxified) form of Bordetella. acellular pertussis antigen selected from toxins, in particular pertussis toxoid, filamentous hemagglutinin, pertactin or fimbriae, in particular pertussis toxoid: 1-50 micrograms (more particularly 8 μg) per 0.5 ml, filamentous hemagglutinin: 1 ˜50 micrograms (more particularly 8 μg), pertactin: 1-20 micrograms (more particularly 2.5 μg), optionally fimbriae: 2-25 micrograms.
</span>
      </p>
      <p num="0476" class="style-scope patent-text">
        <tables num="75" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e6/8f/de/648110f670f2dd/2022546763000076.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000076.jpg" he="250" wi="124" width="496" height="1000" alt="Figure 2022546763000076" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e6/8f/de/648110f670f2dd/2022546763000076.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e6/8f/de/648110f670f2dd/2022546763000076.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000076.jpg" he="250" wi="124" width="496" height="1000" alt="Figure 2022546763000076" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e6/8f/de/648110f670f2dd/2022546763000076.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0477" class="style-scope patent-text">
        <tables num="76" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d0/e4/61/624ebd3028b24b/2022546763000077.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000077.jpg" he="253" wi="137" width="548" height="1012" alt="Figure 2022546763000077" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d0/e4/61/624ebd3028b24b/2022546763000077.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d0/e4/61/624ebd3028b24b/2022546763000077.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000077.jpg" he="253" wi="137" width="548" height="1012" alt="Figure 2022546763000077" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d0/e4/61/624ebd3028b24b/2022546763000077.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0478" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、上に開示される組成物のｐＨを水酸化ナトリウム／炭酸ナトリウムにより約６．０～７．０に調節し、生理食塩水（０．９％）を添加することによって容積をなす。<br class="style-scope patent-text">
  以下の保存剤の組合せの１つをさらに含んでもよい。
</span>Additionally, the pH of the composition disclosed above is adjusted to about 6.0-7.0 with sodium hydroxide/sodium carbonate and made up to volume by adding saline (0.9%).<br class="style-scope patent-text"> It may further include one of the following preservative combinations.</span>
      </p>
      <p num="0479" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、<br class="style-scope patent-text">
  ｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベン、または<br class="style-scope patent-text">
  ｉｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン、または<br class="style-scope patent-text">
  ｉｖ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベンおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン。
</span>i. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v),<br class="style-scope patent-text"> ii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v), or iii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and propylparaben in an amount of 0.05-0.2 mg per 0.5 ml (w/v), or iv. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v), methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v) and 0.05-0.5 mg per 0.5 ml. Propylparaben in an amount of 2 mg (w/v).</span>
      </p>
      <p num="0480" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  低減用量ＩＰＶ、Ｄ、Ｔ、ＨｅｐＢ、ＶｉＰｓ－ＴＴ、ＯＳＰコンジュゲート、無細胞性百日咳およびＨｉｂ抗原を含む組合せワクチン組成物は、無毒化（特に遺伝子的または化学的に無毒化した）形態のボルデテラ毒素、特に百日咳トキソイド、糸状ヘマグルチニン、パータクチン、またはフィムブリエから選択される無細胞性百日咳抗原、特に、０．５ｍｌ当たり百日咳トキソイド：１～５０マイクログラム（より詳細には８μｇ）、糸状ヘマグルチニン：１～５０マイクログラム（より詳細には８μｇ）、パータクチン：１～２０マイクログラム（より詳細には２．５μｇ）、任意選択で、フィムブリエ：２～２５マイクログラムを含んでもよい。
</span>
  A combination vaccine composition comprising reduced dose IPV, D, T, HepB, ViPs-TT, OSP conjugates, acellular pertussis and Hib antigens is a detoxified (particularly genetically or chemically detoxified) form of Bordetella. Acellular pertussis antigens selected from toxins, in particular pertussis toxoid, filamentous hemagglutinin, pertactin or fimbriae, in particular pertussis toxoid: 1-50 micrograms (more particularly 8 μg) per 0.5 ml, filamentous hemagglutinin: 1-50 micrograms per 0.5 ml 50 micrograms (more specifically 8 μg), pertactin: 1-20 micrograms (more specifically 2.5 μg), optionally fimbriae: 2-25 micrograms.
</span>
      </p>
      <p num="0481" class="style-scope patent-text">
        <tables num="77" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e1/3a/13/b0579d8ea76975/2022546763000078.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000078.jpg" he="246" wi="129" width="516" height="984" alt="Figure 2022546763000078" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e1/3a/13/b0579d8ea76975/2022546763000078.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e1/3a/13/b0579d8ea76975/2022546763000078.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000078.jpg" he="246" wi="129" width="516" height="984" alt="Figure 2022546763000078" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e1/3a/13/b0579d8ea76975/2022546763000078.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0482" class="style-scope patent-text">
        <tables num="78" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fb/5d/24/909f10f5284173/2022546763000079.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000079.jpg" he="246" wi="132" width="528" height="984" alt="Figure 2022546763000079" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fb/5d/24/909f10f5284173/2022546763000079.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fb/5d/24/909f10f5284173/2022546763000079.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000079.jpg" he="246" wi="132" width="528" height="984" alt="Figure 2022546763000079" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fb/5d/24/909f10f5284173/2022546763000079.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0483" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、上に開示される組成物のｐＨを水酸化ナトリウム／炭酸ナトリウムにより約６．０～７．０に調節し、生理食塩水（０．９％）を添加することによって容積をなす。<br class="style-scope patent-text">
  以下の保存剤の組合せの１つをさらに含んでもよい。
</span>Additionally, the pH of the composition disclosed above is adjusted to about 6.0-7.0 with sodium hydroxide/sodium carbonate and made up to volume by adding saline (0.9%).<br class="style-scope patent-text"> It may further include one of the following preservative combinations.</span>
      </p>
      <p num="0484" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｖ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、<br class="style-scope patent-text">
  ｖｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、および０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベン、または<br class="style-scope patent-text">
ｖｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、および０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン、または<br class="style-scope patent-text">
  ｖｉｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベン、および０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン。
</span>v. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v),<br class="style-scope patent-text"> vi. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v), or vii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and propylparaben in an amount of 0.05-0.2 mg per 0.5 ml (w/v), or viii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v), methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v), and 0.05-0 per 0.5 ml. .Propylparaben in an amount of 2 mg (w/v).</span>
      </p>
      <p num="0485" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  低減用量ＴＴ、ＩＰＶ、ＩＲＶ、Ｄ、Ｔ、ＨｅｐＢ、ＶｉＰｓ－ＴＴ、無細胞性百日咳およびＨｉｂ抗原を含む組合せワクチン組成物は、無毒化（特に遺伝子的または化学的に無毒化した）形態のボルデテラ毒素、特に百日咳トキソイド、糸状ヘマグルチニン、パータクチン、またはフィムブリエから選択される無細胞性百日咳抗原、特に、０．５ｍｌ当たり、百日咳トキソイド：１～５０マイクログラム（より詳細には８μｇ）、糸状ヘマグルチニン：１～５０マイクログラム（より詳細には８μｇ）、パータクチン：１～２０マイクログラム（より詳細には２．５μｇ）、任意選択で、フィムブリエ：２～２５マイクログラムを含んでもよい。
</span>
  A combination vaccine composition comprising reduced dose TT, IPV, IRV, D, T, HepB, ViPs-TT, acellular pertussis and Hib antigens is a detoxified (particularly genetically or chemically detoxified) form of Bordetella. acellular pertussis antigen selected from toxins, in particular pertussis toxoid, filamentous hemagglutinin, pertactin or fimbriae, in particular pertussis toxoid: 1-50 micrograms (more particularly 8 μg) per 0.5 ml, filamentous hemagglutinin: 1 ˜50 micrograms (more particularly 8 μg), pertactin: 1-20 micrograms (more particularly 2.5 μg), optionally fimbriae: 2-25 micrograms.
</span>
      </p>
      <p num="0486" class="style-scope patent-text">
        <tables num="79" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f7/06/99/348e524e915b18/2022546763000080.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000080.jpg" he="246" wi="137" width="548" height="984" alt="Figure 2022546763000080" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f7/06/99/348e524e915b18/2022546763000080.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f7/06/99/348e524e915b18/2022546763000080.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000080.jpg" he="246" wi="137" width="548" height="984" alt="Figure 2022546763000080" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f7/06/99/348e524e915b18/2022546763000080.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0487" class="style-scope patent-text">
        <tables num="80" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d3/06/df/70791aea0a6f59/2022546763000081.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000081.jpg" he="224" wi="142" width="568" height="896" alt="Figure 2022546763000081" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d3/06/df/70791aea0a6f59/2022546763000081.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/d3/06/df/70791aea0a6f59/2022546763000081.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000081.jpg" he="224" wi="142" width="568" height="896" alt="Figure 2022546763000081" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/d3/06/df/70791aea0a6f59/2022546763000081.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0488" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  さらに、上に開示される組成物のｐＨを水酸化ナトリウム／炭酸ナトリウムにより約６．０～７．０に調節し、生理食塩水（０．９％）を添加することによって容積をなす。<br class="style-scope patent-text">
  以下の保存剤の組合せの１つをさらに含んでもよい<br class="style-scope patent-text">
  ｖ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、<br class="style-scope patent-text">
  ｖｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベン、または<br class="style-scope patent-text">
  ｖｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノールおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン、または<br class="style-scope patent-text">
  ｖｉｉｉ．  ０．５ｍｌ当たり１～１０ｍｇ（ｖ／ｖ）の量の２－フェノキシエタノール、０．５ｍｌ当たり０．１～１．５ｍｇ（ｗ／ｖ）の量のメチルパラベンおよび０．５ｍｌ当たり０．０５～０．２ｍｇ（ｗ／ｖ）の量のプロピルパラベン。
</span>Additionally, the pH of the composition disclosed above is adjusted to about 6.0-7.0 with sodium hydroxide/sodium carbonate and made up to volume by adding saline (0.9%).<br class="style-scope patent-text"> may further include one of the following preservative combinations: v. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v),<br class="style-scope patent-text"> vi. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v), or vii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v) and propylparaben in an amount of 0.05-0.2 mg per 0.5 ml (w/v), or viii. 2-phenoxyethanol in an amount of 1-10 mg per 0.5 ml (v/v), methylparaben in an amount of 0.1-1.5 mg per 0.5 ml (w/v) and 0.05-0.5 mg per 0.5 ml. Propylparaben in an amount of 2 mg (w/v).</span>
      </p>
      <p num="0489" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  低減用量ＩＰＶ、ＩＲＶ、Ｄ、Ｔ、ＨｅｐＢ、ＶｉＰｓ－ＴＴ、ＯＳＰ、無細胞性百日咳およびＨｉｂ抗原を含む組合せワクチン組成物は、無毒化（特に遺伝子的または化学的に無毒化した）形態のボルデテラ毒素、特に百日咳トキソイド、糸状ヘマグルチニン、パータクチン、またはフィムブリエから選択される無細胞性百日咳抗原、特に、０．５ｍｌ当たり、百日咳トキソイド：１～５０マイクログラム（より詳細には８μｇ）、糸状ヘマグルチニン：１～５０マイクログラム（より詳細には８μｇ）、パータクチン：１～２０マイクログラム（より詳細には２．５μｇ）、任意選択で、フィムブリエ：２～２５マイクログラムを含んでもよい。
</span>
  A combination vaccine composition comprising reduced dose IPV, IRV, D, T, HepB, ViPs-TT, OSP, acellular pertussis and Hib antigens is a detoxified (particularly genetically or chemically detoxified) form of Bordetella. acellular pertussis antigen selected from toxins, in particular pertussis toxoid, filamentous hemagglutinin, pertactin or fimbriae, in particular pertussis toxoid: 1-50 micrograms (more particularly 8 μg) per 0.5 ml, filamentous hemagglutinin: 1 ˜50 micrograms (more particularly 8 μg), pertactin: 1-20 micrograms (more particularly 2.5 μg), optionally fimbriae: 2-25 micrograms.
</span>
      </p>
      <p num="0490" class="style-scope patent-text">
        <tables num="81" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/71/84/ef257a63a15fee/2022546763000082.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000082.jpg" he="252" wi="141" width="564" height="1008" alt="Figure 2022546763000082" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/71/84/ef257a63a15fee/2022546763000082.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/71/84/ef257a63a15fee/2022546763000082.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000082.jpg" he="252" wi="141" width="564" height="1008" alt="Figure 2022546763000082" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/71/84/ef257a63a15fee/2022546763000082.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0491" class="style-scope patent-text">
        <tables num="82" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7f/83/12/369dbab8180bce/2022546763000083.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000083.jpg" he="255" wi="141" width="564" height="1020" alt="Figure 2022546763000083" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7f/83/12/369dbab8180bce/2022546763000083.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7f/83/12/369dbab8180bce/2022546763000083.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000083.jpg" he="255" wi="141" width="564" height="1020" alt="Figure 2022546763000083" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7f/83/12/369dbab8180bce/2022546763000083.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0492" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例５：安定性データ<br class="style-scope patent-text">
  ２～８℃で初期（０）、３、６ヶ月、２５℃で初期（０）、１、３ヶ月および４０℃で初期（０）、１４、２８日間の一価Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉコンジュゲートの安定性：
</span>Example 5: Stability data 2-8°C initial (0), 3, 6 months, 25°C initial (0), 1, 3 months and 40°C initial (0), 14, 28 days monovalent Stability of Salmonella typhi conjugates:</span>
      </p>
      <p num="0493" class="style-scope patent-text">
        <tables num="83" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b7/8b/09/e136ae3bfab488/2022546763000084.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000084.jpg" he="247" wi="119" width="476" height="988" alt="Figure 2022546763000084" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b7/8b/09/e136ae3bfab488/2022546763000084.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b7/8b/09/e136ae3bfab488/2022546763000084.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000084.jpg" he="247" wi="119" width="476" height="988" alt="Figure 2022546763000084" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b7/8b/09/e136ae3bfab488/2022546763000084.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0494" class="style-scope patent-text">
        <tables num="84" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/85/8c/71/618e473edcace7/2022546763000085.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000085.jpg" he="243" wi="103" width="412" height="972" alt="Figure 2022546763000085" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/85/8c/71/618e473edcace7/2022546763000085.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/85/8c/71/618e473edcace7/2022546763000085.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000085.jpg" he="243" wi="103" width="412" height="972" alt="Figure 2022546763000085" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/85/8c/71/618e473edcace7/2022546763000085.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0495" class="style-scope patent-text">
        <tables num="85" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fa/0f/e5/721d7c95f96444/2022546763000086.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000086.jpg" he="242" wi="103" width="412" height="968" alt="Figure 2022546763000086" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fa/0f/e5/721d7c95f96444/2022546763000086.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/fa/0f/e5/721d7c95f96444/2022546763000086.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000086.jpg" he="242" wi="103" width="412" height="968" alt="Figure 2022546763000086" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/fa/0f/e5/721d7c95f96444/2022546763000086.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0496" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：<br class="style-scope patent-text">
  遊離Ｐｓ（４０℃／２～８℃／２５℃において、１８０～２２０ｋＤａ  Ｐｓについて「初期＜４．５％、６ヶ月後７．５％以下」対「３８８／８０／４５ｋＤａについて初期５．４％  ６ヶ月後１０．５％以上」）。
</span>observation:<br class="style-scope patent-text"> Free Ps (at 40°C/2-8°C/25°C for 180-220 kDa Ps "initial &lt;4.5%, ≤ 7.5% after 6 months" vs. "initial 5.4% for 388/80/45 kDa 10.5% or more after 6 months”).</span>
      </p>
      <p num="0497" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  １８０～２２０ｋＤａについて、初期の低い遊離Ｐｓ、コンジュゲートのサイズはまた、安定性研究にわたって維持され、６ヶ月後の遊離Ｐｓは、他のサイズと比較してほとんど観察されなかった。<br class="style-scope patent-text">
ＳＥ－ＨＰＬＣ安定性データ<br class="style-scope patent-text">
（トリス、トリス－ＮａＣｌおよび０．１７Ｍ  ＮａＣｌ中のＶＩ－ＴＴコンジュゲート）
</span>For 180-220 kDa, the initial low free Ps, size of the conjugates was also maintained over the stability study, and little free Ps was observed after 6 months compared to other sizes.<br class="style-scope patent-text"> SE-HPLC stability data (VI-TT conjugates in Tris, Tris-NaCl and 0.17M NaCl)</span>
      </p>
      <p num="0498" class="style-scope patent-text">
        <tables num="86" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/c6/21/0524907383780c/2022546763000087.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000087.jpg" he="240" wi="96" width="384" height="960" alt="Figure 2022546763000087" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/c6/21/0524907383780c/2022546763000087.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/45/c6/21/0524907383780c/2022546763000087.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000087.jpg" he="240" wi="96" width="384" height="960" alt="Figure 2022546763000087" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/45/c6/21/0524907383780c/2022546763000087.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0499" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：<br class="style-scope patent-text">
  Ｖｉ－ＴＴコンジュゲートは、１０ｍＭトリス緩衝液中、０．１７Ｍ  ＮａＣｌを含有する１０ｍＭトリス中、および０．１７Ｍ  ＮａＣｌ単独中で安定であることが見出された。
</span>Conclusion:<br class="style-scope patent-text"> The Vi-TT conjugate was found to be stable in 10 mM Tris buffer, 10 mM Tris containing 0.17 M NaCl, and 0.17 M NaCl alone.</span>
      </p>
      <p num="0500" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  異なる濃度のトリス（５ｍＭ、１０ｍＭ、２０ｍＭ、２５ｍＭ、３０ｍＭ、５０ｍＭ）についてのデータは、２５ｍＭトリスが最良であることを示している。<br class="style-scope patent-text">
  ・  Ｖｉ－ＴＴ  ＣＪ濃度は、５ｍＭ、１０ｍＭおよび２０ｍＭの３つの異なる強度のトリス、ｐＨ７．２で維持した。これは、－２０℃、２～８℃、室温および３７℃などの様々な温度条件で維持した。
</span>Data for different concentrations of Tris (5 mM, 10 mM, 20 mM, 25 mM, 30 mM, 50 mM) show that 25 mM Tris is the best.<br class="style-scope patent-text"> • Vi-TT CJ concentrations were maintained at three different strengths of Tris, pH 7.2: 5 mM, 10 mM and 20 mM. This was maintained at various temperature conditions such as -20°C, 2-8°C, room temperature and 37°C.</span>
      </p>
      <p num="0501" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ・  研究は２週間実施し、ｐＨを毎日モニタリングした。<br class="style-scope patent-text">
  ・  試料を、粒径およびゼータ電位について確認した。<br class="style-scope patent-text">
  ｐＨ結果
</span>• The study was conducted for 2 weeks and pH was monitored daily.<br class="style-scope patent-text"> • Samples were checked for particle size and zeta potential.<br class="style-scope patent-text"> pH result</span>
      </p>
      <p num="0502" class="style-scope patent-text">
        <tables num="87" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/29/9a/08/e7c2e3acee22fa/2022546763000088.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000088.jpg" he="240" wi="45" width="180" height="960" alt="Figure 2022546763000088" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/29/9a/08/e7c2e3acee22fa/2022546763000088.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/29/9a/08/e7c2e3acee22fa/2022546763000088.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000088.jpg" he="240" wi="45" width="180" height="960" alt="Figure 2022546763000088" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/29/9a/08/e7c2e3acee22fa/2022546763000088.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0503" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：<br class="style-scope patent-text">
  ・  Ｖｉ－ＴＴ  ＣＪ研究において、コンジュゲートを５、１０および２０ｍＭトリスｐＨ７．２中で維持し、ｐＨは、５、１０および２０ｍＭ濃度中２～８℃において範囲内であった。<br class="style-scope patent-text">
Ｖｉ－ＴＴコンジュゲートの粘度および浸透圧測定<br class="style-scope patent-text">
  パートＡ：コンジュゲートを含まないトリス緩衝液および塩化ナトリウムの粘度および浸透圧結果
</span>Conclusion:<br class="style-scope patent-text"> • In the Vi-TT CJ studies, the conjugates were maintained in 5, 10 and 20 mM Tris pH 7.2 and the pH was in the range at 2-8°C in 5, 10 and 20 mM concentrations.<br class="style-scope patent-text"> Viscosity and Osmolality Measurements of Vi-TT Conjugates Part A: Viscosity and Osmolality Results of Tris Buffer and Sodium Chloride without Conjugates</span>
      </p>
      <p num="0504" class="style-scope patent-text">
        <tables num="88" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/82/c0/51/c33427367a8150/2022546763000089.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000089.jpg" he="103" wi="168" width="672" height="412" alt="Figure 2022546763000089" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/82/c0/51/c33427367a8150/2022546763000089.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/82/c0/51/c33427367a8150/2022546763000089.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000089.jpg" he="103" wi="168" width="672" height="412" alt="Figure 2022546763000089" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/82/c0/51/c33427367a8150/2022546763000089.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0505" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  パートＢ：コンジュゲートを含むトリス緩衝液および塩化ナトリウムの粘度および浸透圧結果
</span>
  Part B: Viscosity and Osmolality Results for Tris Buffer and Sodium Chloride with Conjugates
</span>
      </p>
      <p num="0506" class="style-scope patent-text">
        <tables num="89" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/89/28/08/e9c44b99363b80/2022546763000090.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000090.jpg" he="121" wi="168" width="672" height="484" alt="Figure 2022546763000090" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/89/28/08/e9c44b99363b80/2022546763000090.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/89/28/08/e9c44b99363b80/2022546763000090.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000090.jpg" he="121" wi="168" width="672" height="484" alt="Figure 2022546763000090" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/89/28/08/e9c44b99363b80/2022546763000090.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0507" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：<br class="style-scope patent-text">
  様々なトリス濃度のコンジュゲートは等張であることが見出され、１５０ｍＭ  ＮａＣｌを含むコンジュゲートは等張であることが見出された。
</span>Conclusion:<br class="style-scope patent-text"> Conjugates with varying Tris concentrations were found to be isotonic, and conjugates with 150 mM NaCl were found to be isotonic.</span>
      </p>
      <p num="0508" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  異なるトリス緩衝液およびＮａＣｌ濃度のコンジュゲートで、粘度は同様であることが見出され、粘度は、非経口製剤としての使用に好適である。<br class="style-scope patent-text">
  実施例６：免疫原性データ<br class="style-scope patent-text">
  Ａ．  一価コンジュゲートワクチンの免疫原性研究：<br class="style-scope patent-text">
  ＳＩＩＰ  Ｖｉ  ＴＴワクチンの免疫原性の可能性を、マウスモデルで評価した。<br class="style-scope patent-text">
マウス免疫原性研究＃１：<br class="style-scope patent-text">
  免疫原性研究をマウスで行い、非コンジュゲートおよびＴＴ－コンジュゲートＳＩＩＰＬワクチン（Ｖｉ  ＴＴ）をマウスに筋肉内投与した（１群当たり８匹の動物）。１日目および１４日目に動物に接種し、１４日目（データ示さず）および２１日日に血清試料を収集した。詳細については表８６を参照してほしい。対合血清試料が、各群のすべての動物から利用可能であった。研究室内ＩｇＧ  ＥＬＩＳＡなどの好適な血清学的免疫学的方法を使用して、注射した多糖体に対する抗体の決定のために血清試料を使用した。非コンジュゲートＳＩＩＰＬ多糖体（Ｖｉ  ＰＳ）を受容したマウス由来の血清を、（様々なＰＳサイズの）Ｖｉ  ＰＳのコンジュゲートバージョンを受容したマウス由来の血清におけるＩｇＧ応答の誘導についての比較対照として使用した。<br class="style-scope patent-text">
マウス免疫原性研究＃２：<br class="style-scope patent-text">
  別の同様の研究をマウスにおいて実施した。いずれの研究でも、同様の動物処置プロトコルを用いた。動物プロトコルを以下に簡潔に記載する。両方の研究由来の血清を、同一の免疫学／血清学分析アッセイ、すなわち、ＩｇＧ  ＥＬＩＳＡによって試験した。５～６週齢の雌性マウス（Ｂａｌｂ  Ｃ株；研究室内飼育）を、ＩＡＥＣ認証された動物研究プロトコルを使用する研究において使用した。すべての動物は、特別な病原を含まず、接種および血液試料収集の間、バイオセーフティキャビネット中、無菌条件下で取り扱った。マウスは、研究の開始時、約１８～２０ｇの重量であった。各マウスは、筋肉内経路を介して２．５μｇのコンジュゲートＶｉ  ＴＴワクチンを受容した。ＳＩＩＰＬ  Ｖｉ  ＴＴワクチンを、ビヒクルとしてリン酸緩衝食塩水（ＰＢＳ）で希釈した。いずれの処置群についても、研究においてアジュバントは使用しなかった。
</span>The viscosities were found to be similar for conjugates with different Tris buffers and NaCl concentrations, and the viscosities are suitable for use as a parenteral formulation.<br class="style-scope patent-text"> Example 6: Immunogenicity DataA. Immunogenicity studies of monovalent conjugate vaccines:<br class="style-scope patent-text"> The immunogenic potential of the SIIP Vi TT vaccine was evaluated in a mouse model.<br class="style-scope patent-text"> Mouse immunogenicity study #1:<br class="style-scope patent-text"> Immunogenicity studies were performed in mice where unconjugated and TT-conjugated SIIPL vaccine (Vi TT) were administered intramuscularly to mice (8 animals per group). Animals were inoculated on days 1 and 14 and serum samples were collected on days 14 (data not shown) and 21 days. See Table 86 for details. Paired serum samples were available from all animals in each group. Serum samples were used for determination of antibodies to the injected polysaccharide using suitable serological immunological methods such as in-house IgG ELISA. Sera from mice receiving unconjugated SIIPL polysaccharide (Vi PS) were used as controls for the induction of IgG responses in sera from mice receiving conjugated versions of Vi PS (of varying PS sizes). did.<br class="style-scope patent-text"> Mouse immunogenicity study #2:<br class="style-scope patent-text"> Another similar study was performed in mice. Both studies used similar animal treatment protocols. The animal protocol is briefly described below. Sera from both studies were tested by the same immunological/serological analytical assay, namely IgG ELISA. Female mice (Balb C strain; laboratory-reared) aged 5-6 weeks were used in studies using IAEC-approved animal research protocols. All animals were free of specific pathogens and were handled under sterile conditions in a biosafety cabinet during inoculation and blood sample collection. Mice weighed approximately 18-20 g at the start of the study. Each mouse received 2.5 μg of conjugated Vi TT vaccine via the intramuscular route. The SIIPL Vi TT vaccine was diluted with phosphate-buffered saline (PBS) as vehicle. No adjuvant was used in the study for any treatment group.</span>
      </p>
      <p num="0509" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  処置概要：研究についての全体的な処置計画を以下の表にまとめる。
</span>
  Treatment Summary: The overall treatment plan for the study is summarized in the table below.
</span>
      </p>
      <p num="0510" class="style-scope patent-text">
        <tables num="90" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/4e/67/bbd825c5d386da/2022546763000091.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000091.jpg" he="187" wi="166" width="664" height="748" alt="Figure 2022546763000091" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/4e/67/bbd825c5d386da/2022546763000091.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0e/4e/67/bbd825c5d386da/2022546763000091.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000091.jpg" he="187" wi="166" width="664" height="748" alt="Figure 2022546763000091" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0e/4e/67/bbd825c5d386da/2022546763000091.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0511" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  血清学分析に使用した方法論および技術：<br class="style-scope patent-text">
  血液試料を、滅菌ガラスキャピラリーチューブを使用して、実験動物の後眼窩静脈から収集した。血液収集手順の間、イソフルランを安全な麻酔薬として使用した。血清を、研究室内ＩｇＧ  ＥＬＩＳＡを使用し、非コンジュゲートまたはコンジュゲートＶｉ  ＴＴワクチンの注射に応答して産生されたＩｇＧ抗体の分析に供した。ＥＬＩＳＡは、コーティング抗原としてＮＩＢＳＣ  Ｖｉ  ＰＳ参照標準（カタログ番号１６／１２６；Ｓ．ＴｙｐｈｉのＶｉ  ＰＳについての第１国際標準）を使用した。ＩｇＧレベルを、非コンジュゲートＳＩＩＰＬ多糖体（Ｖｉ  ＰＳ）を受容したマウス由来の血清試料で観察された光学密度（ＯＤ）と比較して、Ｖｉ  ＰＳ（様々なＰＳサイズのＶｉ  ＴＴ）のコンジュゲートを受容したマウス由来の血清中で観察されたＯＤを分析することによって推定した。
</span>Methodologies and techniques used for serological analysis:<br class="style-scope patent-text"> Blood samples were collected from the retro-orbital vein of experimental animals using sterile glass capillary tubes. Isoflurane was used as a safe anesthetic during the blood collection procedure. Sera were subjected to analysis of IgG antibodies produced in response to injection of unconjugated or conjugated Vi TT vaccine using an in-house IgG ELISA. The ELISA used the NIBSC Vi PS reference standard (catalog number 16/126; First International Standard for Vi PS of S. Typhi) as the coating antigen. Comparing IgG levels to the optical density (OD) observed in serum samples from mice that received unconjugated SIIPL polysaccharide (Vi PS), conjugates of Vi PS (Vi TT of various PS sizes) was estimated by analyzing the OD observed in sera from mice that received .</span>
      </p>
      <p num="0512" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下の表は、異なるＶｉ  ＴＴ  ＰＳからの免疫原性誘導データ（２１日目）を示している。<br class="style-scope patent-text">
  表８７、８８、８９および９０：免疫原性結果
</span>The table below shows immunogenicity induction data (day 21) from different Vi TT PS.<br class="style-scope patent-text"> Tables 87, 88, 89 and 90: Immunogenicity Results</span>
      </p>
      <p num="0513" class="style-scope patent-text">
        <tables num="91" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/02/c2/93/d45693b130385b/2022546763000092.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000092.jpg" he="104" wi="167" width="668" height="416" alt="Figure 2022546763000092" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/02/c2/93/d45693b130385b/2022546763000092.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/02/c2/93/d45693b130385b/2022546763000092.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000092.jpg" he="104" wi="167" width="668" height="416" alt="Figure 2022546763000092" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/02/c2/93/d45693b130385b/2022546763000092.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0514" class="style-scope patent-text">
        <tables num="92" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a6/85/06/74ca4f18a42334/2022546763000093.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000093.jpg" he="105" wi="168" width="672" height="420" alt="Figure 2022546763000093" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a6/85/06/74ca4f18a42334/2022546763000093.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a6/85/06/74ca4f18a42334/2022546763000093.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000093.jpg" he="105" wi="168" width="672" height="420" alt="Figure 2022546763000093" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a6/85/06/74ca4f18a42334/2022546763000093.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0515" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：<br class="style-scope patent-text">
  したがって、ＩｇＧの＞４倍高い誘導（非コンジュゲートＶｉ  ＰＳを投与されたマウスと比較して）を示すＶｉ  ＴＴを有するマウス群は、すべてのＰＳサイズにわたって、ＳＩＩＰＬ  ＶＩ  ＴＴの免疫原性の可能性を強く示している。２つの別々の研究を、Ｖｉ  ＴＴで実施し、これらの研究の両方は、Ｖｉ  ＰＳに対してＶｉ  ＴＴへの同様の応答を示した。
</span>observation:<br class="style-scope patent-text"> Thus, a group of mice with Vi TT showing &gt;4-fold higher induction of IgG (compared to mice receiving unconjugated Vi PS), across all PS sizes, is likely to be immunogenic for SIIPL VI TT. strongly indicates sexuality. Two separate studies were performed with Vi TT and both of these studies showed similar responses to Vi TT versus Vi PS.</span>
      </p>
      <p num="0516" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下のパラメーターを、様々な群にわたって比較した。<br class="style-scope patent-text">
  ａ．  ＞４倍上昇：平均倍数上昇は＞６０倍であった。<br class="style-scope patent-text">
  ｂ．  抗体価のＧＭ：すべての群は、非コンジュゲートＰＳで観察されたよりもたかいＧＭを示した（＞１．９）。
</span>The following parameters were compared across the various groups.<br class="style-scope patent-text"> a. &gt;4-fold increase: The average fold increase was &gt;60-fold.<br class="style-scope patent-text"> b. GM of antibody titers: All groups showed higher GM than observed with unconjugated PS (&gt;1.9).</span>
      </p>
      <p num="0517" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｃ．  陽性応答を有するマウスの％：すべてのＶｉ  ＴＴ群のすべてのマウスは、より高い抗体応答を示した（１００％陽性）。<br class="style-scope patent-text">
  血清学的データの分析からの結論：<br class="style-scope patent-text">
  マウスにおける免疫原性研究を、各群８匹の（雌性）マウスで実施した。すべての群において、非コンジュゲートＶｉ  ＰＳに対して注射したＶｉ  ＴＴ（様々なＰＳサイズ）への応答における抗体誘導を評価した。すべてのＶｉ  ＴＴ  ＰＳ形態は、Ｖｉ  ＰＳ単独群と比較して、Ｖｉ  ＴＴ特異的ＩｇＧ抗体の誘導を強く示した（２１日目；第１のブースター後）。マウス血清におけるＩｇＧの誘導は、Ｖｉ  ＴＴへの血清学的応答の強い決定因子である。したがって、一価Ｖｉ  ＴＴは、マウスモデルにおいて強い免疫原性応答を誘導することができ、高等動物における将来の研究への有望な可能性を提供する。
</span>c. % of mice with positive responses: All mice in all Vi TT groups showed higher antibody responses (100% positive).<br class="style-scope patent-text"> Conclusions from analysis of serological data:<br class="style-scope patent-text"> Immunogenicity studies in mice were performed with 8 (female) mice in each group. Antibody induction in response to Vi TT (various PS sizes) injected against unconjugated Vi PS was assessed in all groups. All Vi TT PS forms showed strong induction of Vi TT-specific IgG antibodies compared to the Vi PS alone group (day 21; after the first booster). Induction of IgG in mouse serum is a strong determinant of serological response to Vi TT. Thus, monovalent Vi TT can induce strong immunogenic responses in mouse models, offering promising possibilities for future studies in higher animals.</span>
      </p>
      <p num="0518" class="style-scope patent-text">
        <tables num="93" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e6/8d/ef/09faa09205867e/2022546763000094.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000094.jpg" he="242" wi="102" width="408" height="968" alt="Figure 2022546763000094" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e6/8d/ef/09faa09205867e/2022546763000094.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e6/8d/ef/09faa09205867e/2022546763000094.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000094.jpg" he="242" wi="102" width="408" height="968" alt="Figure 2022546763000094" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e6/8d/ef/09faa09205867e/2022546763000094.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0519" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：<br class="style-scope patent-text">
  １．  免疫原性データを、マウスモデルにおいてＳＩＩＰＬ  Ｖｉ  ＴＴコンジュゲートに応答して観察されたＩｇＧ抗体レベルに関して評価する。
</span>observation:<br class="style-scope patent-text"> 1. Immunogenicity data are evaluated in terms of observed IgG antibody levels in response to SIIPL Vi TT conjugates in the mouse model.</span>
      </p>
      <p num="0520" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  ＩｇＧ誘導は、ＩｇＧ  ＥＬＩＳＡにおいて観察された比色分析応答（ＯＤ）のＧｅｏｍｅｔｒｉｃ  Ｍｅａｎ（幾何平均）として測定する。<br class="style-scope patent-text">
  ３．  ＳＩＩＰＬ  Ｖｉ  ＴＴに応答して観察されたＧＭは、ＶＩ  ＴＴ処置におけるＯＤの倍数上昇が、非コンジュゲートＶｉ  ＰＳに応答して観察されたＯＤよりも４倍高い場合、免疫原性であると考える。
</span>2. IgG induction is measured as the Geometric Mean of the colorimetric responses (OD) observed in the IgG ELISA.<br class="style-scope patent-text"> 3. GMs observed in response to SIIPL Vi TT are considered immunogenic if the fold increase in OD upon VI TT treatment is 4-fold higher than the OD observed in response to unconjugated Vi PS .</span>
      </p>
      <p num="0521" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：<br class="style-scope patent-text">
  １．  すべての一価Ｖｉ－ＴＴコンジュゲートは、血清学アッセイを介して観察された免疫原性応答を誘導することが見出された。
</span>Conclusion:<br class="style-scope patent-text"> 1. All monovalent Vi-TT conjugates were found to induce immunogenic responses observed via serological assays.</span>
      </p>
      <p num="0522" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  すべての一価Ｖｉ－ＴＴコンジュゲートは、Ｔｙｐｂａｒ  ＴＣＶワクチン群において観察されたよりも高いＩｇＧレベルを示した。<br class="style-scope patent-text">
  ３．  免疫原性応答の誘導（ＧＭおよび＞４倍上昇）は、以下の順序で観察された：Ｇ７  ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ（ＰＳサイズ２１４）＞Ｇ７  ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ（ＰＳサイズ３８８）＞Ｔｙｐｂａｒ  ＴＣＶ（市販ワクチン）<br class="style-scope patent-text">
  Ｂ．  二価コンジュゲートワクチンの免疫原性研究<br class="style-scope patent-text">
  二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンの免疫原性の可能性を、マウスモデルにおいて評価した。<br class="style-scope patent-text">
マウス免疫原性研究＃１：<br class="style-scope patent-text">
  免疫原性研究をマウスにおいて行い、ＴＴ、ＤＴおよびＣＲＭなどの担体タンパク質にコンジュゲートした、一価Ｖｉ  ＴＴワクチンおよび一価Ｏ－ＳＰ  Ａ（Ｓ．Ｐａｒａｔｙｐｈｉ  ＡのＯ特異的多糖体抗原）の組合せを含有する二価ワクチンを研究において用いた。これらのワクチンの一価および二価バージョンを、マウスに筋肉内投与した（１群当たり８匹の動物）。１、１４および２８日目に動物に接種した一方、１４、２８および４２日目に血清試料を収集した。対合血清試料が、各群のすべての動物から利用可能であった。処置計画に関する詳細は、以下の表９２を参照してほしい。研究室内ＩｇＧ  ＥＬＩＳＡなどの好適な血清学的免疫学的方法を使用して、注射した多糖体に対する抗体の決定のために血清試料を使用した。それぞれの非コンジュゲートＳＩＩＰＬ  多糖体（Ｖｉ  ＰＳ）およびＯ－ＳＰ単独を受容したマウス由来の血清を、ＩｇＧ応答の誘導についての比較対照として使用した。
</span>2. All monovalent Vi-TT conjugates showed higher IgG levels than observed in the Typbar TCV vaccine group.<br class="style-scope patent-text"> 3. Induction of immunogenic responses (GM and &gt;4-fold elevation) was observed in the following order: G7 SIIPL Vi PS-TT (PS size 214) &gt; G7 SIIPL Vi PS-TT (PS size 388) &gt; Typbar TCV. (commercially available vaccine)<br class="style-scope patent-text"> B. Immunogenicity Studies of Bivalent Conjugate Vaccines The immunogenic potential of bivalent (typhoid and paratyphoid) SIIPL vaccines was evaluated in a mouse model.<br class="style-scope patent-text"> Mouse immunogenicity study #1:<br class="style-scope patent-text"> Immunogenicity studies were performed in mice to combine monovalent Vi TT vaccine and monovalent O-SP A (O-specific polysaccharide antigen of S. Paratyphi A) conjugated to carrier proteins such as TT, DT and CRM. A bivalent vaccine containing was used in the study. Monovalent and bivalent versions of these vaccines were administered intramuscularly to mice (8 animals per group). Animals were inoculated on days 1, 14 and 28, while serum samples were collected on days 14, 28 and 42. Paired serum samples were available from all animals in each group. See Table 92 below for details regarding treatment regimens. Serum samples were used for determination of antibodies to the injected polysaccharide using suitable serological immunological methods such as in-house IgG ELISA. Sera from mice receiving the respective unconjugated SIIPL polysaccharide (Vi PS) and O-SP alone were used as controls for induction of IgG responses.</span>
      </p>
      <p num="0523" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  動物プロトコルを以下の表に簡潔に記載する。<br class="style-scope patent-text">
  血清試料を、免疫学／血清学分析アッセイ、すなわち、ＩｇＧ  ＥＬＩＳＡによって試験した。５～６週齢の雌性マウス（Ｂａｌｂ  Ｃ株；研究室内飼育）を、ＩＡＥＣ認証された動物研究プロトコルを使用する研究において使用した。すべての動物は、特別な病原を含まず、接種および血液試料収集の間、バイオセーフティキャビネット中、無菌条件下で取り扱った。約１８～２０ｇの範囲の重量のマウスを研究に使用した。各マウスは、２．５μｇの一価コンジュゲートＶｉ  ＴＴ単独またはＯ－ＳＰ  Ａ  ＤＴ／ＴＴ／ＣＲＭ単独および２．５μｇの各二価ワクチン（Ｏ－ＳＰ  Ａ  ＤＴ／ＴＴ／ＣＲＭと混合した一価コンジュゲートＶｉ  ＴＴ）を筋肉内経路を介して受容した。ワクチンを、ビヒクルとしてリン酸緩衝食塩水（ＰＢＳ）で希釈した。いずれの処置群についても、研究においてアジュバントは使用しなかった。
</span>The animal protocol is briefly described in the table below.<br class="style-scope patent-text"> Serum samples were tested by an immunological/serological assay, ie IgG ELISA. Female mice (Balb C strain; laboratory-reared) aged 5-6 weeks were used in studies using IAEC-approved animal research protocols. All animals were free of specific pathogens and were handled under sterile conditions in a biosafety cabinet during inoculation and blood sample collection. Mice weighing in the range of approximately 18-20 g were used in the study. Each mouse received 2.5 μg of monovalent conjugated Vi TT alone or O-SP A DT/TT/CRM alone and 2.5 μg of each bivalent vaccine (monovalent mixed with O-SP A DT/TT/CRM). Conjugate Vi TT) was received via the intramuscular route. Vaccines were diluted with phosphate-buffered saline (PBS) as vehicle. No adjuvant was used in the study for any treatment group.</span>
      </p>
      <p num="0524" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  処置概要：研究についての全体的な処置計画を以下の表にまとめる。
</span>
  Treatment Summary: The overall treatment plan for the study is summarized in the table below.
</span>
      </p>
      <p num="0525" class="style-scope patent-text">
        <tables num="94" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b4/0d/1a/a4b27535e9c7d8/2022546763000095.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000095.jpg" he="180" wi="166" width="664" height="720" alt="Figure 2022546763000095" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b4/0d/1a/a4b27535e9c7d8/2022546763000095.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b4/0d/1a/a4b27535e9c7d8/2022546763000095.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000095.jpg" he="180" wi="166" width="664" height="720" alt="Figure 2022546763000095" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b4/0d/1a/a4b27535e9c7d8/2022546763000095.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0526" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  血清学分析に使用した方法論および技術：<br class="style-scope patent-text">
  血液試料を、滅菌ガラスキャピラリーチューブを使用して、実験動物の後眼窩静脈から収集した。血液収集手順の間、イソフルランを安全な麻酔薬として使用した。血清を、研究室内ＩｇＧ  ＥＬＩＳＡを使用し、抗原の注射に応答して産生されたＩｇＧ抗体の分析に供した。ＩｇＧレベルを、比色分析によって、すべての研究群由来の血清試料において推定した。<br class="style-scope patent-text">
観察：<br class="style-scope patent-text">
  以下の表は、異なる二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンからの免疫原性誘導データ（２１日目）を示している。
</span>Methodologies and techniques used for serological analysis:<br class="style-scope patent-text"> Blood samples were collected from the retro-orbital vein of experimental animals using sterile glass capillary tubes. Isoflurane was used as a safe anesthetic during the blood collection procedure. Sera were subjected to analysis of IgG antibodies produced in response to antigen injection using an in-house IgG ELISA. IgG levels were estimated in serum samples from all study groups by colorimetric analysis.<br class="style-scope patent-text"> observation:<br class="style-scope patent-text"> The table below shows immunogenicity induction data (Day 21) from different bivalent (typhoid and paratyphoid) SIIPL vaccines.</span>
      </p>
      <p num="0527" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  表９３、９４、９５、９６：免疫原性結果
</span>
  Tables 93, 94, 95, 96: Immunogenicity Results
</span>
      </p>
      <p num="0528" class="style-scope patent-text">
        <tables num="95" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ba/fc/1f/c478b023035ee1/2022546763000096.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000096.jpg" he="74" wi="168" width="672" height="296" alt="Figure 2022546763000096" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ba/fc/1f/c478b023035ee1/2022546763000096.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ba/fc/1f/c478b023035ee1/2022546763000096.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000096.jpg" he="74" wi="168" width="672" height="296" alt="Figure 2022546763000096" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ba/fc/1f/c478b023035ee1/2022546763000096.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0529" class="style-scope patent-text">
        <tables num="96" class="style-scope patent-text">
          <span class="notranslate style-scope patent-text">
            <span class="google-src-text style-scope patent-text">
              </span></span></tables></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ee/41/21/5a51dc9559c3c0/2022546763000097.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000097.jpg" he="75" wi="168" width="672" height="300" alt="Figure 2022546763000097" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ee/41/21/5a51dc9559c3c0/2022546763000097.png"></a></div>
            
            <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ee/41/21/5a51dc9559c3c0/2022546763000097.png" class="style-scope patent-text"><img img-content="drawing" img-format="jpg" file="2022546763000097.jpg" he="75" wi="168" width="672" height="300" alt="Figure 2022546763000097" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ee/41/21/5a51dc9559c3c0/2022546763000097.png"></a></div>
          
        
      <p class="style-scope patent-text"></p>
      <p num="0530" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：<br class="style-scope patent-text">
  ａ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＤＴ、ｂ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＴＴ、およびｃ）ＳＩＩＰＬ  Ｖｉ  ＰＳ－ＴＴ＋ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＣＲＭ  Ｖｉ  ＴＴなどの二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンを注射されたマウス群は、（非コンジュゲートＶｉ  ＰＳまたは非コンジュゲートＳＩＩＰＬ  Ｏ－ＳＰ  Ａを投与されたマウスと比較して）＞４倍高いＩｇＧの誘導を示したため、Ｖｉ  ＴＴおよびＳＩＩＰＬ  Ｏ－ＳＰ  Ａ（ＤＴ／ＴＴ／ＣＲＭ）の組合せを含有する二価ＳＩＩＰＬワクチンの免疫原性の可能性を示している。
</span>observation:<br class="style-scope patent-text"> Bivalent (typhus and paratyphoid) such as a) SIIPL Vi PS-TT + SIIPL O-SP A DT, b) SIIPL Vi PS-TT + SIIPL O-SP A TT, and c) SIIPL Vi PS-TT + SIIPL O-SP A CRM Vi TT Vi TT and SIIPL, as mice groups injected with SIIPL vaccine showed &gt;4-fold higher induction of IgG (compared to mice receiving unconjugated Vi PS or unconjugated SIIPL O-SP A). Figure 2 shows the immunogenic potential of a bivalent SIIPL vaccine containing a combination of O-SP A (DT/TT/CRM).</span>
      </p>
      <p num="0531" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンによるＩｇＧ誘導は、ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＣＲＭおよび市販Ｖｉ  ＴＴワクチンであるＴｙｐｂａｒ  ＴＣＶを含有する二価ワクチンで観察されたＩｇＧ誘導よりも高かった。
</span>
  IgG induction by the bivalent (typhus and paratyphoid) SIIPL vaccine was higher than that observed with bivalent vaccines containing SIIPL O-SPA CRM and the commercial Vi TT vaccine, Typbar TCV.
</span>
      </p>
      <p num="0532" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  以下のパラメーターを、様々な群にわたって比較した。<br class="style-scope patent-text">
  ａ．  ＞４倍上昇：平均倍数上昇は＞１０倍であった。<br class="style-scope patent-text">
  ｂ．  抗体価のＧＭ：すべての群は、非コンジュゲートＰＳで観察されたよりも高いＧＭを示した。
</span>The following parameters were compared across the various groups.<br class="style-scope patent-text"> a. &gt;4-fold rise: The average fold rise was &gt;10-fold.<br class="style-scope patent-text"> b. GM of antibody titers: All groups showed higher GM than observed with unconjugated PS.</span>
      </p>
      <p num="0533" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｃ．  陽性応答を有するマウスの％：すべてのＶｉ  ＴＴ群のすべてのマウスは、より高い抗体応答を示した（１００％陽性）。<br class="style-scope patent-text">
  血清学的データの分析からの結論：<br class="style-scope patent-text">
  マウスにおいて免疫原性研究を、各群８匹の（雌性）マウスで実施した。すべての群において、非コンジュゲートＶｉ  ＰＳおよびＯ－ＳＰ  Ａ  ＰＳに対して注射した二価Ｖｉ（チフスおよびパラチフス）ＳＩＩＰＬワクチンへの応答における抗体誘導を評価した。すべての二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンは、ＰＳ単独（ＶｉおよびＯ－ＳＰ  Ａ）群と比較して、ＰＳ特異的ＩｇＧ抗体の誘導を強く示した（２１日目；第１のブースター後）。マウス血清におけるＩｇＧの誘導は、二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンへの血清応答の強い決定因子である。したがって、二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンは、マウスモデルにおいて強い免疫原性応答を誘導することができ、高等動物における将来の研究への有望な可能性を提供する。
</span>c. % of mice with positive responses: All mice in all Vi TT groups showed higher antibody responses (100% positive).<br class="style-scope patent-text"> Conclusions from analysis of serological data:<br class="style-scope patent-text"> Immunogenicity studies in mice were performed with 8 (female) mice in each group. Antibody induction in response to bivalent Vi (typhoid and paratyphoid) SIIPL vaccines injected against unconjugated Vi PS and O-SP A PS was assessed in all groups. All bivalent (typhoid and paratyphoid) SIIPL vaccines showed strong induction of PS-specific IgG antibodies compared to the PS alone (Vi and O-SPA) groups (day 21; after the first booster ). Induction of IgG in mouse sera is a strong determinant of serum response to bivalent (typhoid and paratyphoid) SIIPL vaccines. Thus, bivalent (typhoid and paratyphoid) SIIPL vaccines can induce strong immunogenic responses in mouse models, offering promising potential for future studies in higher animals.</span>
      </p>
      <p num="0534" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  観察：<br class="style-scope patent-text">
  １．  免疫原性データを、マウスモデルにおいて、二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンに応答して観察されたＩｇＧ抗体レベルに関して評価する。
</span>observation:<br class="style-scope patent-text"> 1. Immunogenicity data are evaluated with respect to observed IgG antibody levels in response to the bivalent (typhoid and paratyphoid) SIIPL vaccine in a mouse model.</span>
      </p>
      <p num="0535" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  ＩｇＧ誘導は、ＩｇＧ  ＥＬＩＳＡにおいて観察された比色分析応答（ＯＤ）のＧｅｏｍｅｔｒｉｃ  Ｍｅａｎ（幾何平均）として測定する。<br class="style-scope patent-text">
  ３．  二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンに応答して観察されたＧＭは、ＶＩ  ＴＴ処置におけるＯＤの倍数上昇が、非コンジュゲートＶｉ  ＰＳに応答して観察されたＯＤよりも４倍高い場合、免疫原性であると考える。
</span>2. IgG induction is measured as the Geometric Mean of the colorimetric responses (OD) observed in the IgG ELISA.<br class="style-scope patent-text"> 3. The GM observed in response to the bivalent (typhoid and paratyphoid) SIIPL vaccine was immune if the fold increase in OD in VI TT treatment was 4-fold higher than the OD observed in response to unconjugated Vi PS. I think it's primal.</span>
      </p>
      <p num="0536" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  結論：<br class="style-scope patent-text">
  １．  すべての二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンは、血清学アッセイを介して観察された免疫原性応答を誘導することが見出された。
</span>Conclusion:<br class="style-scope patent-text"> 1. All bivalent (typhoid and paratyphoid) SIIPL vaccines were found to induce immunogenic responses observed via serological assays.</span>
      </p>
      <p num="0537" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２．  すべての二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンコンジュゲートは、非コンジュゲート対照物において観察されたよりも高いＩｇＧレベルを示した。<br class="style-scope patent-text">
  ３．  二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンによるＩｇＧ誘導は、ＳＩＩＰＬ  Ｏ－ＳＰ  Ａ  ＣＲＭおよび市販Ｖｉ  ＴＴワクチンであるＴｙｐｖａｒ  ＴＣＶを含有する二価ワクチンで観察されたＩｇＧ誘導よりも高かった。
</span>2. All bivalent (typhoid and paratyphoid) SIIPL vaccine conjugates showed higher IgG levels than observed in the unconjugated controls.<br class="style-scope patent-text"> 3. IgG induction by the bivalent (typhus and paratyphoid) SIIPL vaccine was higher than that observed with bivalent vaccines containing SIIPL O-SPA CRM and the commercial Vi TT vaccine, Typvar TCV.</span>
      </p>
      <p num="0538" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ４．  免疫原性応答の誘導（ＧＭおよび＞４倍上昇）が、「二価（チフスおよびパラチフス）ＳＩＩＰＬワクチン」を受容したマウスにおいて観察され、したがって、二価（チフスおよびパラチフス）ＳＩＩＰＬワクチンは、マウスモデルにおいて強い免疫原性応答を誘導することができ、その臨床免疫原性の可能性が示唆されたと結論することができる。
</span>
  4. Induction of immunogenic responses (GM and &gt;4-fold elevation) was observed in mice receiving the "bivalent (typhoid and paratyphoid) SIIPL vaccine", thus the bivalent (typhoid and paratyphoid) SIIPL vaccine is a mouse model It can be concluded that a strong immunogenic response could be induced in , suggesting its potential clinical immunogenicity.
</span>
      </p>
      <p num="0539" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  実施例７：単回用量ワクチンキット<br class="style-scope patent-text">
Ａ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
  凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器。
</span>Example 7: Single dose vaccine kit A) Single dose vaccine kit comprising:<br class="style-scope patent-text"> Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg of Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a liquid composition for reconstitution of a lyophilized (freeze-dried) immunogenic composition comprising:</span>
      </p>
      <p num="0540" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。<br class="style-scope patent-text">
Ｂ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
  凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器。
</span>interpretation:<br class="style-scope patent-text"> For prophylaxis against typhoid fever caused by Salmonella typhi and Neisseria meningitidis antigens, there is no antigenic interference of ViPs-TT by Neisseria meningitidis antigens, and the vaccine formulation is effective for children under 2 years of age with only one injection including the complete vaccination schedule. including children, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune response against typhi.<br class="style-scope patent-text"> B) A single dose vaccine kit comprising:<br class="style-scope patent-text"> Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197),<br class="style-scope patent-text"> c) 1-10 mg sodium chloride,<br class="style-scope patent-text"> d) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a liquid composition for reconstitution of a lyophilized (freeze-dried) immunogenic composition comprising:</span>
      </p>
      <p num="0541" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスおよびパラチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。<br class="style-scope patent-text">
Ｃ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
  完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または１種もしくは複数の変性アデニレートシクラーゼ、０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｃ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｄ）ポリソルベート２０、および／または<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器。
</span>interpretation:<br class="style-scope patent-text"> Salmonella typhi, S. ViPs-TT with Neisseria meningitidis antigens for prophylaxis against typhoid and paratyphoid fever caused by Neisseria meningitidis antigens; no antigenic interference of OSP antigens, said vaccine formulation, with only one injection comprising a complete vaccination schedule, Including children under 2 years of age, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.<br class="style-scope patent-text"> C) A single dose vaccine kit comprising:<br class="style-scope patent-text"> Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen or one or more denatured adenylate cyclases, pertussis toxin (PT) 1-50 μg per 0.5 ml, filamentous hemagglutinin (FHA) in an amount of 1-50 IOU per 0.5 ml ) acellular pertussis (aP) antigens comprising 1-50 μg, pertactin (P69 or PRN) 1-20 μg or fimbrial proteins (FIM1, 2 and 3) 2-25 μg,<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride, and/or c) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer, and/or d) Polysorbate 20, and/or or e) 1-10 mg of 2-phenoxyethanol, and/or f) a suitable amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a fully liquid immunogenic composition comprising:</span>
      </p>
      <p num="0542" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび六価抗原によって引き起こされるチフスに対する予防について、六価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。<br class="style-scope patent-text">
Ｄ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または１種もしくは複数の変性アデニレートシクラーゼ、０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ    ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｇ）ポリソルベート２０から選択されるポリソルベート、および／または<br class="style-scope patent-text">
  ｈ）１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器。
</span>interpretation:<br class="style-scope patent-text"> For prevention against typhoid fever caused by Salmonella typhi and hexavalent antigens, there was no antigenic interference of ViPs-TT by the hexavalent immunizing composition, and the vaccine formulation was effective against 2-year-olds with only one injection, including the complete vaccination schedule. including children, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune response against typhi.<br class="style-scope patent-text"> D) A single dose vaccine kit comprising:<br class="style-scope patent-text"> Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen or one or more denatured adenylate cyclases, pertussis toxin (PT) 1-50 μg per 0.5 ml, filamentous hemagglutinin (FHA) in an amount of 1-50 IOU per 0.5 ml ) acellular pertussis (aP) antigens comprising 1-50 μg, pertactin (P69 or PRN) 1-20 μg or fimbrial proteins (FIM1, 2 and 3) 2-25 μg,<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197),<br class="style-scope patent-text"> c) 1-10 mg sodium chloride, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer, and/or g) polysorbate 20 and/or h) 1-10 mg of 2-phenoxyethanol, and/or e) a suitable amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a fully liquid immunogenic composition comprising:</span>
      </p>
      <p num="0543" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび六価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、六価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。<br class="style-scope patent-text">
Ｅ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
  完全液体七価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または１種もしくは複数の変性アデニレートシクラーゼ、０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器。
</span>interpretation:<br class="style-scope patent-text"> Salmonella typhi, S. ViPs-TT by hexavalent antigens for prophylaxis against typhoid and paratyphoid caused by paratyphi and hexavalent antigens; Including children under 2 years of age, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.<br class="style-scope patent-text"> E) Single dose vaccine kit comprising:<br class="style-scope patent-text"> Complete Liquid Heptavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml; an inactivated poliovirus (IPV) antigen selected from Sabin or Salk strains;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen or one or more denatured adenylate cyclases, pertussis toxin (PT) 1-50 μg per 0.5 ml, filamentous hemagglutinin (FHA) in an amount of 1-50 IOU per 0.5 ml ) acellular pertussis (aP) antigens comprising 1-50 μg, pertactin (P69 or PRN) 1-20 μg or fimbrial proteins (FIM1, 2 and 3) 2-25 μg,<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a fully liquid immunogenic composition comprising:</span>
      </p>
      <p num="0544" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび七価抗原によって引き起こされるチフスに対する予防について、七価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めてＳ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。<br class="style-scope patent-text">
Ｆ）以下を備える単回用量ワクチンキット：<br class="style-scope patent-text">
  完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または１種もしくは複数の変性アデニレートシクラーゼ、０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ    ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｇ）ポリソルベート２０から選択されるポリソルベート、<br class="style-scope patent-text">
  ｈ）１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、完全液体免疫原性組成物を含有する第２の容器。
</span>interpretation:<br class="style-scope patent-text"> For prevention against typhoid fever caused by Salmonella typhi and heptavalent antigens, there was no antigenic interference of ViPs-TT by the heptavalent immunizing composition, and the vaccine formulation was effective against 2-year-olds with only one injection, including the complete vaccination schedule. including children under the age of 10, teenagers, adults and the elderly. sufficient to elicit the necessary T-dependent immune response against typhi.<br class="style-scope patent-text"> F) Single dose vaccine kit comprising:<br class="style-scope patent-text"> Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml; an inactivated poliovirus (IPV) antigen selected from Sabin or Salk strains;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen or one or more denatured adenylate cyclases, pertussis toxin (PT) 1-50 μg per 0.5 ml, filamentous hemagglutinin (FHA) in an amount of 1-50 IOU per 0.5 ml ) acellular pertussis (aP) antigens comprising 1-50 μg, pertactin (P69 or PRN) 1-20 μg or fimbrial proteins (FIM1, 2 and 3) 2-25 μg,<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197),<br class="style-scope patent-text"> c) 1-10 mg sodium chloride, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer, and/or g) polysorbate 20 polysorbate,<br class="style-scope patent-text"> h) 1-10 mg of 2-phenoxyethanol, and/or e) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> A second container containing a fully liquid immunogenic composition comprising:</span>
      </p>
      <p num="0545" class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  解釈：<br class="style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび七価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、七価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である。
</span>interpretation:<br class="style-scope patent-text"> Salmonella typhi, S. ViPs-TT by heptavalent antigen for prophylaxis against typhoid and paratyphoid caused by paratyphi and heptavalent antigen; Including children under 2 years of age, teenagers, adults and the elderly, S. sufficient to elicit the necessary T-dependent immune responses against typhi and paratyphi.</span>
      </p>
    </embodiments-example>
  </description-of-embodiments>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(129)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Japanese</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM344656114" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ｉ）<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ｂ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ｃ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｅ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｆ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｇ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｃｈｏｌｅｒａｅｓｕｉｓ糖－担体タンパク質コンジュゲート、<br class="style-scope patent-text">
  ｈ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｄｕｂｌｉｎ糖担体タンパク質コンジュゲート、<br class="style-scope patent-text">
から選択される少なくとも１種の抗原；および<br class="style-scope patent-text">
  ｉｉ）任意選択で、サルモネラ菌（非チフス性）、ジフテリアトキソイド（Ｄ）、破傷風トキソイド（Ｔ）、全細胞百日咳（ｗＰ）、Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ  ＰＲＰ－担体タンパク質コンジュゲート（Ηｉｂ）、Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ（ａ、ｃ、ｄ、ｅ、ｆ血清型、および非莢膜型株）、ポリオウイルス、Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ抗原（Ａ、Ｂ、Ｃ、Ｄ、Ｗ１３５、Ｘ、Ｙ、Ｚおよび２９Ｅ）、Ｓｔｒｅｐｔｏｃｏｃｃｕｓ  Ｐｎｅｕｍｏｎｉａｅ抗原（１、２、３、４、５、６Ａ、６Ｂ、６Ｃ、６Ｄ、６Ｅ、６Ｇ、６Ｈ、７Ａ、７Ｂ、７Ｃ、７Ｆ、８、９Ａ、９Ｌ、９Ｆ、９Ｎ、９Ｖ、１０Ｆ、１０Ｂ、１０Ｃ、１０Ａ、１１Ａ、１１Ｆ、１１Ｂ、１１Ｃ、１１Ｄ、１１Ｅ、１２Ａ、１２Ｂ、１２Ｆ、１３、１４、１５Ａ、１５Ｃ、１５Ｂ、１５Ｆ、１６Ａ、１６Ｆ、１７Ａ、１７Ｆ、１８Ｃ、１８Ｆ、１８Ａ、１８Ｂ、１９Ａ、１９Ｂ、１９Ｃ、１９Ｆ、２０、２０Ａ、２０Ｂ、２１、２２Ａ、２２Ｆ、２３Ａ、２３Ｂ、２３Ｆ、２４Ａ、２４Ｂ、２４Ｆ、２５Ｆ、２５Ａ、２７、２８Ｆ、２８Ａ、２９、３１、３２Ｆ、３２Ａ、３３Ａ、３３Ｃ、３３Ｄ、３３Ｅ、３３Ｆ、３３Ｂ、３４、４５、３８、３５Ａ、３５Ｂ、３５Ｃ、３５Ｆ、３６、３７、３８、３９、４０、４１Ｆ、４１Ａ、４２、４３、４４、４５、４６、４７Ｆ、４７Ａ、４８）を含むコンジュゲート、Ａ群連鎖球菌属菌種、Ｂ群連鎖球菌属菌種（群Ｉａ、Ｉｂ、ＩＩ、ＩＩＩ、ＩＶ、Ｖ、Ｖｌ、ＶＩＩ、ＶＩＩＩおよびＩＸ）、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｂ水泡または抗原（ｆＨｂｐ、ＰｏｒＡ、キメラｆＨｂｐ－ｐｏｒＡ）、Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ  ａｕｒｅｕｓ抗原、脾脱疽、ＢＣＧ、肝炎（Ａ、Ｃ、Ｄ、Ｅ、ＦおよびＧ株）抗原、ヒトパピローマウイルス、ＨＩＶ、無細胞性百日咳、変性アデニレートシクラーゼ、マラリア抗原（ＲＴＳ、Ｓ）、麻疹、流行性耳下腺炎、風疹、デング熱、ジカ、エボラ、チクングニア熱、日本脳炎、ロタウイルス、下痢性抗原（大腸菌属菌種、赤痢菌属菌種、カンピロバクター属菌種、Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａ）、フラビウイルス、天然痘、黄熱病、帯状疱疹、水痘ウイルス抗原を含む群から選択される抗原<br class="style-scope patent-text">
を含む免疫原性組成物。
</span>i)<br class="style-scope patent-text"> a) Salmonella enterica serovar typhi sugar-carrier protein conjugates,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate,<br class="style-scope patent-text"> c) Salmonella enterica serovar paratyphi B sugar-carrier protein conjugates,<br class="style-scope patent-text"> d) Salmonella enterica serovar paratyphi C sugar-carrier protein conjugates,<br class="style-scope patent-text"> e) Salmonella enterica serovar typhimurium sugar-carrier protein conjugates,<br class="style-scope patent-text"> f) Salmonella enterica serovar enteritidis sugar-carrier protein conjugates,<br class="style-scope patent-text"> g) Salmonella enterica serovar choleraesuis sugar-carrier protein conjugates,<br class="style-scope patent-text"> h) Salmonella enterica serovar dublin glycocarrier protein conjugates,<br class="style-scope patent-text"> and ii) optionally salmonella (non-typhoid), diphtheria toxoid (D), tetanus toxoid (T), whole cell pertussis (wP), hepatitis B virus surface antigen ( HBsAg), Haemophilus influenzae b PRP-carrier protein conjugate (Hib), Haemophilus influenzae (a, c, d, e, f serotypes and non-capsular strains), poliovirus, N. meningitidis antigens (A, B, C, D, W135, X, Y, Z and 29E), Streptococcus Pneumoniae antigens (1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 6G, 6H, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9F, 9N, 9V, 10F, 10B, 10C, 10A, 11A, 11F, 11B, 11C, 11D, 11E, 12A, 12B, 12F, 13, 14, 15A, 15C, 15B, 15F, 16A, 16F, 17A, 17F, 18C, 18F, 18A, 18B, 19A, 19B, 19C, 19F, 20, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24A, 24B, 24F, 25F, 25A, 27, 28F, 28A, 29, 31, 32F, 32A, 33A, 33C, 33D, 33E, 33F, 33B, 34, 45, 38, 35A, 35B, 35C, 35F, 36, 37, 38, 39, 40, 41F, 41A, 42, 43, 44, 45, 46, 47F, 47A, 48), Group A Streptococcus spp., Group B Streptococcus spp. (groups Ia, Ib, II, III, IV, V, Vl, VII, VIII and IX), Neisseria meningitidis B bulla or antigen (fHbp, PorA, chimeric fHbp-porA), Staphylococcus aureus antigen, splenic anthrax, BCG, hepatitis (A, C, D, E, F and G strains) antigens, human papillomavirus, HIV, acellular pertussis, modified adenylate cyclase, malaria antigens (RTS, S), measles, mumps, Rubella, Dengue fever, Zika, Ebola, Chikungunya fever, Japanese encephalitis, Rotavirus, diarrheal antigens (Escherichia coli spp., Shigella spp., Campylobacter spp., Vibrio cholera), flaviviruses, smallpox, yellow fever, An immunogenic composition comprising an antigen selected from the group comprising shingles, varicella virus antigens.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原<br class="style-scope patent-text">
の少なくとも１つの二価組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) The immunogenic composition of claim 1, comprising at least one bivalent combination of Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigens.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原<br class="style-scope patent-text">
の少なくとも１つの三価組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) The immunogenic composition of claim 1, comprising at least one trivalent combination of Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigens.</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原<br class="style-scope patent-text">
の四価組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) The immunogenic composition of claim 1, comprising a tetravalent combination of Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigens.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｈ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｈ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｉ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｇ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－担体タンパク質コンジュゲート抗原<br class="style-scope patent-text">
の少なくとも１つの組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> h) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> h) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> i) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> g) Neisseria meningitidis X sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) Neisseria meningitidis Y sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> f) Neisseria meningitidis W-135 sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Neisseria meningitidis C sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Neisseria meningitidis A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) The immunogenic composition of claim 1, comprising at least one combination of Neisseria meningitidis C glyco-carrier protein conjugate antigens.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｃ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｆ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｇ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｅ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｆ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｇ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｈ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｄ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｅ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｆ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｇ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｈ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｅ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｆ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｇ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｈ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｉ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｅ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｆ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｇ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｈ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｉ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｅ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｆ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｇ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｈ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｉ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｊ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｆ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｇ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｈ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｉ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｊ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｆ）ＳａｌｋもしくはＳａｂｉｎ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｇ）ジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｈ）破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｉ）全細胞百日咳（ｗＰ）抗原もしくは無細胞性百日咳（ａＰ）、<br class="style-scope patent-text">
  ｊ）Ｂ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、および<br class="style-scope patent-text">
  ｋ）Ｈａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
の少なくとも１つの組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg), and g) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) a diphtheria toxoid (D) antigen;<br class="style-scope patent-text"> e) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> f) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> g) hepatitis B virus surface antigen (HBsAg), and h) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> d) a diphtheria toxoid (D) antigen;<br class="style-scope patent-text"> e) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> f) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> g) hepatitis B virus surface antigen (HBsAg), and h) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> e) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> f) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> g) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> h) hepatitis B virus surface antigen (HBsAg), and i) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> e) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> f) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> g) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> h) hepatitis B virus surface antigen (HBsAg), and i) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) a rotavirus antigen,<br class="style-scope patent-text"> e) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> f) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> g) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> h) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> i) hepatitis B virus surface antigen (HBsAg), and j) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> f) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> g) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> h) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> i) hepatitis B virus surface antigen (HBsAg), and j) Haemophilus influenzae type b antigen (Hib),<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> e) a rotavirus antigen,<br class="style-scope patent-text"> f) an inactivated poliovirus (IPV) antigen selected from Salk or Sabin strains;<br class="style-scope patent-text"> g) diphtheria toxoid (D) antigen,<br class="style-scope patent-text"> h) tetanus toxoid (T) antigen,<br class="style-scope patent-text"> i) whole cell pertussis (wP) antigen or acellular pertussis (aP),<br class="style-scope patent-text"> j) hepatitis B virus surface antigen (HBsAg), and k) Haemophilus influenzae type b antigen (Hib)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising at least one combination of</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｄ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｅ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｆ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｇ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｄ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｅ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｆ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｇ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｅ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｆ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｇ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｈ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原、<br class="style-scope patent-text">
または<br class="style-scope patent-text">
  ａ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）ロタウイルス抗原、<br class="style-scope patent-text">
  ｆ）下痢原生Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ属菌種（腸内毒素原性および腸出血性）抗原、<br class="style-scope patent-text">
  ｇ）赤痢菌属菌種抗原、<br class="style-scope patent-text">
  ｈ）Ｃａｍｐｙｌｏｂａｃｔｅｒ  ｊｅｊｕｎｉ抗原、<br class="style-scope patent-text">
  ｉ）Ｖｉｂｒｉｏ  ｃｈｏｌｅｒａｅ抗原<br class="style-scope patent-text">
の少なくとも１つの組合せを含む、請求項１に記載の免疫原性組成物。
</span>a) Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) a rotavirus antigen,<br class="style-scope patent-text"> c) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> d) Shigella spp. antigen,<br class="style-scope patent-text"> e) a Campylobacter jejuni antigen;<br class="style-scope patent-text"> f) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejuni antigens,<br class="style-scope patent-text"> g) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejun antigen;<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) Shigella spp. antigen,<br class="style-scope patent-text"> or a) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) a rotavirus antigen,<br class="style-scope patent-text"> d) diarrheal native Escherichia coli spp. (enterotoxogenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> e) Shigella spp. antigen,<br class="style-scope patent-text"> f) Campylobacter jejuni antigens,<br class="style-scope patent-text"> g) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) a rotavirus antigen,<br class="style-scope patent-text"> e) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> f) Shigella spp. antigen,<br class="style-scope patent-text"> g) Campylobacter jejuni antigens,<br class="style-scope patent-text"> h) Vibrio cholerae antigen,<br class="style-scope patent-text"> or a) a Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> b) Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> c) Salmonella enterica serovar typhimurium sugar-carrier protein conjugate antigen,<br class="style-scope patent-text"> d) Salmonella enterica serovar enteritidis sugar-carrier protein conjugate antigen;<br class="style-scope patent-text"> e) a rotavirus antigen,<br class="style-scope patent-text"> f) diarrheal native Escherichia coli spp. (enterotoxigenic and enterohemorrhagic) antigens,<br class="style-scope patent-text"> g) Shigella spp. antigen,<br class="style-scope patent-text"> h) Campylobacter jejuni antigens,<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising i) at least one combination of Vibrio cholerae antigens.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質（ＣＰ）が、破傷風毒素、破傷風トキソイド（ＴＴ）、破傷風トキソイドの断片、ジフテリアトキソイド（ＤＴ）、ＣＲＭ１９７、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａトキソイド、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓトキソイド、Ｃｌｏｓｔｒｉｄｉｕｍ  ｐｅｒｆｒｉｎｇｅｎｓトキソイド、Ｅ．ｃｏｌｉ  ＬＴ、Ｅ．ｃｏｌｉ  ＳＴ、Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ易熱性毒素－Ｂサブユニット、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ外膜複合体、ｒＥＰＡ、Ｈ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ、Ｆｌａｇｅｌｌｉｎ  ＦｌｉＣ、カブトガニヘモシアニン、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａからのエキソトキシンＡ、外膜複合体ｃ（ＯＭＰＣ）、ポリン、トランスフェリン結合タンパク質、ニューモリシン、肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）、肺炎球菌表面アドヘシンＡ（ＰｓａＡ）、肺炎球菌ＰｈｔＤ、肺炎球菌表面タンパク質ＢＶＨ－３およびＢＶＨ－１１、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの防御抗原（ＰＡ）ならびにＢａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの解毒浮腫因子（ＥＦ）および致死因子（ＬＦ）、オボアルブミン、キーホールリンペットヘモシアニン（ＫＬＨ）、ヒト血清アルブミン、ウシ血清アルブミン（ＢＳＡ）、ツベルクリンの精製タンパク質誘導体（ＰＰＤ）、合成ペプチド、ヒートショックプロテイン、百日咳タンパク質、サイトカイン、リンホカイン、ホルモン、成長因子、Ｎ  １９などの様々な病原体由来の複数のヒトＣＤ４＋  Ｔ細胞エピトープを含む人工タンパク質、鉄取り込みタンパク質、リンカーありまたはなしのＣ．ｄｉｆｆｉｃｉｌｅおよびＳ．ａｇａｌａｃｔｉａｅタンパク質からの毒素ＡまたはＢ、ならびにその断片、誘導体、変形を含む群から選択される、請求項１から７に記載の免疫原性組成物。
</span>
  Carrier proteins (CP) include tetanus toxin, tetanus toxoid (TT), fragments of tetanus toxoid, diphtheria toxoid (DT), CRM197, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, E. coli LT, E. coli ST, Escherichia coli heat-labile toxin-B subunit, Neisseria meningitidis outer membrane complex, rEPA, H. influenzae protein D, Flagellin FliC, horseshoe crab hemocyanin, exotoxin A from Pseudomonas aeruginosa, outer membrane complex c (OMPC), porin, transferrin binding protein, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11, Bacillus anthracis protective antigen (PA) and Bacillus anthracis detoxification edema factor (EF) and lethal factor (LF), ovalbumin, key Whole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA), purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, N19, etc. engineered proteins containing multiple human CD4+ T cell epitopes from various pathogens of C. difficile and S. 8. The immunogenic composition of claims 1-7, selected from the group comprising toxin A or B from the agalactiae protein, and fragments, derivatives, variants thereof.
</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲート抗原；Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲート抗原；Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－担体タンパク質コンジュゲート抗原；Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－担体タンパク質コンジュゲート抗原が、５μｇ／用量～３０μｇ／用量の用量範囲である、請求項１から７に記載の免疫原性組成物。
</span>
  Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen; Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate antigen; Salmonella enterica typhimurium sugar-carrier protein conjugate antigen; Salmonella enterica serovar typhi sugar-carrier protein conjugate antigen; 8. The immunogenic composition of claims 1-7 in a dosage range of 5 μg/dose to 30 μg/dose.
</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  塩化ナトリウム、酢酸塩、炭酸塩、クエン酸塩、酪酸塩、グルコン酸塩、酒石酸塩、リン酸緩衝食塩水、硼酸塩、ヒスチジン緩衝液、コハク酸緩衝液、ＨＥＰＥＳ、トリスまたはクエン酸塩－リン酸塩の群から選択される薬学的に許容される緩衝液を含む、請求項１から７に記載の免疫原性組成物。
</span>
  sodium chloride, acetate, carbonate, citrate, butyrate, gluconate, tartrate, phosphate buffered saline, borate, histidine buffer, succinate buffer, HEPES, tris or citrate-phosphate 8. The immunogenic composition of claims 1-7, comprising a pharmaceutically acceptable buffer selected from the group of acid salts.
</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  糖、界面活性剤、ポリマー、塩、アミノ酸またはｐＨ調整剤の群から選択される薬学的に許容される賦形剤を含む、請求項１から７に記載の免疫原性組成物。
</span>
  8. The immunogenic composition of claims 1-7, comprising a pharmaceutically acceptable excipient selected from the group of sugars, surfactants, polymers, salts, amino acids or pH modifiers.
</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  賦形剤としてＬ－ヒスチジン、リシン、イソロイシン、メチオニン、グリシン、アスパラギン酸、トリシン、アルギニン、ロイシン、グルタミン、アラニン、ペプチド、加水分解タンパク質または血清アルブミンなどのタンパク質の群から選択されるアミノ酸またはタンパク質を含む、請求項１１に記載の免疫原性組成物。
</span>
  Amino acids or proteins selected from the group of proteins such as L-histidine, lysine, isoleucine, methionine, glycine, aspartic acid, tricine, arginine, leucine, glutamine, alanine, peptides, hydrolyzed proteins or serum albumin as excipients. 12. The immunogenic composition of claim 11, comprising:
</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  賦形剤としてスクロース、マンニトール、トレハロース、マンノース、ラフィノース、ラクチトール、ラクトビオン酸、グルコース、マルツロース、イソマルツロース、マルトース、ラクトースソルビトール、デキストロース、フルクトース、グリセロールまたはその組合せの群から選択される糖を含む、請求項１１に記載の免疫原性組成物。
</span>
  a sugar selected from the group of sucrose, mannitol, trehalose, mannose, raffinose, lactitol, lactobionic acid, glucose, maltulose, isomaltulose, maltose, lactose sorbitol, dextrose, fructose, glycerol or combinations thereof as excipients; 12. The immunogenic composition of claim 11.
</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  賦形剤としてポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマーの群から選択される非イオン性界面活性剤を含む、請求項１１に記載の免疫原性組成物。
</span>
  Excipients such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol 9, triethanolamine, triethanolamine poly 12. The immunogenic composition of claim 11, comprising a nonionic surfactant selected from the group of peptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soybean lecithin and poloxamer. .
</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  賦形剤としてデキストラン、カルボキシメチルセルロース、ヒアルロン酸、シクロデキストリンの群から選択されるポリマーを含む、請求項１１に記載の免疫原性組成物。
</span>
  12. The immunogenic composition of claim 11, comprising as excipient a polymer selected from the group of dextran, carboxymethylcellulose, hyaluronic acid, cyclodextrin.
</span>
    </claim-text>
  </claim>
  <claim num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  賦形剤としてＮａＣｌ、ＫＣｌ、ＫＨ<sub class="style-scope patent-text">２</sub>ＰＯ<sub class="style-scope patent-text">４</sub>、Ｎａ<sub class="style-scope patent-text">２</sub>ＨＰＯ<sub class="style-scope patent-text">４</sub>．２Ｈ<sub class="style-scope patent-text">２</sub>Ｏ、ＣａＣｌ<sub class="style-scope patent-text">２</sub>およびＭｇＣｌ<sub class="style-scope patent-text">２</sub>から選択される塩を含む、請求項１１に記載の免疫原性組成物。
</span> <sub class="style-scope patent-text">NaCl</sub> , <sub class="style-scope patent-text">KCl</sub> , <sub class="style-scope patent-text">KH2PO4</sub> , <sub class="style-scope patent-text">Na2HPO4</sub> . 12. <sub class="style-scope patent-text">The</sub> immunogenic composition of claim <sub class="style-scope patent-text">11</sub> , comprising a salt selected from <sub class="style-scope patent-text">2H2O</sub> , CaCl2 and MgCl2.</span>
    </claim-text>
  </claim>
  <claim num="17" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  単回用量組成物が、保存剤を含まない、請求項１から７に記載の免疫原性組成物。
</span>
  8. The immunogenic composition of claims 1-7, wherein the single dose composition is preservative-free.
</span>
    </claim-text>
  </claim>
  <claim num="18" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  多回用量組成物が、２－フェノキシエタノール、塩化ベンゼトニウム（フェメロール）、フェノール、チオメルサール、ホルムアルデヒド、パラベンエステル（例えば、メチル－、エチル－、プロピル－またはブチル－パラベン）、ベンジルアルコール、ｍ－クレゾール、塩化ベンザルコニウム、ベンジルアルコール、クロロブタノール、ｐ－クロロ－ｍ－クレゾールの群から選択される１種または複数の保存剤を含む、請求項１から７に記載の免疫原性組成物。
</span>
  Multidose compositions include 2-phenoxyethanol, benzethonium chloride (femerol), phenol, thiomersal, formaldehyde, paraben esters (eg methyl-, ethyl-, propyl- or butyl-paraben), benzyl alcohol, m-cresol, chloride Immunogenic composition according to claims 1 to 7, comprising one or more preservatives selected from the group of benzalkonium, benzyl alcohol, chlorobutanol, p-chloro-m-cresol.
</span>
    </claim-text>
  </claim>
  <claim num="19" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  水酸化アルミニウム、リン酸アルミニウム、ヒドロキシリン酸アルミニウムおよび硫酸アルミニウムカリウムまたはその混合物の群から選択されるアジュバントをさらに含む、請求項１から７に記載の免疫原性組成物。
</span>
  8. The immunogenic composition of claims 1-7, further comprising an adjuvant selected from the group of aluminum hydroxide, aluminum phosphate, aluminum hydroxyphosphate and potassium aluminum sulfate or mixtures thereof.
</span>
    </claim-text>
  </claim>
  <claim num="20" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  油水エマルジョン、ＭＦ－５９、リポソーム、リポ多糖、サポニン、リピドＡ、リピドＡ誘導体、モノホスホリルリピドＡ、３－デアシル化モノホスホリルリピドＡ、ＡＳ０１、ＡＳ０３、オリゴヌクレオチド、少なくとも１つの非メチル化ＣｐＧおよび／またはリポソームを含むオリゴヌクレオチド、フロイントアジュバント、フロイント完全アジュバント、フロイント不完全アジュバント、ＣＲＬ－８３００アジュバント、ムラミルジペプチド、ＴＬＲ－４アゴニスト、フラゲリン、グラム陰性菌由来のフラゲリン、ｄｍＬＴ、ＴＬＲ－５アゴニスト、ＴＬＲ－５受容体に結合することが可能なフラゲリンの断片、ＱＳ－２１、ＩＳＣＯＭＳ、キトサン、ステロールおよび脂質とのサポニン組合せの群から選択される免疫刺激成分をさらに含む、請求項１から７に記載の免疫原性組成物。
</span>
  oil-water emulsion, MF-59, liposomes, lipopolysaccharides, saponins, lipid A, lipid A derivatives, monophosphoryl lipid A, 3-deacylated monophosphoryl lipid A, AS01, AS03, oligonucleotides, at least one unmethylated CpG and / or oligonucleotides containing liposomes, Freund's adjuvant, Freund's complete adjuvant, Freund's incomplete adjuvant, CRL-8300 adjuvant, muramyl dipeptide, TLR-4 agonist, flagellin, flagellin from Gram-negative bacteria, dmLT, TLR-5 agonist, Fragments of flagellin capable of binding to TLR-5 receptors, QS-21, ISCOMS, chitosan, sterols and saponin combinations with lipids. An immunogenic composition as described.
</span>
    </claim-text>
  </claim>
  <claim num="21" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1-10 mg sodium chloride c) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="22" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1-10 mg sodium chloride c) 1-10 mg 2-phenoxyethanol d) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="23" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 0.1 mg to 1.6 mg Tris or citrate or histidine or succinate buffer c) 1 to 10 mg sodium chloride d) suitable amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="24" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 0.1 mg to 1.6 mg Tris buffer or citrate buffer or histidine buffer or succinate buffer c) 1 to 10 mg sodium chloride d) 1 to 10 mg 2-phenoxyethanol e) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="25" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ    ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="26" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="27" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="28" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="29" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="30" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="31" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="32" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="33" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="34" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="35" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="36" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="37" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="38" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="39" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
  を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="40" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="41" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="42" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ    ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="43" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="44" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="45" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="46" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="47" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="48" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="49" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="50" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="51" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="52" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="53" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="54" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="55" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="56" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 1-10 mg 2-phenoxyethanol e) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="57" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="58" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="59" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 1-10 mg of 2-phenoxyethanol g) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="60" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｄ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1-10 mg sodium chloride d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer e) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer f) 2.5-25 mg sucrose g) 1-10 mg 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="61" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="62" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 1-10 mg 2-phenoxyethanol f) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="63" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, in an amount of 25-500 μg , octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soybean lecithin and poloxamer f) water for injection (WFI )<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="64" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, in an amount of 25-500 μg , octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) 2.5-25 mg of Sucrose g) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="65" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, in an amount of 25-500 μg , octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) 1-10 mg of 2- Phenoxyethanol g) Water for Injection (WFI) in appropriate amounts<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="66" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｆ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, in an amount of 25-500 μg , octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer f) 2.5-25 mg of sucrose g) 1-10 mg of 2-phenoxyethanol h) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="67" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soy lecithin and poloxamer g) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="68" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="69" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 1-10 mg of 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="70" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｈ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｉ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) 1-10 mg 2-phenoxyethanol i) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="71" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="72" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 1-10 mg 2-phenoxyethanol f) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="73" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Water for injection (WFI) appropriate amount<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="74" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris buffer or citrate buffer or histidine buffer or succinate buffer f) 1-10 mg 2-phenoxyethanol g) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="75" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soy lecithin and poloxamer g) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="76" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="77" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 1-10 mg of 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="78" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｈ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｉ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) 1-10 mg 2-phenoxyethanol i) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="79" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="80" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 1-10 mg 2-phenoxyethanol f) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="81" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Water for injection (WFI) appropriate amount<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="82" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris buffer or citrate buffer or histidine buffer or succinate buffer f) 1-10 mg 2-phenoxyethanol g) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="83" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soy lecithin and poloxamer g) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="84" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) water for injection (WFI) qs<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="85" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 1-10 mg of 2-phenoxyethanol h) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="86" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
ｄ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
ｅ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
ｆ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
ｇ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
ｈ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
ｉ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1-10 mg sodium chloride e) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer f) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer g) 2.5-25 mg sucrose h) 1-10 mg 2-phenoxyethanol i) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="87" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="88" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 1-10 mg 2-phenoxyethanol g) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="89" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer g) Water for injection (WFI) appropriate amount<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="90" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris buffer or citrate buffer or histidine buffer or succinate buffer g) 1-10 mg 2-phenoxyethanol h) appropriate amount of water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="91" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｈ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer g) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer h) water for injection (WFI) in moderation<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="92" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｈ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｉ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer g) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer h) 2.5-25 mg sucrose i) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="93" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｈ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｉ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer g) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer h) 1-10 mg of 2-phenoxyethanol i) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="94" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ０．５ｍｌの組成物が、<br class="style-scope patent-text">
  ａ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原；<br class="style-scope patent-text">
  ｂ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｃ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉｍｕｒｉｕｍ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｄ）１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｅｎｔｅｒｉｔｉｄｉｓ糖－ＣＰコンジュゲート抗原；（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）<br class="style-scope patent-text">
  ｅ）１～１０ｍｇの塩化ナトリウム<br class="style-scope patent-text">
  ｆ）０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液<br class="style-scope patent-text">
  ｇ）２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー<br class="style-scope patent-text">
  ｈ）２．５～２５ｍｇのスクロース<br class="style-scope patent-text">
  ｉ）１～１０ｍｇの２－フェノキシエタノール<br class="style-scope patent-text">
  ｊ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む、請求項１に記載の免疫原性組成物。
</span>0.5 ml of the composition<br class="style-scope patent-text"> a) 1.25-50 μg Salmonella enterica serovar typhi ViPs-TT conjugate antigen;<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> c) 1.25-50 μg Salmonella enterica serovar typhimurium sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> d) 1.25-50 μg Salmonella enterica serovar enteritidis sugar-CP conjugate antigen; (CP is either TT or DT or CRM197)<br class="style-scope patent-text"> e) 1-10 mg sodium chloride f) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer g) Polysorbate 20, Polysorbate 40, Polysorbate in an amount of 25-500 μg 60, polysorbate 65, polysorbate 80, polysorbate selected from polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, poly Oxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinolate, soya lecithin and poloxamer h) 2.5-25 mg sucrose i) 1-10 mg 2-phenoxyethanol j) qs water for injection (WFI)<br class="style-scope patent-text"> 2. The immunogenic composition of claim 1, comprising</span>
    </claim-text>
  </claim>
  <claim num="95" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A single dose vaccine kit comprising a second container containing a liquid composition for reconstitution of a lyophilized (freeze-dried) immunogenic composition comprising typhoid fever caused by Salmonella typhi and Neisseria meningitidis antigens There is no antigenic interference of ViPs-TT by Neisseria meningitidis antigens for prophylaxis against Neisseria meningitidis antigens, and the vaccine formulation is effective in children under 2 years of age, adolescents, adults and the elderly with only one injection, including the complete vaccination schedule. including S. A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </claim-text>
  </claim>
  <claim num="96" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  凍結乾燥（フリーズドライ）免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ａ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｃ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｙ糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｗ－１３５糖－ＣＲＭ１９７コンジュゲート抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり５μｇのＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ  Ｘ糖－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１２ｍｇのスクロース、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり０．１～２ｍｇのクエン酸ナトリウム（二水和物）、<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり０．０５～０．５ｍｇのトリス緩衝液<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｄ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む凍結乾燥（フリーズドライ）免疫原性組成物の再構成のための液体組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよびＮｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によって引き起こされるチフスおよびパラチフスに対する予防について、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Lyophilized (freeze-dried) immunogenic compositions:<br class="style-scope patent-text"> a) 5 μg of Neisseria meningitidis A sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> b) 5 μg of Neisseria meningitidis C sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> c) 5 μg of Neisseria meningitidis Y sugar-CRM197 conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> d) 5 μg of Neisseria meningitidis W-135 saccharide-CRM197 conjugate antigen per 0.5 ml;<br class="style-scope patent-text"> e) 5 μg Neisseria meningitidis X sugar-TT conjugate antigen per 0.5 ml,<br class="style-scope patent-text"> f) 1-12 mg sucrose per 0.5 ml;<br class="style-scope patent-text"> g) 0.1-2 mg sodium citrate (dihydrate) per 0.5 ml,<br class="style-scope patent-text"> h) a first container containing 0.05-0.5 mg Tris buffer per 0.5 ml;<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> d) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> A single dose vaccine kit comprising a second container containing a liquid composition for reconstitution of a lyophilized (freeze-dried) immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT with Neisseria meningitidis antigens for prophylaxis against typhoid and paratyphoid fever caused by Neisseria meningitidis antigens; no antigenic interference of OSP antigens, said vaccine formulation, with only one injection comprising a complete vaccination schedule, Including children under 2 years of age, teenagers, adults and the elderly, S. A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi and paratyphi.</span>
    </claim-text>
  </claim>
  <claim num="97" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される１種または複数の変性アデニレートシクラーゼを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｆ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび六価抗原によって引き起こされるチフスに対する予防について、六価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml, and/or c) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or or d) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxy in an amount of 25-500 μg per 0.5 ml nol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or e) 1 per 0.5 ml ~10 mg 2-phenoxyethanol, and/or f) Water for Injection (WFI) as appropriate<br class="style-scope patent-text"> ViPs-TT with a hexavalent immune composition for prophylaxis against typhoid fever caused by Salmonella typhi and hexavalent antigens Without the antigenic interference of S. cerevisiae, the vaccine formulation is effective against S . A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </claim-text>
  </claim>
  <claim num="98" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  完全液体六価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原、または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される１種または複数の変性アデニレートシクラーゼを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｇ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび六価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、六価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Complete Liquid Hexavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> c) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> d) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from 1-20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> e) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> f) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride per 0.5 ml, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or or e) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxy in an amount of 25-500 μg per 0.5 ml nol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or f) 1 per 0.5 ml ~10 mg of 2-phenoxyethanol, and/or g) water for injection (WFI) as appropriate<br class="style-scope patent-text"> A single dose vaccine kit comprising a second container containing a complete liquid immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT by hexavalent antigens for prophylaxis against typhoid and paratyphoid caused by paratyphi and hexavalent antigens; Including children under 2 years of age, teenagers, adults and the elderly, S. A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi and paratyphi.</span>
    </claim-text>
  </claim>
  <claim num="99" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  完全液体七価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される１種または複数の変性アデニレートシクラーゼを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
および<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、<br class="style-scope patent-text">
  ｃ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉおよび七価抗原によって引き起こされるチフスに対する予防について、七価免疫組成物によるＶｉＰｓ－ＴＴの抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Complete Liquid Heptavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) 1 per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from ~20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1-10 mg sodium chloride per 0.5 ml,<br class="style-scope patent-text"> c) adequate amount of water for injection (WFI)<br class="style-scope patent-text"> ViPs-TT with a heptavalent immune composition for prophylaxis against typhoid fever caused by Salmonella typhi and heptavalent antigen Without the antigenic interference of S. cerevisiae, the vaccine formulation is effective against S . A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi.</span>
    </claim-text>
  </claim>
  <claim num="100" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
完全液体七価免疫原性組成物：<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり、ＩＰＶ１型は１～５０Ｄ抗原単位（ＤＵ）の用量、ＩＰＶ２型は１～５０Ｄ抗原単位（ＤＵ）の用量、またはＩＰＶ３型は１～５０Ｄ抗原単位（ＤＵ）の用量の、ＳａｂｉｎまたはＳａｌｋ株から選択される不活化ポリオウイルス（ＩＰＶ）抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たりの１～５０μｇの範囲の量で存在するＣＤＣ－９、ＣＤＣ－６６または任意の他の不活化ロタウイルス株から選択される不活化ロタウイルス抗原、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～５０Ｌｆの量のジフテリアトキソイド（Ｄ）抗原、<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり１～３０Ｌｆの量の破傷風トキソイド（Ｔ）抗原、<br class="style-scope patent-text">
  ｅ）０．５ｍｌ当たり１～５０ＩＯＵの量の全細胞百日咳（ｗＰ）抗原または０．５ｍｌ当たり、百日咳毒素（ＰＴ）１～５０μｇ、糸状ヘマグルチニン（ＦＨＡ）１～５０μｇ、パータクチン（Ｐ６９またはＰＲＮ）１～２０μｇもしくは線毛タンパク質（ＦＩＭ１、２および３）２～２５μｇから選択される１種または複数の変性アデニレートシクラーゼを含む無細胞性百日咳（ａＰ）抗原、<br class="style-scope patent-text">
  ｆ）０．５ｍｌ当たり１～２０μｇの量のＢ型肝炎ウイルス表面抗原（ＨＢｓＡｇ）、<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり１～２０μｇの量のＨａｅｍｏｐｈｉｌｕｓ  ｉｎｆｌｕｅｎｚａｅ  ｂ型抗原（Ηｉｂ）<br class="style-scope patent-text">
を含有する第１の容器；<br class="style-scope patent-text">
ならびに<br class="style-scope patent-text">
  ａ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ  ＶｉＰｓ－ＴＴコンジュゲート抗原、<br class="style-scope patent-text">
  ｂ）０．５ｍｌ当たり１．２５～５０μｇのＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｐａｒａｔｙｐｈｉ  Ａ  ＯＳＰ－ＣＰコンジュゲート抗原（ＣＰは、ＴＴまたはＤＴまたはＣＲＭ１９７のいずれかである）、<br class="style-scope patent-text">
  ｃ）０．５ｍｌ当たり１～１０ｍｇの塩化ナトリウム、および／または<br class="style-scope patent-text">
  ｄ）０．５ｍｌ当たり０．１ｍｇ～１．６ｍｇのトリス緩衝液もしくはクエン酸緩衝液もしくはヒスチジン緩衝液もしくはコハク酸緩衝液、および／または<br class="style-scope patent-text">
  ｇ）０．５ｍｌ当たり２５～５００μｇの量のポリソルベート２０、ポリソルベート４０、ポリソルベート６０、ポリソルベート６５、ポリソルベート８０、ポリソルベート８５から選択されるポリソルベート、ノニルフェノキシポリエトキシエタノール、オクチルフェノキシポリエトキシエタノール、オクトキシノール４０、ノノキシノール－９、トリエタノールアミン、トリエタノールアミンポリペプチドオレエート、ポリオキシエチレン－６６０ヒドロキシステアレート、ポリオキシエチレン－３５リシノレート、大豆レシチンおよびポロキサマー、および／または<br class="style-scope patent-text">
  ｈ）０．５ｍｌ当たり１～１０ｍｇの２－フェノキシエタノール、および／または<br class="style-scope patent-text">
  ｅ）適量の注射用水（ＷＦＩ）<br class="style-scope patent-text">
を含む完全液体免疫原性組成物を含有する第２の容器<br class="style-scope patent-text">
を備える単回用量ワクチンキットであって、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓ．ｐａｒａｔｙｐｈｉおよび七価抗原によって引き起こされるチフスおよびパラチフスに対する予防について、七価抗原によるＶｉＰｓ－ＴＴ；ＯＳＰ抗原の抗原性干渉はなく、前記ワクチン製剤は、完全ワクチン接種スケジュールを含む１回のみの注射により、２歳未満の小児、１０代の者、成人および年配者を含めて、Ｓ．ｔｙｐｈｉおよびｐａｒａｔｙｐｈｉに対する必要なＴ依存性免疫応答を誘発するのに十分である、単回用量ワクチンキット。
</span>Complete Liquid Heptavalent Immunogenic Composition:<br class="style-scope patent-text"> a) IPV type 1 at a dose of 1-50 D antigen units (DU), IPV type 2 at a dose of 1-50 D antigen units (DU), or IPV type 3 at a dose of 1-50 D antigen units (DU) per 0.5 ml , an inactivated poliovirus (IPV) antigen selected from strains Sabin or Salk;<br class="style-scope patent-text"> b) an inactivated rotavirus antigen selected from CDC-9, CDC-66 or any other inactivated rotavirus strain present in an amount ranging from 1 to 50 μg per 0.5 ml;<br class="style-scope patent-text"> c) diphtheria toxoid (D) antigen in an amount of 1-50 Lf per 0.5 ml;<br class="style-scope patent-text"> d) tetanus toxoid (T) antigen in an amount of 1-30 Lf per 0.5 ml;<br class="style-scope patent-text"> e) whole cell pertussis (wP) antigen in an amount of 1-50 IOU per 0.5 ml or pertussis toxin (PT) 1-50 μg, filamentous hemagglutinin (FHA) 1-50 μg, pertactin (P69 or PRN) 1 per 0.5 ml an acellular pertussis (aP) antigen comprising one or more modified adenylate cyclases selected from ~20 μg or 2-25 μg of pilus proteins (FIM1, 2 and 3);<br class="style-scope patent-text"> f) hepatitis B virus surface antigen (HBsAg) in an amount of 1-20 μg per 0.5 ml;<br class="style-scope patent-text"> g) Haemophilus influenzae type b antigen (Hib) in an amount of 1-20 μg per 0.5 ml<br class="style-scope patent-text"> a first container containing<br class="style-scope patent-text"> and a) Salmonella enterica serovar typhi ViPs-TT conjugate antigen at 1.25-50 μg per 0.5 ml,<br class="style-scope patent-text"> b) 1.25-50 μg Salmonella enterica serovar paratyphi A OSP-CP conjugate antigen (CP is either TT or DT or CRM197) per 0.5 ml;<br class="style-scope patent-text"> c) 1-10 mg sodium chloride per 0.5 ml, and/or d) 0.1 mg-1.6 mg Tris or citrate or histidine or succinate buffer per 0.5 ml, and/or or g) a polysorbate selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, nonylphenoxypolyethoxyethanol, octylphenoxypolyethoxyethanol, octoxy in an amount of 25-500 μg per 0.5 ml Nol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate, polyoxyethylene-35 ricinoleate, soy lecithin and poloxamer, and/or h) 1 per 0.5 ml ~10 mg of 2-phenoxyethanol, and/or e) a suitable amount of water for injection (WFI)<br class="style-scope patent-text"> A single dose vaccine kit comprising a second container containing a complete liquid immunogenic composition comprising Salmonella typhi, S. et al. ViPs-TT by heptavalent antigen for prophylaxis against typhoid and paratyphoid caused by paratyphi and heptavalent antigen; Including children under 2 years of age, teenagers, adults and the elderly, S. A single dose vaccine kit sufficient to elicit the necessary T-dependent immune response against typhi and paratyphi.</span>
    </claim-text>
  </claim>
  <claim num="101" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法であって、<br class="style-scope patent-text">
  ａ．  Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ莢膜Ｖｉ多糖体（ＶｉＰｓ）の高収率収穫を得るための流加モードの培養ステップであって、培養の間、消泡剤、４０～７０ｇ／Ｌの範囲の大豆ペプトンおよび４０～７０ｇ／Ｌの範囲の酵母抽出物の組合せの使用の結果、収率が改善し（１００～７００ｍｇ／Ｌ）、発酵パラメーターは、６．７～７．１の範囲に維持されたｐＨ、３４．０～３８．０℃の範囲に維持された温度、３６～３９％に維持された溶存酸素レベル、１５０～５００に維持された撹拌（ｒｐｍ）および４００～６００ｍＯｓｍｏｌ／ｋｇの浸透圧で構成される、ステップ、<br class="style-scope patent-text">
  ｂ．  ２％未満のアニオン性洗剤、より好ましくドデシル硫酸ナトリウム（ＳＤＳ）およびカチオン性洗剤、好ましくはＣＴＡＢ、エチレンジアミン四酢酸（ＥＤＴＡ）（４～１０ｍＭ）、酢酸ナトリウム（５％～１０％）、アルコール沈殿（３０％～６０％）による処理、ならびに濃縮および様々なステップにおける３０ｋＤａ分画膜によってＳａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ莢膜ＶｉＰｓを精製するステップであって、プロセスの結果、エンドトキシン（ＰＳ  １μｇ当たり＜１００ＥＵのエンドトキシン）、タンパク質（＜１％）および核酸（＜２％）不純物の大幅な減少、好適には４０％～６５％の範囲のより高い莢膜多糖体回収率と共に、所望のＯ－アセチルレベル（＞２．０ｍｍｏｌ／多糖体１ｇ）、１００～４０００ｍｇ／Ｌの範囲の精製Ｖｉ多糖体収率、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に＞５０％のＰＳが溶出する）がもたらされ、精製Ｖｉ多糖体の平均分子量が、４０～４００ｋＤａの範囲、好ましくは１５０～２５０ｋＤａであり得る、ステップ、<br class="style-scope patent-text">
  ｃ．  カルボジイミド、還元的アミノ化またはシアニル化コンジュゲーション反応を使用して、精製ＶｉＰｓを担体タンパク質（ＣＰ）にコンジュゲートするステップ、<br class="style-scope patent-text">
  ｄ．  ゲルろ過クロマトグラフィーまたは限外ろ過を使用してＶｉＰｓ－担体タンパク質コンジュゲートを精製するステップであって、これによって、コンジュゲートバルクが少なくとも３倍濃縮され、実質的にすべての未反応化合物、非コンジュゲート多糖体、非コンジュゲートタンパク質が除去され、１０００～１５００ｋＤａのサイズを有する精製Ｖｉ多糖体コンジュゲートワクチンが得られ、コンジュゲート収率は≧５０％である、ステップ<br class="style-scope patent-text">
を含む、方法。
</span>A method for producing a Salmonella enterica serovar typhi sugar-carrier protein conjugate comprising:<br class="style-scope patent-text"> a. Fed-batch mode cultivation step for obtaining high yield harvest of Salmonella typhi capsular Vi polysaccharides (ViPs), comprising antifoaming agent, soybean peptone in the range of 40-70 g/L and soybean peptone in the range of 40-70 g/L during cultivation. The use of yeast extract combinations in the range of 70 g/L resulted in improved yields (100-700 mg/L) and fermentation parameters maintained in the range of 6.7-7.1 pH, 34. temperature maintained in the range 0-38.0° C., dissolved oxygen level maintained between 36-39%, agitation (rpm) maintained between 150-500 and osmolality between 400-600 mOsmol/kg. , step,<br class="style-scope patent-text"> b. Less than 2% anionic detergent, more preferably sodium dodecyl sulfate (SDS) and cationic detergent, preferably CTAB, ethylenediaminetetraacetic acid (EDTA) (4-10 mM), sodium acetate (5%-10%), alcohol precipitation ( 30%-60%) and purifying Salmonella typhi capsular ViPs by 30 kDa fractionation membranes in various steps of concentration and different steps, the process resulting in endotoxin (&lt;100 EU endotoxin per μg of PS), protein (&lt;1%) and nucleic acid (&lt;2%) impurities, preferably with higher capsular polysaccharide recovery in the range of 40% to 65%, together with desired O-acetyl levels (&gt;2.0 mmol). /g polysaccharide), resulting in purified Vi polysaccharide yields ranging from 100 to 4000 mg/L, molecular size distribution (&gt;50% PS elutes before reaching a distribution coefficient (KD) of 0.25). and the average molecular weight of the purified Vi polysaccharide can be in the range of 40-400 kDa, preferably 150-250 kDa,<br class="style-scope patent-text"> c. conjugating the purified ViPs to a carrier protein (CP) using a carbodiimide, reductive amination or cyanylation conjugation reaction;<br class="style-scope patent-text"> d. Purifying the ViPs-carrier protein conjugate using gel filtration chromatography or ultrafiltration, which concentrates the conjugate bulk at least 3-fold and removes substantially all unreacted compounds, unconjugated wherein the gate polysaccharide, non-conjugated proteins are removed to yield a purified Vi polysaccharide conjugate vaccine having a size of 1000-1500 kDa, the conjugate yield being ≧50%.</span>
    </claim-text>
  </claim>
  <claim num="102" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、ＶｉＰｓが、ＦｅＣｌ３、Ｈ<sub class="style-scope patent-text">２</sub>Ｏ<sub class="style-scope patent-text">２</sub>、メタ過ヨウ素酸ナトリウムおよび酢酸ナトリウムの群から選択される化学的手段、または高圧細胞破壊、ホモジナイザー、超音波処理の群から選択される機械的手段によって解重合／サイジングに供される、請求項１０１に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>Prior to conjugation, the <sub class="style-scope patent-text">ViPs</sub> are treated with chemical means selected from the group of FeCl3, H2O2, sodium metaperiodate and sodium acetate, or mechanically selected from the group of <sub class="style-scope patent-text">high</sub> pressure cell disruption, homogenizer, sonication. 102. A method of making a Salmonella enterica serovar typhi saccharide-carrier protein conjugate according to claim 101, wherein the Salmonella enterica serovar typhi saccharide-carrier protein conjugate is subjected to depolymerization/sizing by means of a method.</span>
    </claim-text>
  </claim>
  <claim num="103" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  精製ＶｉＰｓが、ＶｉＰｓ：ＥＤＡＣの重量比１：０．５～１：２で混合された１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＡＣ）の存在下でのカルボジイミドコンジュゲーション反応を使用して担体タンパク質（ＣＰ）に共有結合され、Ｖｉ多糖体および担体タンパク質の比は、０．５～１．５であり、ＶｉＰｓ：ＣＰ：ＥＤＡＣ比は、好ましくは、１：１：２または１：０．９：２または１：０．８：１．８または１：０．７：１．８であり、反応は、５～７のｐＨ、２℃～３０℃の範囲の温度で実施される、請求項１０１に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Purified ViPs used a carbodiimide conjugation reaction in the presence of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDAC) mixed in a ViPs:EDAC weight ratio of 1:0.5 to 1:2. and the ratio of Vi polysaccharide to carrier protein is 0.5-1.5, ViPs:CP:EDAC ratio is preferably 1:1:2 or 1 : 0.9:2 or 1:0.8:1.8 or 1:0.7:1.8 and the reaction is carried out at a pH of 5-7 and a temperature ranging from 2°C to 30°C. 102. A method of making a Salmonella enterica serovar typhi sugar-carrier protein conjugate according to claim 101, wherein
</span>
    </claim-text>
  </claim>
  <claim num="104" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、多糖体または担体タンパク質が、カルボジイミド、還元的アミノ化またはシアニル化反応を使用して、ヒドラジン、カルボヒドラジド、塩化ヒドラジン、ジヒドラジド、ε－アミノヘキサン酸、クロロヘキサノールジメチルアセタール、Ｄ－グルクロノラクトン、シスタミンおよびｐ－ニトロフェニルエチルアミン、ヘキサンジアミン、エチレンジアミン、１，６－ジアミノオキシヘキサンまたはβ－プロピオンアミド、ニトロフェニルエチルアミン、ハロゲン化ハロアルキル、６－アミノカプロン酸からなる群から選択されるヘテロまたはホモ二官能性リンカーにより誘導体化される、請求項１０１または１０３に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, polysaccharides or carrier proteins are converted to hydrazine, carbohydrazide, hydrazine chloride, dihydrazide, ε-aminohexanoic acid, chlorohexanol dimethylacetal, D- glucuronolactone, cystamine and a hetero hetero selected from the group consisting of p-nitrophenylethylamine, hexanediamine, ethylenediamine, 1,6-diaminooxyhexane or β-propionamide, nitrophenylethylamine, haloalkyl halides, 6-aminocaproic acid or derivatized with a homobifunctional linker.
</span>
    </claim-text>
  </claim>
  <claim num="105" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、担体タンパク質（ＣＰ）が、カルボジイミド、例えば１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＡＣ）の存在下、５～７の範囲のｐＨで実施される１時間の反応継続時間にわたって、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化される、請求項１０４に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, the carrier protein (CP) is reacted in the presence of a carbodiimide such as 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDAC) for 1 hour at a pH ranging from 5 to 7. 105. A method of making a Salmonella enterica serovar typhi sugar-carrier protein conjugate according to claim 104, wherein the Salmonella enterica serovar typhi sugar-carrier protein conjugate is derivatized with an adipic acid dihydrazide (ADH) linker for a duration of time.
</span>
    </claim-text>
  </claim>
  <claim num="106" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質が、破傷風毒素、破傷風トキソイド、破傷風トキソイドの断片、ジフテリアトキソイド、ＣＲＭ１９７、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａトキソイド、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓトキソイド、Ｃｌｏｓｔｒｉｄｉｕｍ  ｐｅｒｆｒｉｎｇｅｎｓトキソイド、Ｅ．ｃｏｌｉ  ＬＴ、Ｅ．  ｃｏｌｉ  ＳＴ、Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ易熱性毒素－Ｂサブユニット、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ外膜複合体、ｒＥＰＡ、Ｈ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ、Ｆｌａｇｅｌｌｉｎ  ＦｌｉＣ、カブトガニヘモシアニン、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａからのエキソトキシンＡ、外膜複合体ｃ（ＯＭＰＣ）、ポリン、トランスフェリン結合タンパク質、ニューモリシン、肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）、肺炎球菌表面アドヘシンＡ（ＰｓａＡ）、肺炎球菌ＰｈｔＤ、肺炎球菌表面タンパク質ＢＶＨ－３およびＢＶＨ－１１、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの防御抗原（ＰＡ）ならびにＢａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの解毒浮腫因子（ＥＦ）および致死因子（ＬＦ）、オボアルブミン、キーホールリンペットヘモシアニン（ＫＬＨ）、ヒト血清アルブミン、ウシ血清アルブミン（ＢＳＡ）、ツベルクリンの精製タンパク質誘導体（ＰＰＤ）、合成ペプチド、ヒートショックプロテイン、百日咳タンパク質、サイトカイン、リンホカイン、ホルモン、成長因子、Ｎ  １９などの様々な病原体由来の複数のヒトＣＤ４＋  Ｔ細胞エピトープを含む人工タンパク質、鉄取り込みタンパク質、リンカーありまたはなしのＣ．ｄｉｆｆｉｃｉｌｅおよびＳ．ａｇａｌａｃｔｉａｅタンパク質からの毒素ＡまたはＢ、ならびにその断片、誘導体、変形で構成される群から選択される、請求項１０１、１０２、１０３、１０４または１０５に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Carrier proteins include tetanus toxin, tetanus toxoid, fragments of tetanus toxoid, diphtheria toxoid, CRM197, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, E. coli LT, E. coli ST, Escherichia coli heat-labile toxin-B subunit, Neisseria meningitidis outer membrane complex, rEPA, H. influenzae protein D, Flagellin FliC, horseshoe crab hemocyanin, exotoxin A from Pseudomonas aeruginosa, outer membrane complex c (OMPC), porin, transferrin binding protein, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11, Bacillus anthracis protective antigen (PA) and Bacillus anthracis detoxification edema factor (EF) and lethal factor (LF), ovalbumin, key Whole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA), purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, N19, etc. engineered proteins containing multiple human CD4+ T cell epitopes from various pathogens of C. difficile and S. Salmonella enterica serovar typhi sugar-carrier protein conjugate according to claim 101, 102, 103, 104 or 105, selected from the group consisting of toxin A or B from the agalactiae protein, and fragments, derivatives, variants thereof How to manufacture
</span>
    </claim-text>
  </claim>
  <claim num="107" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質が破傷風トキソイド（ＴＴ）である、請求項１０６に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  107. A method of making a Salmonella enterica serovar typhi saccharide-carrier protein conjugate according to claim 106, wherein the carrier protein is tetanus toxoid (TT).
</span>
    </claim-text>
  </claim>
  <claim num="108" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質がジフテリアトキソイド（ＤＴ）である、請求項１０６に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  107. A method of making a Salmonella enterica serovar typhi saccharide-carrier protein conjugate according to claim 106, wherein the carrier protein is diphtheria toxoid (DT).
</span>
    </claim-text>
  </claim>
  <claim num="109" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質がＣＲＭ１９７である、請求項１０６に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  ｔｙｐｈｉ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  107. A method of making a Salmonella enterica serovar typhi saccharide-carrier protein conjugate according to claim 106, wherein the carrier protein is CRM197.
</span>
    </claim-text>
  </claim>
  <claim num="110" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  Ｓａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法であって、<br class="style-scope patent-text">
  ａ．  好ましくは酢酸（最終濃度０．５～５％）ｐＨ約２．０～３．０によるＬＰＳの酸加水分解、アンモニア水、デオキシコール酸ナトリウム（最終濃度０．５～５％）によるｐＨ７．０への中和、ならびに濃縮および様々なステップにおける１０ｋＤａ～３０ｋＤａ分画膜を使用した透析ろ過によってリポ多糖（ＬＰＳ）のＳａｌｍｏｎｅｌｌａ  Ｐａｒａｔｙｐｈｉ  Ａ  Ｏ特異的多糖体（ＯＳＰ）を精製するステップであって、プロセスの結果、エンドトキシン（ＰＳ  １μｇ当たり＜１００ＥＵのエンドトキシン）、タンパク質（＜１％）および核酸（＜２％）不純物の大幅な減少、好適には４０％～６５％の範囲のより高い莢膜多糖体回収率と共に、所望のＯ－アセチルレベル（＞２．０ｍｍｏｌ／多糖体１ｇ）、分子サイズ分布（０．２５の分布係数（ＫＤ）に達する前に＞５０％のＰＳが溶出する）がもたらされ、精製Ｏ特異的多糖体（ＯＳＰ）の平均分子量が、４０～４００ｋＤａであり得る、ステップ、<br class="style-scope patent-text">
  ｂ．  カルボジイミド、還元的アミノ化またはシアニル化コンジュゲーション反応を使用して、精製ＯＳＰを担体タンパク質（ＣＰ）にコンジュゲートするステップ、<br class="style-scope patent-text">
  ｃ）ゲルろ過クロマトグラフィーまたは限外ろ過を使用してＯＳＰ－担体タンパク質コンジュゲートを精製するステップであって、これによって、コンジュゲートバルクが少なくとも３倍濃縮され、実質的にすべての未反応化合物、非コンジュゲート多糖体、非コンジュゲートタンパク質が除去され、精製ＯＳＰ担体タンパク質コンジュゲートワクチンが得られ、コンジュゲート収率は≧５０％である、ステップ<br class="style-scope patent-text">
を含む、方法。
</span>1. A method for producing a Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate comprising:<br class="style-scope patent-text"> a. Acid hydrolysis of LPS, preferably with acetic acid (0.5-5% final concentration) pH about 2.0-3.0, aqueous ammonia, pH 7.0 with sodium deoxycholate (0.5-5% final concentration) and purifying the Salmonella Paratyphi A O-specific polysaccharide (OSP) of lipopolysaccharide (LPS) by neutralization to and concentration and diafiltration using 10 kDa to 30 kDa fractionation membranes in various steps, the process comprising: results in a significant reduction in endotoxin (&lt;100 EU endotoxin per μg of PS), protein (&lt;1%) and nucleic acid (&lt;2%) impurities, preferably higher capsular polysaccharides ranging from 40% to 65%. Recovery yielded desired O-acetyl levels (&gt;2.0 mmol/g polysaccharide), molecular size distribution (&gt;50% PS elutes before reaching a distribution coefficient (KD) of 0.25). and the average molecular weight of the purified O-specific polysaccharide (OSP) can be 40-400 kDa;<br class="style-scope patent-text"> b. conjugating the purified OSP to a carrier protein (CP) using a carbodiimide, reductive amination or cyanylation conjugation reaction;<br class="style-scope patent-text"> c) purifying the OSP-carrier protein conjugate using gel filtration chromatography or ultrafiltration, which concentrates the conjugate bulk at least 3-fold and removes substantially all unreacted compounds; wherein unconjugated polysaccharides, unconjugated proteins are removed to obtain a purified OSP carrier protein conjugate vaccine, the conjugate yield being ≧50%.</span>
    </claim-text>
  </claim>
  <claim num="111" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、ＯＰＳが、ＦｅＣｌ<sub class="style-scope patent-text">３</sub>、Ｈ<sub class="style-scope patent-text">２</sub>Ｏ<sub class="style-scope patent-text">２</sub>、メタ過ヨウ素酸ナトリウムおよび酢酸ナトリウムの群から選択される化学的手段、または高圧細胞破壊、超音波処理およびホモジナイザーの群から選択される機械的手段によって解重合／サイジングに供される、請求項１１０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>Prior to conjugation, the OPS is selected from the group of chemical means selected from the group of FeCl <sub class="style-scope patent-text">3</sub> , H <sub class="style-scope patent-text">2</sub> O <sub class="style-scope patent-text">2</sub> , sodium metaperiodate and sodium acetate, or from the group of high pressure cell disruption, sonication and homogenizer. 111. A method of producing a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 110, wherein the Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate is subjected to depolymerization/sizing by mechanical means.</span>
    </claim-text>
  </claim>
  <claim num="112" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  精製ＯＳＰが、シアニル化コンジュゲーション化学を使用して、担体タンパク質（ＣＰ）に共有結合され、シアニル化試薬が、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される、請求項１１０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Purified OSP is covalently attached to a carrier protein (CP) using cyanylation conjugation chemistry, where the cyanylating reagents are 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP), 1- Cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”), p-nitrophenylcyanate and N-cyano Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate according to claim 110, selected from the group of triethylammonium tetrafluoroborate ("CTEA") or 2-cyanopyridazin-3(2H)one (2-CPO) How to manufacture
</span>
    </claim-text>
  </claim>
  <claim num="113" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  精製ＯＳＰが、シアニル化コンジュゲーション化学を使用して担体タンパク質（ＣＰ）に共有結合され、シアニル化試薬が、ＯＳＰ：ＣＰＰＴの重量比１：０．５～１：２で混合された１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）であり、ＯＳＰおよび担体タンパク質の比は、０．５～１．５であってもよく、反応が、５～７の範囲のｐＨ、２℃～３０℃の範囲の温度で実施される、請求項１１２に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Purified OSP was covalently attached to a carrier protein (CP) using cyanylation conjugation chemistry, and 1-cyano where the cyanylating reagent was mixed in a weight ratio of OSP:CPPT from 1:0.5 to 1:2. - 4-pyrrolidinopyridinium tetrafluoroborate (CPPT), the ratio of OSP and carrier protein may be 0.5-1.5, the reaction is carried out at a pH in the range of 5-7, at 2°C to 113. A method for producing a Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate according to claim 112, which is carried out at a temperature in the range of 30°C.
</span>
    </claim-text>
  </claim>
  <claim num="114" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、担体タンパク質が、カルボジイミド、還元的アミノ化またはシアニル化反応を使用して、ヒドラジン、カルボヒドラジド、塩化ヒドラジン、ジヒドラジド、ε－アミノヘキサン酸、クロロヘキサノールジメチルアセタール、Ｄ－グルクロノラクトン、シスタミンおよびｐ－ニトロフェニルエチルアミン、ヘキサンジアミン、エチレンジアミン、１，６－ジアミノオキシヘキサンまたはβ－プロピオンアミド、ニトロフェニルエチルアミン、ハロゲン化ハロアルキル、６－アミノカプロン酸からなる群から選択されるヘテロまたはホモ二官能性リンカーにより誘導体化される、請求項１１２または１１３に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, the carrier protein is converted to hydrazine, carbohydrazide, hydrazine chloride, dihydrazide, ε-aminohexanoic acid, chlorohexanol dimethylacetal, D-glucuronolactone using carbodiimide, reductive amination or cyanylation reactions. , cystamine and p-nitrophenylethylamine, hexanediamine, ethylenediamine, 1,6-diaminooxyhexane or β-propionamide, nitrophenylethylamine, haloalkyl halides, 6-aminocaproic acid. 114. A method of making a Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate according to claim 112 or 113, which is derivatized with a functional linker.
</span>
    </claim-text>
  </claim>
  <claim num="115" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、担体タンパク質（ＣＰ）が、カルボジイミド、例えばＯＳＰ：ＡＤＨの重量比１：１～１：１０で混合された１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＡＣ）の存在下、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化され、ＯＳＰ：ＥＤＡＣの比は、０．５～１．５であってもよく、反応が、５～７の範囲のｐＨで、１～２時間の反応継続時間、２℃～３０℃の範囲の温度で実施される、請求項１１４に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  The presence of 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide (EDAC) mixed with a carrier protein (CP) prior to conjugation in a carbodiimide, such as OSP:ADH weight ratio of 1:1 to 1:10. Below, derivatized with an adipic acid dihydrazide (ADH) linker, the OSP:EDAC ratio may be 0.5-1.5, and the reaction is allowed to proceed for 1-2 hours at a pH ranging from 5-7. 115. A process for producing a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 114, which is carried out at a temperature in the range of 2°C to 30°C for a reaction duration of .
</span>
    </claim-text>
  </claim>
  <claim num="116" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ＯＳＰ：ＥＤＡＣの重量比１：０．５～１：２で混合された１－エチル－３（３－ジメチルアミノプロピル）カルボジイミド（ＥＤＡＣ）の存在下、ＯＳＰ多糖体および担体タンパク質の比は、０．５～１．５であってもよく、反応が、５～７のｐＨ、２℃～３０℃の範囲の温度で実施される、カルボジイミドコンジュゲーション反応を使用して、精製ＯＳＰが担体タンパク質（ＣＰ）に共有結合される、請求項１１０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  In the presence of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDAC) mixed at an OSP:EDAC weight ratio of 1:0.5 to 1:2, the ratio of OSP polysaccharide and carrier protein was 0. .5-1.5, and the reaction is carried out at a pH of 5-7 and a temperature ranging from 2°C to 30°C to convert the purified OSP to the carrier protein ( 111. A method of producing a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate of claim 110 covalently attached to CP).
</span>
    </claim-text>
  </claim>
  <claim num="117" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、ＯＳＰが、カルボジイミド、還元的アミノ化またはシアニル化反応を使用して、ヒドラジン、カルボヒドラジド、塩化ヒドラジン、ジヒドラジド、ε－アミノヘキサン酸、クロロヘキサノールジメチルアセタール、Ｄ－グルクロノラクトン、シスタミンおよびｐ－ニトロフェニルエチルアミン、ヘキサンジアミン、エチレンジアミン、１，６－ジアミノオキシヘキサンまたはβ－プロピオンアミド、ニトロフェニルエチルアミン、ハロゲン化ハロアルキル、６－アミノカプロン酸からなる群から選択されるヘテロまたはホモ二官能性リンカーにより誘導体化される、請求項１１６に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, OSP is converted to hydrazine, carbohydrazide, hydrazine chloride, dihydrazide, ε-aminohexanoic acid, chlorohexanol dimethylacetal, D-glucuronolactone, using carbodiimide, reductive amination or cyanylation reactions. hetero- or homobifunctional selected from the group consisting of cystamine and p-nitrophenylethylamine, hexanediamine, ethylenediamine, 1,6-diaminooxyhexane or β-propionamide, nitrophenylethylamine, haloalkyl halides, 6-aminocaproic acid 117. A method of making a Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate according to claim 116, which is derivatized with a sexual linker.
</span>
    </claim-text>
  </claim>
  <claim num="118" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、ＯＳＰが、シアニル化コンジュゲーション化学を使用して、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化され、シアニル化試薬が、１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）、１－シアノ－イミダゾール（１－ＣＩ）、１－シアノベンゾトリアゾール（１－ＣＢＴ）、１－シアノ－４－（ジメチルアミノ）－ピリジニウムテトラフルオロボレート（「ＣＤＡＰ」）、ｐ－ニトロフェニルシアネートおよびＮ－シアノトリエチルアンモニウムテトラフルオロボレート（「ＣＴＥＡ」）または２－シアノピリダジン－３（２Ｈ）オン（２－ＣＰＯ）の群から選択される、請求項１１７に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, OSP is derivatized with an adipic acid dihydrazide (ADH) linker using cyanylation conjugation chemistry, where the cyanylating reagent is 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT). (CPIP), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (“CDAP”), p-nitro Salmonella enterica serovar Paratyphi A according to claim 117, selected from the group of phenylcyanate and N-cyanotriethylammonium tetrafluoroborate (“CTEA”) or 2-cyanopyridazin-3(2H)one (2-CPO) A method for producing a sugar-carrier protein conjugate.
</span>
    </claim-text>
  </claim>
  <claim num="119" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  コンジュゲーション前に、ＯＳＰが、シアニル化コンジュゲーション化学を使用して、アジピン酸ジヒドラジド（ＡＤＨ）リンカーにより誘導体化され、シアニル化試薬は、ＯＳＰ：ＡＤＨの重量比１：１～１：１０で混合された１－シアノ－４－ピロリジノピリジニウムテトラフルオロボレート（ＣＰＰＴ）（ＣＰＩＰ）であり、ＯＳＰ：ＣＰＰＴの比は、０．５～１．５であってもよく、反応が、７～１０の範囲のｐＨで、１～２時間の反応継続時間、２℃～３０℃の範囲の温度で実施される、請求項１１８に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Prior to conjugation, OSP is derivatized with an adipic acid dihydrazide (ADH) linker using cyanylation conjugation chemistry, where the cyanylating reagents are mixed in a weight ratio of OSP:ADH from 1:1 to 1:10. 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT) (CPIP), the ratio of OSP:CPPT may be from 0.5 to 1.5, the reaction is 7-10 119. A method of producing a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 118, which is carried out at a pH range of 1 to 2 hours, a temperature range of 2°C to 30°C.
</span>
    </claim-text>
  </claim>
  <claim num="120" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質が、破傷風毒素、破傷風トキソイド、破傷風トキソイドの断片、ジフテリアトキソイド、ＣＲＭ１９７、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａトキソイド、Ｂｏｒｄｅｔｅｌｌａ  ｐｅｒｔｕｓｓｉｓトキソイド、Ｃｌｏｓｔｒｉｄｉｕｍ  ｐｅｒｆｒｉｎｇｅｎｓトキソイド、Ｅ．ｃｏｌｉ  ＬＴ、Ｅ．ｃｏｌｉ  ＳＴ、Ｅｓｃｈｅｒｉｃｈｉａ  ｃｏｌｉ易熱性毒素－Ｂサブユニット、Ｎｅｉｓｓｅｒｉａ  ｍｅｎｉｎｇｉｔｉｄｉｓ外膜複合体、ｒＥＰＡ、Ｈ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ、Ｆｌａｇｅｌｌｉｎ  ＦｌｉＣ、カブトガニヘモシアニン、Ｐｓｅｕｄｏｍｏｎａｓ  ａｅｒｕｇｉｎｏｓａからのエキソトキシンＡ、外膜複合体ｃ（ＯＭＰＣ）、ポリン、トランスフェリン結合タンパク質、ニューモリシン、肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）、肺炎球菌表面アドヘシンＡ（ＰｓａＡ）、肺炎球菌ＰｈｔＤ、肺炎球菌表面タンパク質ＢＶＨ－３およびＢＶＨ－１１、Ｂａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの防御抗原（ＰＡ）ならびにＢａｃｉｌｌｕｓ  ａｎｔｈｒａｃｉｓの解毒浮腫因子（ＥＦ）および致死因子（ＬＦ）、オボアルブミン、キーホールリンペットヘモシアニン（ＫＬＨ）、ヒト血清アルブミン、ウシ血清アルブミン（ＢＳＡ）、ツベルクリンの精製タンパク質誘導体（ＰＰＤ）、合成ペプチド、ヒートショックプロテイン、百日咳タンパク質、サイトカイン、リンホカイン、ホルモン、成長因子、Ｎ  １９などの様々な病原体由来の複数のヒトＣＤ４＋  Ｔ細胞エピトープを含む人工タンパク質、鉄取り込みタンパク質、リンカーありまたはなしのＣ．ｄｉｆｆｉｃｉｌｅおよびＳ．ａｇａｌａｃｔｉａｅタンパク質からの毒素ＡまたはＢ、ならびにその断片、誘導体、変形で構成される群から選択される、請求項１１０～１１９のいずれか一項に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  Carrier proteins include tetanus toxin, tetanus toxoid, fragments of tetanus toxoid, diphtheria toxoid, CRM197, Pseudomonas aeruginosa toxoid, Bordetella pertussis toxoid, Clostridium perfringens toxoid, E. coli LT, E. coli ST, Escherichia coli heat-labile toxin-B subunit, Neisseria meningitidis outer membrane complex, rEPA, H. influenzae protein D, Flagellin FliC, horseshoe crab hemocyanin, exotoxin A from Pseudomonas aeruginosa, outer membrane complex c (OMPC), porin, transferrin binding protein, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal surface adhesin A (PsaA), pneumococcal PhtD, pneumococcal surface proteins BVH-3 and BVH-11, Bacillus anthracis protective antigen (PA) and Bacillus anthracis detoxification edema factor (EF) and lethal factor (LF), ovalbumin, key Whole limpet hemocyanin (KLH), human serum albumin, bovine serum albumin (BSA), purified protein derivative of tuberculin (PPD), synthetic peptides, heat shock proteins, pertussis proteins, cytokines, lymphokines, hormones, growth factors, N19, etc. engineered proteins containing multiple human CD4+ T cell epitopes from various pathogens of C. difficile and S. Salmonella enterica serovar Paratyphi A sugar-carrier protein conjugate according to any one of claims 110 to 119, selected from the group consisting of toxin A or B from the agalactiae protein, and fragments, derivatives, variants thereof How to manufacture
</span>
    </claim-text>
  </claim>
  <claim num="121" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質が破傷風トキソイド（ＴＴ）である、請求項１２０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  121. A method of making a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 120, wherein the carrier protein is tetanus toxoid (TT).
</span>
    </claim-text>
  </claim>
  <claim num="122" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質がジフテリアトキソイド（ＤＴ）である、請求項１２０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  121. A method of making a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 120, wherein the carrier protein is diphtheria toxoid (DT).
</span>
    </claim-text>
  </claim>
  <claim num="123" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  担体タンパク質がＣＲＭ１９７である、請求項１２０に記載のＳａｌｍｏｎｅｌｌａ  ｅｎｔｅｒｉｃａ  ｓｅｒｏｖａｒ  Ｐａｒａｔｙｐｈｉ  Ａ糖－担体タンパク質コンジュゲートを製造する方法。
</span>
  121. A method of making a Salmonella enterica serovar Paratyphi A saccharide-carrier protein conjugate according to claim 120, wherein the carrier protein is CRM197.
</span>
    </claim-text>
  </claim>
  <claim num="124" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  免疫原性組成物が、チフス、パラチフスおよび非チフス感染に対する予防、Ｓａｌｍｏｎｅｌｌａ  ｔｙｐｈｉ、Ｓａｌｍｏｎｅｌｌａ  ｐａｒａｔｙｐｈｉおよびサルモネラ菌非チフス関連属菌種によって引き起こされる感染の発症を低減するまたは防止するための方法における使用のために製剤化され、方法が、有効量の免疫原性組成物を、非経口、または皮下、または皮内、または筋肉内、または腹腔内、または静脈内投与、または注射可能投与、またはインプラントからの持続放出、または点眼もしくは経鼻もしくは頬側もしくは膣内、経口もしくは胃内もしくは粘膜もしくは舌下、歯槽もしくは歯肉もしくは嗅覚器もしくは呼吸粘膜投与、または任意の他の免疫化経路を介して、２歳以下、１０代の者、成人または年配のヒト対象に投与するステップを含む、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  For use in a method for prophylaxis against typhoid, paratyphoid and non-typhoid infections, reducing or preventing the onset of infections caused by Salmonella typhi, Salmonella paratyphi and Salmonella non-typhoid related spp. A method is formulated to administer an effective amount of an immunogenic composition parenterally, or subcutaneously, or intradermally, or intramuscularly, or intraperitoneally, or intravenously, or injectable administration, or sustained from an implant. Release, or via ocular or nasal or buccal or intravaginal, oral or intragastric or mucosal or sublingual, alveolar or gingival or olfactory or respiratory mucosal administration, or any other route of immunization, up to 2 years of age 4. The immunogenic composition of any one of the preceding claims, comprising administering to a human subject, a teen, adult or senior.
</span>
    </claim-text>
  </claim>
  <claim num="125" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２～８℃、２５℃および４０℃で６ヶ月の期間にわたって安定である、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  An immunogenic composition according to any one of the preceding claims which is stable at 2-8°C, 25°C and 40°C for a period of 6 months.
</span>
    </claim-text>
  </claim>
  <claim num="126" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  ２～８℃、２５℃および４０℃で安定であり、６ヶ月後の遊離多糖体が、１８０～２２０ｋＤａ多糖体について７．５％以下であり、遊離多糖体が、３８８ｋＤａ、８０ｋＤａおよび４５ｋＤａ多糖体について１０．５％以下である、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  Stable at 2-8°C, 25°C and 40°C, free polysaccharide after 6 months below 7.5% for 180-220 kDa polysaccharide and free polysaccharide for 388 kDa, 80 kDa and 45 kDa polysaccharide 10.5% or less of the immunogenic composition of any one of the preceding claims.
</span>
    </claim-text>
  </claim>
  <claim num="127" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  免疫原性組成物が、前記ワクチン組成物の単回用量からなる１用量レジメンに従って、２歳以下、１０代の者、成人または年配のヒト対象に投与するために製剤化される、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  12. The preceding claim, wherein the immunogenic composition is formulated for administration to a human subject under the age of 2, teenager, adult or senior according to a single dose regimen consisting of a single dose of said vaccine composition. The immunogenic composition of any one of Claims 1 to 3.
</span>
    </claim-text>
  </claim>
  <claim num="128" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  免疫原性組成物が、第１の用量および、第１の用量の３ヶ月～２年後に投与される第２の用量からなる２用量レジメンに従って、２歳以下、１０代の者、成人または年配のヒト対象に投与するために製剤化される、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  The immunogenic composition is administered to children under the age of 2, teenagers, adults or the elderly according to a two-dose regimen consisting of a first dose and a second dose administered 3 months to 2 years after the first dose. 10. The immunogenic composition of any one of the preceding claims, formulated for administration to a human subject of.
</span>
    </claim-text>
  </claim>
  <claim num="129" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
  免疫原性組成物が、第１の用量、第１の用量の３ヶ月～２年後に投与される第２の用量、および第２の用量の３ヶ月～２年後に投与される第３の用量からなる３用量レジメンに従って、２歳以下、１０代の者、成人または年配のヒト対象に投与するために製剤化される、前記請求項のいずれか一項に記載の免疫原性組成物。
</span>
  The immunogenic composition is administered in a first dose, a second dose administered 3 months to 2 years after the first dose, and a third dose administered 3 months to 2 years after the second dose. 3. The immunogenic composition of any one of the preceding claims, formulated for administration to human subjects under the age of 2, teenagers, adults or seniors according to a three-dose regimen consisting of:
</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (21)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4057685A/en"><a id="link" href="#" class="style-scope state-modifier">US4057685A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1972-02-02</span>
                    <span class="td style-scope patent-result">1977-11-08</span>
                    <span class="td style-scope patent-result">Abbott Laboratories</span>
                    <span class="td style-scope patent-result">Chemically modified endotoxin immunizing agent 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4673574A/en"><a id="link" href="#" class="style-scope state-modifier">US4673574A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-08-31</span>
                    <span class="td style-scope patent-result">1987-06-16</span>
                    <span class="td style-scope patent-result">Anderson Porter W</span>
                    <span class="td style-scope patent-result">Immunogenic conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4459286A/en"><a id="link" href="#" class="style-scope state-modifier">US4459286A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-01-31</span>
                    <span class="td style-scope patent-result">1984-07-10</span>
                    <span class="td style-scope patent-result">Merck &amp; Co., Inc.</span>
                    <span class="td style-scope patent-result">Coupled H. influenzae type B vaccine 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU1420897A/en"><a id="link" href="#" class="style-scope state-modifier">AU1420897A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-12-18</span>
                    <span class="td style-scope patent-result">1998-07-15</span>
                    <span class="td style-scope patent-result">Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The</span>
                    <span class="td style-scope patent-result">Conjugate vaccine for (salmonella paratyphi) a 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000010599A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2000010599A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-08-19</span>
                    <span class="td style-scope patent-result">2000-03-02</span>
                    <span class="td style-scope patent-result">North American Vaccine, Inc.</span>
                    <span class="td style-scope patent-result">IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20070184072A1/en"><a id="link" href="#" class="style-scope state-modifier">US20070184072A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-08</span>
                    <span class="td style-scope patent-result">2007-08-09</span>
                    <span class="td style-scope patent-result">Wyeth</span>
                    <span class="td style-scope patent-result">Multivalent pneumococcal polysaccharide-protein conjugate composition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HUE031380T2/en"><a id="link" href="#" class="style-scope state-modifier">HUE031380T2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-06-27</span>
                    <span class="td style-scope patent-result">2017-07-28</span>
                    <span class="td style-scope patent-result">Glaxosmithkline Biologicals Sa</span>
                    <span class="td style-scope patent-result">Process for manufacturing vaccines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008033517A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008033517A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-09-13</span>
                    <span class="td style-scope patent-result">2008-03-20</span>
                    <span class="td style-scope patent-result">Abbott Laboratories</span>
                    <span class="td style-scope patent-result">Cell culture improvements 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0700135D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0700135D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-01-04</span>
                    <span class="td style-scope patent-result">2007-02-14</span>
                    <span class="td style-scope patent-result">Glaxosmithkline Biolog Sa</span>
                    <span class="td style-scope patent-result">Vaccine 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2938265B1/en"><a id="link" href="#" class="style-scope state-modifier">FR2938265B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-11-12</span>
                    <span class="td style-scope patent-result">2011-07-15</span>
                    <span class="td style-scope patent-result">Univ Claude Bernard Lyon</span>
                    <span class="td style-scope patent-result">
  METHOD FOR CONTROLLING AN ULTRASOUND DEPOLYMERIZATION TREATMENT OF A WATER SOLUBLE BIOPOLYMER
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9044517B2/en"><a id="link" href="#" class="style-scope state-modifier">US9044517B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-12-17</span>
                    <span class="td style-scope patent-result">2015-06-02</span>
                    <span class="td style-scope patent-result">Fina Biosolutions, Llc</span>
                    <span class="td style-scope patent-result">Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9011871B2/en"><a id="link" href="#" class="style-scope state-modifier">US9011871B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-11-07</span>
                    <span class="td style-scope patent-result">2015-04-21</span>
                    <span class="td style-scope patent-result">University Of Maryland, Baltimore</span>
                    <span class="td style-scope patent-result">Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9283270B2/en"><a id="link" href="#" class="style-scope state-modifier">US9283270B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-20</span>
                    <span class="td style-scope patent-result">2016-03-15</span>
                    <span class="td style-scope patent-result">Serum Institute Of India Ltd.</span>
                    <span class="td style-scope patent-result">Method for stabilization of biological molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6042455B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6042455B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-01-30</span>
                    <span class="td style-scope patent-result">2016-12-14</span>
                    <span class="td style-scope patent-result">セラム インスティチュート オブ インディア プライベイト リミテッド</span>
                    <span class="td style-scope patent-result">
  Method for preparing an immunogenic composition
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102935226B/en"><a id="link" href="#" class="style-scope state-modifier">CN102935226B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-16</span>
                    <span class="td style-scope patent-result">2014-01-22</span>
                    <span class="td style-scope patent-result">罗益（无锡）生物制药有限公司</span>
                    <span class="td style-scope patent-result">Typhoid fever and paratyphoid fever combined vaccine and preparation method thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2684615C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2684615C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-24</span>
                    <span class="td style-scope patent-result">2019-04-10</span>
                    <span class="td style-scope patent-result">Бхарат Байотек Интернэшнл Лимитед</span>
                    <span class="td style-scope patent-result">Bacterial vaccine and methods for production thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MY183392A/en"><a id="link" href="#" class="style-scope state-modifier">MY183392A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-07-04</span>
                    <span class="td style-scope patent-result">2021-02-18</span>
                    <span class="td style-scope patent-result">Bharat Biotech Int Ltd</span>
                    <span class="td style-scope patent-result">Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2017316768B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2017316768B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-08-26</span>
                    <span class="td style-scope patent-result">2024-04-11</span>
                    <span class="td style-scope patent-result">Serum Institute Of India Private Limited</span>
                    <span class="td style-scope patent-result">Multivalent vaccine composition 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EA201992636A1/en"><a id="link" href="#" class="style-scope state-modifier">EA201992636A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-05-05</span>
                    <span class="td style-scope patent-result">2020-04-17</span>
                    <span class="td style-scope patent-result">Серум Инститьют Оф Индия Прайват Лимитед</span>
                    <span class="td style-scope patent-result">
  METHOD FOR REMOVING IMPURITIES FROM DRUGS BASED ON BACTERIAL CAPSULAR POLYSACCHARIDES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EA202090316A1/en"><a id="link" href="#" class="style-scope state-modifier">EA202090316A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-07-18</span>
                    <span class="td style-scope patent-result">2020-12-08</span>
                    <span class="td style-scope patent-result">Серум Инститьют Оф Индия Пвт Лтд.</span>
                    <span class="td style-scope patent-result">
  IMMUNOGENIC COMPOSITION WITH INCREASED STABILITY, INCREASED IMMUNOGENICITY AND DECREASED REACTOGENICITY AND METHOD FOR ITS PREPARATION
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JOP20190242A1/en"><a id="link" href="#" class="style-scope state-modifier">JOP20190242A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-12</span>
                    <span class="td style-scope patent-result">2020-04-12</span>
                    <span class="td style-scope patent-result">Serum Institute Of India Pvt Ltd</span>
                    <span class="td style-scope patent-result">Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP7458682B2/en"><a id="link" href="#" class="style-scope state-modifier">JP7458682B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-04-01</span>
                    <span class="td style-scope patent-result">
  Compositions containing pneumococcal polysaccharide-protein conjugates and methods of use thereof
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107427568B/en"><a id="link" href="#" class="style-scope state-modifier">CN107427568B</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-12-14</span>
                    <span class="td style-scope patent-result">Immunogenic compositions for use in pneumococcal vaccines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6884145B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6884145B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-06-09</span>
                    <span class="td style-scope patent-result">
  Immunogenic composition for use in Streptococcus pneumoniae vaccine
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023036953A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023036953A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-03-14</span>
                    <span class="td style-scope patent-result">Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6093302B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6093302B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-03-08</span>
                    <span class="td style-scope patent-result">
  Immunogenic composition
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN114887048A/en"><a id="link" href="#" class="style-scope state-modifier">CN114887048A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-08-12</span>
                    <span class="td style-scope patent-result">Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023100822A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023100822A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-07-19</span>
                    <span class="td style-scope patent-result">Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20190055063A/en"><a id="link" href="#" class="style-scope state-modifier">KR20190055063A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-05-22</span>
                    <span class="td style-scope patent-result">
  Polyvalent pneumococcal polysaccharide-protein conjugate composition
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2018115159A/en"><a id="link" href="#" class="style-scope state-modifier">JP2018115159A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-07-26</span>
                    <span class="td style-scope patent-result">Immunogenic compositions for use in pneumococcal vaccines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20220017996A/en"><a id="link" href="#" class="style-scope state-modifier">KR20220017996A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-02-14</span>
                    <span class="td style-scope patent-result">
  Immunogenic serotype 35B pneumococcal polysaccharide-protein conjugate and conjugation method for preparing same
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2018518512A/en"><a id="link" href="#" class="style-scope state-modifier">JP2018518512A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-07-12</span>
                    <span class="td style-scope patent-result">
  Multivalent pneumococcal conjugate vaccine
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2022512345A/en"><a id="link" href="#" class="style-scope state-modifier">JP2022512345A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-02-03</span>
                    <span class="td style-scope patent-result">
  Immunogenic Multiple Heteroantigen Polysaccharide-Protein Conjugates and Their Use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4918356B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4918356B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-04-18</span>
                    <span class="td style-scope patent-result">
  Y group meningococcal vaccine and their meningococcal combination vaccine
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2022546763A/en"><a id="link" href="#" class="style-scope state-modifier">JP2022546763A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-11-08</span>
                    <span class="td style-scope patent-result">
  Immunogenic composition against intestinal disease and method for its preparation
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018074296A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018074296A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-04-26</span>
                    <span class="td style-scope patent-result">METHOD FOR PRODUCING Hib CONJUGATE VACCINE USING LOW MOLECULAR WEIGHT PRP 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL308902A/en"><a id="link" href="#" class="style-scope state-modifier">IL308902A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-01-01</span>
                    <span class="td style-scope patent-result">Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA20613A/en"><a id="link" href="#" class="style-scope state-modifier">OA20613A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-11-29</span>
                    <span class="td style-scope patent-result">Immunogenic compositions against enteric diseases and methods for its preparation thereof. 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11246918B2/en"><a id="link" href="#" class="style-scope state-modifier">US11246918B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-02-15</span>
                    <span class="td style-scope patent-result">Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2016029103A/en"><a id="link" href="#" class="style-scope state-modifier">JP2016029103A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-03</span>
                    <span class="td style-scope patent-result">Immunogenic composition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2024075506A/en"><a id="link" href="#" class="style-scope state-modifier">JP2024075506A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-06-03</span>
                    <span class="td style-scope patent-result">
  Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2024521847A/en"><a id="link" href="#" class="style-scope state-modifier">JP2024521847A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-06-04</span>
                    <span class="td style-scope patent-result">
  Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA20569A/en"><a id="link" href="#" class="style-scope state-modifier">OA20569A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-10-27</span>
                    <span class="td style-scope patent-result">Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof. 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPWO2021044436A5/en"><a id="link" href="#" class="style-scope state-modifier">JPWO2021044436A5</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-08-01</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        IN201921035435<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-09-03</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        IN201921035435<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-09-03</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021044436A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/IN2020/050763</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2020-09-02</span>
                    <span class="td style-scope patent-result">Immunogenic compositions against enteric diseases and methods for its preparation thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2023-07-24</span>
                    <span class="td nowrap style-scope patent-result">A521</span>
                    <span class="td nowrap style-scope patent-result">Request for written amendment filed</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A523</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20230724</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2023-07-24</span>
                    <span class="td nowrap style-scope patent-result">A621</span>
                    <span class="td nowrap style-scope patent-result">Written request for application examination</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: JAPANESE INTERMEDIATE CODE: A621</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Effective date</strong>: 20230724</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3903812082" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3903812082" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=1508490769" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>